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cópias 
resumo 
 
 
O atraso mental (AM) é uma doença que apresenta desafios para a vida tanto 
nas famílias como na sociedade. É caracterizada por um funcionamento sub-
óptimo do sistema nervoso central que manifesta limitações quer ao nível da 
capacidade intelectual quer do comportamento adaptativo e tem uma 
incidência de aproximadamente 2-3% de nados vivos em todo o mundo. A 
determinação da causa da doença é importante para o correcto 
encaminhamento clínico, aconselhamento genético e estratégias de coping a 
desenvolver pela família. 
A técnica de hibridação genómica comparativa (aCGH), também designada de 
cariótipo molecular (CM), permite medir variações no número de cópias entre o 
genoma do doente e de um controlo. A totalidade do genoma de um indivíduo 
é representado num cariótipo virtual de alta resolução, permitindo assim a 
detecção de alterações submicroscópicas indetectáveis por métodos de 
cariotipaem standard ou de alta resolução.  
Em Portugal, as recomendações para os testes genéticos a realizar num 
doente com AM indicam o cariótipo tradicional de bandas G como primeira 
abordagem e, sempre que o resultado seja negativo, a pesquisa relativa às 
patologias unigénicas mais comuns (Síndrome de X frágil, por exemplo), 
rearranjos subteloméricos e sondas de FISH específicas. No entanto, estas 
tecnologias não são aplicáveis para análise de todo o genoma no contexto de 
diagnóstico de rotina, tanto pela sua baixa resolução (caso do cariítpo 
convencional) como pela elevada laboriosidade e/ou custos monetários (caso 
do FISH).   
A introdução de aCGH pretende contribuir para a classificação etiológica de 
grande parte dos doentes com AM, assim como, concluir acerca da utilidade 
desta tecnologia para o diagnóstico de AM idiopático no contexto clínico. 
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abstract 
 
 
Development delay/Intellectual disability (DD/ID) is a serious and life-long 
condition which represents a challenge for families and public health services. 
It is characterized by suboptimal functioning of the central nervous system 
resulting in limitations both in intellectual functioning and in adaptive behavior, 
and it is observed in approximately 2-3% of the population worldwide. 
Establishing the disease etiology is important for clinical management, genetic 
counseling and coping strategies of the families.  
Array-based comparative genomic hybridization technique (aCGH), also called 
molecular karyotyping (MC), allows us to directly measure genomic copy 
number variations between the patient and a control DNA. The whole genome 
of an individual is represented in a high-resolution “virtual karyotype”, allowing 
the detection of submicroscopic alterations, undetectable by standard or high-
resolution karyotyping techniques. 
In Portugal, the guidelines for testing patients with DD/ID indicate the G-
banding karyotyping in first place and, whenever the result is normal, testing for 
the most common single gene disorders (Fragile X, for instance), for 
subtelomeric rearrangements and with specific FISH probes. However, the 
latter technologies are not suitable for whole genome scans in routine 
diagnosis, both because of the lower resolution levels (the case of conventional 
karyotyping), the extensive time consumption and high costs (the FISH case). 
The introduction of aCGH should contribute to the etiological classification of a 
large proportion of the DD/ID patients as well as to conclude about the utility of 
using these technologies for diagnosis of idiopathic DD/ID in the clinical 
context.    
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General introduction and thesis overview 
 
Genomic imbalances in the genome can occur due to a wide variety of alterations in DNA 
sequences. Alterations in the dosage of a certain genomic portion are currently accepted as an 
appreciable cause of a wide spectrum of diseases. This type of genetic alterations can adopt many 
forms of presentation, ranging from deletions/duplications large enough to be observed by regular 
karyotyping, insertions, multisite rearrangements or microdeletions or microduplications only 
detectable with high resolution techniques 1.  
Many times, and besides the incredible technical advances in the field, the real functional 
significance of some alterations is difficult to evaluate. Many times, inside a copy number variable 
region only a small quantity of alterations turns to be causative of the disease. Furthermore, copy 
number variations can occur at “gene desert” regions of the genome and still indirectly influence 
the expression of other genes 2. 
Several efforts have been taken in order to fully, or at least better understand, the real impact of 
this type of genetic variation in human health and disease. Projects such as The Copy Number 
Variation Project (http://www.sanger.ac.uk/humgen/cnv/) intend to help in the clarification of how 
frequent genomic imbalances really are, their impact in gene expression, mechanism of origin and 
its contribution for evolution, variability, genetic diseases and complex trait disorders. 
Despite the amount of doubts still existing around this type of genetic alteration, its association with 
diseases such as cancer and developmental disorders is currently accepted. We can say that, so 
far, all kinds of genomic imbalances were found to be associated with intellectual disability and that 
at least one type of these alterations were found in each of the human chromosomes 3. 
In this dissertation, the author will review the physiological mechanisms thought to be associated 
with intellectual disability with focus on genomic imbalances as the causative mechanism (chapter 
1), present the experimental work and results regarding the presence of this type of alterations in a 
group of Portuguese patients with idiopathic intellectual disability and a brief discussion of the work 
(chapter 2). 
The results respecting the FISH and MLPA analysis were performed in other laboratory. All the 
data presented in this work regarding the validation of findings by quantitative real time PCR was 
performed by a colleague and, consequently, will be not described in detail in the present thesis.  
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Developmental disabilities 
 
The term “disability” refers, with respect to an individual, to a physical and/or mental impairment 
that substantially limits one or more major life activities 4. Developmental disabilities (DD) are a 
large group of chronic disorders that begin during any step of the development process (including 
conception, birth and growth). These diseases stem from fundamental deficits in the developing 
brain due to several factors (genetic, prenatal, perinatal, metabolic and environmental). Prevention 
and an early diagnosis, as well as intervention, are extremely important to mitigate the personal 
and socioeconomical impact of these disorders 4, 5.  
According to the International Classification of Functioning, Disability and Health of World Health 
Organization, a person is considered to have a development disability if he/she has impairment in 
three key components: (I) body functioning and activity (problems in body structure and functioning 
as a significant deviation or loss); (II) activity (limitations an individual may have in executing 
activities); (III) participation (restrictions an individual may have in dealing with a life situation). 
When these tree main categories are impaired the term disability is used 6.  
When a child is proceeding normally, the development process is considered normal in four 
domains: (I) motor development (fine and gross motor domains); (II) speech and language 
(receptive and expressive domains); (III) social/emotional (combination of other domains such as 
fine-motor adaptative abilities, communication, cognitive), (IV) cognitive development (visual 
perception, problem-solving skills, intellectual abilities). Although not all children achieve the 
predicted milestones at the same time, the manner of progression is predictable in a typical healthy 
child. For example, the generalized reflexes evolve to complex motor patterns for later voluntary 
motor development to be achieved 7-9.  
The rate of development may measured by the development quotient (DQ) 5. This quotient 
measures the progression in a given development domain and it is calculate as follows: DQ = 
developmental age (DA) / chronological age (CA) X 100. Whenever this value is less than 70 a 
significant delay is considered to occur in the child. The intelligence quotient (IQ) is a measure of 
cognitive abilities and it is calculated as follows: IQ = mental age (MA) / chronological age (CA) X 
100. A child is considered to present an atypical development whenever a delay, deviation, 
dissociation or regression is present 5.         
 
Intellectual disability 
 
Intellectual disability (ID) is one of the most frequent and disabling neurological impairments in 
school-age children 8. 
In order to define ID in a child 3 main criteria are necessary: I) significant sub-average general 
intellectual functioning; II) criterium I needs to be accompanied by limitations in adaptative behavior 
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in at last 2 of the following skills: communication, self-care, home living, social/interpersonal skills, 
use of community resources, self-direction, functional academic skills, work, leisure, health and 
safety; III) the onset of the symptoms should be before 18 years 8,13. 
In a more summarized way, general ID can be diagnosed in children below 18 years, with 
compromised general intellectual functioning (defined by IQ below 70) and impairment in 
adaptative behavior (how effectively individuals cope with common life demands). Although the 
observations regarding the adaptative functioning of the child are less objective (since they rely on 
information provided by family, teachers and medical history) they are extremely useful in 
assessing the children and recommended by ICD-10 Classification of Mental and Behavior 
Disorders (World Health Organization) and the DSM-IV Diagnostic Classification (USA) 6. 
According to ICD-10, ID is defined as a “condition of arrested or incomplete development of the 
mind, which is specially characterized by impairment of skills manifested during the developmental 
period, skills which contribute to the overall level of intelligence, i.e. cognition, language, motor and 
social abilities”. ID can be seen alone or together with other mental and/or physical abnormalities 6.  
In the general population IQ in normally distributed around a mean of 100. It is accepted that when 
an individual presents an IQ lower than 70, this person is classified as intellectually handicapped. 
The levels of ID are divided in mild ID (IQ between 50 and 69), moderate (IQ of 35-49), severe (IQ 
of 20-34) and profound (IQ lower than 20) (8,15). The most frequent form of ID are the mild and 
moderate forms that have a frequency of 2-3% in the population, while 0,5%-1% presents severe to 
profound ID 8, 7.    
The different degrees of ID are stipulated by conventionally standardized tests that can be used 
together with scales for assessing social adaptation to the surrounding environment. Depending on 
the severity of ID and of the social rehabilitation of the patient since early life, the ID level of a given 
individual can change over time, although always in a very poor and unextended way 14, 7.  
In table 1.1 are described the expected outcomes for patients with ID according to their IQ level.   
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Table 1.1 - Classification of ID level according to the IQ range, percentage of individuals affected, correspondent mental age in adults and supported needed in daily living activities. 
The predicted adult outcome for the individuals in each group is also described (adapted from 5 - 7).  
Severity 
Level 
% 
Individuals 
with ID 
IQ 
Range 
Equivalent 
MA (as 
adults) 
Support needed in daily living activities Predicted adult outcome 
Mild 85% 50-69 9-12 years 
Intermittent; Support on “as needed” basis, episodic or short 
term. Likely to results in learning difficult in school.  
Many adults will be able to work and maintain good social 
relationships and contribute to society. Reads at 4th-5th grade 
level; able to perform simple multiplications / divisions; writes 
simple letters, lists; completes job applications; basic 
independent job skills (arrive on time, stay at task, interact with 
co-workers); uses public transportation; may qualify for 
recipes. 
Moderate 10% 35-49 6-9 years 
Limited. Consistent over time but time limited. Likely to result in 
marked DD in childhood but most can learn to develop some 
levels of independence in self-care and acquire adequate 
communication and academic skills.  
Adults will need varying degrees of support to live and work in 
the community. Sight-word reading; copies information 
(address); matches written numbers to number of items; 
recognizes time on clock; communicates; some independence 
in self-care; housekeeping with supervision or cue cards; meal 
preparation; can follow picture recipe cards; job skills learned 
with much repetition; uses public transportation with some 
supervision. 
Severe 4% 20-34 3-6 years 
Extensive. Regular, consistent, lifetime support. Regular 
support in at least one aspect such as school, work or home.  
Likely to result in continuous need of support and supervision; 
may communicate wants and needs sometimes with 
augmentation communication techniques. 
Profound 1% <20 <3 years 
Pervasive. High intensity across all environments, lifetime and 
potentially life-sustaining. Results in severe limitations in self-
care, continence, communication and mobility. 
Limitations of self-care; continence; communication and 
mobility; may need complete custodial or nursing care. 
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The severity of ID can be assessed based on a combination of IQ level, adaptative functioning and 
intensity of support needed 5. When the level of ID cannot be reliably assessed but there is a high 
level of confidence based on the clinical observations, the diagnosis of ID can be made without 
specifying the severity of intellectual impairment 6. The differences in the ID prevalence found 
between studies reflect the variation in the definition used, method of assessment and the different 
characteristics of the studied populations. Nevertheless, based on the normal distribution of IQ 
levels in the general population and using two standard deviations below the mean as a cutoff, it is 
predictable that around 2,5% of the population has ID. Among these 2,5%, around 85% of the 
individuals are reported to have mild ID, 10% to have moderate ID, 4% to have severe and 1% to 
have profound ID 6, 7. ID is more frequent in more males than in females. The ratio of males to 
females has been substantiated by numerous studies that arrive to the same conclusion: an 
approximately 30% excess of males being affected by ID 16, 17, 18.   
 
Causes of intellectual disability 
 
The likelihood of identifying a specific etiology increases with the severity of the ID 6. 
The most common form of ID (mild) is mainly associated with environmental risk factors and a 
specific etiology can be identified in less than half of the cases. In contrast, in severe ID, more than 
2/3 of the affected individuals are found to have a biological or neurological etiology 7. The most 
common conditions identified in children with severe ID include genetic imbalances, single gene 
disorders, congenital brain malformations, congenital infections, inborn errors of metabolism and 
birth injury 9, 7. 
According to etiology and severity of ID, children present distinct symptoms and signs. Children 
who have severe ID generally present an earlier symptomatology while children with mild ID are 
only diagnosed at school age. Among the most common signs that parents report to the clinicians 
are the following: the child is late to sit, crawl or walk; is late to learn to talk; has difficulties in 
speech; finds it hard to remember things; has trouble understanding social rules; has trouble 
seeing the results of his/her actions; has trouble solving problems 8, 7.    
Once the ID is suspected by the parents and clinicians, additional clinical history should be 
obtained and a complete physical examination should be performed. By definition, a diagnosis of 
ID requires evaluation by qualified examiners using standardized psychometric instruments. The 
nature of the tests should take into account the mental age of the child and should be culturally 
sensitive. A workup should also include complete audiologic and vision evaluation in all children 8, 7, 
19
. 
Parents are frequently faced with the need to understand and establish an etiology for their child’s 
condition. In about 75% of individuals with severe ID a biological cause can be found. In many 
cases disease-specific features may indicate which tests to order and, if more children are planned, 
genetic counseling and pre-natal diagnosis can be offered to the parents 15, 17 - 18, 20, 21. Adding the 
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fact that associated complications can often be expected, etiologic information may suggest that 
the specific case may be treatable, or allow the development of prevention strategies 5. 
Contribution to the research, early intervention for behavioral problems and help in log-term life 
planning are also factors that contribute to the decision of searching for an etiology of the disease 7, 
8
. 
Some of the known causes of ID include fetal alcohol syndrome, brain malformations, iron 
deficiency, genetic syndromes and several single gene mutations (such as fragile X syndrome and 
tuberous sclerosis) 8, 22. 
When the clinical characteristics don´t allow the suspicion of a syndrome, a workup of genetic 
testing, neuroimagin analysis and metabolic screenings is needed. The yield of these tests in 
dentifying a cause of disease varies depending on the presence or absence of associated 
symptoms and signs. In developed countries, newborn screening programs generally identify 
metabolic errors early after birth and the yield of metabolic testing in a child with ID is lower than 
1%. Neuroimaging approaches to detect abnormalities in brain have yields of 33% to 63% although 
they may or may not be helpful in establishing the cause of ID (many times the findings are seen as 
a consequence rather than a cause) 6. In the genetic testing field, the outcomes are strictly related 
with the extent of the investigation, in which cost is an important limitation 19 . 
 
The importance of a diagnosis 
 
In the Portuguese national public health system, when a child is born a detailed clinical evaluation 
is performed by the obstetrician and then by a pediatrician. Whenever the child is inserted in a 
functional and caring family or environment, development surveillance is performed by the parents 
or other caretakers, teachers and health care professionals (usually the family doctors or 
pediatricians). The observation and summary of the developmental progress of a child has the 
main goal of identification of an individual who may have a developmental problem 20. When a 
suspicion is raised, the child must be evaluated using more structured tests performed by a 
credited health-care professional. The goal is to identify a specific developmental disorder and its 
etiology if possible. If the evaluation performed by the clinician yields suspicion for a developmental 
disorder, a formal and advanced battery of tests is necessary (including neuroimaging, 
electroencephalography and specific laboratory tests for genetic or metabolic alterations). 
Consultations with appropriated medical specialties should also be recommended if necessary 10,7. 
All children with significant developmental delay or regression should also be referred to a more 
detailed evaluation by a clinical psychologist who may propose an intervention plan 21. 
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Pathophysiology 
 
ID is a very heterogeneous group of diseases that can result from genetic and non-genetic 
alterations (maternal intoxication, prematurity, ischemia, infectious diseases). When the intellectual 
limitation is the only manifestation of the disease ID is categorized as non-syndromic. On the other 
hand, when it occurs as one phenotypic feature of a more global clinical presentation, it is called 
syndromic 22. 
The disruption of prenatal and early postnatal brain development can be associated with ID in 
humans 23.  During development, a strict spatiotemporal control of neurogenesis and cell migration 
occurs, and neurons form intricate axonal and denditric connections resulting from both intrinsic 
genetic characteristics and functional cell to cell interactions. Small disruptions in any of these 
processes during development can lead to cognitive dysfunction in children 24, 23.  
 
Cerebral human cortex development: a matter of fine-tuning regulations 
 
 
The mammalian cortex is a remarkably complex organ formed by several different types of 
neurons, oligodendrocytes and glial cells, forming intricate connections with other regions of the 
nervous system 25.   
In mammals, cerebral cortex development is not only a quantitative process. Cortical expansion 
and development requires a series of tightly regulated procedures at the genetic, molecular, 
cellular and anatomic levels 26.  
In the late eighties, two main theoretical hypotheses regarding the human cortical development 
were proposed: the protocortex hypothesis and the protomap hypothesis. The protocortex theory 
stated that at the onset of cortical development, all the cortical neurons had the same potential and 
that their development pattern resulted from external specific stimulations. On the other hand, the 
protomap theory stated that neurons, at their birth at the ventricular zone (a pseudostratified 
neuroepithelium that surrounds the lateral ventricules), already had the genetic instructions 
required to correctly migrate, connect and establish their final place at the developed cortex. This 
model also states that the correct road of each neuron is find through their recognition of secreted 
molecular patterns that acts like “maps” for the guidance of the neuron (protomap) 25, 26. Currently, 
the protocortex and protomap hypotheses of cortical development are not seen anymore as 
alternative and mutually exclusive, instead they are increasingly being viewed as complementary 
aspects of a single mechanism 27.   
Many times disorders of the cerebral cortex, cortical dysgenesis (CD), are associated with 
intellectual disability, autism, schizophrenia, epilepsy and focal or widespread neurological deficits 
28
. Currently it is known that external injuries (chemical or physical) during embryonic development 
can affect the development by deregulating molecular patterns at crucial time points. 
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Cortical malformations may arise in isolation, together with other brain malformations or occur as a 
component of a generalized malformation syndrome. The cerebral cortex is the outer layer of the 
brain and is a complex laminated structure composed of six organized layers of neurons, nerve 
fibers and supporting cells. During development, the brain transforms from a smooth hollow tube to 
a complex organ with a surface full of folds (gyri) and fissures (sulci) 26, 27. The neurons present in 
the cortical layer are not born there, but instead are generated from neuronal precursors in the 
germinal zone. As a consequence, they have to migrate along specialized radial-glial cells to their 
final destination. It is currently believe that this complex process is genetically regulated (protomap 
theory) and that even the smallest deregulation may result in significant cortical malformations and 
account for the ID phenotype in many patients 30.   
It is currently accepted that the classification of cortical developmental abnormalities should take 
into account pathological, genetic and neuroimaging features during the three main stages of 
cortical development: neuronal proliferation, growth and differentiation (neurogenesis), neuronal 
migration and cortical maturation and folding (organization). Whenever damage occurs in one of 
these 3 steps of cortical development, a malformation will occur 31 .  
 
Malformations associated with abnormal neurogenesis 
 
During embryonic development, the first formed neurons arise from two different daughter cells: 
one daughter cell gives rise to a neuron that will migrate to the cortex, while the other daughter cell 
continues to proliferate as a stem cell or dies 24. Nowadays it is known that, although in the cerebral 
hemispheres the majority of neurogenesis occurs in the first half of gestation, neurogenesis also 
occurs in the olfactory bulb, sub-ventricular zone and hippocampus in adults 24, 27.  
Excess or defects in germinal epithelial proliferation can lead to macro- or microcephaly. This 
classification enrolls a heterogeneous group of disorders that can be de novo or familial, often 
associated with an increase incidence of cognitive impairments 24, 32.     
Regarding the malformations associated with alterations in neuronal proliferation, they can be 
divided in microcephaly, megalencephaly, hemimegalencephaly and cortical dysplasia. 
  
Microcephaly (MCPH) is characterized by a reduced frontal-occipital head circumference (FOC), 
more than 3 standard deviations below the mean of age and sex-matched controls 25. MCPH can 
be classified as primary or secondary (acquired). Patients with primary MCPH usually display small 
but architecturally normal brains or with mildly simplified gyral patterns, and have mild ID. This for 
or MCPH is distinct from holoprosencephaly and lissencephaly, two forms of microcephaly 
associated with cortical malformations 33, 34. In secondary MCPH the cause in presumed to be 
traumatic, in primary MCPH the cause is genetic and heterogeneous 33, 25. Mutations in several 
genes have been identified in primary MCPH, all of them associated with cell division and cell cycle 
regulation 34. In figure 1.1 is represented a scheme for the different types of microcephaly. 
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Megalencephaly refers to an abnormal large head (macrocephaly) due to the enlargement of the 
brain parenchyma. This condition is also related with disturbances in cell proliferation. Non-
syndromic macrocephaly refers to a condition in which the brain enlargement is the predominant 
abnormality and not associated with any other physical alterations. Minor craniofacial changes can 
be present but they are a consequence of the enlarged cranial cavity 36. The classification of 
syndromic megalencephaly is used when a large brain size is associated with other significant 
physical and behavior abnormalities. Syndromic megalencephaly should also be distinguished from 
other genetic syndromes in which an enlarged brain size is an occasional but not consistent finding 
(autism, Fragile X Syndrome and Sotos syndrome, for instance) 31, 36.     
 
Hemimegalencephaly is the classification attributed to the enlargement of only one hemisphere. 
Histopathologicaly presents similar features to the ones of cortical dysplasia, with the difference 
that is located in one side of the brain specifically.  Refractory epilepsy, hemiparesis and ID are 
common clinical findings among hemimegalencephaly patients and not megalencephaly 31. 
Hemimegalencephaly has been observed in patients with tuberous sclerosis complex, 
Neurofibromatosis type I and linear epidermal nevus syndrome 34, 36.  
 
Cortical dysplasia is characterized by the disturbance of the cortical lamination and the term is 
applied to focal areas of cortical malformations in which neuronal orientation is disrupted 34. In this 
type of malformations dysmorphic neurons are seen; these may be undifferentiated balloon-shaped 
cells or giant cells, both resulting from abnormal regulation of cell growth 34. Cortical dysplasia is 
recognized as the major cause of intractable epilepsy in childhood and the second most common 
etiology in adult epilepsy patients recommended for surgery 31.  
 
Malformations associated with abnormal neuronal migration 
 
After neurogenesis, postmitotic neurons are organized in columns and migrate away from the 
ventricular zone in a radial pattern 24. Neuronal migration consists in the movement of those 
A B C D 
Figure 1.1 – Schematic representation of microcephalic brains. (A) Normal brain; (B) 
microcephalic brain with conserved architecture; (C) microcephalic brain with a simplified gyral 
pattern; (D) microlissencephalic brain. Adapted from 34. 
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postmitotic neurons from the ventricular zone to their final destination in the cerebral cortex 37. The 
strict regulation of the migration pattern and timing is essential for the correct development and 
functioning of the intellectual functioning in an individual 30.  
Neuronal migration disorders are a heterogeneous group of disorders of the nervous system 
development and are considered one of the most common causes of neurologic, development and 
epileptic seizures in childhood 28, 37. This category of disorders includes lissencephaly and 
heterotopia.  
Lissencephaly (which literally means “smooth brain”) refers to the occurrence of a smoother brain 
surface without gyri or sulci and it is associated with severe ID and refractory epilepsy. In some 
cases it is possible to observe, in the same patient, brain region without gyri (agyria) and brain 
regions with broad and large gyri (pachygyria) 31, 34. At least five distinct types of lissencephaly 
exist: type I lissencephaly (also known as classic), type II lissencephaly (also called Cobblestone 
lissencephaly), lissencephaly X-linked with agenesis of the corpus callosum (XLAG), lissencephaly 
with cerebellar hypoplasia (LCH) and microlissencephaly 34. A schematic representation of a 
lissencephalic brain is presented in figure 1.2.  
 
 
 
 
 
 
 
 
 
Classic lissencephaly causes a combination of agyria and pachygyria and presents a poorly 
structured cortex with only four immature layers instead of the six fully organized layers present in 
the well-developed brain. The cortex is extremely thick as well as the underlying white matter that, 
sometimes, can contain single neurons or small heterotopias 36, 32.  
Cobblestone lissencephaly (or type II lissencephaly) is a complex brain malformation characterized 
by global disorganization of cerebral organogenesis 38. In this form of lissencephaly the surface of 
the cortex is not necessarily smooth but, instead, frequently shows a broad smooth paving that 
looks like cobblestones. As in type I lissencephaly, the cortex layer is thickened with no 
recognizable layers. However, in this type of lissencephaly the ratio of cortex to white matter in 
approximately 1:1 (similar to the one present in the normal adult brain) and not 4:1 as in 
lissencephaly type I 32.  
X-linked lissencephaly with agenesis of corpus callosum (XLAG) includes thickened cortex with 
gyral malformations that are more severe in the posterior than anterior brain regions together with 
agenesis of corpus callosum and ambiguous genitalia 38.    
Figure 1.2 – Schematic representation of a lissencephalic brain (B) and normal brain (A) (adapted from 38). 
A B 
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Lissencephaly with cerebellar hypoplasia (LCH) is the term adopted to classify the type of 
lissencephaly that is not included in either classic or cobblestone type. It is characterized by 
cerebellar underdevelopment ranging from vermian hypoplasia to total aplasia 37, 38.  
Microlissencephaly is characterized by the presence of a severe microcephaly in the patients and it 
is caused by an abnormal proliferation together with a defect in neuronal migration 38. A summary 
of the genes known to be associated with each type of lissencephaly as well as the syndromes 
commonly presenting each type is present in table 1.2. 
 
Table 1.2 - Classification of lissencephalies, syndromes and genes associated (adapted from 38). 
Type of Lyssencephaly Associated syndrome Genes involved 
Type I Lissencephaly 
• Isolated lissencephaly sequence 
• Miller-Dieker syndrome 
• LIS1, DCX, TUBA1A 
• LIS1 and YHAWAE 
deletion 
Cobblestone Lissencephaly 
• Walker-Warburg syndrome 
• Muscle-Eye-Brain disease 
• Fukuyama congenital muscular 
dystrophy 
• POMT1, POMT2. FKTN, 
FKRP, LARGE 
• POMGnT1 
• FKTN 
Lissencephaly X-Linked with 
agenesis of corpus callosum 
(XLAG) 
• Lissencephaly • ARX 
Lissencephaly with 
cerebellar hypoplasia (LCH) • Lissencephaly • RELN, VLDLR 
Microlissencephaly 
• Norman-Roberts syndrome 
• Barth syndrome 
• Primordial osteodysplastic 
dwarfism and microcephaly 
(MOPD type 1) 
• Not described 
  
 
 
Heterotopia is a neuronal migration disorder characterized by the collection of grey matter in 
inappropriate places. There are three main groups of heterotopia: periventricular (the most frequent 
form), subcortical and leptomeningeal 30, 32.   
Subcortical band heterotopia (or double cortex) (figure 1.3) refers to the occurrence of a second 
cortex layer. In this pathology bands of gray matter are interposed with bands of white matter 
between the cortex and the lateral ventricles 28, 30. In other forms of heterotopias (that are not band 
heterotopia), neuronal migration is only affected in subsets of neurons along the cortex. These 
alterations may be found in patients with ID varying from mild to severe 31. 
 
 13 
 
 
 
 
 
 
 
 
 
 
 
Malformations associated with abnormal cortical organization   
 
When neurons finally reach their destination in the cortex, it is necessary that they both send axons 
and receive dendrites and synapses with other neurons 25. Maturation of the cortex includes not 
only the establishment of intercellular connections but also the acquisition of a population of glial 
cells in order to unpack the closely arranged immature neurons 34. Cortical neurons also maturate 
in a specific phenotype thought the production of appropriate neurotransmitters and receptors. 
Similar to the previous stages of cortical development, in this phase there is a balanced molecular 
regulation where cells must be able to receive afferent connections, target efferent pathways and 
develop specialized synaptic connections. Therefore, any disturbance in synaptogenesis, either by 
a delaying in the onset or by preventing the formation of the necessary number of synapses, can 
have a dramatic effect in the future cognitive function of an individual 24, 34.         
Polymicrogyria is a cortical malformation characterized by an irregular brain surface with an 
excessive number of small and partly fused gyri separated by shallow sulci. Two types of 
polymicrogyria can be identified histopatologically: simplified four-layered form (layer of intracortical 
laminar necrosis with alterations of late migration and postmigration disruption of cortical 
organization) and an unlayered form (the molecular layer is continuous and does not follow the 
borders of convolutions. Polymicrogyria can also be focal or diffused, bilateral or unilateral 36. In 
this type of malformation, convolutions and the neurons below have radial distribution while laminar 
organization is absent) 28, 29, 30. Because of its heterogeneity polymicrogyria has unknown 
incidence. Almost all the children with polymicrogyria have a high risk of developing epilepsy. 
Among other characteristics are global development, motor and language delay, and mild to 
moderate ID 36.  
 
Schizencephaly is one of the most common cortical malformations (prevalence of 1.5/100 000 
newborns) and occurs when a deep vascular insult reaches the white matter and sometimes even 
reaches the ventricle, leading to the formation of a fissure 31, 34. The cleft spans the cerebral 
hemisphere from the pial surface to the lateral ventricle and lined by cortical gray matter. Cleft 
Figure 1.3 – Schematic representation of subcortical laminar heterotopia. A normal brain (A)
and a brain with subcortical heterotopia (B) where it is possible to see a second layer of grey matter 
(adapted from 37).  
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organization varies widely but the perisylvian region is more frequently involved 37. In patients, the 
extent of the malformation correlates with the severity of the clinical manifestation either in the 
cognition and motor areas. When the fissure is open, patients have mild to moderate ID and 
hemiparesis; patients with bilateral fissures present severe ID and severe motor abnormalities such 
as quadriparesis.  Several types of seizures have been reported in patients with schizencephaly, 
such as tonic-clonic, partial motor and sensorial seizures, being usually resistant to medical 
therapy 34, 37.  
       
Synaptogenesis  
 
The points of contact that allow exchange of information between neurons are called synapses. 
The synapse is the most fundamental mean of transmission in the nervous system and can be 
divided in two types: electrical or chemical. Electrical synapses are less common than chemical 
synapses in the brain and occur by means of current flow through gap junctions that connect the 
cytoplasm of pre- and postsynaptic cells. This type of transmission is an extremely rapid process 39.    
The chemical synapse represents a specialized functional and morphological structure where a 
presynaptic neuron communicates with a postsynaptic one. For most neurons, in a chemical 
synapse a set of small molecules (called neurotransmitters) mediate information transfer between 
neurons. The presynaptic neuron is responsible for the controlled release of neurotransmitters that 
bind and activate specific receptors proteins located in the pre and postsynaptic membranes, 
triggering the opening of ion channels and activation of signaling cascades 40. The process that 
determines how, when, were and with who a synapse will be established is called synaptogenesis.  
During brain development, when neurons arrive at the cortical layer they start to extend apical and 
basilar dendrites followed by oblique branches of the apical dendrite. Synapses appear in the 
human cerebral cortex in the third month of gestation development. The number of synapses 
increases during the following months together with the elaboration of the dendritic spines and the 
specificity of synaptic connections appears to be determined by molecular clues 24. The number of 
cortical synapses increases until eight months of life in the striatum and until 24 months of life in 
the cortex. The specificity of the synaptic connections is determined by molecular clues and the 
existing molecules in the neuronal surface and surrounding area determine the linking of axons to 
specific neurons by chemoaffinity 24. Moreover, several factors secreted by neurons and glial cells 
and cell-adhesion molecules (CAMs) are involved in the stimulation of axon growth and guidance. 
Synaptogenesis requires the activation of genes coding for synaptic proteins as well as elements 
involved in vesicle formation, accumulation and trafficking of proteins complexes involved in both 
pre and postsynaptic levels 20. We can even compare the process of forming a new synapse with 
the guidance patterns seen in the neuronal migration process from the ventricular zone to the 
cortex: it involves coordinated cell morphologic and structures changes, intracellular signaling 
cascades and protein complexes remodeling; all these processes don´t occur in an isolated form 
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and there are also cell intrinsic determining factors that contribute to the pre-establishment of long 
before the arrival of the axon to the synaptic site, as well as to the prohibit formation of 
inappropriate synapses 40. Additionally, there is a period that follows the synaptic overgrowth where 
a massive pruning of synaptic connections occurs 41. Even though it is amazing how the 
destruction of such a massive amount of synapses doesn´t have a negative effect in brain function, 
this mechanism is indeed essential for the correct establishment of functional and fully developed 
memory mechanisms through the elimination of weaker synapses 42.      
 
Axon guidance and synapse formation 
 
The correct target of axons to their final destination is an essential process of the correct neuronal 
network formation. Axon guidance requires the action of receptor proteins located in the surface of 
the growth cone and proteins located in the cell surface of cells found in the migration pathway of 
the target field 40. The creation of a connection between the ligand and receptors molecules of the 
growth cone and target field molecules, usually targets the activation of signaling cascades that 
induce complex cell morphological changes in the axon growth cone, making it move forward 
(attraction) or away from (repulsion) the guidance molecular clue, either by contact (contact 
attraction and repulsion) or by chemical signaling (chemical attraction and repulsion) 43. The 
morphological changes required for the migration of the axon, as well as for the formation and 
plasticity of dendritic spines, are mediated by the correct assembly and disassembly of the F-actin 
cytoskeleton 44.  In axon growth, the rapid extension and retraction of F-actin cytoskeleton is 
mediated by the search for local molecular clues. However, protrusions arrive from the dendritic 
shafts and “evaluate” the surrounding space in order to search for presynaptic axons “willing” to 
establish a synaptic 40. An illustrative picture scheme of the processes described above is 
presented in figure 1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Schematic representation of an initial stage 
of synaptic formation. In yellow is represented an axon 
and in blue a nearby dendrite. These two cells interact via 
cell-to-cell contacts through collateral axon branches and 
dendritic filopodial extensions. In some regions of the axon 
may happen that there are pre-established synaptic 
specialization regions that mark the location of a future 
synapse. Whenever a stable contact is established proteins, 
vesicles and ion channels both at presynaptic and 
postsynaptic sites are recruited to the synaptic site in order 
to mature and definitely establish a functional synapse
(adapted from 40).     
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After the establishment of synapses there is a period of synaptic rearrangements that has a 
fundamental role in the future normal neural functioning. During this period, weaker connections 
are eliminated while the stronger ones are reinforced trough competition for trophic substances. A 
series of synaptic rearrangements occur as a response to neuronal activity. The most ilustractive 
case is the developing of the visual cortex. In this area of the cortex, cells from layer IV are 
arranged in ocular dominant columns.  If the normal pattern of neural activity is interrupted during 
this crucial period in the first few months of life by closing one eye, the inputs into the mature cortex 
are permanently altered, resulting in abnormal binocular vision and decreased acuity for the rest of 
life.  However, if the eye is closed after this critical period, no damage is created in the adult visual 
cortex activity 24. These findings support the idea that the development of connections at neuronal 
level accommodates inputs from a combination of spontaneously generated and experience-
dependent events 20. All these structural rearrangements that occur during cortex maturation seem 
to be related with the balance between excitatory and inhibitory neurotransmission as well as with 
activity-dependent forms of synaptic plasticity such as long-term depression (LTD) and long-term 
potentiation (LTP). Mechanisms involved in the transformation of translating activities into structural 
relevant changes are also considered to play a role in the establishment of synapses during 
development. One of the proposed mechanisms is the local release of neurotrophins such as 
BDNF (Brain Derived Neurorophic Factor) that may have a role in controlling neuronal survival and 
differentiation 20. 
Besides the general proposed mechanisms of synaptogenesis, it is currently known that different 
synapse types have different formation and plasticity mechanisms. The most extensively studied 
cases are the formation of the cholinergic neuromuscular junction synapses and the glutamatergic 
axo-dendritic synapse 40.  
In the basis of learning and memory is the information storage in the brain by strengthening or 
weakening already existing synapses by creating or eliminating dendritic spines, which leads to the 
formation of elimination of synaptic sites 44.      
 
Axon growth and synapse stabilization – the role of the cytoskeleton 
 
Axon guidance and synaptic maturation involve partially similar processes and shared molecular 
elements. During axon elongation, actin filaments move towards areas of attraction, signaled by 
molecules that not only regulate the straight movement of the axon but also condition the turning of 
the axons. On the other hand, synapse formation involves the transformation of an undifferentiated 
region of the presynaptic plasma membrane into a highly specialized complex 40. 
Dendritic filopodia are dynamic protrusions that are thought to play an active role in synaptogenesis 
and serve as precursors to spine synapses. These structures cover the dendritic space, increase 
the probability that this dendritic region will interact with an axon and increase the number of 
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synapses formed. Indeed, filopodial motility is an essential aspect of the complex process of 
synapse creation and facilitates proper synapse density 45.   
Once a synaptic site is determined, a complex chain of molecular partners must be recruited in 
order to form a stable and efficient synapse. At the presynaptic level, synaptic vesicles, 
transmembrane receptors, ion channels, vesicle docking and mitochondrial proteins are allocated, 
while at the postsynaptic region, signaling proteins, ion channels, scaffolding proteins and 
translational machinery are recruited 40.       
 
BDNF/ TrkB 
 
BDNF and its receptor, tropomycin-related kinase B (TrkB), are important molecules for axon 
guidance, synapse formation and plasticity46. At the early stages of synaptogenesis, these two 
molecules play an important role in the determination of dendritic spine density and morphology in 
a variety of neuron types, as well as in the determination of the synapse number. This pathway is 
thoughy to regulate synapse number in early development by stimulating filopodial motility.  At 
more developed and mature synapses, BDNF/ TrkB signaling pathway function is more restricted 
to the regulation of synapse morphology and plasticity 40.   
 
Ephrins and Ephs 
 
Ephrins are cell-surface expressed molecules recognized by Eph receptors. Together, these two 
types of molecules play a crucial role in guidance of pathfinding axons 47. The ephrin receptor 
EphB2 (EphB2) is required not only for filopodial motility and increased frequency of axon-dendritic 
contacts, but also for stabilization of synaptic contacts trough cell to cell adhesion mechanisms. 
EphB2 has an extracellular domain function that may function as a contact stabilizing protein. In 
fact, the extracellular domain of EphB2 recruits NMDA receptors and is implicate in dendritic 
formation and increased number of synapses. Also, Ephrins and Ephs seem to be related with 
presynaptic maturation and development as well. In summary, Ephrins and Ephs are currently 
associated with synapse formation either by regulation of cell to cell adhesions, activation of 
cytoskeleton, recruitment of proteins and signaling activation 47.  
 
Wnts 
 
The WNT signaling members are a family of highly conserved developmental control genes that 
play important roles in embryonic development as well as in neuronal development and plasticity in 
the nervous system. At least two Wnt proteins have been associated with functions at synaptic 
levels - Wnt-7a and Wnt-5a. Wnt-7a stimulates presynaptic protein clustering and facilitates 
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neurotransmitter release while wnt-5a modulates glutamatergic synaptic transmission trough a 
postsynaptic mechanism 40, 48. 
  
Semaphorins, Neuropilins and Plexins 
 
Semaphorins are a large family of highly conserved proteins that play a crucial role in axon 
guidance during synaptogenesis. Neuropilins and plexins are transmembrane proteins that, for 
being semaphorin receptors, are also involved in neuronal development 49.  
So far, there are 3 main semaphorin classes involved in synaptic development: class 3 
semaphorins (which promote axonal repulsion or attraction), class 4 semaphorins (regulators of 
synaptogenesis) and class 5 semaphorins (which regulate synaptic density). Animal models lacking 
semaphorins, neuropilins and plexins have altered patterns of spine density and sizes. These 
proteins are thought to re related neurodevelopmental disorders, such as intellectual disability 40, 49.        
 
NOGO Receptor 
 
NOGO molecules constitute a group of myelin-associated inhibitors that don´t belong to any of the 
known families of axon guidance molecules. NOGO ligands or receptors were originally described 
for their function in blocking axon outgrowth after spinal cord injury but were recently associated 
with hyppocampal synaptic plasticity 50.  
In a mouse model, it was described that nogo-66 receptor 1 (NgR1) interacts with fibroblast growth 
factor 1 and 2 (FGF1 and FGF2, respectively) and that, whenever deregulated, NgR1 inhibits 
FGF2-elicited axonal branching. Loss of NgR1 results in altered spine morphology along apical 
dendrites in hippocampus 50, 40.  
  
Synapse structure and function 
 
Chemical synapses regulate the electrical communication within neurons and pass information 
from presynaptic axon terminals to postsynaptic dendritic regions.  Most excitatory synapses in the 
brain are formed at tiny dendritic protrusions called dendritic spines 44.  
The molecular architecture of chemical synapses consists of pre-synaptic axon terminals harboring 
synaptic vesicles and a post-synaptic region (on dendrites) containing neurotransmitter receptors. 
The presynaptic and postsynaptic sites are separated by the synaptic cleft (10 to 25 nm) and a 
variety of cell adhesion molecules hold them together at the proper distance 28, 11.  
On the presynaptic region neurotransmitters, such as glutamate or ɣ - aminobutyric acid (GABA), 
are produced and stored in synaptic vesicles at the presynaptic terminals. When a nerve impulse 
travels through the axon of the presynaptic neuron, it cannot cross the synaptic cleft in order to 
communicate with the next neuron 52. A regulated exocytosis pathway is necessary for synaptic 
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vesicles to make contact with the plasma membrane, where vesicle fusion and exocytosis of the 
neurotransmitter occur. The vesicles of this pathway undergo exocytosis only in response to a 
particular stimulus, such as an increase in calcium ion concentration 29, 30. The docking and fusion 
of the vesicles of the membrane is controlled by the soluble N–ethylmalei–mide–sensitive factor 
attachment protein receptor (SNARE) complex. Many other presynaptic proteins play a role not 
only in synaptic vesicle fusion but also in other steps of synaptic vesicle trafficking such as 
targeting, docking and priming 53.  
Information about the mechanisms of synaptic vesicle docking and fusion are the key to 
understand synaptic transmission itself and also to discover the transmission modifications that 
may play a role in synaptic plasticity, learning and memory 54. 
In the postsynaptic structures, the dendritic spines, is located the postsynaptic machinery. This 
includes a series of neurotransmitter receptors (glutamate receptors), postsynaptic density (PSD), 
actin cytoskeleton and a wide variety of membrane-bound organelles (mitochondria, endoplasmatic 
reticulum and endosomes). There are two types of postsynaptic receptors that recognize 
neurotransmitters: (I) ionotropic receptors that are ligand-gated ion channels (AMPA-type [amino-3-
hydroxyl-5-methyl-4-isoxazolepropionic acid] and (II) NMDA-type [N-methyl-D-aspartate], that lead 
to excitatory synapse transmission. An inhibitory synapse is present when an interaction between 
GABA and GABAA receptors allows an influx of negatively charged chloride ions. Precise 
mechanisms must exist to maintain the balance between the excitatory and inhibitory synapses (E/I 
balance). The presence of the postsynaptic density (PSD) is characteristic of excitatory synapses. 
Glutamate receptors and PSD proteins play an important role in excitatory synaptic plasticity 52.  
Numerous regulatory pathways have been found to participate in an ever-growing signaling 
pathway network in dendritic spines. 
 
Dendritic spine morphology and neuronal plasticity 
 
Dendritic spines are small protrusions that receive input from a single excitatory presynaptic 
terminal. Spine density varies with the type of neuron where it is located, but in the majority of 
neurons they occur at a density of 1-10 spines per micrometer of dendritic length 44.   
Dendrites of neurons are covered by small protrusions known as dendritic spines. These structures 
are the main site of synaptic input in neurons and neurotransmitter receptors (localized to the 
surface of dendritic spines in the PSD). The classical structure of a spine consists of a head that is 
connected to the dendritic shaft by a narrow neck and can be divided in three different basic 
compartments: (I) a delta-shaped base at the junction with the dendritic shaft, (II) a constricted 
neck and (III) a bulbous head that contacts with the axon. In addition to this general morphology, 
there are several categories of spines based on their shape and size: thin (filodopia-like 
protrusions), stubby (short spines without a well-defined neck) and mushroom shaped (spines with 
a large bulbous head) 44, 45. One interesting finding about dendritic spines is that they are not static 
 20 
 
in time, but change their morphology continuously even in adulthood.  The shape of the spines is 
strongly related with maturity of the synaptic connection and it is currently though that spines don´t 
present the same shape throughout their entire life, but instead, there is a continuum change of 
shape between the categories related above (11,35,38). The size of the spine head is related with 
the size of the PSD; for instance, mushroom shaped spines have larger and more complex PSDs 
with a higher density of glutamate receptors. Genes that encode factors involved in spine structure 
and organization have been found to be altered in several brain diseases 52.  Adjacent to the PSD 
is a region specialized in the endocytosis of postsynaptic receptors. The main function of this 
region is to capture and recycle the synaptic pool of mobile AMPA-type glutamate receptors 
required for synaptic potentiation 44.      
Independently of the factor(s) that contributed to the disease, abnormalities in dendritic spine 
structures and morphology are often associated with ID 56.  
 
Cytoskeleton organization in dendritic spines 
 
Since the structure and dynamics of dendritic spines are determined by the underlying 
cytoskeleton, mutations in genes involved in the organization of these structures could be the 
cause of the ID phenotype in patients. The actin cytoskeleton, which controls neuronal connectivity 
and synaptic function, is crucial for morphological differentiation, cell polarity, neurite outgrowth, 
dendritic morphology, synapse formation, synapse plasticity and protein transport 26,29,31. The 
structure of dendritic spines achieved during brain development is essential for the function of 
mature synapses as well as for the formation of new ones. When an excitatory transmission 
occurs, the actin network mediates structural changes in dendritic spines 53. 
It is currently assumed that there is a strong relation between spine morphology, synapse strength 
and the actin cytoskeleton. The volume enlargement seen in dendritic spines during long LTP and 
the decrease during LTD is an activity-dependent spine structural plasticity caused by 
reorganization of the actin cytoskeleton. Additionally, an ever increasing number of ID-associated 
genes have been described many of which are components or somehow related with actin 
remodeling and cytoskeleton organization 57.  The function of actin filaments in developed 
synapses is to stabilize postsynaptic proteins and modulate spine head structure in response to 
signaling. A network of long and short branching actin filaments is present in the spine neck, while 
a series of short branched filaments are localized on the spine head just underneath the PSD 44.  
Actin filaments are polar structures that grow more rapidly in one end (barbed end) than in the 
other (pointed end). In the migrating cell, the barbed end pushes the cell membrane and inducing 
changes in the shape of the cell that look like filament extensions. In the spine head, a branched 
actin filament network and capping proteins are present in great amount. In the spine neck and 
base, there is an actin network composed by the combination of branched and intersecting linear 
filaments 57.               
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The first cytoskeleton genes to be associated with ID were members of the Rho GTPase pathway, 
frequently associated with the cytoskeletal regulation. Rho GTPases are guanine-nucleotide-
binding proteins that act as recycling molecules, switching between an active GTP-bound and an 
inactive GDP-bound state. The proteins belonging to this cascade are best known for their effects 
on the actin cytoskeleton and microtubule organization 58. Rho GTPases include Ras homologous 
member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1)) and cell division cycle 42 
(Cdc42). Studies in several animal models have revealed the implication of these Rho GTPases in 
dendritic and spine growth and morphogenesis. RhoA, Rac1 and Cdc42 regulate microtubule 
growth and stabilization, actin polymerization and assembly, myosin contractibility and local protein 
translation through interaction with FMRP protein 20.   
Table 1.3 lists the most widely studied genes from the Rho GTPase pathway associated with ID or 
ID-related syndromes.  
 
Table 1.3 - Rho GTPase pathway associated genes involved in ID or ID-related phenotypes (adapted from 58, 20. 
Gene Locus Protein Function 
Associated 
phenotype 
Reference 
OPHN1 Xq12 
Oligophrenin-
1 
OPHN1 protein negatively regulates 
RhoA, Rac1 and Cdcc42 
ID 
58
 
PAK3 Xq22 PAK3 
PAK3 protein mediates Cdc42 and 
Rac1 effects on the cytoskeleton 
ID 
ARHGEF6 Xq26 ARHGEF6 
ARHGEF6 protein interact with PAK 
kinases and is essential for spine 
morphogenesis 
ID 
MEGAP 3p25 MEGAP 
MEGAP  is a GTPase activating protein 
that acts  towards both Rac1 and 
Cdc42 
3p deletion 
syndrome 
LIMK1 7q11 LIMK1 LIMK1 is a Ser/Thr kinase acting 
downstream of Rac1/Cdc42 
Williams syndrome 
   
 
Presynaptic vesicle cycling  
 
The electric signal that is travelling in a neuron is not able to cross the synaptic cleft by itself. As a 
consequence, the signal translation is carried by neurotransmitters that are transported by synaptic 
vesicles. These structures make contact and merge with the presynaptic plasma membrane, where 
the fusion and exocytosis occurs 52. Even though a large catalog of proteins known to be involved 
in vesicle synthesis, targeting, mobilization, fusion and recycling already exists, there is still a large 
lack of information regarding the exact mechanisms by which synaptic vesicles are regulated. In 
the centerpiece of these hypothesis is the SNARE-mediated membrane fusion and the proteins 
associated with remodeling and assembly of the SNARE complex 53.  
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The essence of neurotransmission relies on the fusion of the vesicle and plasma membranes. The 
neuronal SNARE proteins VAMP2 (vesicle associated membrane protein 2), syntaxin 1 and SNAP-
25 (synaptosome-associated protein of 25 kDa) are essential for membrane fusion 53. 
Polymorphisms in SNAP25 gene have been associated with attention deficit and hyperactivity 
disorder (Feng et al, 2005). STXBP1 (syntaxin-binding protein 1) is the human homologous of rat 
n-Sec1 gene. This gene is a neuronal specific syntaxin-binding protein that plays a role in in the 
regulation of synaptic vesicle docking and fusion. STXBP1 is also a regulatory protein of VAMP2, 
syntaxin 1 and SNAP-25 proteins. Mutations in STXBP1 gene were found in patients with 
autosomal dominant ID and epilepsy 59.  
The trafficking cycle of synaptic vesicles is regulated by Rab GTPase activity. Three major proteins 
involved in this process have been associated with ID: the GDI1 (GDP dissociation inhibitor-1 
gene), that regulates the GDP-GTP exchange reaction of members of the rab family, the IL1RAPL 
(interleukin 1 receptor accessory protein-like 1) that interacts with neuronal calcium sensor-1 
(NCS1) through its specific C-terminal domain and plays a role in the regulation of calcium-
dependent exocytosis and RAB3GAP1 (RAB3 GTPase-activating protein, catalytic subunit) that 
specifically converts active RAB3-GTP to the inactive form RAB3-GDP and regulate glutamate 
release 20, 60, 61. 
More recently, mutations in genes encoding components of the synaptic vesicle or elements 
necessary for its formation were found in ID or ID associated syndromes. In 2004, mutations in 
synapsin 1 gene (SYN1) gene, a neuronal phosphoprotein associated with the membranes of small 
synaptic vesicles, were found in members of families with epilepsy and variable learning disabilities 
and behavioural disorders62. SLC6A8 (solute carrier family 6, neurotransmitter and creatine 
transporter, member 8) gene has also been associated with X-linked ID with high levels of creatine 
in urine. Creatine transport has important roles in the maintenance of energy supply to the cell and 
resonance spectroscopic imaging studies in ID patients showed absence of creatine in the whole 
brain 63, 64. SAP102 (synapse associated protein 102), also known as DLG3, belongs to the 
subfamily of the membrane-associated guanylate kinase (MAGUK) protein family and is an 
important component of specialized cell junctions. Mutations in in the human DLG3 gene were 
found in families with moderate to severe X-linked ID 65. 
 
Organization of postsynaptic protein complexes and cell adhesion molecules 
 
Cell adhesion molecules (CAM) such as neurexins (NRXNs) and neuroligins (NLGNs) are involved 
in the formation of functional presynaptic regions specialized in vesicle fusion to the plasma 
membrane and correct release of the neurotransmitters to the synaptic cleft. NRXNs are 
presynaptic receptors while NLGNs are the ligands of NRXNs located in the postsynaptic side 52, 20. 
Both these molecules are thought to be crucial for synapse maturation but not for their initial 
development. Mutations in NLGN4 (neuroligin 4) gene were found in patients with ID and/or ASD. 
NLGN4 is involved in formation of active regions at presynaptic terminals through interactions with 
 23 
 
its presynaptic receptor β-neurexin 20. More recently, mutations in neurexin 1 and 2 were described 
in patients with ASD and schizophrenia 66.    
During postsynaptic differentiation a series of scaffolding proteins of the membrane-associated 
guanylate kinase (MAGUK) family are required. Among these, we can refer PSD95 (postsynaptic 
density 95, also known as DLG4) and SAP102, that are required for recruitment of NMDAR. SAP97 
(synapse-associated protein 97, also known as DLG1) is required for the recruitment of AMPAr. 
MAGUKs play a role in the determination of the number of glutamate receptors at the synapse as 
well as the synaptic trafficking of these receptors during the morphological changes that are related 
with synapse plasticity 20. One of the genes from this group of proteins involved in ID is the AMPAr 
subunit GluR3 (glutamate receptor 3) that was found to be mutated in X-linked ID 67.     
Shank proteins are multidomain scaffold proteins of the postsynaptic density, connecting 
neurotransmitter receptors and other membrane proteins with signaling proteins and the actin 
cytoskeleton. By virtue of their protein interactions, Shank proteins assemble signaling platforms for 
G-protein-mediated signaling and the control of calcium homeostasis in dendritic spines. In 
addition, they participate in morphological changes, leading to maturation of dendritic spines and 
synapse formation. The importance of the Shank scaffolding function is demonstrated by 
genetically determined forms of ID, which may be caused by haploinsufficiency for the SHANK3 
(SH3 and multiple ankyrin repeat domains 3) gene and SHANK2 (SH3 and multiple ankyrin repeat 
domains 2) in which copy number variations were recently described to be associated with ID and 
ASD 20, 68, 69. 
 
Transcription regulation 
 
Several ID disorders result from mutations in genes encoding regulators of signal transduction 
pathways, transcription factors and cofactors involved in chromatin remodeling, gene expression 
and protein maturation 20. The synthesis of functional proteins is a multistage process also 
determined by the balance between transcriptional activators/repressors and the regulation of RNA 
splicing, export and degradation 11, 48. Altered regulation of chromatin structure and transcription 
mechanisms may result in deregulation of gene expression and abnormal expression of genes in 
specific cell-types and developmental stages, resulting in defective brain development and/or 
functioning 20.  
Several genes known to be involved in transcription regulation were already described as causative 
of ID or ID related syndromes. Examples of those genes are NF1 (neurofibromatosis type 1) gene, 
responsible for the ID phenotype in neurofibromatosis type 1 patients, the RSK2 (ribosomal S6 
kinase 2) gene, responsible for Coffin-Lowry syndrome and CBP (CREB-binding protein), involved 
in Rubinstein-Taybi syndrome. These three genes MAPK/ERK cascade displaying functions in the 
chromatin remodeling and transcription processes 20. Genes encoding for proteins that are located 
in the cell nucleus and participate in large chromatin remodeling complexes that control gene 
transcription are also associated with ID, including MECP2 (methyl-CpG-binding protein 2) gene, 
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causative of about 80% of the Rett Syndrome cases, ZNF41 (zinc finger protein 41), ATRX 
(helicase 2), CDKL5 (cycling dependent kinase 5), ARX (Aristaless-related homebox), PQBP1 
(polyglutamine-binding protein 1) and FMR2 (fragile X mental retardation 2)  are examples of 
genes that, once disrupted, may account of ID phenotype 20. In table 1.4 there is a summary of 
some transcription regulator genes known to be involved ID or ID associated phenotypes.  
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 Gene Locus Protein Function Associated phenotype 
Chromatin 
remodelling 
ATRX Xq13 ATRX ATPase/helicase 
Alpha-thalassemia/mental retardation 
syndrome 
CHD7 8q12.1 CHD7 
ATP-dependent chromatin 
remodeller 
CHARGE syndrome 
ERCC6 10q11 Rad26 ATPase/helicase 
Cerebrooculofacioskeletal (COFS) 
syndrome 
DNA 
methylation 
CDKL5 Xp22 CDKL5 
Dnmt1 phosphorylase, 
MeCP2-binding protein 
West syndrome; Rett syndrome variant 
DNMT3B 20q11.2 DNMT3B DNA methyltransferase 
Immunodeficiency, centromeric instability 
and facial dysmorphisms (ICF) syndrome 
MECP2 Xq28 MeCP2 Methyl DNA-binding protein Rett syndrome 
Histone 
modification 
BCOR Xp11.4 BCOR 
Histone modifier binding 
protein 
Oculofaciocardiodental (OFCD) syndrome 
CREBBP 16p13.3 CREBBP Histone acethyltransferase Rubinstein-Taybi syndrome 
EHMT1 9q34.3 EHMT1 Histone methyltransferase Kleefstra syndrome 
EP300 22q13 P300 Histone acethyltransferase Rubinstein-Taybi syndrome 
HUWE1 Xp11.2 HUWE1 Histone ubiquitin ligase Non-syndromic X-linked ID 
MED12 Xq13 TRAP230 
Histone methyltransferase 
binding protein, histone 
phosphorylation activator 
Optiz-Kaveggia syndrome; Lujan-Fryns 
syndrome 
NSD1 5q35 NSD1 Histone methyltransferase 
Sotos syndrome; weaver syndrome; 
Beckwith-Wiedemann syndrome 
PHF8 Xp11.2 PHF8 Histone demetyhylase Siderius X-linked ID syndrome 
RPS6KA3 
Xp22.2-
p22.1 
RPS6KA3 
Kinase-histone 
phosphorylation 
Coffin-Lowry syndrome; X-linked ID 
JARID1C 
Xp11.22-
p11.21 
JARID1C Histone demetyhylase X-linked ID 
DNA 
/Chromatin 
binding 
BRWD3 Xq13 BRWD3 
Chromatine binding protein 
(putative) 
Non-syndromic X-linked ID with 
macrocephaly 
PHF6 Xq26.3 PHF6 
Chromatine binding protein 
(putative) Borjeson-Forssman-Lehmann syndrome 
ZNF41 Xp22.1 ZNF41 DNA-binding protein Non-syndromic X-linked ID 
ZNF81 Xp221-p11 ZNF81 DNA-binding protein Non-syndromic X-linked ID 
ZNF674 Xp11 ZNF674 DNA-binding protein Non-syndromic X-linked ID 
ZNF711 
Xq21.1-
q21.1 
ZNF711 DNA-binding protein Non-syndromic X-linked ID 
Table 1.4- Transcription regulators genes known to be associated with ID (adapted from 71). 
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mRNA regulation 
 
Mutations in some RNA binding proteins are also known to account for some forms of ID. The most 
widely known case is FMRP (produced by FMR1 gene) and that is causative of fragile X syndrome. 
FMRP is an RNA binding protein that associates with many mRNAs, some of which encode 
proteins important for neuronal development and plasticity. FMRP controls activity-dependent 
dendritic mRNA localization and translational efficiency of dendritic mRNAs in response to 
stimulation of mGluRs 49,48. It is currently known that neurons are highly specialized cells where 
some specific aspects of RNA metabolism play critical roles for their function specially during 
development, when trafficking of mRNAs to growth cones (axonal and dendritic) regulates neuronal 
growth. After synapse formation, mRNAs continue to be transported to dendrites and axons where 
they are locally translated at the synapse. This process has extreme importance for synaptic 
plasticity (the biological correlate of memory/learning) and its deregulation can have an important 
impact on cognition 70.        
 
miRNAs 
 
miRNAs are small non-coding RNA molecules (~21 bp) encoded in the genome that regulate gene 
expression by binding to the 3’UTR of specific target mRNAs. This regulatory process may occur 
via translational repression and/or mRNA destabilization/degradation 73, 74.  
miRNAs are known to be involved in several developmental processes, such as development 
timing, apoptosis, myogenesis and glucose homeostasis and currently there are 1424 miRNA 
sequences listed for the human genome in the online database miRBase 
(http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa) 75. Many of these miRNAs are 
expressed in the brain and seem to be essential for neuronal cell development and to interfere in 
processes such as neurite outgrowth, synaptic development and neuronal plasticity 74, 75.  
Although a number of miRNAs have been shown to be important for neuronal development very 
little is known about the mechanisms by which these molecules regulate synapse formation and 
maturation. One of the most well studied cases is the miR132 that has been shown to influence the 
Rac1-PAK-mediated spinogenesis and influence dendritic growth in hippocampal neurons 73. 
Additionally, miR132 was also shown to regulate expression of MECP2, the gene responsible for 
Rett syndrome73, 76. Indeed, miR132 transgenic mice displaied decreased Mecp2 protein 
expression and showed significant deficits in novel object recognition 73. The authors propose that 
miR132 is a regulatory miRNA in neurons and raise the hypothesis that miR132 may contribute not 
only for the cognitive defect in Rett syndrome, but also for a larger set of ID-related disorders.  
In order to further explore the actual function of these small molecules in brain development it 
would be interesting to characterize the function of the miRNAs known to be specifically expressed 
in central nervous system.     
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Ubiquitin-proteasome system (UPS) 
 
The programmed, fast and specific degradation of proteins in the cell is essential for survival and 
plays an important role in virtually all the cell events, and thus also in the function of neurons and 
synapses. The process of targeting proteins for degradation is accomplished by covalent 
attachment of ubiquitin to the protein substract. These ubiquin tags act as a label for proteins that 
must be degraded because they are no longer useful for the cell 77. The specificity and timing of 
ubiquitin attachment to particular proteins is determined by ubiquitin ligase proteins (E3 ubiquitin 
ligases, for instance) is extremely important for the fine tuning of protein levels in the cell. Cullins 
are highly conserved among species and serve as catalytic core components of E3 enzymes. 
Recently, mutations in cullin proteins have been described in patients with ID 22, 46, 47. Examples of 
genes involved in this regulatory pathway that are associated with ID are CUL4B (cullin 4B), CUL7 
(cullin 7) and HUWE1 (HECT, UBA, and WWE domains-containing protein 1) 79, 80. 
Additionally to his role in substrate tagging for degradation, the UPS is also associated with 
neurotransmitter receptors, protein kinases, synaptic proteins and transcription factors regulation, 
all considered important molecules for synaptic plasticity 81. 
 
Synaptic and dendritic spine malformation in intellectual disability: two examples 
 
Abnormalities in dendritic spines in ID patients were first described in 1970 by Huttenlocher 82. That 
report showed that dendrites of cortical neuron of ID children had abnormal long, thin spines 
instead of short and thick spines. Nowadays it is generally accepted that abnormalities in dendritic 
structure and/or dendritic spine morphology give rise to altered neuronal activity and contribute to 
the cognitive disabilities of ID.  
Changes in the size of the spines as well as the number of those have been associated with 
learning. For example, it has been demonstrated that spatial learning is associated with an 
increase in the number of spine densities in hippocampus while the reduction of those same spines 
reflect deficiencies in spatial memory in aged mice 56. ID is often accompanied by an increase in 
spine length, indicating a relationship between the length of the dendritic spines and the efficacy of 
transmission 56. 
 
 
Fragile X syndrome (FXS) 
FXS is the most common form of inherited ID affecting approximately 1:4000 males and 1:8000 
females. This syndrome is characterized by intellectual disability, development delay, hyperactivity, 
hypersensitive to stimuli, mood instability and autism. The FXS is caused by the expansion of the 
trinucleotide repeat CGC at FMR1 gene in the X chromosome, leading to the absence of FMRP 
protein. Although its function is still not completely characterized, FMRP seems to act as an RNA 
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binding protein and some mRNAs responsible for the synthesis of several proteins with variable 
functions were found to bind to FMRP 32, 33, 34 .  
It is thought that FMRP plays an important role in synaptic plasticity through regulation of mRNA 
transport and translational inhibition of local protein synthesis ate synapses 85. In neurons, FMRP is 
localized at the base of dendritic spines in association with the polyribosome. It is currently thought 
that FMRP is a translation repressor of microtubule associated protein 1B (MAP1B). MAP1B is 
essential for stabilization of microtubules during elongation of dendrites and neuritis and it is 
involved in the dynamics of morphological structures. It is hypothesized that the lack of FMRP 
results in altered microtubule dynamics that may contribute to the altered spine morphology seen in 
FXS patients. Studies in patients and animal models of FXS have identified increased spine density 
and an excess of abnormal long, thin and immature spines which are indicative of alterations in 
synapse development and/or function in this patients 86. 
 
Rett syndrome (RTT) 
 
RTT is a neurodevelopmental disease also associated with abnormalities in brain size, branching 
and synaptic morphology, neurotransmitter receptors and genes expression. Taken together, these 
alterations strongly suggest a disorder of brain growth, especially the growth and development of 
gray matter and axonodendritic connections 87. Post-mortem studies revealed that the neuronal cell 
packing and synaptic density lower in RTT cerebral cortex when compared to controls 88. At the 
mRNA level, the same type of studies revealed that synaptic markers such as MAP-2, synapsin II 
and synaptotagmins 1 and 5 presented decreased levels of expression. Mutations in the MECP2 
gene can account for the disruption of synaptic formation, maturation and refinement 44, 45.     
 
The increasing number of genes identified over the last years as associated with ID suggest that 
this phenotype can emerge as the final common pathway of many different types of abnormal 
cellular processes, and that there isn´t a single main general mechanism responsible for the 
disease. These findings went against the first hopes of ID researchers who thought that the 
identification of the genes responsible for the disease would lead them into the mechanisms of 
pathology in a very straightforward way. On the other hand, it is consistent with the fact that 
intellectual processing in humans is both sophisticated and complex. The purpose of understanding 
the patophysiology of this disease is to provide a better clinical service to the patients and their 
families 7.         
 
The emerging theory of the tetrapartite synapse: non-neuronal brain plasticity 
 
It has been said in this work that chemical synapse are units of signal transfer the brain that are 
composed by a bipartite mechanism: presynaptic cells and postsynaptic cells. However, over the 
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last years new findings have proposed glia and the extracellular matrix (ECM) as important 
participants in the synaptic machinery, giving rise to the hypothesis of a tetrapartite synapse 90, 91, 
92
. For long it has been thought that glia must be doing something more than just filling the spaces 
between neurons. In spite of not being able to fire action potentials, glial cells are highly excitable 
cells that communicate with neurons and other glia through chemical signal 93. The major types of 
glia that in the central nervous system communicates with synapses are the astrocytes, 
oligodendrocites (myelination glia) and microglia. Besides the glia, there is also the ECM that 
accounts for about 20% of the total volume of the mature brain 91. ECM molecules are synthesized 
by neurons, glial and non-neuronal cells and secreted into the extracellular space and is manly 
composed by collagen, proteoglycans, glycoproteins and integrins 90. 
Astrocytes are the most abundant cell type in the brain and are able to “listen” and respond to 
synaptic activity. During development, the formation of mature neuronal circuits requires the 
selective elimination of inappropriate synaptic connections as well as the stabilization of other 
ones. It is currently believed that glial cells may have a role in these processes as well 93.  
In the last decade, closer attention has been given to the many forms of structural and synaptic 
changes that rely on interactions between the ECM and astroglia, and it is becoming increasingly 
clear that glia plays a crucial and dynamic role in the synapse development and influence functions 
that for years have been strictly associated with neuronal control 90, 93. Consequently, further 
attention must be paid to the function of these two factors (ECM and glia) in the search for the 
genes associated with ID.                
 
 
 
 30 
 
Types of mutations underlying ID 
 
Chromosomal rearrangements and structural variations in the genome 
 
Chromosomal aberrations can be numeric or structural. Numeric aberration can be due to the loss 
or gain of an entire chromosome (leading to the monosomy or trisomy) or of the whole 
chromosome complement (given rise to triploidy and tetraploidy). In a general perspective, the 
absence of a chromosome is far more drastic than its excess. These consequences are not the 
same for autosomal and sexual chromosomes since the absence of an entire autosomal 
chromosome is not compatible with life while the same alteration in a sexual chromosome may 
result in a liveborn female (45, X – Turner syndrome) 94. This type of alteration is usually found in 
cancer cells but can also lead to a variety of human genetic disorders, such as Down syndrome, 
Cri du Chat syndrome, Klinefelter's syndrome, etc. 95. Chromosomal aberrations that large can be 
detected by low-resolution cytogenetic methods.        
Structural variation is a term used to describe all types of genomic rearrangements, including 
deletions, duplications, insertions, inversions, translocations, loss of heterozygosity (LOH) and 
more complex alterations. The most common form of structural variation in the genome are copy 
number variations 96. Structural abnormalities are a consequence of double-strand breaks and 
inappropriate DNA repair. These types of alterations can be balanced or unbalanced, but both 
require a break in the DNA phosphodiester backbone.  In figure 1.5 is represented a scheme of the 
most common structural variations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
During many years genomic DNA copy-number gains and losses were assumed to be few and to 
have limited impact on the total content of human genetic variations 97. With the development and 
improvement of genome-wide analysis tools to study the genome, it was shown that CNVs are 
relatively frequent, spread throughout the genome and represent a very significant source of 
Figure 1.5  – Schematic representation of the most common structural variations occurring in the genome 
(adapted from 94).   
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genetic variation in human populations. Until now, thousands of heritable copy number variations 
have been identifying regions potential variability corresponding to approximadetly 13% of the 
human genome 98.  
Using aCGH methodologies it is possible to identify unbalanced alterations within the genome. 
However, alterations where there isn´t an alteration in the amount of DNA, such as balanced 
inversions that only alter the orientation of a portion of a genomic region, are not detected by 
aCGH. As a consequence, and despite the great improvements in mapping deletions and 
duplications, the mapping of inversions has lagged behind 96. Thus the real number of common 
inversion and regions prone to develop this kind of alteration is currently not clear. With the 
availability of themost recent high-throughput sequencing techniques, this type of variation is 
possible to detect and, consequently, our knowledge about them has increased greatly 1.  
      
Copy number variations 
 
The definition of a CNV says that it is a DNA segment larger than 1Kb that present variable copy 
number when compared to another reference genome. If these alterations are so common, can 
happen along the entire genome and reach a considerable size, it is likely that CNVs can influence 
the transcriptional and/or translational levels of overlapping and nearby genes 56, 57. In fact, 
whenever the deletion or duplication harbors one or more dosage-sensitive genes or occurs 
simultaneously with point mutations in the other allele, an abnormal phenotype can result from the 
alteration 1.  
Copy number variations are often sporadic and caused by de novo rearrangements. It is accepted 
that these types of variations can occur with/at a 1000 to 10.000 higher frequency than point 
mutations 1,100. Although CNVs occur at similar frequencies between populations, several 
significant differences in the frequency of some CNVs were found between different populations in 
the world, revealing that variations in the genomic architecture can not only account for disease, 
but also for ethnic differences and selective evolution 101.   
The distribution of CNVs in the genome is thought to be non-random and several “hot spots” in the 
genome have been identified, such as in centromere and telomere regions). The higher frequency 
of CNVs in these regions is perhaps due to their repetitive nature. Also, the CNV occurrence rate 
does not correlate with the chromosome size. Some chromosomes have relatively high proportion 
of CNVs, while others have lower proportions. For instance, about 20% of the chromosome 18 
sequence is covered by CNVs, while for chromosomes 16, 17, 19 and 22 more than 40% of their 
sequence is covered by CNVs 102. There are two main theories to explain this non-random 
distribution of CNVs throughout the genome: (I) the mutational hypothesis that defends that most 
CNVs are phenotypically neutral but, because they are flanked by repetitive sequences that 
predispose to its occurrence, are more frequent in that regions and (II) the selection hypothesis that 
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states that negative and positive selection determine the bias occurrence of CNVs in certain 
regions 101.          
Despite the extensive studies performed in the last decade, the real amount, position, size, gene 
content and distribution in population of common CNVs remain unclear. The wider application of 
high-resolution aCGH technologies and next generation sequencing will reveal will contribute to the 
description of many more different CNVs between individuals and populations, as the majority of 
CNVs will appear at smaller sizes 1.  
CNVs described in presumelly healthy individuals have been cataloged at DGV (Toronto Database 
of Genomic Variants, site), while clinically relevant CNVs can be found in DECIPHER (DatabasE of 
Chromosomal Imbalances and Phenotype in Humans using Ensembl Resources, site). However, 
Decipher database is not always clear since it describes all the CNVs found for the patient, not 
always has the phenotypic description of the case and parental analysis for the alterations.                
  
CNVs occur in about 13% of the human genome and can be categorized into two major groups 
based on the breakpoint pattern analysis: (I) recurrent rearrangements, occurring in multiple 
unrelated individuals with clustering of breakpoints and sharing a rearrangements with a minimal 
overlapping region and (II) non-recurrent rearrangements, with variable breakpoints 1, 100, 101.  
It is estimated that about 45% of the human genome is composed by repetitive sequences 
including transposon-derived repeats, processed pseudogenes, simple sequence repeats and 
blocks of tandem repetitive sequences. These types of variants are many times called common 
repeats 103. In addition to these elements, low copy repeats (LCRs), also called segmental 
duplications, constitute another kind of repeated sequences that account for about 5% of the 
genome. LCRs are DNA fragments that range in size from 1Kb to 400 Kb, and share a high level of 
sequence identity (higher than 90%). These alterations are present in at least two copies of the 
genome and many times have complex structures. 
Both LCRs and common repeats cause genomic instability and have been implicated in the 
generation of constitutional genomic rearrangements 100, 103.          
 
Mechanisms underlying copy number variation origin 
 
So far, four mechanisms of origin have been proposed to underlie these alterations: nonalelic-
homologous recombination (NAHR), nonhomologous end-joining (NHEJ), L1 retrotransposition and 
fork stalling and template switching (FoSTeS). Nonalelic-homologous recombination and 
nonhomologous end-joining account for the majority of CNVs 3, 6, 58, 59, 60, 61, 62. It is important to say 
that many structural variations display features of origin that can be interpreted as NAHR, NHEJ, 
FoSTeS and retrotransposition, and many times, there isn´t a single possible mechanism 
associated with the alteration 100.   
 
 33 
 
 
 
Nonalelic-homologous recombination (NAHR) 
 
NAHR is caused by the alignment and crossover of two nonallelic DNA sequence repeats sharing 
high similarity to each other 100. When two LCRs have sequence identity higher than 97% and are 
located at a distance less than 10 Mb from each other, they can lead to misalignment of chromatids 
and mediate an alteration in the genome. The formation of a stable reciprocal translocation 
mediated by interchromosomal NAHR between LCRs is dependent upon the orientation of the 
LCRs and the chromosome arms involved. When LCRs are directly oriented they give raise to 
deletions or duplications of the region between them. If the LCRs are in different directions they will 
result in an inversion of the region 1, 108.  
Recurrent interstitial rearrangements are often flanked by LCRs, indicating that NAHR is a major 
causative mechanism for these structural variations.  
In addition to LCRs, smaller but equally highly similar DNA sequences can lead to NAHR. These 
sequences can be retrotransposable L1 elements, LINE elements (long interspersed nuclear 
elements), Alu elements (a class of SINEs, short interspersed nuclear elements), LTRs (long 
terminal repeats) or matching pseudogenes 102, 94, 100.  Such shorter sequence subtracts mediate 
NAHR of smaller DNA regions and that many times are out of reach of aCGH platforms of lower 
resolutions. With the advent of massive paralel sequencing techniques, the amount of NAHR-
related alterations mediated by these types of sequences that are detected will certainly increase 
108
.    
 
Nonhomologous end-joining (NHEJ) 
 
While in recurrent rearrangements the most common originating method proposed is NAHR, 
regarding nonrecurrent CNVs the most common method causative method is thought to be 
nonhomologous end joining (NHEJ). NHEJ is a natural DNA repair mechanism responsible for 
correction of DNA double strands breaks caused by ionizing radiation or reactive oxygen species 1. 
Unlike NAHR, NHEJ does not require LCRs or any other type of highly similar sequences to occur 
and often leaves a “DNA scar” resulting from the addition of extra nucleotides at the DNA junction. 
Breakpoints of NHEJ-mediated rearrangements are often located within repetitive elements such 
as Alu, LINE or LTR sequences. Additionally, sequence motifs like TTTAAA, known to be able to 
cause double strand DNA breaking and curving of the DNA, are present in the proximity of many of 
these breakpoints. These data suggest that, even without any necessity of LCRs for occurring, 
NHEJ may still be stimulated by them 1, 100, 109.           
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Fork stalling and template switching (FoSTeS) 
 
FoSTeS is a replication error based mechanism that has been recently implicated in the origin of 
genomic-disorder-associated nonrecurrent rearrangements of complex structure (for instance, 
deletions or duplications interrupted by normal copy number regions and also triplicated segments) 
1
. According to this mechanism, during DNA replication the replication fork can be stalled and the 
polymerase can switch to other replication fork and restart DNA replication in the new fork. This 
exchange occurs via the microhomology between the switched template site and the original fork 
100
, 
106
. The new template sequence doesn´t have to be necessarily adjacent to the original 
replication fork, but needs to at least be located in three-dimensional physical distance 100.  
Depending on the direction of the fork progression and whether the lagging or leading strand of the 
new fork is used as template, the wrongly incorporated fragment can be in the same direction or 
inverted when related with its original position. Moreover, if the new fork is located downstream of 
the original fork, the alteration will give rise to a deletion, while if the new fork is located upstream 
of the original one, the new fragment will be duplicated 1, 100, 106.   
This mechanism can generate not only complex and relatively small rearrangements (sometimes 
even single exons), but also large genomic alterations. Sometimes, analysis of the breakpoints 
reveals not only one but more FoTSeS events as originators of the rearrangement 106. One 
example is the genomic rearrangements find in MECP2 locus, that for many years were not 
explained by NHAR or NHEJ, is now though to be caused by FoTSeS 1.  
 
L1 Retrotransposition 
 
Transposons are mobile genetic elements that can affect gene expression in virtually all higher 
eukaryotes. Transposons are elements that can be transcribed into RNA, reverse transcribed into 
cDNA, and then reintegrated as cDNAs into the genome at a new location.   In the human genome, 
long interspersed element-1 (L1) elements cover around 17% of the genome 100. L1s are also 
capable of mobilizing Alu and SINE elements as well as retrogenes within the genome. A high 
amount of inversions and deletions in the genome are attributed to retrotransposition 100.  
 
A schematic representation of these 4 mechanisms of origin is described in figure 1.6. 
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Microhomology-mediated break-induced replication (MMBIR) 
 
Microhomology-mediated break-induced replication is a general model, based on observations not 
only in humans but also in other animal models, proposed to explain nonrecurrent CNVs and 
complex genomic rearrangements in all life forms 1. The MMBIR model follows the same basic 
principles of the FoSTeS model: the rearrangement is initiated by a single-end double-strand DNA 
break resulting from a collapsed replication fork 94. The single-strand 3’ tails from the broken 
replication fork will anneal with a microhomologous single-stranded DNA nearby, where it forms a 
new replication fork. Similar to what happens in the FoSTeS mechanism, the replication in the new 
fork is of low processivity and the extended end will dissociate and invade different templates 94, 106.  
The schematic representation of the MMBRI mechanism is briefly summarized in figure 1.7. 
 
 
 
 
 
 
 
 
 
 
 
It has been proposed that both FoSTeS and MMBIR mechanisms may be a major cause of 
nonrecurrent complex structural variations in the human genome, as well as in the formation of 
LCRs that, consequently, will predispose to NAHR 1, 100.  
NAHR NHEJ 
FoSTeS 
FoSTeS x 1 FoSTeS x 2 L1 retrotransposition 
Figure1.6 – Schematic representation of the four most common molecular mechanisms of origin by which CNVs 
can occur (adapted from 100) 
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Figure 1.7 – Schematic representation of MMBIR 
mechanism. (A) Shows the broken arm of a collapsed 
replication fork that forms a microhomology junction 
(arrow) leading to the formation of a new low-processivity 
fork (B). The extended end dissociates (C) originating a 
duplicated region in the genome (D). Adapted from 94  
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Copy number variations in health and disease 
 
Before the last decade, it was thought that healthy individuals were diploid for each chromosome 
inheriting one copy from the mother and other from the father and that any alteration of this pattern 
could result in an altered phenotype. Also, before the beginning of the sequencing of the human 
genome, it was thought that two healthy individuals should share about 99,9% of the genome, 
being the 0,1% of due to single nucleotide polymorphisms 102. This perception of the human 
genome has completely changed in the last decade, mainly because of the technical improvements 
for the detection of CNVs and other structural variants. 
Copy number variations are frequent and widespread through all the genome. Genomic 
rearrangements may cause Mendelian diseases, complex traits with complex inheritance patterns 
(such as behavioral disorders) or just represent benign polymorphisms with relatively high 
frequency in general population 1.   During the years many diseases have been associated with 
DNA rearrangements that result in gain, loss or disruption of genes for which dosage is critical. The 
impairment in gene expression may not only be due to deletions or duplications covering the gene 
(and consequently less or more quantity of the gene, respectively), but also alterations in gene 
regulatory regions. Whatever the mechanism, these disorders are often characterized by 
overlapping genomic features and clinical symptoms. Genomic imbalance disorders are often 
sporadic and caused by de novo alterations 110. 
It is known that CNVs can affect gene expression and play an important role in the etiology of 
common diseases. About 15% of the genes present in OMIM database are within CNV regions 
and, many times, these dosage alterations turn to be relevant for molecular-environmental 
interactions 101, 111.  
There are several molecular mechanisms that can lead to clinically significant alterations. The most 
obvious and widely described mechanism is the coverage of an entire gene that is sensitive to 
dosage, such as duplications or deletions. Another important aspect is when the alteration doesn´t 
cover the entire region and there is a breakpoint occurring inside the gene. These breakpoints can 
be due to deletions, duplication, translocations or inversions (figure 8). This type of alteration may 
lead to loss-of-function of the gene or gain-of-function (through the creation of new transcripts by 
gene fusion or exon shuffling). Structural alterations can also lead to deregulation of a gene (either 
by down regulation or over expression) by affecting regions outside the gene (such as the promoter 
region or other important regulatory elements). Many times alteration in regions that don´t cover 
any gene are found and present themselves as almost impossible to interpret because of the lack 
of information regarding the sequence 94. 
Not only CNVs in dosage-sensitive genes can account for the phenotype. A deletion in one allele 
can unmask a recessive mutation in the other allele or even a heterozygous polymorphism with 
functional significance while in homozygosity. Finally, it is also hypothesized that a CNV in one 
allele can interfere with the interaction mechanism between them (transvection) 94. In figure 1.8 
there is a schematic representation of the mechanisms described above.            
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Figure 1.8 - Molecular mechanisms by which chromosomal rearrangements can influence phenotypes. The 
rearrangement can encompass a dosage sensitive gene that causes disease (A); disrupt a dosage sensitive gene 
through deletion (B), duplication, translocation or inversion (C); create a fusion gene (D); exert a position effect by 
affecting a regulatory element (E); unmask a recessive allele (F) or functional polymorphism (G) on the homologous 
chromosome; interrupt effects of transvection (H) where the deletion of a gene affects communication between alleles. 
Genes are depicted as green or red rectangles, regulatory elements (purple boxes) as purple rectangles and an asterisk 
(*) indicates a recessive point nucleotide variation. Adapted from 94.  
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Genetic testing of children with ID 
 
A child with ID is deserving of the best diagnostic evaluation available in order to improve the 
health and well being of that child and his/her family. Clinicians report that the family of a child with 
global DD and/or ID often experiences the feeling of loss of control and guilt. A specific diagnosis is 
one that can be used by the family in obtaining information about prognosis, recurrence risks and 
available therapy 6.  
The preliminary clarification of the type of DD presented by the child is an important step because it 
is going to lead the path of the genetic investigation followed. The diagnostic approach that should 
be undertaken for a child with ID includes the following steps: collection of the clinical history 
(including prenatal and birth histories), family history and physical and neurologic examination. 
These two last parameters are of extreme importance since the extended examination for minor 
anomalies, neurologic and behavioral signs may suggest a specific recognizable syndrome. Only 
after the clinical genetic evaluation and determination of the diagnosis path to be followed, 
laboratory tests, imaging and other consultants should be required 4. During the years, several 
studies have estimated 4 to 40% of all cases of ID to have a genetic etiology, with variable rates of 
success in this estimate likely to be due to patient selection criteria and available laboratory 
technologies 112. 
The reason most commonly cited by parents for pursuing diagnostic testing is “to know”. The 
establishment of a medical cause for their child´s condition and the end of the uncertain of “not 
knowing” is one of the most important aspects for families affected by the disease. Several 
additional reasons and expected outcomes for establishing a diagnosis were: to understand 
prognosis and future needs, to improve response by medical and educational services, to obtain 
early access to educational and social services, to test other offspring with questionable symptoms 
and make future reproductive decisions based on appropriately estimated recurrence rate 21. 
The final clinical benefits of achieving a specific genetic diagnosis from the clinical point of view 
are, among others, the following: end the diagnostic odyssey, alleviate parents´ fears about other 
causes, pass on patients to an appropriated specialist, determine possible prognosis, guide optimal 
management and surveillance of associated co-morbidities, advise of the risk of recurrence in 
future offspring, increase knowledge about precise genotype-phenotype correlations; provide 
potential insight into disease mechanisms and eventual development of therapeutic interventions 
56
. 
 
Standard cytogenetic analysis 
 
The purpose of cytogenetic testing is to look for chromosomal rearrangements that could explain 
the disease in the child. It is now known that the most commonly found chromosomal 
rearrangements are copy number variations. These types of alterations consist in deletions or 
duplications of large segments of DNA (above 1Kb) and have been described the in context of 
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diseases and also in healthy controls. Less common, but likely to account for some causes of DD 
in children are apparently balanced translocations (exchanges of DNA segments of the same size 
between chromosomes) and inversions (inversion of a DNA segment within a chromosome) 37, 38.   
Cytogenetic studies are recommended in the evaluation of all children with ID whose etiology is not 
clinically evident 114. The currently guidelines adopted in Portugal for genetic testing of these 
patients suggest the search of genomic imbalances or rearrangements by regular G-banded 
karyotyping in first place, followed, whenever the result is normal, by analysis of subtelomeric 
rearrangements, use of specific FISH probes according to clinical presentation and by the testing of 
the most common single gene disorders (for instance, Fragile X syndrome) 115.  
Conventional cytogenetic techniques were developed in the early 1970’s and have allowed the 
identification of each of the human chromosomes. This kind of analysis uses light microscopy to 
examine stained metaphase or prometaphase chromosomes to produce a distinct banding pattern 
for each chromosome 116.  This approach requires dividing cells (usually peripheral blood 
leucocytes, bone marrow cells or fibroblasts) at a stage when chromosomes are highly condensed 
allowing a resolution (detectable size of chromosomal abnormalities) of a series of 400-550 
light/dark bands in each genome 116, 117, 118, 119, 120. In spite of its important role as a medical 
diagnostic tool, subtle deletions and duplications can´t be detected by regular chromosome 
banding 121. To overcome this obstacle, high-resolution chromosome analysis, developed in 1976 
by J.J. Yunis, allows a resolution up to 2000 bands per haploid genome 122. This approach is only 
used when a suspicion is raised about a specific chromosomal region, because it requires 
extended prometaphase chromosomes (that are often overlapped and entangled after the cell 
preparation), which represent increased difficulty in the analysis 121.        
Other stains and techniques can be used to improve information and resolution. The most 
commonly used technique to investigate target regions is fluorescent in situ hybridization (FISH). In 
the patients with ID/DD, when karyotype analysis is normal, FISH can be used to detect 
submicroscopic alterations. This type of technique requires that the differential diagnosis must be 
first decided so that the specific chromosomal location for analysis could be targeted by the FISH 
probe 57, 58. FISH uses fluorescence-labeled DNA probes to detect the presence, number and 
location of genomic regions that are too small to be visualized by more conventional techniques 121. 
This technique can confirm or exclude a clinical suspicion of know and clinically established 
microdeletions and microduplications syndromes 124. When a differential diagnosis and/or target 
analysis are not possible, a screening of the subtelomeric regions is recommended 125. The use of 
subtelomere FISH panels during the years has revealed that, in the absence of specific clinical 
features suggestive of a syndrome, patients with ID should also be screened for this group of 
genomic imbalances. The developments in FISH techniques generated the second revolution in 
cytogenetic analysis 126. First, the chromosome painting allowed the observation of complex 
rearrangements and second, the Human Genome Project allowed the generation of single locus 
probes that facilitated the delineation of critical deleted/duplicated regions associated with specific 
disease phenotypes 61, 62. This development was the first step for the shift from the traditional 
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“phenotype-first” approach, to a “genotype-first” approach. This last approach allows the 
characterization of a common genetic alteration in first place, followed by a more detailed clinical 
characterization as more patients with the same alteration are discovered 62, 63.  
During the years, the development of labeling and detection methods that allowed the visualization 
of the all chromosomes in different colors provided the first prospect of a “molecular” karyotype. 
These techniques, named multiplex-FISH (M-FISH) and spectral karyotyping (SKY-FISH), 
combined the global screening power with the accuracy of the molecular analysis 126. Besides its 
incredible ability to discriminate the components of highly complex rearrangements, obtaining 
metaphase cells is not always easy and increases the cost of the analysis. The development of 
FISH techniques that don´t require dividing cells (interphase FISH) enabled the analysis of samples 
which otherwise would be impossible to analyze 61, 64.        
Rearrangements of the subtelomeric regions of chromosomes are a significant cause of both 
idiopathic and familial ID 42, 43, 44. The telomere protects the chromosome from end-to-end fusion 
and degradation. However, due to the sequence similarity that exists between non-homologous 
chromosomes in these areas, rearrangements in these regions are relatively frequent. Because 
such rearrangements are too small to be detected by conventional karyotyping, a series of different 
protocols have been described to be useful for the detection of subtelomeric alterations (multiprobe 
FISH, microsatellite marker analysis, multiplex ligation-dependent probe amplification, quantitative 
PCR, multicolor FISH, among others), MLPA being the most commonly used technique for this kind 
of analysis 43, 45, 46 .  
Although it has been broadly used for more than 30 years, normal karyotyping has a low resolution 
power (it can miss alterations within the 3Mb-10Mb size range) and it is also subject to inter-
observer variations, leading to variable detection rates between operators and laboratories. 
Importantly, it leaves the majority of cases without identification of the genetic abnormality 
associated with the child´s condition 5, 133. 
 
aCGH based cytogenetic analysis 
 
Microarray technology was developed more than a decade ago and has now become a routine tool 
in genetic research. This methodology was first used in the clinical genetics field for the analysis of 
CNVs in all human telomeres in patients with ID (48,20). Since then, aCGH has been adopted by 
hundreds of genetic laboratories although the vast majority of the platforms now target the entire 
genome and not only the telomeres 135. 
 
aCGH formats and technical principles  
 
In an aCGH experiment, DNA from a test sample (e.g. patient with ID) and a reference DNA are 
differentially labeled with a fluorescent dye and hybridized in a glass slide containing the 
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based amplifications before this step. Over the years, oligonucleotide-based arrays (oligo arrays) 
have been considered to have large advantages over the BAC arrays.  These platforms are 
characterized by single-stranded oligonucleotides (25 to 85 bp in length, depending on the 
platform) attached to the array slide, allowing CNV detection and analysis with much higher 
resolution 3.  
The development of the aCGH platforms has lead to an important increase in the resolution of CNV 
detection. Although BAC arrays present the advantage of clearly identifying copy number changes 
in a sensitive and very precise way, the spatial resolution of the array is determined by the 
sensitivity, the number, the chromosomal distribution and the length of the probes in the array. 
Facing this fact, platforms with shorter probes will allow more probes in the same space, leading to 
higher resolution. In the early years of this technology, the “proof of principle” required before 
aCGH could be adopted to diagnostic uses was still missing and there was a lack of international 
databases and population studies regarding pathogenic and non-pathogenic CNVs, which lead to 
use of BAC arrays as a more safe and robust strategy. As the years went by, the increase in 
knowledge concerning the significance of CNVs lead to the need of platforms with higher resolution 
power and, as a consequence, the oligo arrays started to be used in a widespread and routinely 
manner 50, 49, 51, 52.  
 The successful implementation and use of aCGH technologies requires the use of many statistical 
methods and techniques for synthesis and spotting of the probes in the right place, detection of 
hybridized samples and informatic analysis of the data. The informatic analysis usually requires the 
detection of the ratio of the signal generated at each probe location in the test and control sample 
52, 53, 54
. The slide is scanned to obtain the complete hybridization pattern of the entire array (figure 
9-C). During the years, a series of bioinformatic tools have been developed to transform the 
complex data and artifacts into useful information 55, 62. 
 
CNVs and diagnosis of ID 
 
The increased offer in commercially available oligo microarrays allowed the relatively easy 
implementation of the technique in clinical practice. The increasing genome coverage and 
resolution and the high levels of production according to standardized and controlled conditions 
seems to overcome all the major technical problems that were present years ago. However, the 
clinical relevance of many of the CNVs found is still presenting challenges and doubts. The 
problem is the existence of CNVs in about 12% of the human genome and the fact that often those 
are present both in healthy individuals and in subjects with the most varied pathological conditions 
106
.  
The main strategy for distinguish pathogenic CNVs from benign variants is the study of unaffected 
relatives (mostly parents) of a patient, as well as large normal control cohorts. However, often both 
parents are not available for testing, are not completely asymptomatic (which difficult the CNV 
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interpretation and association with the disease) and many times the clinical information regarding 
the parents is also not available and/or assessed. Additionally, many times the currently used 
databases don´t provide enough information to clarify whether the CNV is a very rare alteration 
that, alone or together with other theoretically benign CNVs, can account for the phenotype 63, 37. In 
spite of our current knowledge about the clinical implications of some of the alterations found, it is 
unlikely that the CNVs most frequently found in population are directly related with ID. However, we 
should be careful when comparing CNVs from ID patients with the ones described in public 
databases only by the presence-absence criteria. Instead, attention to the amount of overlap and 
number of individuals described should also be paid 134.  
There are public databases created with the purpose of help clarifying these questions, such as the 
Database of Genomic Variants (http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg18/). However, it 
is important to realize that these databases were created with research purposes and, as a 
consequence, most of the CNVs are identified by high-resolution microarrays or high throughput 
sequencing techniques. Also, only a small portion of the CNVs described have been validated 
leading to doubts in the real percentage of false positive CNVs. Also, when the CNVs reported 
were discovered using low resolution platforms (BAC arrays), it is difficult to determine the size of 
the genomic region affected and, therefore, the real size of the relevant variation may be much 
smaller than previously estimated 48, 56.  
Another limitation of the aCGH technique is the incapacity to detect balanced translocations and 
inversions, that occur in 0,75% of all ID patients 145.  
Thus, G-banded karyotyping is still important for detection of balanced rearrangements and low-
level mosaicism. These two types of alterations are not yet uniformly detected by aCGH since it 
depends of the existence of pathogenic balanced translocations and percentage of mosaic material 
present in the patient. A study performed by Miller DT et al in 2010 concluded that (I) truly balanced 
rearrangements account only for a small proportion (<1%) of clinically significant genomic events in 
patients and (II) many apparently balanced rearrangements detected by regular karyotyping show 
submicroscopic imbalances at breakpoints when analyzed by aCGH 114.    
    
Microdeletions/microduplications syndromes in ID 
 
The development in aCGH technique allows genome-wide studies in patients with ID. As a 
consequence, the discovery of new microdeletion and microduplication syndromes has 
substantially increased. When searching for the genetic basis of clinical phenotypes different types 
of approaches can be used, such as: (I) collection of a series of patients with similar clinical 
phenotypes and identifications of the genomic imbalance that account for phenotype (phenotype 
first), (II) the identification of additional patients with previously described clinical features and the 
proposal of the genetic etiology of the disease, (III) delineation of a minimal critical region that can 
account for the phenotype as well as further identification of more patients (genotype first) and (IV) 
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identification of genomic imbalances by large-scale screening techniques common to several 
patients and highlight of the common phenotypical features among them (reverse phenotyping) 40, 
65
. Any of these approaches have proven to be successful considering the amount of established 
phenotypes nowadays. Table 1.5 summarizes the microdeletion and microduplication syndromes 
associated with ID reported so far in the Decipher database (http://decipher.sanger.ac.uk/).   
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Table 1.5 - Recurrent interstitial microdeletion/duplications associated with ID. List of syndromes associated with ID first recognized by molecular karyotyping. Adapted from 146, 147. 
Syndrome Name Other Alias 
Minimal 
Alteration 
Size 
Supposed 
Origin 
Mechanism 
Clinical Features 
1q21.1 microdeletion - 1,35 Mb NAHR 
Highly variable: mild to moderate ID, microcephaly, multiple congenital abnormalities. It’s clear the 
incomplete penetrance of the alteration since it was find in patients and in unaffected parents. 
1q21.1 microduplication -  1,35 Mb NAHR 
Mild to moderate ID, mild facial dysmorphic features, microcephaly/macrocephaly, autism and 
autistic features. 
1q41q42 microdeletion - 1,2 Mb Unknown ID, seizures, dysmorphic features, cleft palate and diaphragmatic hernia. 
2p15p16.1 microdeletion - 3,9 Mb Unknown 
Moderate to severe ID, feeding problems, microcephaly, optic nerve hypoplasia, hydronephrosis, 
dysmorphic features, telecanthus, ptosis and downslanting, short palpebral fissures, high nasal 
bridge, long straight eyelashes. 
3q29 microdeletion - 1,6 Mb NAHR 
Mild to moderate ID, mildly dysmorphic features (including long narrow face, short philtrum and 
high nasal bridge).  
3q29 microduplication - 1,6 Mb LCR 
Very variable with few common features. Mild to moderate ID, Microcephaly and obesity. The 
clinical significance of this finding remains somewhat uncertain.  
7q11.23 microdeletion 
Williams-Beuren 
Syndrome 
1,55 Mb NAHR 
Mild to moderate ID or learning disabilities. Facial features include periorbital fullness, bulbous 
nasal tip, long philtrum, wide mouth, full lips, full cheeks and small widely spaced teeth. Anxiety, 
attention deficit hyperactivity disorder, overfriendliness and congenital heart defects. 
7q11.23 microduplication - 1.5 Mb NAHR 
Speech and language delay, mild growth retardation and subtle facial dysmorphism (high and 
broad nose, short philtrum). Intellectual strengths and weaknesses are in direct contrast to those 
typically seen in Williams-Beuren syndrome. The patient has a normal cardiovascular system and 
autistic features. 
8p23.1 microdeletion  - 3,4 Mb NAHR 
Congenital heart disease, congenital diaphragmatic hernia, developmental delay and a 
characteristic behavior profile with hyperactivity and impulsiveness. 
8p23.1 microduplication - 3,75 Mb NAHR 
Prominent forehead, arched eyebrows, development delay (not present in all individuals) and 
variable congenital abnormalities. 
9q22.3 microdeletion - 6,5 Mb ? ID, hyperactivity, overgrowth, trigonocephaly, macrocephaly and facial dysmorphisms.  
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9q34.3 microdeletion  - 0,7 Mb ? 
Severe development delay and learning disabilities, hypotonia, microcephaly, congenital heart 
disease, seizures and facial dysmorphisms.  
11p11.2 microdeletion Potocki-Shaffer syndrome 2,1 Mb ? 
Development delay, ID, multiple exostoses, parietal foramina, enlarged anterior fontanel, minor 
craniofacial abnormalities, ophthalmologic anomalies and genital anomalies in males.  
11p13 microdeletion WAGR syndrome 1 Mb ? 
WAGR: Wilms tumor, Aniridia, Genitourinary abnormalities, growth retardation and ID are the 
cardinal features of the syndrome. In females, malformations of the uterus and/or vagina may also 
be present. 
12q14 microdeletion - 3,4 Mb NHEJ Mild ID, failure to thrive, proportionate short stature and osteopoikilosis. 
14q11.2 microdeletion - 0,4 Mb ? 
ID, widely spaced eyes, short nose with flat nasal bridge, long philtrum, Cupid´s bow of the upper 
lip, full lower lip and auricular abnormalities. 
15q13.3 microdeletion  - 1,5 Mb NHAR 
Developmental delay with mild to moderated ID, seizures, subtle facial dysmorphism, hypotonia, 
short stature and cardiac defects. 
15q24  microdeletion - 1,7 Mb NAHR 
Mild ID, growth retardation, microcephaly, digital abnormalities, genital abnormalities, hypospadias 
and loose connective tissue. High frontal hairline, broad medial eyebrows, downslanted palpebral 
fissures and long philtrum. 
16p11.2 
microdeletion/duplication 
- 0,6 Mb NAHR Associated with autism, schizophrenia and ID. 
16p11.2-p12.2 microdeletion - 7,1 Mb NAHR 
ID and development delay and subtly dysmorphic facial features including flat faces, downslanting 
palpebral fissures, low-set ears and eye anomalies. 
16p13.1 microdeletion - 1,7 Mb LCRs ID, microcephaly, epilepsy, short stature. A wide range of phenotypic variability. 
16p13.1 microduplication - 1,7 Mb LCRs Associated with autism (significance uncertain); Neurocognitive disorders susceptibility locus. 
17p11.2 microdeletion Smith-Magenis Syndrome 3,7 Mb NAHR 
Mild to severe ID, short stature, obesity, small hands and feet, hypotonia, developmental delay and 
behavior disturbance (sometimes food-searching behavior).  
17p11.2 microduplication Potocki-Lupski syndrome 3,7 Mb LCR 
Mild ID to borderline normal cognitive function. Attention deficit disorder, hyperactivity and autistic 
features. Most have short stature and cardiovascular anomalies. 
17q21.31 microdeletion - 0,5 Mb NAHR 
Very variable phenotype. Neonatal hypotonia, poor feeding in infancy, oromotor dyspraxia, 
moderated ID and friendly/amiable behavior. Epilepsy, heart defects (ASD, VSD) and 
kidney/urological anomalies. 
 47 
 
19q13.11 microdeletion - 0,7 Mb ? 
ID, pre and postnatal growth retardation, primary microcephaly, hypospoadias, ectodermal 
dysplasia, dysplastic nails and dry skin. 
22q11.2 microduplication - 3,7 Mb NAHR 
Highly variable. ID and facial dysmorphisms (widely spaced eyes, downslanting palpebral fissures, 
velopharyngeal insufficiency, conotruncal hearth disease. 
22q11.2 distal microdeletion - 1,4 Mb NAHR 
ID, prenatal and postnatal growth delay, mild skeletal abnormalities, arched eyebrows, deep-set 
eyes, smooth philtrum and thin upper lip. 
Xq28 microduplication 
 0,4 Mb ? ID, severe hypotonia, progressive lower limb spasticity, absent or very limited speech. 
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Cytogenetic diagnostic: past, present and future 
 
Conventional cytogenetic testing has been available for almost 40 years and has the advantage of 
being a widely accepted and used technique. In contrast, molecular karyotyping is a relatively new 
and more diverse technique concerning platforms used, genome coverage and data interpretation. 
A review study performed by Miller D et al in 2010 concluded that molecular kayotyping detected 
pathogenic genomic imbalances in 10% more patients than G-banded karyotyping alone. However, 
it is important to say that this review was performed in 33 published studies (total of 21 698 
subjects) of which only 10 of the publications were performed in oligo-based arrays platforms. 
Additionally, these types of platforms often revealed higher positives yields compared with the 
BAC-based studies also covered by the review 114.  
G-banded karyotyping techniques can sometimes detect genomic imbalances as small as 3 Mb 
depending on the genomic region involved and/or assay conditions. However, it can easily miss 
alterations in the 5-10 Mb range the analysis of which is based on “subjective” assessment by 
technicians, leading to variability in detection rates among laboratories 114.  
Currently many clinical geneticists and pediatricians are increasingly requesting molecular 
karyotyping studies to clarify the cause of the disease in children with DD/ID 133. In many countries 
MC is already used as the first-tier genetic test instead of G-banded karyotype and current 
international recommendations of the International Standard Cytogenetic Array (ISCA) Consortium 
(https://www.iscaconsortium.org/) and the American College of Medical Genetics 
(http://www.acmg.net//AM/Template.cfm?Section=Home3)  propose this approach in first place as 
well (5,66). Despite being a relatively expensive technique, it may cost less than a regular 
karyotype analysis plus a customized FISH, such as subtelomeric FISH and has increased yield. 
Following these same guidelines, the circumstances in which traditional cytogenetic methods are 
indicated instead of MC is when the patient has a recognizable chromosomal syndrome such as 
trisomy 21, trisomy 13, Turner syndrome or Klinefelter syndrome 114.  
In order to replace conventional karyotyping MC has to provide high resolution whole-genome 
coverage. This higher resolution across the entire genome also raises concerns about the 
interpretation of CNVs of unknown significance leading to hesitation about adoption of MC as a 
first-tier test. However this issue can be adequately addressed through (I) choosing a level of 
resolution that balances sensitivity and specificity, (II) increased data sharing trough national and 
international databases and (III) parental studies to determine whether CNVs are de novo or 
inherited 5, 7, 66. 
During the last years enormous technical progress has been achieved not only the array-
technology field but also in DNA sequencing technologies. These two technologies are leading to 
new strategies in the analysis of monogenic diseases allowing the identification of causative 
mutations in disorders which weren´t previously possible to identify by linkage analysis and 
positional cloning. Over the past two decades the automated Sanger sequencing was used as the 
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dominant method in the sequencing industry and led to a number of accomplishments including the 
completion of the human genome sequence. Despite many technical improvements during the 
years, the limitations of automated Sanger sequencing showed a need for a new and improved 
technologies for sequencing large numbers of human genomes 150.  
Next generation sequencing (NGS) or massive parallel sequencing (MPS) has some fundamental 
differences compared to conventional Sanger sequencing. Sanger sequencing always followed the 
same technical principle (sequencing was directed to a candidate target regions), but NGS uses a 
number of different technical approaches and is not directed, except if there is a previous 
enrichment step. NGS is based on sequencing clonally amplified single molecules of genomic DNA 
and needs between 10-50 reads of the same base to reliable identify heterozygous sequence 
variants since every read shows only one of the possible two alleles in the sequence. Other 
advantages of NGS are the possibility of dosage quantification, simultaneously with sequence 
determining, and the fact that is much cheaper than Sanger sequencing on a per basis manner 
(although still quite expensive on a genome scale). Another important aspect contributing to the 
NGS limitations nowadays is the huge amount of data generated and the even more dramatic 
limitations in accurately distinguish the disease-associated alterations from the benign and 
evolution-related genome aspects. Besides the limitations faced today by this technology, we can´t 
overlook the fact that many obstacles now attributed to next-generation sequencing were 
experienced in much of the same way by Sanger sequencing and MC at their early stages 68, 69.   
In the years ahead of us, we will certainly see NGS acquiring the “first-tier test” position leaving 
behind MC in the same way that we watch in the present regular karyotyping being left behind by 
MC. Nevertheless, we cannot forget that with these new powerful diagnostic instruments come 
large amounts of genomic data and with this come increased responsibility in the data 
interpretation, achieved conclusion and communication to the patient, also with new ethical issues.  
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Aims of the work 
 
The main goal of this thesis was to study 130 consecutive patients with idiopathic ID using an 
aCGH platform (Agilent 180K), in order to contribute for the etiologic classification of these cases. 
The laboratorial work of this thesis was divided in 3 parts: (I) establishment of a DNA bank from 
blood samples for the patients the patients, both parents and, whenever significant, other relatives; 
(II) study genomic imbalance for the whole genome in patients with idiopathic ID by aCGH 
technique; (III) to determine the contribution of the CNVs found in the patients to their phenotype.   
 
The specific aims of this work were: 
1. Establishment of a DNA bank for trios of families for which the child have unexplained ID. 
The establishment of these DNA bank will allow the possibility for future study of the 
negative cases by different techniques.   
2. Establishment of a neurocognitive profile for all the patients involved in the study for further 
correlations of genetic and clinical features. 
3. Discovery of CNVs that allow the etiologic classification of the disease in the patients. 
4. Discovery of previously unreported CNVs that can account for the phenotype of ID. 
5. Pinpoint the genes, within the CNVs found, that may be important for nervous system 
development or synaptic functioning. 
6. Conclude about the utility of using these technologies for diagnosis of idiopathic ID in the 
clinical context. 
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Chapter 2 
 
Results and Discussion 
 
Copy number variations in Portuguese patients with idiopathic 
intellectual disability  
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Foreground for the work  
 
The increasing number of publications and guidelines referring aCGH as the first line diagnostic 
tool while testing children with ID gives rise to the need for implementation of such technique as a 
diagnostic tool in Portugal. The performance of a pioneer study using aCGH to analyze patients 
with previously unknown ID etiology, has advantages such as (I) the determination of detection rate 
in previously negative cases and (II) the epidemiologic study of the Portuguese ID patients for 
CNVs type and incidence.  
The determination of the CNVs responsible for this disorder in patients either with syndromic and 
non-syndromic ID is important for the clinical correspondence in a future diagnostic perspective. 
The discovery of previously reported as well as new CNVs in a set of well characterized patients is 
also relevant for a research point of view as enabling the possibility for the discovery of new genes 
associated with the clinical features of the patient and in the elucidation of the mechanisms 
involved in neuronal development, maturation and functioning of the nervous system. 
Since the real extent of CNVs occurrence in the human genome is not yet completely characterized 
and this kind of variations usually occur de novo and spread along the genome, another 
challenging aspect in the molecular study of a group of Portuguese patients is the lack of 
knowledge regarding the genomic landscape of the population per se. This aspect may give rise to 
problems in distinguish from pathogenic CNVs from rare and population specific benign variants. 
Additionally, the determination of the alteration effect at molecular and functional level can also 
become a challenge. In order to accurately distinguish a pathogenic CNV from a benign alteration it 
is necessary (I) search for the alteration in described control populations, (II) to study the parents 
and any other relevant sibling for the presence of the alteration and (III) review the literature for the 
genes involved in the alteration and try to hypothesize about their relevance in the molecular 
pathways involved in ID.       
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Material and methods 
 
Patients 
 
We have collected detailed clinical information and DNA samples from 260 patients with idiopathic 
ID. So far we have performed aCGH and analyzed data for a total of 130 patients (number of 
patients described in this study). 
The vast majority of the patients were observed by a clinical geneticist, a neuropediatrician and a 
psychologist.  
All the 130 patients have detailed clinical information regarding the clinical genetic field, 59 were 
observed by a neuropediatrician and 128 were evaluated by a psychologist. Their clinical features 
and cognitive profile have been registered in detail, but in an anonymous manner, in an online 
secure database in parallel to the genetic study, allowing collaborators from different regions of 
Portugal to share and discuss the information (http://www.neurodevgen.org/). Clinical and genetic 
information is kept anonymous and confidential in the same database. A DNA bank from blood 
samples for patients and families was also established.    
All the patients included in the study tested negative for the routinely performed laboratory tests 
such as, documented high-resolution G-banding karyotype, flourescence in situ hybridization 
(FISH) studies when specific syndrome suspected and fragile X testing when clinically indicated 
(FRAXA and FRAXE). The eligibility criteria for the patients included in the study are listed in more 
detail in table 2.1. 
All the patients involved in the study were selected by clinical geneticists from Centro de Genética 
Médica Jacinto Magalhães do INSA (Porto), and neuropediatricians from Hospital de Geral de Stº 
António and Hospital Pediátrico de Coimbra.  
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Table 2.1 – Eligibility criteria for the studied patients. All the patients included in the study needed to fulfill 
the criteria described below.  
Eligibility criteria for the studied patients 
Inclusion criteria 
1. Documented developmental delay/ ID on basis of an individually administered IQ test equal/below 70 for 
individuals with ages 3 or higher; 
2. Dysfunction/impairment in more than 2 areas of: communication, self-care, home living, social/interpersonal skills, 
use of community resources, self direction, functional academic skills, work, leisure and safety. 
3. Documented developmental delay on basis of clinical evaluation by a paediatrician for individuals with ages 
between 1 and 3 years of age. Individuals included in this group will be individually administered IQ test when 
they reach age of three. 
4. Unknown aetiology/unexplained developmental delay/ID. 
5. Onset of the developmental delay/ID during childhood. 
6. Previous normal investigation including: baseline general investigation including biochemistry workup (renal, liver, 
thyroid function tests) and full blood count; documented high-resolution karyotype (>650 bands); fragile X testing 
when clinically indicated (FRAXA and FRAXE); ATRX (HgH inclusion bodies in red cells); metabolic screen when 
clinical findings or laboratory anormalities suggesting a metabolic disorder; flourescence in situ hybridization 
(FISH) studies when specific syndrome suspected (e.g. VeloCadioFacial, Williams-Beuren, Smith-Magenis...); 
pregnancy TORCH serologies if available or Guthrie's 
7. DNA of the proband and both parents available. 
Exclusion criteria 
1. Not meeting any of the inclusion criteria; 
2. Presence of a recognizable pattern pattern of anomalies (known syndrome or association); 
3. Establishment of the aetiology, or specific diagnosis during the ongoing study. 
 
Within the 130 patients studied in this work, 56 patients have non-syndromic ID while 74 were 
syndromic. We have colected a total of 126 trios; for 4 patients, only one of the parents was 
collected. A total of 40 females and 90 males were included in this analysis. Only 53 patients 
characterized didn´t present familial history of ID, congenital abnormalities and/or repetitive 
abortions. 77 of the cases had familial history of ID, CA or epilepsy. Of those 77 cases, 80% 
presented familial history of ID, 19.5% familial history of congenital abnormalities and 13% familial 
history of epilepsy.  
Neurologic alterations were present in were present in 48 of the cases (epilepsy in 33% of the 
cases, ataxia in 16%, tremor in 4.2%, hypotony in 46% and diminished sensibility to pain in 2%), 
Ophtalmologic impairments were found in 47 cases while otorrinolaringologic alterations were 
present in 19 cases. Electroencephalogram analysis revealed alterations for 13 cases while 
nuclear magnetic resonance and/or computed axial tomography revealed alterations for 44 cases. 
Facial dysmorphisms were present in 74 cases and a total of 37 patient presented head 
circumference alteration (26 cases with microcephaly and 11 cases with macrocephaly).  
Behavior abnormalities were present in 70 of the patients (autism or autistic features in 12 cases, 
aggressiveness in 25 cases and hyperactivity in 52 cases. Sleep disturbances were aslo present in 
6 cases.  
Skeleton alterations were found in 19 patients, skin alterations in 36 cases and stereotypies in 33 
patients.  
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DNA extraction 
 
Genomic DNA was extracted from peripheral blood using the Citogene® DNA isolation kit 
(Citomed, Portugal) according to the manufacturer´s protocol 
(http://www.citomed.com/index.php?option=com_content&view=article&id=46&Itemid=63). 
 
Oligonucleotide aCGH 
 
The aCGH analysis was performed on a human genome CGH Agilent 180K custom array designed 
by the Low Lands Consortium (LLC, Professor Klass Kok) in order to be used in the analysis of 
children with ID/DD (AMADID:023363; Agilent, Santa Clara, CA). The array contained about 
180.000 in situ synthesized 60-mer oligonucleotide probes with a mean resolution of approximately 
one probe every 17Kb (the resolution can reach 11Kb in the RefSeq genes rich regions)  designed 
specially for the study of neurodevelopment and/or congenital abnormalities associated disorders 
(probes enrichment in regions known to be associated with DD/ID spectrum disorders). In the lower 
resolution areas, the array is garranteed to detect at least CNVs above 75Kb.  DNA labeling was 
performed using the ENZO Labeling Kit for Oligo Arrays (Enzo Life Sciences, Inc.). With this kit 
random hexamers are annealed to a denatured template DNA, and Cy3 or Cy5 dUTPs are then 
incorporated into new DNA strands by exo-Klenow fragment. A total of 500 ng of DNA was labeled 
with Cy3 (test DNA) and Cy5 (reference DNA) using Klenow fragment at 37ºC during 4 hours 
(http://www.enzolifesciences.com/ENZ-42671/cgh-labeling-kit-for-oligo-arrays/). The removal of 
uncoupled nucleotides as carried out in a MinElute PCR purification kit (Qiagen) according to the 
manufacturer´s instructions 
(http://www.qiagen.com/Products/DnaCleanup/GelPcrSiCleanupSystems/MinEluteReactionCleanu
pKit.aspx?r=1644).      
As reference DNA was used Kreatech´s MegaPoll Reference DNA (Kreatech Diagnostics), a 
homogeneous DNA pool from male or female human genomic DNA which has been isolated from 
100 different anonymous healthy individuals. The ethnic background of the DNA poll is 85% of 
Caucasian and Hispanic and 15% of Afro-American. This product was specifically developed as a 
reference DNA for aCGH use.  
Arrays were then hybridized using the Agilent SurePint G3 Human CGH Microarray Kit. Briefly, 
samples and controls were hybridized in the presence of Cot-1 DNA and blocking agents for 24 
hours, 65ºC and 20rpm. After the hybridization period, the slides were washed and scanned with 
Agilent Microrray Scanner. Data was extracted with the Agilent Feature Extraction (FE) Software 
v10.5 using default settings for CGH hybridizations.   
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HUMARA X-chromosome inactivation (XCI) assay 
 
The X-inactivation assay was carried out in the HUMARA (human androgen receptor) locus, which 
is a highly polymorphic CAG repeat with a very near Hhal enzyme restriction site, according to the 
protocol designed by 153. Enzymatic digestion was carried out in 100 ng of genomic DNA at 37ºC 
for 16 hours. The restriction enzyme hydrolyzed only the unmethylated alleles.  
PCR reaction was carried out for both digested and non-digested DNA in a final volume of 25 µl 
reaction mixtures (1x enzyme buffer, 37.5 mM of MgCl2, 5 mM of dNTPs, 2.5 µM of each primer 
and 1U of Taq DNA polymerase (Invitrogen)). The thermal cycling profile (Eppendorf) consisted of 
an initial denaturation step for 10 minutes at 96ºC, followed by 40 cycles of denaturing at 96ºC for 
45 seconds, annealing at 67ºC for 30 seconds and extension at 72ºC for 45 seconds, followed by a 
final extension at 72ºC for 15 minutes. PCR primers and cycling conditions are described in detail 
in appendix 1 (table S1).     
After PCR gel visualization the products were separated on an automated DNA-sequencer (ABI-
3130 Genetic Analyzer, Applied Biosystems, Life technologies) serving the allele peak height as 
the semiquantitative measure of the amount of PCR product amplified from each allele. The 
samples were defined as having a deviated XCI patter if they presented a corrected allele ratio out 
of the 0.33 – 3 range.    
  
Data analysis 
 
Image analysis were performed using the across-array methodology described previously 140. CGH 
data was analyzed using Nexus Copy Number 5.0 software with FASST Segmentation algorithm 
and a minimum of three probes in a region required to be considered a copy number alteration. 
The FASST Segmentation algorithm is a novel Hidden Markov Model (HMM) based approach that, 
unlike other HMM methods, does not aim to estimate the copy number state at each probe but 
uses many states to cover possibilities, such as mosaic events, and then make calls based on a 
second level threshold. The stipulated minimal thresholds for calling a copy number gain were 0.2 
(Copy number Gain) and 0.6 (High Copy Gain) and for calling a copy number loss were -0.2 (Copy 
number Loss) and -1 (Homozygous Copy Loss).  
The arrays design, database consultation and comparative analysis was performed using genome 
build 36.1/HG18.   
 
Interpretation of CNVs 
 
Interpretation of CNVs found was carried out based on the workflow proposed by 154. For each 
patient the total number of CNVs was listed according to the position in the chromosome and 
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Figure 2.1 – Schematic representation of the workflow followed for the interpretation of the CNVs found 
in each patient.  
classified according to the workflow represented in figure 2.1. The list of all the CNVs found for the 
patients with pathogenic or very likely pathogenic alterations can be seen in the appendix 2 of the 
thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Prioritization 
 
The prioritization of the genes discussed for each patient was based on the data regarding its 
function described in OMIM and PubMed databases.  An informatics analysis was also performed 
for each patient using the TS-CoExp Disease Gene Prediction web tool (http://87.253.99.109/ts-
coexp/index.php?site_section=NULL). TS-CoExp basis its predictions on conserved co-expression 
data at either multi-tissue, tissue-specific or condition specific levels. This tool leveraged with data 
from the OMIM/PubMed databases regarding described/predicted protein function. For all the 
patients the search was performed using the “Brain” network and a MinMiner value fo 0, 4.  The list 
of reference syndromes (training set) was obtained by the search in OMIM database for entrances 
with “mental retardation” or “Intellectual disability” expressions in title, text and synopsis and the 
results were limited to the entries with phenotype description and known basis. The search 
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retrieved a list of 727 OMIM entrances (appendix 1, table S2) for the previous criteria. For the 
discussion were selected the 3 genes with the best p-values.   
 
 
Web resources  
The following web resources were used for the interpretation of CNVs significance in the patients: 
• Database of Genomic Variants (http://projects.tcag.ca/variation/), used for search of CNVs 
described in healthy controls; 
• UCSC Genome Bioinformatics (http://genome.ucsc.edu/), used for upload and visualization 
of “house-detected” CNVs databases;  
•  DECIPHER (https://decipher.sanger.ac.uk/application/), used for search of clinically 
significant CNVs; 
• Ensembl (http://www.ensembl.org/index.html), used for gene search; 
• OMIM- Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim) used for 
gene and clinical  associated data search; 
• PUBMED (http://www.ncbi.nlm.nih.gov/pubmed/), for bibliographic information search; 
• WHO - International Statistical Classification of Diseases and Related Health Problems 
(http://apps.who.int/classifications/apps/icd/icd10online/), for ID classification.  
• TS-CoExp - Disease Gene Prediction web tool (http://87.253.99.109/ts-
coexp/index.php?site_section=NULL)  
 
 
 62 
 
  
 63 
 
Results 
 
We have analyzed the aCGH data from 130 patients and discovered non polymorphic genomic 
imbalances in 53 patients. For each analyzed genome an average of 25 CNVs with more than 3 
consecutive altered probes was found. The lists of all the CNVs found for each patient are present 
in appendix 1 (table S3).  Of the 53 patients, 27 patients had copy number variations of unknown 
significance and, consequently, further studies need to be performed to clarify the pathogenicity of 
those alterations. A summary of these alterations is described below: 
• 3 cases presented already described microdeletion /microduplication syndromes: 
o MECP2 gene duplication syndrome (2 patients); 
o 8p23.1 microdeletion syndrome (1 patient);  
• In 20 patients we found alterations not described previously and that, considering the size 
and the implicated genes, are very likely to be pathogenic: 
o 1p36.21p36.23 deletion; 
o 1q43-q44 deletion; 
o 2p13.1-13.3 deletion; 
o 2q11.2-q12.2 deletion; 
o 2q11.2 duplication; 
o 3q22.1-q23 deletion; 
o 5q35.3 dup  + 1q21.3-q22 dup + 19p13.2 dup; 
o 5q35.3 duplication; 
o 6q25.3 deletion; 
o 7q11.23 deletion (2 patients); 
o 7q33 deletion; 
o 9q34.2-q34.3 duplication + 14q32.31-q32.33 duplication; 
o 9q33.2-q33.3 duplication; 
o 10q26.3 deletion; 
o 12q24.21-24.2 deletion; 
o 12q24.21 duplication;  
o 20q13.12-q13.13 deletion; 
o Xq24 duplication; 
• In 3 patients genomic imbalances concerning susceptibility loci were found: 
o 1q21.1 duplication; 
o 16p13.11 duplication (2 patients); 
• For 27 other patients, several smaller but likely significant alterations were found. For 
those, it is necessary the search in the parents in order to clarify the relevance for the 
phenotype.  
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The summary of the alterations as well as the total number of patients for each alteration is 
described in table 2.2. 
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Table 2.2 - Summary of the alteration found in the patients. 
Classification Number of patients 
Patient 
code Description Size (Mb) 
Number of 
genes 
involved 
Known syndrome 
Parents analysis Total 
number of 
patients Done Result 
Known 
syndromes 
2 #1 and #2 Xq28 Dup 2.8; 0.5 78; 16 MECP2 gene duplication Yes De novo; Carrier mother 3 
1 #3 8p23.1 Del 5.5 70 8p23.1 microdeletion Yes De novo 
Novel, very likely 
pathogenic CNVs 
1 #4 1p36.21p36.23 Del 6.7 86 - Yes De novo 
20 
1 #5 1q43-q44 (AKT3) Del 0.18 2 - Yes De novo 
1 #6 2p13.1-13.3 Del 4 62 - Yes De novo 
1 #7 2q11.2-q12.2 deletion 4.5 24 - No - 
1 #8 2q11.2 Dup 1.5 24 - No - 
1 #9 3q22.1-q23 (FOXL2) Del 10.2 62 BPES + ID Yes De novo 
1 #10 5q35.3 dup  + 1q21.3-q22 dup + 19p13.2 dup 0.12 + 0.2 + 0.28 6 + 6 + 6 
Inside the Sotos 
syndrome region Yes De novo 
1 #11 5q35.3 Dup 0.9 12 - No - 
1 #12 
6q21 dup + 9p22.2 dup 
+16q24.3 dup + Xq26.3 
dup 
0.3 + 0.05 + 0.1 3 + 2 + 2 - Yes De novo and inherited 
1 #13 6q25.3 Del 2.6 7 - Yes De novo 
2 #14 and #15 7q11.23 Del 0.4; 0.3 11; 12 Inside the WBS region No - 
1 #16 7q33 Del 2 15 - No - 
1 #17 9q34.2-q34.3 Dup + 14q32.31-q32.33 Dup 5.5 + 3 135 + 46 - Yes 
9q34.2-q34.3 dup (de novo); 
14q32.31-q32.33 dup (de 
novo) 
1 #18 9q33.2-q33.3 Dup 3.6 52 - No - 
1 #19 10q26.3 Del (EBF3) 0.65 3 - No - 
1 #20 12q24.21-24.2 Del 1 8 - No - 
1 #21 12q24.21 Dup 0.3 2 - No - 
1 #22 20q13.12-q13.13 Del 5.5 88 - Yes De novo 
1 #23 Xq24 Dup 0.3 4 - Yes Carrier mother 
Susceptibility loci 
1 #24 1q21.1 Del 2.5 43 1q21.1 Del  Yes Carrier father 
3 
2 #25 and #26 16p13.11 Dup 0.8; 0.9 9; 11 16p13.11 Dup  Yes Carrier mother 
CNVs of unknown 
significance 27 - Several Variable Variable - No - 27 
    
 
   
TOTAL 53 
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The MECP2 (methyl-CpG-binding protein 2) gene encodes for a homonymous protein (MeCP2) 
with capacity to both activate and repress transcription. MeCP2 is required for maturation of 
neurons and is correct development. Mutations in the MECP2 gene are associated with Rett 
Syndrome, a severe neurodevelopment disorder that affects 1:10000 girls worldwide. Mutations in 
MECP2 were also found in boys with severe infantile encephalopathy, ID and development delay 
155
. 
The RAB39B (Ras-associated protein RAB39B) gene encodes a small GTPase involved in the 
regulation of vesicular trafficking between membrane compartments with high expression levels 
neuronal precursors and neurons of the brain, mainly in hippocampus 156. Mutations in RAB39B 
gene were identified in patients with X-linked ID in two different families 156. Further studies in a 
mouse model reveal that absence of RAB39B protein resulted in decreased number of growth 
cones in neuritis and, consequently, decreased number of neuronal branches. This reduced 
number of neuronal terminals is thought to be associated with deficient synapse formation and 
instability. Until this date, there is no CNVs described involving RAB39B gene in PUBMED or 
OMIM databases.  
The SLC6A8 (solute carrier family 6; neurotransmitter transporter, creatine; member 8) gene 
encodes a creatine transporter that was found to be mutated in patients with ID. SLC6A8 protein 
has a crucial role in the temporal and spatial maintenance of the energy supply to muscle and brain 
157
. The lack of SLC6A8 leads to a very strong deficiency of creatine in the central nervous system 
and patients affected by mutations in this gene can present severe neurodevelopment delay, ID, 
impairment in speech acquisition and also epilepsy 158.  
The GDI1 (GDP dissociation inhibitor 1) gene encodes a protein necessary for the GDP-GTP 
exchange reaction of members of the Rab family. Inactive Rab GTPases are maintained in the 
cytosol by binding to GDP-dissociation inhibitor. GDI1 is highly expressed in the brain and has 
been considered the most likely candidate for the explanation of ID phenotype in patients carrying 
duplications at Xq28 region not covering the MECP2 gene. In fact, GDI1 duplicated copies perfectly 
correlated with ID severity in patients with this type of alterations 159.       
Another 7 genes involved in the duplication encode for proteins that act or may act in different 
molecular pathways known to be involved in ID etiology. These genes are listed in table 2.3. 
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Table 2.3 – Summary of other genes covered by the duplication that may contribute for the patient’s phenotype. 
Gene Locus Protein Function Phenotype 
HAUS7 Xq28 HAUS7 
Is a subunit of a complex that is a microtubule-
binding complex involved in microtubule 
generation within the mitotic spindle and is vital to 
mitotic spindle assembly 
Not described 
FAM58A Xq28 FAM58A 
Contains a cyclin box-fold domain, a protein-
binding domain found in cyclins with a role in cell 
cycle and transcription control. 
STAR syndrome 
PLXNB3 Xq28 PLXNB3 Is a plexin with high affinity for semaphorin-5a 
Possibly associated with X-
linked 
adrenoleukodystrophy 
together with ALD gene 
L1CAM Xq28 L1CAM 
Is a cellular adhesion molecule found primarily in 
the nervous system of several species and may be 
more aptly called a neural recognition molecule. 
X-linked hydrocephalus; 
MASA syndrome;X-linked 
spastic paraplegia 
ARHGAP4 Xq28 ARHGAP4 Is a Rho GTPase-activating protein 4 
Possible association with 
nephrogenic diabetes 
insipidus 
FLNA Xq28 Filamin A 
Actin-binding protein that regulates reorganization 
of the actin cytoskeleton by interacting with 
integrins, transmembrane receptor complexes, and 
second messengers. 
X-linked dominant 
periventricular heterotopia; 
PLXNA3 Xq28 PLXNA3 Is a plexin with high affinity for semaphorin-3f Not described 
 
FLNA (Filamin A) gene encodes a protein named filamin A that regulates reorganization of the 
actin cytoskeleton by interacting with integrins, transmembrane receptor complexes, and second 
messengers. Filamins are responsible for the creation of crosslinks between actin filaments 
generating orthogonal networks in the cytoplasm and participating in the anchoring of membrane 
proteins to the actin cytoskeleton. Remodeling of the cytoskeleton is a central process involved in 
the modulation of cell shape during migration 160. Mutations in FLNA gene have been identified in 
patients with periventricular heterotopia and otopalatodigital syndrome spectrum disorders. 
Otopalatodigital syndrome is characterized by malformations that arrive from the incorrect 
development of craniofacial and long bones 161. Although there are no duplications described 
affecting the entire gene in otopalatodigital syndrome patients, the duplication of this gene in our 
patient may account for the facial dysmorphisms and unequal skull structure of the patient.  
Even though the MECP2 duplication syndrome is a severe neurodevelopment disorder affecting 
males, patient 1 seems to have a more severe phenotype when compared with the reported 
features in the literature. This aspect may be due the due the fact that the alteration in patient 1 
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encompasses three additional ID-related genes. The predicted outcome of duplications covering 
entire genes is not well characterized. Even if the isolated extra amount of genomic DNA for these 
genes resulted in a benign alteration, patient 1 has at least three more genes related with ID 
(besides MECP2) that are duplicated at the same time. We believe that the MECP2 duplication 
syndrome phenotype in the patient is due to MECP2 alteration, while the others genes are 
contributing for the severity of the phenotype and malformations found in the patient. 
 
TS-CoExp analysis for patient 1 retrieved RAB39B (RAB39B, member RAS oncogene family), 
ATP6AP1 (ATPase, H+ transporting, lysosomal accessory protein 1) and L1CAM (L1 cell adhesion 
molecule) genes as the 3 more likely to cause ID, among those covered by the duplication. 
ATP6AP1 gene encodes for a vacuolar H(+)-ATPase protein expressed in microglia 162. Mutations 
in a member of the same family - ATP6AP2 (ATPase, H+ transporting, lysosomal accessory protein 
2) were described in patients with X-linked ID and epilepsy 163. The other 2 genes were described 
above.     
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.4.  
 
Table 2.4 – Summary of the alteration in patient 1 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function.  
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#1 Xq28 (152,001,572-154,881,207) X 2 73 260 
ABCD1, ARHGAP4, ATP2B3, ATP6AP1, AVPR2, 
BCAP31, BGN, BRCC3, CLIC2, CTAG1A, CTAG1B, 
CTAG2, DKC1, DNASE1L1, DUSP9, EMD, F8, F8A1, 
F8A2, F8A3, FAM3A, FAM50A, FAM58A, FLNA, 
FUNDC2, G6PD, GAB3, GDI1, H2AFB1, H2AFB2, 
H2AFB3, HAUS7, HCFC1, IDH3G, IKBKG, IRAK1, 
L1CAM, LAGE3, LOC100132963, MAGEA1, MECP2, 
MIR718, MPP1, MTCP1, MTCP1NB, NAA10, 
NCRNA00204, NCRNA00204B, OPN1LW, OPN1MW, 
OPN1MW2, PDZD4, PLXNA3, PLXNB3, PNCK, 
RAB39B, RENBP, RPL10, SLC10A3, SLC6A8, 
SNORA36A, SNORA56, SNORA70, SRPK3, SSR4, 
TAZ, TEX28, TKTL1, TMEM187, TMLHE, TREX2, 
UBL4A, VBP1, ZFP92, ZNF275, IL9R, SPRY3, VAMP7 
RAB39B, 
ATP6AP1, 
L1CAM 
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month of age after a premature labour. It would be interesting to study the other brother for the 
same alteration. 
Similar to patient 1, patient 2 also displays plagiocephaly. The fact that the FLNA gene is also 
duplicated in this patient lead us to believe that it may also account for the cranial abnormalities in 
patient 2. 
We also believe that the differences between the ID severity in both cases is due to the size of the 
duplication that, in patient 2, doesn´t cover any other previously described ID associated gene.   
The MECP2 duplication syndrome is 100% penetrant in males, leading to severe ID, infantile 
hypotonia and speech impairment. Table 2.5 describes the main features presented by patient 1 
and 2 and compared with the clinical accepted phenotype for the MECP2 duplication syndrome 
patients.     
 
Table 2.5 – Comparison between patient 1 and 2. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
TS-CoExp analysis for patient 2 retrieved L1CAM , MECP2 and FLNA genes as the 3 more likely to 
cause ID, among those covered by the duplication. These 3 genes were described above. 
MECP2 duplication patients Patient 1 Patient 2 
Severe ID Present (Profound ID) Present (Mild ID) 
Poor or absent speech Absent Poor 
Hypotonia No No 
Progressive spasticity Not determined Not determined 
Recurrent respiratory infections Present Not determined 
Seizures No No 
Severe impairment in mobility Yes (ataxia) No 
Autistic features Present No 
Gastrointestinal dysfunction Present Present 
 72 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented on table 2.6. 
 
Table 2.6 - Summary of the alteration in patient 2 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#2 Xq28 (152,783,739-153,255,487) X 2 16 57 
ARHGAP4, AVPR2, FLNA, HCFC1, IRAK1, L1CAM, 
MECP2, MIR718, NAA10, OPN1LW, OPN1MW, 
OPN1MW2, RENBP, TEX28, TKTL1, TMEM187 
L1CAM, 
MECP2, FLNA 
 
The XCI study for the mother of the patient 2 retrieved no conclusive results since both alleles for 
HUMARA studied locus have the same repeat number, making it impossible to determine the XCI 
pattern for this locus. 
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2. 8p23.1 deletion syndrome 
 
Patient #3 
 
This patient is a 13 years old girl with moderate ID (IQ= 48) with microcephaly (head circumference 
4.4 standard deviations below the normal), lower weight, arched eyebrows, high arched palate, 
pulmonary stenosis, ventricular septal defect, hyperactivity and attention deficit. aCGH revealed a 
5.5 Mb de novo deletion at chromosome region 8p23.1 (chr8:7,026,686-12,529,929) containing 70 
genes. Figure 2.4A presents the facial appearance of patient 3 while figure 2.4B shows the 
alteration detected by aCGH.   
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 8p23.1 deletion syndrome is a clinically recognized syndrome characterized by congenital 
heart abnormalities (atrial and/or ventricular septal defects and general heart abnormalities), 
congenital diaphragmatic hernia, hyperactivity, intellectual disability and development delay164. In 
Figure 2.4 - Facial appearance, schematic representation of the genomic alteration and pedigree representation for 
patient 3. (A) The facial appearance of the patient reveals its microcephaly and arched eyebrows. (B) The genomic alteration 
is represented by the red line bellow the 8p23.1 cytoband where it is possible to observe the diminished mean ratio of the 
probes contained in that region. The UCSC genes present in the genomic region altered in the patient in also represented. (C) 
The patient is represented by the arrow.  
Lo
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Spina bifida 
ID 
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general terms, the congenital heart defects presented by the patients are attributed to the GATA4 
(GATA-binding protein 4) gene haploinsufficiency. GATA4 is a zinc finger transcription factor that 
belongs to a group of transcription factors that recognize a consensus sequence known as “GATA” 
motif present in the promoter region of many genes. GATA-binding proteins control gene 
expression and cell differentiation in a variety of tissues 165. Due to the large variability of heart 
malformations found among patients carrying 8p23.1 deletions, it was hypothesized that maybe not 
only the GATA4 gene plays a crucial role in heart formation. Additionally to this gene, SOX7 (SRY-
box 7) has been associated with the cardiac phenotype seen in the patients.  SOX7 encodes a 
protein containing a high mobility group (HMG) characteristic of proteins that are transcription 
factors with critical roles in the regulation of diverse developmental processes 166. It seems that 
patients carrying deletions involving both GATA4 and SOX7 have more severe cardiac defects 167. 
A recent publication by Ballarati L and colleagues, report the case of a boy with an alteration very 
similar to the one present in our patient 168. As in the reported case, our patient has a 5 Mb deletion 
flanked by two low copy repeats created by the olfactory receptors gene clusters REPD and REPP 
169, 170
. Figure 2.5 represents the alignment of the alteration found in patient 3 with the ones 
reviewed in Ballarati et al, 2011.        
 
      
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
70266 125299
Present case 
Ballarati et al, 2011 
Wat et al, 2009 
Wat et al, 2009 
Paez et al, 2008 
Paez et al, 2008 
Chen et al, 2007 
Shimokawa et al, 2005 
Slavotinek et al, 2005 
Giglio et al, 2000 
Giglio et al, 2000 
Devriendt et al, 1999 
Giglio et al, 2000 
Devriendt et al, 1999 
Devriendt et al, 1999 
Devriendt et al, 1999 
Devriendt et al, 1999 
Faivre et al, 1998 
Figure 2.5 – Schematic comparison of the alteration present in patient 3 with the ones described in the literature. 
Patient 3 (in red) carries a 5.5 Mb deletion highly similar to the one described by 
168, 167
. 
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The 8p23.1 deletion has an associated clinical phenotype of growth impairment, ID, facial 
dysmorphisms, cardiac abnormalities, microcephaly and psychiatric troubles.  Our patient has a 5 
Mb deletion and shows the main clinical features of the syndrome. As the deletion is located inside 
the two LCR clusters that are thought to be responsible for the origin of this imbalance, we believe 
that NAHR was the originating mechanisms for the deletion in the patient. As was said before, our 
patient has a very similar alteration to the one recently described by Ballarati et al, 2011. The 
clinical comparison is made in table 2.7.   
 
Table 2.7 – Clinical comparison between the patient described by Ballarati et al, 2001 168and patient 3. 
8p23.1 deletion syndrome Ballarati et al, 2011 168 Present case 
Cardiac malformations Yes (ventricular septal defect) Yes (ventricular septal defect) 
Development delay Yes Yes 
ID Yes (mild ID) Yes (moderate ID) 
Diaphragmatic hernia No No 
Hypospadias No Not applicable 
Hyperactivity/attention 
deficit/impulsiveness 
Yes (Attention deficit disorder) Yes (Attention deficit disorder) 
Microcephaly Yes Yes 
Dysmorphic facial features 
Yes (sloping forehead, high nasal bridge, 
deep-set eyes) 
Yes (arched eyebrows, high 
arched palate) 
 
 
Another interesting gene present in the deleted region is TNKS (TRF1-interacting, ankyrin-related 
ADP-ribose polymerase), which was recently proposed as responsible for Cornelia de Lange 
syndrome1 171. This gene encodes a protein (tankyrase) that acts as an acceptor for adenosine 
diphosphate (ADP) ribosylation. Although TNKS function have not been assessed in patients with 
8p231 deletion and Cornelia de Lange syndrome yet, the phenotype of the patients is very different 
and most likely not related with TNKS haploinsufficiency.   
 
TS-CoExp analysis for patient 3 retrieved CTSB (cathepsin B), FDFT1 (farnesyl-diphosphate 
farnesyltransferase 1) and MTMR9 (myotubularin related protein 9) genes as the 3 more likely to 
cause ID, among those covered by the deletion. 
The CTSB gene, also called amyloid precursor protein secretase (APP), suffers a cleavage of the 
amyloid beta peptide sequence during constitutive processing of its precursor, leading to the 
deposition of Aβ. It was suggested that a deregulation in this mechanism could be in related with 
                                                          
1
 Cornelia de Lange syndrome is characterized by typical facial dysmorphisms, hirsutism, limb abnormalities, internal organ 
abnormalities (including diaphragmatic hernia), impaired pre and postnatal growth, microcephaly and ID.   
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Alzheimer disease2 172. CTSB was found to be overexpressed in tumors of the lung, prostate, 
colon, breast and stomach 173. According to TS-CoExp tool, the CSTB gene is co-expressed in the 
brain with PRPS1 (phosphoribosyl pyrophosphate synthetase 1) gene. PRPS1 catalyzes the 
phosphoribosylation of ribose 5-phosphate to 5-phosphoribosyl-1-pyrophosphate, necessary for 
purine and pyrimidine biosynthesis pathways 174. Mutations in this gene were described in patients 
with neurodevelopment abnormalities, deafness and hyperuricemia3. However, these phenotypes 
were found in patients carrying mutations causing gain of function in the protein leading to 
phosphoribosyl pyrophosphate synthetase 1 superactivity 175. 
Farnesyldiphosphate farnesyltransferase (FDFT1) catalyzes the conversion of trans-
farnesyldiphosphate to squalene during cholesterol biosynthesis pathway. Patterson et al, 1995 
studied the breakpoints of an 8p23.1 inversion and verified that it affected the 5-prime coding 
region of the FDFT1 gene. This alteration was found in patients with Recombinant chromosome 8 
syndrome4, an autosomal dominant disorder characterized by growth retardation, multiple 
congenital malformations (such as cardiac and genitourinary defects), postnatal microcephaly, 
facial dysmorphisms and DD/ID 176. These findings suggest FDFT1 gene as a good candidate for 
the ID phenotype displayed by the patient.   
MTMR9 is a myotubularin-related protein that contains a double-helical motif though to be 
associated with a function in cell proliferation 177. This characteristic may indicates MTMR9 as a 
good candidate, together with the previously described gene), for the severe microcephaly of the 
patient.  
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.8.  
                                                          
2
 Alzheimer disease is a pathology associated with memory loss and other intellectual abilities.  Symptoms usually develop 
slowly and get worse over time, interfering with daily life activities. Alzheimer's disease accounts for 50 to 80 percent of 
dementia cases.  
3
 Hyperuricemia refers to the abnormally high levels of uric acid in the blood.  
4
 Recombinant chromosome 8 syndrome is caused by a recombinant chromosome 8 characterized by duplication of 
8q22.1-qter and deletion of 8pter-p23.1.  
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Table 2.8 - Summary of the alteration in patient 3 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#3 8p23.1(7,026,686-12,529,929)X1 70 275 
AMAC1L2, BLK, C8orf12, C8orf74, CLDN23, CTSB, 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, 
DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1, DEFB109P1B, DEFB130, DEFB134, DEFB135, 
DEFB136, DEFB4, ERI1, FAM167A, FAM66A, FAM66B, 
FAM66D, FAM66E, FAM86B1, FAM86B2, FAM90A10, 
FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, 
FAM90A5, FAM90A7, FAM90A8, FAM90A9, FDFT1, 
FLJ10661, GATA4, LOC157627, LOC349196, LOC392196, 
MFHAS1, MIR124-1, MIR1322, MIR548I3, MIR597, MIR598, 
MSRA, MTMR9, NEIL2, PINX1, PPP1R3B, PRAGMIN, RP1L1, 
SOX7, SPAG11A, SPAG11B, T-SP1, TDH, TNKS, USP17L2, 
XKR6, ZNF705D, ZNF705G 
CTSB, 
MTMR9, 
FDFT1 
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with the one find in patient 4 has a deletion of 6.15 Mb and a clinical presentation of ID, 
microcephaly, camptodactyly, seizures, short stature, eczema and facial dysmorphisms (down-
turned corners of the mouth, lateral hypoplasia of eyebrows, palpebral fissures slant up and pits of 
ear helix). When compared to our patient, we can see that they share features such as ID, 
microcephaly and facial dysmorphisms (even though they are not exactly the same).  
Regarding the genes altered in both cases, there are 4 genes referred in Decipher as likely 
pathogenic: ANGPTL7 (angiopoietin-like 7), CASZ1 (castor zinc-finger protein 1), MAD2L2 (mitotic 
arrest-deficient 2, S. Cerevisiae, homolog-like 2) and RERE (RE repeats-encoding gene).  
The ANGPTL7 gene encodes the angiopoietin-like 7 protein that is a molecular of the extra-cellular 
matrix and belongs to the Angiopoietin-like proteins family. These proteins contain an amino-
terminal coiled-coil domain and a carboxyl-terminal fibrinogen-like domain and are known as 
angiogenic factors. Several members of ANGPTLs also regulate lipid metabolism independently of 
angiogenic effects, but most of their functions during vertebrate development are not 
demonstrated, besides the expression of some members of the family in the central nervous 
system 178.  
The CASZ1 gene encodes a zinc finger transcription factor and is a neural fate-determination gene 
179
.  
MAD2L2 encodes proteins that play a role in the mitotic spindle checkpoint 180.  
Rere act as transcriptional corepressor by binding to histone deacetylase 1 and 2. RERE gene 
mutation leads to the formation of symmetrical somites in mouse embryos, similar to embryos 
deprived of retinoic acid. Furthermore, Rere also controls retinoic acid signalling, which is required 
to maintain somite symmetry 181. Based on their functional roles, these four genes can be good 
candidates for explaining the ID and morphologic alterations presented by the patient.     
 
Unexpectedly, TS-CoExp analysis for patient 4 retrieved PRAMEF2 (PRAME family member 2), 
PRAMEF1 (PRAME family member 1) and PRAMEF13 (PRAME family member 13) genes as the 
3 more likely to cause ID, among those covered by the deletion. 
These three genes belong to the PRAME gene family, for which the expression limited in normal 
tissue (such as the testis) and increased in a variety of cancers (such as melanomas) 182. The most 
reasonable explanation for the detection of these 3 genes as good candidates for causing ID by the 
Ts-CoExp web tool is their expression in neurologic tumors.    
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.9. 
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Table 2.9 - Summary of the alteration in patient 4 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#4 
1p36.21-
p36.23(chr1:8,516,
261-15,269,259)X1 
86 364 
AADACL3, AADACL4, AGTRAP, ANGPTL7, APITD1, 
C1orf127, C1orf158, C1orf187, C1orf200, CA6, CASZ1, 
CLCN6, CLSTN1, CORT, CTNNBIP1, DFFA, DHRS3, 
ENO1, EXOSC10, FBXO2, FBXO44, FBXO6, GPR157, 
H6PD, HNRNPCL1, KIAA1026, KIAA2013, KIF1B, 
LOC440563, LOC649330, LZIC, MAD2L2, MASP2, 
MFN2, MIIP, MIR34A, MTHFR, MTOR, NMNAT1, 
NPPA, NPPB, PDPN, PEX14, PGD, PIK3CD, PLOD1, 
PRAMEF1, PRAMEF10, PRAMEF11, PRAMEF12, 
PRAMEF13, PRAMEF14, PRAMEF15, PRAMEF16, 
PRAMEF17, PRAMEF18, PRAMEF19, PRAMEF2, 
PRAMEF20, PRAMEF21, PRAMEF22, PRAMEF3, 
PRAMEF4, PRAMEF5, PRAMEF6, PRAMEF7, 
PRAMEF8, PRAMEF9, PRDM2, PTCHD2, RBP7, 
RERE, SLC25A33, SLC2A5, SLC2A7, SNORA59A, 
SNORA59B, SPSB1, SRM, TARDBP, TMEM201, 
TNFRSF1B, TNFRSF8, UBE4B, UBIAD1, VPS13D 
PRAMEF2, 
PRAMEF13, 
PRAMEF1 
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include ID, the alteration that is causing disease is recessive 183. On the other hand, AKT3 is highly 
expressed in the brain and is implicated in numerous biological processes including cell 
proliferation 184. Deletions and translocation breakpoints have been described for region 1q44 in 
patients with microcephaly and agenesis of the corpus callosum. It is important to refer that not all 
the patients described in the paper that had deletion mapping for the region presented agenesis of 
corpus callosum. Some of them presented microcephaly without anomalies in corpus callosum, a 
phenotype that is partially overlapping with that of our patient. The authors propose the AKT3 gene 
as an excellent candidate for developmental human microcephaly and agenesis of the corpus 
callosum 185.  
Another important aspect to highlight is that there are patients described in Decipher with similar 
genomic imbalances (Decipher# 252432 and #252434) for which no phenotypic description is 
provided. Decipher# 252432 carries a 0.12 Mb deletion inherited from a normal parent covering a 
very similar alteration to the one present in patient 18. Decipher#252434 carries a 0.35 Mb de novo 
deletion that affects one gene more than the one present in our patient. In spite of the presence of 
a similar case eventually not associated with disease in Decipher, we cannot exclude the fact that 
this alteration arises de novo in our patient and is phenotypically correlated with the literature.   
 
TS-CoExp analysis for patient 5 retrieved only AKT3 gene, as the one more likely to cause ID, 
among those covered by the deletion (table 2.10). 
 
Table 2.10 - Summary of the alteration in patient 5 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes TS-CoExp 
#5 
1q43-
q44(chr1:241,618,630-
241,805,298)X1 
2 11 AKT3, SDCCAG8 AKT3 
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Patient 6  
Decipher#248972  
Decipher#249203  
genes. In the Decipher database there are only 2 patients with alterations partially overlapping with 
the one present in patient 6. Decipher patient #248972 carries a de novo 12 Mb duplication 
involving cytobands 2p13.3-p12, while decipher patient #249203 carries a de novo 0.9 Mb deletion 
on 2p13.2 cytoband. The schematic comparison between the 3 cases is represented in figure 2.9.       
 
 
 
 
 
Although the comparison of the 3 cases is very limited due to the differences in the imbalance 
sizes, the ID feature is common to all the cases.  
In patient 6, one of the genes deleted is the SEMA4F (semaphorin 4) gene. Even though no direct 
association between SEMA4F deficiency and ID phenotype has been made, this gene encodes a 
very important protein for axon guidance (as reviewed in the introduction), making it a good 
candidate to cause ID 186.  Only the Decipher case #248972 has this gene altered as well. 
 
TS-CoExp analysis for patient 6 retrieved ADD2 (adducin 2, beta), SEMA4F (semaphorin 4F) and 
DYSF (dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) genes as the 3 more 
likely to cause ID, among those covered by the deletion. 
Add2 is a heterodimeric calmodulin-binding protein of the cell-membrane skeleton that is thought to 
play a role in assembly of the spectrin-actin lattice that underlies the plasma membrane 187. A study 
performed by Gillian et al, 1999, demonstrates the important role of Add2 for red blood cells 
membrane stability 188.  
Dysferlin is a transmembrane protein that has is implicated in calcium-dependent membrane fusion 
events and has an important role in muscle fiber repair, being mutated in patients with myopathies 
189
.  
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.11. 
 
 
 
 
 
 
Figure 2.9 - Schematic comparison of the alteration present in patient 6 with the ones described in decipher 
database. Patient 6 carries a 5.5 Mb deletion (red), Decipher#248972 carries a 12 Mb duplication (green) and 
Decipher#249203 carries a 0.9 Mb deletion (red). 
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Table 2.11 - Summary of the alteration in patient 6 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#6 
2p13.3-
p13.1(70,748,41
4- 74,840,026)X1 
62 265 
ACTG2, ADD2, ALMS1, ALMS1P, ANKRD53, 
ATP6V1B1, BOLA3, C2orf7, C2orf78, C2orf81, 
CCT7, CD207, CLEC4F, CYP26B1, DCTN1, 
DGUOK, DUSP11, DYSF, EGR4, EMX1, EXOC6B, 
FBXO41, FIGLA, INO80B, LOC100189589, MCEE, 
MOBKL1B, MPHOSPH10, MTHFD2, NAGK, NAT8, 
NAT8B, NOTO, OR7E91P, PAIP2B, RAB11FIP5, 
RTKN, SFXN5, SLC4A5, SMYD5, SPR, STAMBP, 
TET3, TEX261, TPRKB, VAX2, WBP1, WDR54, 
ZNF638, AUP1, C2orf65, CCDC142, DOK1, DQX1, 
HTRA2, LBX2, LOC151534, LOXL3, PCGF1, 
SEMA4F, TLX2, TTC31 
ADD2, 
SEMA4F, 
DYSF 
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6. 2q11.2-q12.2 deletion 
 
Patient #7 
 
This patient is a 12 years old girl for which no psychometric evaluation could be performed yet. She 
has ventricular enlargement, dysmorphic features (low set ears, bulbous nose, arched eyebrows, 
open mouth appearance, dysplasic teeth), hirsutism, aggressiveness and hyperactivity. Her mother 
is also suspected to have mild ID (picture 2.10C), however this impression has not been confirmed 
by psychometric assessment.         
aCGH revealed a 4.5 Mb deletion at chromosome region 2q11.2-q12.2 (chr2:101,122,697-
105,631,450) containing 24 genes. Figure 2.10A presents the facial appearance of patient 7 while 
figure 2.10B shows the alteration detected by aCGH.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 - Facial appearance, schematic representation of the genomic alteration and pedigree representation for 
patient 7. (A) The facial appearance of the patient shows her low set ears, bulbous nose, arched eyebrows, and open mouth 
appearance. (B) The genomic alteration is represented by the red line bellow the 2q11.2-q12.2 cytoband where it is possible to 
observe the diminished mean ratio of the probes contained in that region. The UCSC genes present in the genomic region altered 
in the patient in also represented. (C) The patient is represented by the arrow; her mother is suspected to have mild ID. 
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The Decipher patient with the most similar alteration (Decipher #250511) has a 6.6 Mb deletion that 
partially overlaps with the one found in patient 7. Decipher #250511 displays some overlapping 
characteristics with our patient such as, ID, open mouth appearance, irregular teeth and facial 
dysmorphisms.  
The fact that the mother of the patient is suspected to have mild ID leads us to hypothesize if the 
same or a similar alteration is also present in the mother. In order to clarify this aspect aCGH in the 
mother will be also performed.   
The OMIM search for the genes covered by the deletion revealed, among others, three interesting 
candidates:  GPR45 (G protein-coupled receptor 45), POU3F3 (POU domain, class 3, transcription 
factor 3) and GREG2 (cellular repressor of E1A-stimulated genes).   
GPR45 encodes a protein belonging to the G protein-coupled receptors that are integral membrane 
proteins and mediate signals to the interior of the cell. GPR45 transcript was detected in basal 
forebrain, frontal cortex and caudate 190.  
POU3F3 is a member of the class III POU family of transcription factors that are expressed in the 
central nervous system and thought to control multiple aspects of the neurogenic program 191. 
CREG2 is a member of the cellular repressor of E1A-stimulated genes, and encodes a secreted 
glycoprotein expressed specifically in the brain 192. 
 
TS-CoExp analysis for patient 7 retrieved MRPS9 (mitochondrial ribosomal protein S9), IL1RL1 
(interleukin 1 receptor-like 1) and CREG2 (cellular repressor of E1A-stimulated genes) genes as 
the 3 more likely to cause ID, among those covered by the deletion. 
MRPS9 is a component of the small subunit of the mitochondrial ribosome that is encoded by the 
nuclear genome 193. IL1RL1 is a receptor for interleukin 1 and an association between atopic 
dermatitis and single nucleotide polymorphisms in IL1RL1 promoter 194. Although referred by TS-
CoExp tool as good candidate genes for ID in the patients it is likely that these two genes are false 
positive detections of the software and not related with the phenotype in the patient. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.12. 
 
Table 2.12 - Summary of the alteration in patient 7 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes TS-CoExp 
#7 
2q11.2-q12.2 
(101,122,697-
105,631,450)X1 
24 196 
C2orf29, C2orf49, CREG2, FHL2, GPR45, 
IL18R1, IL18RAP, IL1R1, IL1R2, IL1RL1, 
IL1RL2, LOC150568, MAP4K4, MFSD9, MRPS9, 
POU3F3, RFX8, RNF149, SLC9A2, SLC9A4, 
SNORD89, TBC1D8, TGFBRAP1, TMEM182 
CREG2, 
IL1R1, 
MRPS9  
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7. 2q11.2 duplication 
 
Patient #8 
 
This patient is a 9 years old boy with mild ID (IQ=61) and skin pigment alterations (one café-au-lait 
spot). The patient presented no significant facial dysmorphisms but has abnormal skin texture (thin 
skin). No photograph or genealogic tree is available yet for this patient.   
aCGH revealed a 1.5 Mb duplication at chromosome region 2q11.2 (chr2:96,098,910-97,594,697) 
containing 24 genes. Figure 2.11 shows the alteration detected by aCGH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A similar alteration was reported by Rudd et al in 2009. The patient carries a 1.5 duplication 
partially overlapping with the one from patient 8. The reported patient had moderate ID, short 
stature, macrocephaly and was hypotonic.  
In Decipher there is also a patient described (Decipher #254924) with a smaller (0.9 Mb) 
duplication affecting partially the 2q11.2 cytoband. The alteration in Decipher #254924 was 
inherited from a parent with similar phenotype as the child. Additionally to this duplication, the 
patient also carries a de novo Xp22.31 duplication covering 5 genes. Smaller duplications in 
controls from the DGV databases are described but only covering the FAHD2B 
(fumarylacetoacetate hydrolase domain containing 2B), ANKRD36 (ankyrin repeat domain 36) and 
ANKRD36B (ankyrin repeat domain 36 B) genes. No description of the phenotype of the patient 
Decipher#254924 is present in Decipher database.  
Figure 2.11 - Facial appearance, schematic representation of the genomic alteration and pedigree 
representation for patient 8. (A) The facial appearance of the patient shows his lack of significant dysmorphisms. 
(B) The genomic alteration is represented by the green line above the 2q11.2 cytoband where it is possible to 
observe the increased mean ratio of the probes contained in that region. The UCSC genes present in the genomic 
region altered in the patient in also represented. (C) The patient is represented by the arrow. 
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Regarding the genes present in the duplicated region of patient 8 we can find SEMA4C 
(semaphorin 4C) which encodes a semaphorin. Semaphorins are known to be transmembrane and 
secreted proteins that appear to function during growth cone guidance and network establishment 
in the developing brain (as reviewed in the first chapter). 
ADRA2B (alpha 2B adrenergic receptor) gene encodes an adrenergic receptor with high 
expression in liver and kidney. Polymorphisms in ADRA2B gene are thought to be associated with 
metabolic disorder by altering the autonomic nervous systems normal functions 195.  
 
TS-CoExp analysis for patient 8 retrieved CNNM3 (cyclin M3), TMEM127 (transmembrane protein 
127) and LMAN2L (lectin, mannose-binding 2 like protein) genes as the 3 more likely to cause ID, 
among those covered by the deletion. 
CNNM3 encodes an ancient conserved domain protein that is evolutionarily conserved in diverse 
species and is ubiquitously expressed in developing and adult tissues 196. No association with 
disease was established so far for this gene. 
TMEM127 encodes a transmembrane protein that localizes in the Golgi and lysosomes, suggesting 
that it may be involved in protein trafficking between these structures 197. Quin et al, 2010 
suggested that TMEM127 limits mTORC1 activation and that it occupies the same intracellular 
domain as active mTOR. These authors also concluded that mutations in TMEM127 conferred 
susceptibility for pheochromocytoma5 197. 
The LMAN2L protein highly expressed in kidney and skeletal muscle; it is also expressed in brain. 
This protein is thought to participate in the exportation of glycoproteins from the endoplasmic 
reticulum 198.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.13. 
 
Table 2.13 - Summary of the alteration in patient 8 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
                                                          
5
 Pheochromocytomas are neuroendocrine tumors of the medulla and adrenal glands of neural crest origin that are 
frequently hereditary. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#8 
2q11.2 
(96,098,910-
97,594,697)X3 
24 88 
ADRA2B, ANKRD23, ANKRD36, ANKRD36B, 
ANKRD39, ARID5A, ASTL, CIAO1, CNNM3, CNNM4, 
DUSP2, FAHD2B, FAM178B, FER1L5, ITPRIPL1, 
KIAA1310, LMAN2L, LOC285033, NCAPH, NEURL3, 
SEMA4C, SNRNP200, STARD7, TMEM127 
CNNM3,  
TMEM127, 
LMAN2L,    
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8. 3q22.1-q23 deletion (FOXL2)  
 
Patient #9  
 
This patient is a 9 years old boy with mild ID (IQ= 54), Von Willebrand disease6, cortical atrophy, 
interventricular communication, low weight, hypoplastic genitalia, hypospadias, sandal gap, 
brachicephaly, arched highbrows, micrognathia, small mouth and thin lips. This patient has also a 
peculiar eye dysmorphology characterized by microphtalmia, epicanthus and ptosis. Additionally, 
the patient also displays a hyperactivity disorder.   
aCGH revealed a 10.2 Mb de novo deletion at chromosome region 3q22.1-q23 (chr3:132,898,329-
143,101,242) containing 65 genes. Figure 2.12A presents the facial appearance of patient 9 while 
figure 2.12B shows the alteration detected by aCGH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 2008, Croft et al described a 15 years old female with a 3q22.1-q23 deletion, blepharophimosis, 
ptosis and epicanthus inversus (BPES), microcephaly and ID 199. The alteration covered several 
                                                          
6
 Von Willebrand disease is a bleeding disorder caused by a defect or deficiency of a blood clotting protein, called von 
Willebrand Factor. 
Figure 2.12 - Facial appearance, schematic representation of the genomic alteration and pedigree representation for 
patient 9. (A) The facial appearance of the patient shows his brachicephaly, arched highbrows, micrognathia, small mouth 
and thin lips. (B) The genomic alteration is represented by the red line bellow the3q22.1-q23 cytoband where it is possible to 
observe the diminished mean ratio of the probes contained in that region. The UCSC genes present in the genomic region 
altered in the patient in also represented. (C) The patient is represented by the arrow and no familial history of ID is described 
in the family.  
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genes, among them the FOXL2 (helix/forkhead transcription factor) gene, for which 
haploinsufficiency has been confirmed as causative of the BPES phenotype 200.  
Patient 9 displays similar phenotypic characteristics with the ones described in the literature: 
BPES, short stature, facial dysmorphisms, ID/DD. We believe that the BPES phenotype in the 
patient is due to the haploinsufficiency of FOXL2 gene. Since point mutations FOXL2 have been 
described in BPES patients without any intellectual limitation or development abnormality, it is 
currently stipulated that FOXL2 haploinsufficiency is only responsible for the eye phenotype in the 
patients carrying large genomic rearrangements. The causative gene for the ID/DD phenotype was 
never fully investigated in those cases.  
EPHB1 (ephrin receptor EphB1), RAB6B (RAB6B, member RAS oncogene family) and UBA5 
(ubiquitin-activating enzyme E1 domain-containing 1) are genes covered by the deletion and that 
constitute good candidates for the ID phenotype in the patient.  
EPHB1 protein is an ephrin receptor highly expressed in brain regions were the facial and inner ear 
efferent neurons are localized 201, 202. Rab6b belongs to the subfamily of small GTPases Rab6 and 
is predominantly expressed in brain. The actual function of this protein still remains unclear. 
However, Wanschers BF in 2007 proposed that Rab6b interacts with dynein/dynactin complex 
playing a role in the retrograde transport of cargo in neurons 203. UBA5 is an E1-like activating 
protein that activates ubiquitin-fold modifier 1 (Umf1) and SUMO2 204, 205. Alterations in this 
pathway may interfere with the correct degradation of other proteins (substrates), leading to a 
variety of diseases (such as ID).    
 
TS-CoExp analysis for patient 9 retrieved COPB2 (coatomer protein complex, subunit beta 2, beta 
prime), MRPS22 (mitochondrial ribosomal protein S22) and RAB6B (RAB6B, member RAS 
oncogene family) genes as the 3 more likely to cause ID, among those covered by the deletion.  
 
COPB2 encodes a protein that belongs to the Golgi coatomer protein complex, a set of proteins 
that participate in protein transport between the endoplasmic reticulum and Gogi complex. No 
association with COPB2 and the disease has been made so far 206.  
The MRPS22 gene was identified in the BPES syndrome critical region. Mutations in this gene 
were recently associated with Cornelia de Lange-like phenotype, brain abnormalities and 
hypertrophic cardiomyopathy revealing the importance of mitochondrial synthesized proteins 207.  
RAB6B gene encodes a small GTPase that is predominantly expressed in the brain and thought to 
regulate protein transport in neuronal cells by interaction with the dynein/dynactin complex 208.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.14. 
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Table 2.14 - Summary of the alteration in patient 9 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#9 
3q22.1-
q23(132,898,329
-143,101,242)X1 
65 622 
CPNE4, ACAD11, ACPP, AMOTL2, ANAPC13, BFSP2, 
C3orf36, CCRL1, CDV3, CEP63, CPNE4, DNAJC13, EPHB1, 
KY, NCRNA00119, NPHP3, RAB6B, RYK, SLCO2A1, 
SRPRB, TF, TMEM108, TOPBP1, UBA5, A4GNT, ACPL2, 
ARMC8, ATP1B3, BPESC1, C3orf72, CEP70, CLDN18, 
CLSTN2, COPB2, DBR1, DZIP1L, ESYT3, FAIM, FOXL2, 
GRK7, IL20RB, MRAS, MRPS22, MSL2, NCK1, NMNAT3, 
PCCB, PIK3CB, PISRT1, PPP2R3A, PRR23A, PRR23B, 
PRR23C, RASA2, RBP1, RBP2, RNF7, SLC25A36, SOX14, 
SPSB4, STAG1, TMEM22, TRIM42, TXNDC6, ZBTB38 
 RAB6B,  
COPB2, 
MRPS22  
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9. 5q35.3 duplication 
 
Patient #10 
 
This patient is a 6 years old boy with moderate ID (IQ=48), with familial history of ID (paternal 
grandmother suspected to have mild ID although no psychometric assessment was performed) 
who at birth presented weight, stature and head circumference above 98th centile. The patient also 
has liquor space enlargement, epilepsy (controlled with medication) and hypermetropia. He also 
presents dysmorphic face (epicanthus, bulbous nose, and harsh  hair), generalized 
hypopigmentation of the skin and hair, weight above the 98th centile, aggressiveness, anxious 
behavior and hyperactivity and attention deficit disorder.  Additionally he displays motor 
stereotypies (shaking hands when excited).  
aCGH revealed a 1q21.3-q22 de novo duplication (chr1:153,239,357-153,361,162), containing 6 
genes, a de novo 0.2 Mb duplication at chromosome region 5q35.3 (chr5:176,544,003-
176,734,904), containing 6 genes and  a 19p13.2 de novo duplication (chr19:9,468,575-9,748,852), 
containing 6 genes.  
Figure 2.13A presents the facial appearance of patient 10 while figure 2.13B 1-3 shows the 
alteration detected by aCGH.      
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The 1q21.3-q22 duplication covers, among others, the ADAM15 (disintegrin and metalloproteinase 
domain 15), EFNA3 (ephrin A3) and EFNA4 (ephrin A4) genes.  
ADAM15 encodes a transmembrane glycoprotein that is important for cell adhesion and proteolytic 
shedding of cell surface receptors 209. Few functional studies have been performed so far. In 
mouse, Adam15 is highly expressed in vascular cells and in hippocampus and cerebellum. In the 
same mouse model, the null mice showed no major development defects and reduced 
neovascularization210.  
EphA3 protein is the ligand for EphA4 and, in mice, is localized in dendritic spines of pyramidal 
neurons in the adult hippocampus. EphrA4 and EphnA3 communication in neuroglial cells 
regulates the structure of synaptic connections (activation of EphA4 by ephrin-A3 was found to 
induce spinal retraction and reduce spine density) 211.   
 
The 5q35.3 duplication, if located in tandem, may disrupt the NSD1 (nuclear receptor-binding Su-
var, enhancer of zeste and trithorax domain protein 1) gene. NSD1protein is a coregulator protein 
of the steroid receptor superfamily 212. Haploinsufficiency of NSD1 protein is the major cause of 
Sotos syndrome, also called cerebral gigantism, which is a disorder characterized by excessively 
Figure 2.13 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 10. (A) The facial appearance of the patient shows his dysmorphic face (epicanthus, bulbous nose, and 
bitter hair) and generalized hypopigmentation of the skin and hair. (B) The genomic alteration is represented by the 
green line above the 1q21.3-22 cytoband (B-1), above the 5q35.3 cytoband (B-2) and above the 19p13.2 cytoband (B-
3) where it is possible to observe the increased mean ratio of the probes contained in those regions. The UCSC genes 
present in the genomic region altered in the patient in also represented. (C) The patient is represented by the arrow. His 
mother is suspected to have a milder form of ID, although not formally accessed. 
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rapid growth, acromegalic features, and a nonprogressive cerebral disorder with ID. High-arched 
palate and prominent jaw are also common features among the patients. At birth, length is usually 
between the 90th and 97th centiles in all the patients and bone age is also advanced for the 
majority of the cases 213. Nagai et al, in 2003 reviewed the phenotypes for two groups of patients 
with Sotos syndrome: patients carrying point mutations in NSD1 and patients with a deletion 
involving the whole NSD1 gene. The results suggested that the clinical features of Sotos syndrome 
patients can de divided in two major categories: (I) overgrowth, advanced maturation in infancy to 
early childhood, ID, hypotonia, hyperreflexia and minor anomalies were present in patients with 
point mutations in the gene, while (II) major anomalies in the central nervous system (such as 
agenesis or hypoplasia of the corpus callosum), cardiovascular system defects and urinary system 
abnormalities were exhibited by patients with deletions 214.  
Additionally to NSD1, PRELID1 (preli domain-containing protein 1) and RAB24 (RAs-associated 
protein 24) genes are also covered by the duplication and may be contributing for the phenotype of 
the patient. PRELID1 encodes a protein (PRELI) that in chicken is expressed in late 
embryogenesis and that is thought to contribute for hemopoiesis. In human, PRELI is known to be 
a mitochondrial regulator of human primary T-helper cell apoptosis and Th-2 cell differentiation 215. 
RAB24 is a small GTPase of the Rab subfamily of Ras-related proteins that regulate intracellular 
protein trafficking, highly expressed in the brain 216.   
 
The 19p13.2 duplication covers 6 genes, for which only ZNF121 (zinc finger protein 121) has 
entrance in OMIM. ZNF121 was isolated from a brain cDNA library and localizes to a region in 
chromosome 19 where other zinc finger sequences and multiple cosmid clones containing zinc 
fingers had previously been localized 217.  
 
TS-CoExp analysis for patient 10 retrieved ADAM15, ZNF562 (zinc finger protein 562) and ZNF561 
(zinc finger protein 561) genes as the 3 more likely to cause ID, among those covered by the 
alterations.  
The ADAM15 gene was described before (see page 88) and the ZNF562 and ZNF561 genes don´t 
have an entrance in OMIM and PubMed databases.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.15.  
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Table 2.15 - Summary of the alteration in patient 10 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes TS-CoExp 
#10 
1q21.3-q22 
(153,239,357-
153,361,162)X3 
6 9 ADAM15, DCST1, DCST2, EFNA3, EFNA4, ZBTB7B 
ADAM15,  
ZNF562,  
ZNF561 
5q35.3 (176,544,003-
176,734,904)X3 6 14 
LMAN2, MXD3, NSD1, PRELID1, RAB24, 
RGS14 
19p13.2 (9,468,575-
9,748,852) X3 6 17 
ZNF121, ZNF426, ZNF560, ZNF561, ZNF562, 
ZNF846 
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Among the affected genes, CNOT6 (CCR4-not transcription complex, subunit 6) and MAPK9 
(mitogen-activated protein kinase 9) genes may constitute good candidates for the ID phenotype of 
the patient. 
CNOT6 is a general transcriptional regulatory complex involved in several aspects of mRNA 
metabolism, including transcription initiation and elongation and mRNA degradation, with high 
expression levels in brain 219. 
MAPK9 is a mitogen-activated protein kinase that plays an important role in during brain 
development through its essential role in regulation of region-specific apoptosis during brain 
development 220.   
Both genes described above are good candidates for the phenotype displayed by the patient. 
 
TS-CoExp analysis for patient 11 retrieved RNF130 (ring finger protein 130) and MAPK9 genes as 
the 2 more likely to cause ID, among those covered by the duplication. 
RNF130 encodes a protein that has a protease-associated, a transmembrane and a RING 
domains. RNF130 protein is the human homolog of Drosophila´s g1, a zinc-finger protein involved 
in apoptosis in embryonic development 221.   
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.16. 
  
Table 2.16 - Summary of the alteration in patient 11 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
 
 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#11 5q35.3(179,345,860-180,237,221)X3 12 57 
CNOT6, FLT4, GFPT2, LOC729678, MAPK9, MGAT1, 
MIR340, OR2Y1, RASGEF1C, RNF130, SCGB3A1, 
ZFP62 
RNF130,  
MAPK9 
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10. 6q21 duplication, 16q24.3 duplication (FANCA gene) and Xq26.3 duplication  
 
Patient #12 
 
This patient is a 13 years old boy with severe ID (IQ= 27) with familial history of epilepsy (father), 
speech delay and learning difficulties (maternal cousins) and congenital anomalies (2nd grade 
paternal cousin born with meromelia [absence of both feet]). The mother was suspected of 
toxoplasmosis infection during 2nd-3rd trimester. The patient has thin corpus callosum, 
hyperintensive signal in the substantia nigra, ventricular asymmetry, repetitive ear infections, squint 
and constipation. The patient also presents stature and weight above the 98th centile, facial 
dysmorphisms (thin and low set eyebrows, bulbous, pending and right deviated nose, cupid bow 
upper lip, wrong dental implantation, and anteriorly located anus. Additionally, the patient also 
presents recurrent kneecap lesion and increased activity.           
aCGH revealed a 0.3 Mb maternal duplication at chromosome region 6q21 (chr6:108,537,896-
108,829,534) containing 3 genes, a 0.05 Mb maternal duplication at chromosome 16q24.3 
(chr16:88,395,085-88,444,115) containing 2 genes and a 0.1 Mb de novo duplication at 
chromosome  Xq26.3 (chrX:137,447,004-137,563,727) containing 2 genes.  
Figure 2.15A presents the facial appearance of patient 12 while figure 2.15B 1-3 shows the 
alterations detected by aCGH. 
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The 6q21 duplication was inherited from the mother and covers the NR2E1 (nuclear receptor 
subfamily 2, group E, member 1) gene. The NR2E1 drosophila homologous gene (TLX) is highly 
expressed in brain and is required for its development 222. Shi et al in 2004 demonstrated that TLX 
was able to maintain adult neural stem cells in an undifferentiated state thought its recruitment of a 
set of histone deacetylase that target gene sot repress their expression 223. TLX null mice are 
viable at birth but display reduced size of the olfactory, infrarhinal and entorhinal cortex, 
amygdala and dentate gyrus structures in the brain. Also, males tended to be more aggressive and 
females lacked maternal instincts 224. 6q16-q22 has also been described as a locus for occipital 
polymicrogyria 225.    
 
The 16q24.3 duplication, if located in tandem, can disrupt the FANCA (Fanconi anemia7 
complementation group A) gene.  Although patient 12 doesn’t have Fanconi anemia, this disorder 
is recessive and some of the patients also show ID and congenital malformations.  The FANCA 
gene has a transcript that is exclusively expressed in brain where it is expressed in a stage-specific 
manner during embryogenesis 226. Another important aspect of this finding is the fact that both 
mother and son may be carriers for a recessive mutation for Faconi anemia (is the gene is 
disrupted). In order to clarify this aspect and provide better counseling to the parents, FISH 
analysis need to be performed in order to determine if the duplication is in tandem or not.      
 
                                                          
7
 Fanconi anemia is an autosomal recessive disorder affecting all bone marrow elements and associated with cardiac, renal, 
and limb malformations as well as dermal pigmentary changes.  
Epilepsy 
Absence of both feet 
Speech delay and learning difficulties 
ID (index case) 
C 
Figure 2.15 - Facial appearance, schematic representation of the genomic alteration and pedigree 
representation for patient 12. (A) The facial appearance of the patient shows his thin and low set eyebrows, 
bulbous, pending and right deviated nose and cupid bow upper lip. (B) The genomic alteration is represented by 
the green line above 6q21 cytoband (B-1), 16q24.3 cytoband (B-2) and Xq26.3 cytoband (B-3) where it is 
possible to observe the increased mean ratio of the probes contained in those regions. The UCSC genes present 
in the genomic region altered in the patient in also represented for each case. (C) The patient is represented by 
the arrow; he has two cousins with learning difficulties and a 3rd grade cousin with meromelia. His father also 
displays epilepsy.  
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 The Xq26.3 duplication occurs de novo in the patient and covers the FGF13 (fibroblast growth 
factor 13) gene.  FGF13 is expressed in the developing and adult central nervous system (mainly in 
the cerebellum and cortex) and has a mitogenic and cell survival function 227. 
 
TS-CoExp analysis for patient 12 retrieved SNX3 (sorting nexin 3), FGF13 (fibroblast growth factor 
13) and SPIRE2 (spire, drosophila homolog of, 2) genes as the 3 more likely to cause ID, among 
those covered by the alterations.  
SNX3 encodes a protein member of the sorting nexin family of molecules that acts in intracellular 
trafficking of proteins to various organelles 228. A translocation between chromosome 6 and 13 that 
disrupted the SNX3 gene was described in a patient with microcephaly, microphtalmia, ectrodactyly 
and prognathism 229.  
SPIRE2 encodes a protein that belongs to the Spir protein family, a class of WH2 domain. These 
proteins initiate actin polymerization and, in a mice model, Spire-2 was mainly expressed in 
developing and adult neuronal cells 230. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.17. 
 
Table 2.17 - Summary of the alteration in patient 12 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#12 
6q21 (108,537,896-
108,829,534)X3 3 18 LACE1, NR2E1, SNX3 
SNX3,  
FGF13,  
SPIRE2 
16q24.3 (88,395,085-
88,444,115)X3 2 4 FANCA, SPIRE2 
Xq26.3 (137,447,004-
137,563,727)X3 2 7 FGF13, LOC158696 
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11. 6q25.3 deletion 
 
Patient #13 
 
This patient is a 7 years old boy with mild ID (IQ= 56) with familial history of ID/DD (cousin and 
second - grade cousins), who suffered sepsis after birth, has an enlarged liver and spleen (without 
criteria for organomegaly), hirsutism, dysmorphic face (bulbous nose, large mouth, thin upper lip), 
squint, short stature, severe delay in language acquisition, hyperactivity, aggressiveness and 
stereotypies (shaking hands when excited).   
aCGH revealed a 2.6 Mb de novo deletion at chromosome region 6q25.3 (chr6:156,054,446-
158,724,482) containing 7 genes. Figure 2.16A presents the facial appearance of patient 13 while 
figure 2.16B shows the alteration detected by aCGH 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 - Facial appearance, schematic representation of the genomic alteration and pedigree 
representation for patient 13. (A) The facial appearance of the patient shows his bulbous nose, large mouth, thin 
upper lip and squint. (B) The genomic alteration is represented by the red line bellow 6q25.3 cytoband where it is 
possible to observe the diminished mean ratio of the probes contained in that region. The UCSC genes present in the 
genomic region altered in the patient are also represented. (C) The patient is represented by the arrow; he has a 
cousin and a second-grade cousin with development delay. 
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Patient 13 aCGH revealed a 2.6 Mb deletion encompassing a critical region associated with 
sacro/anorectal malformations 231. A publication by Nagamani S. et al, 2009 described partially 
overlapping deletions (2q25.2-q25.3) associated with DD, hearing loss, microcephaly and 
dysmorphic features 232. Search in the Decipher database revealed the existence of a patient 
(Decipher#248472) with a deletion very similar to the one of our patient. Similar to our patient, 
Decipher#248472 presented ID and facial dysmorphic features. However, Decipher#248472 had 
an atrial septum defect while our patient doesn´t seem to have cardiac problems.   
The genes pinpointed as crucial for the phenotype in these patients that are also deleted in patient 
13 are SYNJ2 (synaptojanin 2), SERAC1 (serine active site containing 1), GTF2H5 (general 
transcriptor factor IIH, polypeptide 5) and TULP4 (tubby-like protein 4).  
SYNJ2 encodes a protein shown to be involved in the regulation of invadopodia and lamellipodia in 
a glioblastoma cell line 233. SERAC1 mutations were shown to cause sterility in mice. Mutations in 
GTF2H5 subunits cause trichothiodystrophy syndrome8. We found that, although not described 
before, this patient also shows brittle hair. This feature may be due to the deficiency of GTF2H5 
protein 234. 
TULP4 is a putative transcriptor factor of unknown function so far. However, in Drosophila it was 
shown that the TULP protein is mostly expressed in the embryonic central and peripheral nervous 
systems 235. 
 
TS-CoExp analysis for patient 13 retrieved GTF2H5 (general transcriptor factor IIH, polypeptide 5), 
SYNJ2 (synaptojanin 2) and SNX9 (shorting nexin 9) genes as those with the 3 more likely to 
cause ID, among those covered by the deletion. 
 
SNX9 contains a phospholipid-binding module called the phox homology and plays a role in 
endocytosis through physically binding F-actin nucleation to plasma membrane during endocytosis 
236
.  
A summary of the alteration, genes involved and genes pinpointed by then TS-CoExp tool is 
represented on table 2.18. 
  
                                                          
8
 Trichothiodystrophy syndrome is caused by mutations in 2 subunits of GTF2H5 gene. Ppatients with trichothiodystrophy 
have brittle hair and nails (because of reduced content of cysteine-rich matrix proteins), ichthyotic skin, and physical and 
mental retardation. Approximately half of the patients display photosensitivity, correlated with a nucleotide excision repair 
defect. 
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Table 2.18 - Summary of the alteration in patient 13 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#13 6q25.3(156,054,446
-158,724,482)X1 7 140 
ARID1B, GTF2H5, SERAC1, 
SNX9, SYNJ2, TULP4, ZDHHC14 
GTF2H5, 
SYNJ2, SNX9 
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12. 7q11.23 deletion (Williams-Beuren syndrome region)  
 
Patient  #14 
 
This patient is a 13 years old boy with severe ID (IQ=21) and possible familial history of ID (the 
mother is suspected to have mild ID, although no psychometric assessment was performed). The 
patient also displays cerebral atrophy, microcephaly, recurrent respiratory infections, epilepsy, 
plagiocephaly, hypoplastic teeth, short neck, hirsutism, genital abnormalities (cryptorchid) and 
facial dysmorphisms. Additionally the patient also presents motor stereotypies (hand clapping, 
hand mouthing and shifting the weight from one leg to the other), as well increased activity, 
aggressiveness and sleep disturbances.       
aCGH revealed a 0.4 Mb deletion at chromosome region 7q11.23 (chr7:72,379,797-72,783,852) 
containing 11 genes. Figure 2.17A presents the facial appearance of patient 14 while figure 2.17B 
shows the alteration detected by aCGH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This alteration is located inside the Williams-Beuren syndrome (WBS) critical region, a 
microdeletion syndrome characterized by mild to moderate ID, weakness in visuospatial 
construction with relatively high performance in verbal short term memory and language. The 
Figure 2.17 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 14. (A) The facial appearance of the patient shows his facial dysmorphisms, plagiocephaly and short neck. (B)
The genomic alteration is represented by the red line bellow 7q11.23 cytoband where it is possible to observe the 
diminished mean ratio of the probes contained in that region. The UCSC genes present in the genomic region altered in the 
patient in also represented. (C) The patient is represented by the arrow; his mother is suspected to have ID although not 
psychometric assessment was performed.  
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patient also presents characteristic facial dysmorphisms (bulbous nose, wide mouth, full lips and 
cheeks, small widely spaced teeth and periorbital fullness), anxious behavior, attention deficit and 
hyperactive disorder, overfriendliness and congenital heart disease (usually supravalvular aortic 
stenosis). This feature is often associated to the haploinsufficiency of the ELN (elastin) gene 237.  
Search in Decipher revealed no patients with deletion of a similar size to the one found in patient 
14.  
Two interesting genes affected by the deletion are STX1A (syntaxin 1A) and MLXIPL (MLX-
interacting protein-like). STX1A encodes a protein that acts in the vesicle fusion process and plays 
a central role in neurotransmitter release through multiple protein-protein interactions 238. Syntaxin 
1a is thought to give rise to some behavioral phenotypes of Williams-Beuren syndrome such as 
hyperactivity and attention deficit disorder 239.  
MLXIPL encodes a protein expressed in multiples tissues, including regions of the brain and the 
intestinal tract. This protein belongs to the family of helix-loop-helix leucine-zipper transcription 
factors. It currently supposed that MLXIPL is a key element of a transcription factor network and 
plays a role in cell proliferation and/or differentiation. It was suggested that haploinsufficiency of 
this gene may contribute to some features of Williams-Beuren syndrome, however the precise 
correlation between MLXIPL and a specific feature was never described 240.  
The elastin gene is not covered by the deletion present in our patient, which is concordant with the 
fact that he has no apparent cardiac abnormalities.  
It is intriguing that, although patient 14 has a smaller deletion than is common in WBS patients, he 
seems to display, except for the cardiac problems, a more severe ID phenotype than WBS 
classical patients.  
 
TS-CoExp analysis for patient 14 retrieved DNAJC30 (DnaJ (Hsp40) homolog, subfamily C, 
member 30), STX1A (syntaxin 1A) and BAZ1B (bromodomain adjacent to zinc finger domain, 1B) 
genes as the 3 more likely to cause ID, among those covered by the deletion. 
DNAJC30 has no relevant information regarding its function in OMIM and PubMed databases.  
The BAZ1B protein contains a bromodomain motif which is characteristic of proteins involved in 
chromatin-dependent transcription regulation. BAZ1B is thought to be the Williams syndrome 
transcription factor associated gene 241. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.19.  
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Table 2.19 - Summary of the alteration in patient 14 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#14 
7q11.23 
(72,379,797-
72,783,852)X1 
11 28 
BAZ1B, BCL7B, DNAJC30, FKBP6, FZD9, 
MLXIPL, STX1A, TBL2, TRIM50, VPS37D, 
WBSCR22 
DNAJC30, 
STX1A, 
BAZ1B 
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Patient #15 
 
This patient is a 10 years old boy with mild ID (IQ=52) and familial history of ID (cousin from the 
maternal side of the family), who has microcephaly (head circumference bellow 3rd centile), 
recurrent respiratory infections, hyperactivity and no significant dysmorphic features (the only facial 
observation for the patient is his hypotelorism).     
aCGH revealed a 0.3 Mb deletion at chromosome region 7q11.23 (chr7:72,052,516-72,359,842) 
containing 12 genes. Figure 2.18A presents the facial appearance of patient 15 while figure 2.18B 
shows the alteration detected by aCGH.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The deletion present in patient 15 doesn´t overlap with the one described for patient 14, although it 
is still inside the WBS critical region. The only feature shared by patient 15 with WBS classic 
patients and patient 14 is the hyperactivity disorder. Considering only patient 14 and 15 they share 
microcephaly and hyperactivity. 
 
Figure 2.18 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 15. (A) The facial appearance of the patient shows his lack of significant facial dysmorphisms. (B) The genomic 
alteration is represented by the red line bellow 7q11.23 cytoband where it is possible to observe the diminished mean ratio 
of the probes contained in that region. The UCSC genes present in the genomic region altered in the patient in also 
represented. (C) The patient is represented by the arrow; he has a maternal cousin with ID. 
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The most interesting genes deleted in this patient are GTF2IP1 (general transcription factor II-I, 
pseudogene) and GTF2IRD2P1 (2I repeat domain containing 2 pseudogene) genes. 
GTF2IP1 is the centromeric copy of GTF2I (general transcription factor II-I) and seems to be 
partially truncated expressed pseudogene with no protein product. These two genes (GTF2I, 
located in a more telomeric region, and GTF2IP1, located closer to the centromere) seems to have 
a role in the predisposition for WBS deletion 242. Only GTF2IP1 is deleted in patient 15 and only the 
haploinsufficiency of GTF2I have been attributed to ID feature of WBS 243.   
 
GTF2IRD2P1 is also a pseudogene that has been implicated in the visual-spatial construction 
defects seem in WBS patients. A study performed by Dai L et al in 2009 in WBS patients with 
atypical rare small deletions retrieved the conclusion that GTF2IRD2P1 deletion could be 
associated with WBS facial appearance and visual-spatial construction 244 
 
TS-CoExp analysis for patient 15 retrieved POM121 (POM121 membrane glycoprotein, rat) gene 
as the most likely to cause ID, among those covered by the deletion. 
POM121 encodes an integral membrane component of the nuclear pore complex 245. Other than 
integrating WBS deletions, no association with disease has been made so far for POM121 gene.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.20. 
 
Table 2.20 - Summary of the alteration in patient 14 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#15 
7q11.23 
(chr7:72,052,516-
72,359,842)X1 
12 14 
GTF2IP1, GTF2IRD2P1, LOC100093631, 
NCF1B, NSUN5, NSUN5C, NSUN5P2, 
PMS2L2, POM121, SPDYE8P, STAG3L3, 
TRIM74 
POM121 
 
 
In table 2.21 is possible to observe a brief comparison between WBS classic patients, patient 14 
and patient 15.  
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Table 2.21 – Phenotypic comparison between WBS core features, patient 14 and patient 15. 
WBS feature Patient 14 Patient 15 
Mild to moderated ID No (severe ID) Yes (mild ID) 
Facial dysmorphisms Present (some of them) Not present 
Congenital heart disease No No 
Anxious behavior No No 
Attention deficit and hyperactive 
disorder 
Yes Yes 
Overfriendliness No (aggressiveness) No 
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13.  7q33 deletion 
 
Patient #16 
 
This patient is a 19 years old boy with mild ID (IQ= 53), familial history of ID (mother and sister 
affected; a second-grade cousin with ID, dysmorphic features and epilepsy), seizures, reduced 
vision, hypotony, dysmorphisms (sunken eyes, high and thin palate, thin upper lip, bulbous nose, 
prognathism, open mouth), aggressiveness and hyperactivity.     
aCGH revealed a 2 Mb deletion at chromosome region 7q33 (chr7:132,827,191-134,903,411) 
containing 15 genes. Figure 2.19A presents the facial appearance of patient 16 while figure 2.19B 
shows the alteration detected by aCGH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A slightly larger deletion (3 Mb) is described in one patient from Decipher (Decipher #256036) in a 
patient with ID and behavioral problems (emotional instability) among other features, two 
characteristics are also present in patient 16.  
Figure 2.19 - Facial appearance, schematic representation of the genomic alteration and pedigree representation for 
patient 16. (A) The facial appearance of the patient shows his sunken eyes, thin upper lip, bulbous nose and prognathism. 
(B) The genomic alteration is represented by the red line bellow 7q33  cytoband where it is possible to observe the 
diminished mean ratio of the probes contained in that region. The UCSC genes present in the genomic region altered in the 
patient in also represented. (C) The patient is represented by the arrow; he has the sister and the mother with learning 
difficulties and a second-grade cousin with ID, dysmorphic features and epilepsy. 
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One of the genes covered by the deletion is the CNOT4 (CCR4-NOT transcription factor complex, 
subunit 4) gene. The CNOT4 protein has both positive and negative roles in transcriptional 
regulation and a positive role in transcriptional elongation. In yeast, the human homolog (Not4) 
functioned as an E3 ubiquitin ligase and controlled the level of Jhd2 (the yest ortholog of JARID1C) 
246
. Mutations in JARID1C (lysine-specific demethylase 5C) were reported in patients with X-linked 
ID, reveling that the correct expression of this protein is probably essential for correct neuronal 
function 247. 
 
TS-CoExp analysis for patient 16 retrieved CALD1 (caldesmon 1), CNOT4 (CCR4-NOT 
transcription complex, subunit 4) and EXOC4 (exocyst complex component 4) genes as the 3 more 
likely to cause ID, among those covered by the deletion. 
CALD1 encodes for the caldesmon protein which is found in smoothe muscle and nonmuscle cells 
(in this last case, the low molecular weight caldesmon variant).  Caldesmon is an actin-linked 
regulatory protein that binds and stabilizes actin filaments, and regulates actin-myosin interaction 
248
. Since caldesmon has numerous functions in cell motility (such as migration, invasion, and 
proliferation), executed through the reorganization of the actin cytoskeleton, this protein is likely to 
have a functional contribution for ID pathogenesis 249. 
EXOC4 is part of a multiprotein complex involved in vesicle trafficking at neural synapses and 
vesicle targeting in polarized epithelial cells 250. 
  
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.22. 
 
Table 2.22 - Summary of the alteration in patient 16 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes Ts-CoExp 
#16 7q33(132,827,191
-134,903,411)X1 15 131 
AGBL3, AKR1B1, AKR1B10, AKR1B15, BPGM, 
C7orf49, CALD1, CNOT4, EXOC4, LRGUK, 
NUP205, SLC35B4, STRA8, TMEM140, WDR91 
EXOC4, 
CNOT4 
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14. 9q34.13-q34.3 duplication and 14q32.31-q32.33 duplication 
 
Patient #17 
 
This patient is a 10 years old boy with mild ID (IQ= 57), elph-like face, low-set and prominent and 
large ears, submucous cleft palate, short philtrum, hypochromic macules and café-au-lait spots, 
stereotypies, obsessive behaviors aggressiveness, hyperactivity and attention deficit. 
aCGH revealed a 5.5 Mb de novo duplication at chromosome region 9q34.13-q34.3 
(chr9:134,757,732-140,273,252) containing 135 genes and a 3 Mb de novo  (figure 2.20B) 
duplication at chromosome region 14q32.31-q32.33 (chr14:102,028,863- 105,602,384) containing 
46 genes (figure 2.21B). Figure 2.20A presents the facial appearance of patient 17 while figure 
2.20B shows the 9q34.13-q34.3 alteration detected by aCGH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.20 - Facial appearance, schematic representation of the genomic alteration and pedigree 
representation for patient 17. (A) The facial appearance of the patient shows his elph-like face, low-set and 
prominent and large ears. (B) The genomic alteration is represented by the green line above 9q34.13-q34.3 cytoband 
where it is possible to observe the increased mean ratio of the probes contained in that region. The UCSC genes 
present in the genomic region altered in the patient in also represented. (C) The patient is represented by the arrow; he 
has a deaf-mute uncle and aunt. 
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The Decipher patient with the most similar alteration (Decipher#254131) has a 6.3 Mb duplication 
(larger than the one from patient 17) and has hypotonia, ID, alterations in skin pigmentation and 
speech delay. When compared to our patient, we can see that they overlap in ID and pigment 
alteration but not in hypotonia (which is not present in our patient) 251. 
Kleefstra syndrome (also known as 9q34.3 microdeletion syndrome) is characterized by ID, 
childhood hypotonia and distinctive facial features. It is currently believed that the EHMT1 gene is 
the key gene, or at least of the most relevant, for the cognitive phenotype presented by the 
patients.  
The duplicated region present in our patient also covers the EHMT1 (euchromatic histone methyl 
transferase 1) gene. EHMT1 haploinsufficiency is thought to be the core molecular change 
explaining the cognitive phenotype of this entity. Studies in a Drosophila EHMT mutant model 
revealed that its expression is required for memory and cognitive function.  Moreover, the re-
expression of EHMT in adulthood could rescue the cognitive defects caused by its lack during 
development 252.    
 
TS-CoExp analysis for 9q34.13-q34.3 duplication retrieved RXRA (retinoid X receptor, alfa), GRIN1 
(glutamate receptor, ionotropic, N-methyl D-aspartate 1) and UAP1L1 (UDP-N-acteylglucosamine 
pyrophosphorylase 1-like 1) genes as the 3 more likely to cause ID, among those covered by the 
duplication. 
RXRA is a nuclear receptor protein, expressed in the brain, member of the steroid and thyroid 
hormone receptor superfamily of transcriptional regulators. A RXRA knockout mice model 
displayed embryonic heart failure by low levels of ventricular contractions 253.  
The GRIN1 gene encodes a glutamate receptor. Polymorphisms in GRIN1 were associated with 
susceptibility for schizophrenia, suggesting that this gene may indeed be a good candidate gene 
for the disorder 254. 
For UAP1L1 gene no entrance is found in OMIM database and PubMed only retrieves one paper 
regarding breast cancer.  
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The 14q32.31-q32.33 duplication (figure 29) covers the 46 genes, of which MARK3 
(MAP/microtubule affinity-regulating kinase 3) and KLC1 (kinesin light chain 1) could be candidate 
genes for the cognitive phenotype in the patient.  
MARK3 belongs to the MARK proteins family known to be involved in the phosphorylation of 
microtubule associated proteins (such as TAU) 255. A recent study from 2010 performed by Chia 
CY and colleagues reported that MARK3 is a gene with very stable expression, making it a good 
reference gene 256.  
 
KLC1 encodes a kinesin that acts as a tubulin molecular precursor for transport of organelles within 
cells and in the movement of chromosomes along microtubules during cell division. Moreover, in 
neurons the axonal transport of APP is mediated by its binding to kinesin light chain subunit of 
kinesin-1 257.  
 
TS-CoExp analysis for 14q32.31-q32.33 duplication retrieved EIF5 (eukaryotic translation initiation 
factor 5) and MRPL41 (mitochondrial ribosomal protein L41) genes as those with the 2 more likely 
to cause ID, among those covered by the duplication. 
 
Figure 2.21 – Skin pigmentation alterations and schematic representation of the genomic alteration. The patient 
presents and café-au-lait (A) and hypochromic (B) spots on the skin. (C) The genomic alteration is represented by the 
green line above 14q32.31-q32.33 cytoband where it is possible to observe the increased mean ratio of the probes 
contained in that region. The UCSC genes present in the genomic region altered in the patient in also represented.  
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EIF5 function as a GTPase-activating protein that plays a role in the establishment of the EIF2-
GTP-tRNAi(Met) ternary complex of the ribosome during mRNA translation 258.  
 
MRPL41 is one of the protein components of mitochondrial ribosomes encoded by the nuclear 
genome of the cell 259.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.23. 
 
Table 2.23 - Summary of the alteration in patient 17 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
 
When notified for the participation in the study, subtelomeric studies were still ongoing for patient 
17. Together with the aCGH result, the subtelomeric studies for the patient retrieved an altered 
result. MLPA studies reveal a duplication of the gene EHMT1 (chromosome 9) and gene MAT1 
(chromosome 14). These results were confirmed further confirmed by FISH.  
 
In figure 2.22 is possible to see the FISH studies for patient 17.  
 
 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#17 
9q34.13-
q34.3(134,757,73
2-140,273,252)X3 
135 371 
ABCA2, ABO, ADAMTS13, ADAMTSL2, AGPAT2, ANAPC2, 
ARRDC1, BRD3, C8G, C9orf116, C9orf139, C9orf140, C9orf142, 
C9orf163, C9orf167, C9orf169, C9orf172, C9orf173, C9orf37, 
C9orf69, C9orf7, C9orf75, C9orf86, C9orf96, CACNA1B, CAMSAP1, 
CARD9, CEL, CELP, CLIC3, COBRA1, COL5A1, DBH, DNLZ, DPP7, 
EDF1, EGFL7, EHMT1, ENTPD2, ENTPD8, EXD3, FAM157B, 
FAM163B, FAM166A, FAM69B, FBXW5, FCN1, FCN2, FLJ40292, 
FUT7, GBGT1, GFI1B, GLT6D1, GPSM1, GRIN1, GTF3C5, INPP5E, 
KCNT1, KIAA0649, KIAA1984, LCN1, LCN10, LCN12, LCN15, 
LCN6, LCN8, LCN9, LCNL1, LHX3, LOC100131193, 
LOC100289341, LOC26102, LRRC26, MAMDC4, MAN1B1, MED22, 
MIR126, MIR602, MRPL41, MRPS2, NACC2, NCRNA00094, 
NDOR1, NELF, NOTCH1, NOXA1, NPDC1, NRARP, OBP2A, 
OBP2B, OLFM1, PAEP, PHPT1, PMPCA, PNPLA7, PTGDS, 
QSOX2, RALGDS, REXO4, RNF208, RNU6ATAC, RPL7A, RXRA, 
SARDH, SDCCAG3, SEC16A, SLC2A6, SLC34A3, SNAPC4, 
SNHG7, SNORA17, SNORA43, SNORD24, SNORD36A, 
SNORD36B, SNORD36C, SOHLH1, SSNA1, SURF1, SURF2, 
SURF4, SURF6, TMEM141, TMEM203, TMEM8C, TRAF2, TSC1, 
TUBB2C, TUBBP5, UAP1L1, UBAC1, VAV2, WDR5, WDR85, 
ZMYND19 
RXRA,  
GRIN1,  
UAP1L1  
 
14q32.31-
q32.33(102,028,8
63- 
105,602,384)X3  
46 211 
AMN, ANKRD9, ASPG, BAG5, C14orf153, C14orf2, C14orf73, 
CDC42BPB, CKB, EIF5, KLC1, MARK3, PPP1R13B, RCOR1, 
SNORA28, TDRD9, TECPR2, TNFAIP2, TRAF3, TRMT61A, XRCC3, 
ZFYVE21, ADAM6, ADSSL1, AHNAK2, AKT1, BRF1, BTBD6, 
C14orf79, C14orf80, CDCA4, CRIP1, CRIP2, GPR132, INF2, JAG2, 
KIAA0125, KIAA0284, MGC23270, MTA1, NUDT14, PACS2, PLD4, 
SIVA1, TMEM121, ZBTB42 
EIF5,,  
MRPL41 
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The MLPA and FISH analysis suggested a the 46,XY.ish 
der(14)t(9;14)(D9S325+),14qsubtel(D14S1420?+).mlpa9qsubtel(P036,P070)x3,14qsubtel(P036,P0
70)x3 karyotype for the patient. Patient 17 has a derivative chromosome that results from a de 
novo translocation for which the 9q duplicated region is located in 14p. It was not possible to 
determine in which chromosome 14 is located the 14q duplication (in the derivative or in the normal 
one). 
Because it is located in tandem, the 14q32.31-q32.33 duplication may lead to the disruption of the 
genes involved in the breakpoints. However, since both duplications are very large and cover very 
interesting genes the most likely scenario is that both duplications encompass dosage sensitive 
genes and together account for the phenotype in the children. 
      
Figure 2.22 – FISH study for patient 17. The 
FISH analysis suggested the  
46,XY.ishder(14)t(9;14)(D9S325+),14qsubtel(D14
S1420?+) karyotype for patient 17. (A) 
Subtelomeric 9q signal (red) and 9p (green 
signal). Red arrow showing the der (14) with the 
9q duplicated region located in 14p. (B) The 
apparently normal 14q region for both 
chromosomes (red arrows) and (C) the apparently 
duplicated 14q in one of the chromosomes (red 
arrow).       
 
A B 
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15. 9q33.2-q33.3 duplication 
 
Patient #18 
 
This patient is a 12 years old girl with mild ID (IQ=53) and familial history of ID (figure 25C). During 
the perinatal period the patient manifested epilepsy, hypothyroidism and cardiac insufficiency 
(heart murmur). Currently she has a three years delay in bone maturation, short stature, relative 
macrocephaly, short neck and dysmorphic face (high nasal bridge, high palate, micro and 
retrognathia, epicantus and long face and expressionless face) and reduced activity.   
aCGH revealed a 3.6 Mb duplication at chromosome region 9q33.2-q33.3 (chr9:122,564,885-
126,227,440) containing 52 genes. Figure 2.23A presents the facial appearance of patient 18 while 
figure 2.23B shows the alteration detected by aCGH.       
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23  - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 18. (A) The facial appearance of the patient shows her relative macrocephaly, short neck, high nasal bridge, 
micro and retrognathia, epicantus and long face and expressionless face. (B) The genomic alteration is represented by the 
green line above 9q33.2-q33.3 cytoband where it is possible to observe the increased mean ratio of the probes contained 
in that region. The UCSC genes present in the genomic region altered in the patient in also represented. (C) The patient is 
represented by the arrow. An aunt of the mother´s patients had ID (maternal side). Uncles and direct cousins of the 
mother’s patient have epilepsy.  
Chromosome 9 
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The most similar alteration described in Decipher is a 2.65 Mb deletion (Decipher# 249332) 
partially overlapping with the duplication of patient 18, however, the only feature shared by both 
patients seems to be ID.  
Among the genes affected, LHX2 (LIM homebox gene 2), LHX6 (LIM homebox gene 6) and 
STRBP (Spermatid perinuclear RNA-binding protein) seem to play important functions in brain. 
 
LHX2 encodes a protein expressed both in developing and adult rodent central nervous system. 
LHX2 acts as a classic selector gene and an essential intrinsic determinant of cortical identity. 
Indeed, Lhx2 -/- mice had defects in the development of the eyes, forebrain, and erythrocytes and 
died a few days before birth due to severe anemia 260. 
LHX6 is expressed in GABAergic neurons from the medial ganglionic eminence, an early neuronal 
population that migrates to the developing cerebral cortex 261, 262. 
STRBP encodes a protein mainly expressed in testis but with lower levels of expression in other 
tissues (such as brain). STRBP is both a RNA-binding protein and a microtubule-associated protein 
and, although it is mainly studied in sperm cells, its function in the assembly of the microtubules in 
other tissues cannot be excluded. In fact, a mouse model lacking STRBP expression displayed 
severe defects in brain, spinal cord and dorsal root ganglia 263. 
 
TS-CoExp analysis for patient 18 retrieved LHX2 (LIM homebox gene 2), LHX6 (LIM homebox 
gene 6) and STOM (stomatin) genes as the 3 more likely to cause ID, among those covered by the 
duplication. 
STOM, also known as EPB72, encodes the band integral membrane protein, a major protein of the 
erythrocyte membrane. The STOM -/- mice, despite the complete absence of protein, presented no 
hemolytic anemia and red blood cells were morphologically normal. Thus, their experiments 
suggested that 7.2b deficiency plays no direct role in the etiology of stomatocytosis and excluded 
any role of this protein as a mediator of cation transport in red blood cells 264.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.24. 
 
Table 2.24 - Summary of the alteration in patient 18 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number 
of Genes 
Involved 
Number 
of Probes 
Involved 
Genes Ts-CoExp 
#18 
9q33.2-q33.3 
(122,564,885-
126,227,440)X3 
52 232 
C5, FBXW2, LOC253039, LOC402377, PHF19, PSMD5, 
TRAF1, C9orf45, CEP110, CRB2, DAB2IP, DENND1A, 
GGTA1, GPR21, GSN, LHX2, LHX6, LOC100129034, 
MIR548D1, MIR600, MIR601, MORN5, MRRF, NDUFA8, 
NEK6, OR1B1, OR1J1, OR1J2, OR1J4, OR1K1, OR1L1, 
OR1L3, OR1L4, OR1L6, OR1L8, OR1N1, OR1N2, OR1Q1, 
OR5C1, PDCL, PSMB7, PTGS1, RAB14, RABGAP1, RBM18, 
RC3H2, SNORD90, STOM, STRBP, TTLL11, ZBTB26, ZBTB6 
LHX2, 
LHX6 
STOM 
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16. 10q26.3 deletion 
 
Patient #19 
 
This patient is a 5 years old girl with mild ID (IQ=52), short stature, squint, short neck, mild 
hypotony, lack of sensibility to peripheral pain, axial hypertonia, altered EEG, conductive 
hypoacusia, reduced activity and dysmorphic face (triangular face - looking like Trisomy 21, 
although similar to the parents’ - and arched eyebrows). The patient also presents spherocytosis9, 
as do several members of her family (maternal side).     
aCGH revealed a de novo (determined by qPCR analysis) 0.65 Mb deletion at chromosome region 
10q26.3 (chr10:131,264,691-131,920,458) containing 3 genes Figure 2.24A presents the facial 
appearance of patient 19 while figure 2.24B shows the alteration detected by aCGH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
9
 Spherocytosis is an auto-hemolytic anemia characterized by the production of abnormal red blood cells. In spherocytosis 
patients these cell are sphere-shaped instead of bi-concave disk shaped. This disorder is caused by alterations in one or 
more proteins of the red blood cells cytoskeleton.  
Figure 2.24 - Facial appearance, schematic representation of the genomic alteration and pedigree 
representation for patient 19. (A) The facial appearance of the patient shows her squint, short neck, triangular and 
arched eyebrows. (B) The genomic alteration is represented by the red line bellow 10q26.3 cytoband where it is 
possible to observe the decreased mean ratio of the probes contained in that region. The UCSC genes present in the 
genomic region altered in the patient in also represented. (C) The patient is represented by the arrow. Together with 
DD/ID she also presents spherocytosis, as do many other members from the maternal side of the family. 
 
Chromosome 10 
 
Spherocytosis 
ID + spherocytosis (index case) 
A B 
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A patient with a smaller deletion causing the disruption of EBF3 (early B-cell factor 3) and MGMT 
(methylguanine-DNA methyl transferase) genes is described in the Decipher database 
(Decipher#257229). The phenotype and classification of the alteration are not described in 
Decipher.  
The EBF3 gene is a transcription factor expressed in adult brain that regulates the transcription of 
genes involved in neurogenesis 265. EBF3 gene expression is regulated by ARX, a gene known to 
be involved in syndromic and non-syndromic forms of ID 266.  
Besides the EBF3 gene, the deletion present in the patient also covers the GLRX3 (glutaredoxin 3) 
and MGMT (methylguanine-DNA methyltranferase) genes.  
GLRX3 is a protein kinase c-interacting cousin of thioredoxin (PICOT) that inhibits pressure 
overload, inducing cardiac hypertrophy in rats by disrupting the Mlp-calcineurin interaction and 
thereby negatively regulating calcineurin-Nfat signaling 267.  Interestingly, calcineurin-Nfat signaling 
regulates genes necessary for myelination and is essential for neuregulin and ErbB signaling, 
neural crest diversification, and differentiation of Schwann cells 268.  
MGMT is a repair protein involved in the correction of the DNA replicative error O(6)-alkylguanine. 
In glioblastoma patients the methylation status of MGMT predicts sensitivity to temozolomide, an 
alkylating agent used to treat glioblastoma patients 269.  
 
TS-CoExp analysis for patient 19 retrieved GLRX3 (glutaredoxin 3) gene as the one more likely to 
cause ID, among those covered by the deletion. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.25. 
 
Table 2.25 - Summary of the alteration in patient 19 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
   
 
Patient 
Number Event 
Number 
of Genes 
Involved 
Number 
of Probes 
Involved 
Genes Ts-CoExp 
#19 10q26.3 (131,264,691-131,920,458)X1 3 40 EBF3, GLRX3, MGMT GLRX3 
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in 2006 by Ruiter et al, who described a 2.3 Mb duplication partially overlapping with the one from 
patient 20.  
Similar to Decipher #4135, our patient has ID, anal malformations and facial dysmorphisms. 
Additionally, our patient also has cardiac defects. The fact that these two patients share the      
MED13L absence may indicate its importance for the disease. MED13L encodes the THRAP2 
(thyroid hormone receptor-associated protein 2) protein, that belongs to a family of proteins with 
important functions in embryonic development. More precisely, it is a subunit of a large mediator 
complex that functions with DNA-binding transcription factors and RNA polymerase II for gene 
activation. Point mutations in the MED13L gene have been described in patients with cardiac 
malformations, namely isolated dextro-looped transposition of the great arteries, and one of these 
patients also presented ID 270.  
Regarding the case described by Ruiter et al, patient 20 shared the ID phenotype, dysmorphic 
facial appearance and hypoplastic nipples. Although the alteration described by the authors was a 
duplication while the one present in our case is a deletion, the number of overlapping genes is very 
consistent. Besides MED13L, other interesting genes are located within the deleted region, for 
instance: FBXW8 (F-box and WD40 domain protein 8) and HRK (karakiri).  
FBXW8 encodes for a protein that is part of a complex that act as protein-ubiquitin ligases and 
binds to cullin 7. CUL7 protein was also found to interact with that complex and have a crucial role 
in the stabilization of the complex 271.   
HRK encodes an apoptosis regulator protein, which is thought to activate cell death, and is 
expressed also in brian 272.  
 
TS-CoExp analysis for patient 20 retrieved MED13L (mediator complex subunit 13-like), HRK 
(harakiri, BCL2 interacting protein, contains only BH3 domain) and RNFT2 (ring finger protein, 
transmembrane 2) genes the 3 more likely to cause ID, among those covered by the deletion. 
RNFT2 gene has currently no entrance in OMIM and PubMed databases.  
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.26. 
 
Table 2.26 - Summary of the alteration in patient 20 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes Ts-CoExp 
#20 
12q24.21-
q24.22(113,989,883
-115,926,066)X1 
8 114  C12orf49, FBXW8, HRK, MAP1LC3B2, MED13L, MIR620, NCRNA00173, RNFT2 
MED13L  HRK,  
RNFT2   
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Patient 21 has a smaller duplication in the same region where patient 20 has a deletion. This 
duplication encompasses the MED13L gene and, if located in tandem, may cause its disruption. 
The only shared clinical feature between patient 20 and21 seems to be the moderate level of ID.    
In Decipher there is one patient (Decipher# 255109) with a 0.06 Mb de novo duplication that can 
disrupt the MED13L gene as well. Decipher# 255109 is described as having ID, auricular tags and 
macrostomia.  Patient 21 also have ID and an increased mouth size, however, for the last one it is 
not clear if it a dysmorphisms or a just a familial similarity (mother).  
 
TS-CoExp analysis for patient 21 retrieved MED13L (mediator complex subunit 13-like) gene as 
the one more likely to cause ID, among those covered by the duplication. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.27. 
 
Table 2.27 - Summary of the alteration in patient 21 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
 
 
 
 
 
 
Figure 2.27 displays a schematic comparison between the alteration present in patients 20 and 21, 
and the two referred Decipher cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes Ts-CoExp 
#21 12q24.21(114,893,119-115,188,686)X3 2 19 MED13L, MIR620 MED13L 
Figure 2.27 – Schematic comparison of the alterations present in patients 20 and 21 with the ones described in 
Decipher database. Patient 20 carries a 1 Mb deletion, patient 21 carries a 0,3 Mb duplication (both covering the MED13L
gene), decipher #4135 carries a 1,23 Mb deletion and decipher #255109 carriers a 0,06 Mb duplication. Bothe Decipher cases 
are thought to also encompass the MED13L gene.  
Patient 20 
Patient 21 
Decipher #4135 
Decipher #255109 
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speech delay, microcephaly, hypoplasic genitals (small penis), feeding problems and facial 
dysmorphisms. When compared with patient 22, we can see that they share the microcephaly, 
hypoplasic genitals and speech delay. One of the genes referred as likely haploinsufficient within 
the affected region is the CSE1L (chromosome segregation 1-like), that encodes a protein 
important for apoptosis and cell proliferation. Recently duplications in the 20q13.13 region were 
described, which are associated with isolated growth hormone deficiency, a condition where infants 
have, among others features, micropenis and growth failure 273.     
SPATA2 (spermatogenesis-associated protein 2) encodes a highly hydrophilic protein expressed, 
among other tissues, in brain. In zebrafish, the Spata2 orthologue was shown to be expressed and 
strongly localized at central nervous system at early development stages. Thus, although this 
protein was first described as involved in the spermatogenic process, further functional studies 
need to be performed in order to clarify its importance for brain development 274.   
UBE2C (ubiquitin-conjugating enzyme E2C) encodes a protein that is essential for the transition of 
the anaphase-promoting complex into a state of permission for cyclin and accumulation during G1 
phase of mitosis 275, 276.  
 
TS-CoExp analysis retrieved ARFGEF2 (ADP-ribosylation factor guanine nucleotide exchange 
factor 2), RNF114 (ring finger protein 114) and CEBPB (CCAAT/enhancer binding protein (C/EBP), 
beta) genes as the 3 more likely to cause ID, among those covered by the deletion. 
 
The ARFGEF2/BIG2 protein is required for vesicle and membrane trafficking from the TGN and 
inhibition of ARFGEF2 has been shown to decrease neural expansion. Mutations in the ARFGEF2 
gene are the cause of autosomal recessive periventricular heterotopia with microcephaly 277.  
RNF114 belongs to a family of RING domain E3 ubiquitin ligases characterized by 3 zinc fingers 
and an ubiquitin-interacting motif. RNF114 has high expression levels in testis and much lower 
expression in the other tissues 278.   
CEBPB has a DNA-binding activity in the S phase of mitosis. Studies in mouse revealed that 
CEBPB was expressed in cortical progenitor cells and could induce expression of a reporter gene 
containing the minimal promoter of alpha-tubulin (a neuron-specific gene) 279. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.28.  
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Table 2.28 - Summary of the alteration in patient 22 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
  
  
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#22 
20q13.12-q13.13 
(42,717,234-
48,284,251)X1 
88 363 
ACOT8, ARFGEF2, B4GALT5, C20orf123, C20orf165, 
C20orf199, CD40, CDH22, CEBPB, CSE1L, CTSA, 
DBNDD2, DDX27, DNTTIP1, ELMO2, EYA2, KCNB1, 
KCNK15, KCNS1, LOC100131496, LOC100240726, 
LOC284749, MATN4, MIR1259, MMP9, NCOA3, 
NCOA5, NEURL2, PABPC1L, PCIF1, PI3, PIGT, PLTP, 
PREX1, PTGIS, RBPJL, RIMS4, RNF114, SDC4, 
SEMG1, SEMG2, SLC12A5, SLC13A3, SLC2A10, 
SLC35C2, SLC9A8, SLPI, SNAI1, SNORD12, 
SNORD12B, SNORD12C, SNX21, SPATA2, 
SPINLW1, SPINT3, SPINT4, STAU1, STK4, SULF2, 
SYS1, SYS1-DBNDD2, TMEM189, TMEM189-
UBE2V1, TNNC2, TOMM34, TP53RK, TP53TG5, 
UBE2C, UBE2V1, WFDC10A, WFDC10B, WFDC11, 
WFDC12, WFDC13, WFDC2, WFDC3, WFDC5, 
WFDC6, WFDC8, WFDC9, WISP2, YWHAB, ZMYND8, 
ZNF334, ZNF335, ZNFX1, ZSWIM1, ZSWIM3 
ARFGEF2,  
RNF114,  
CEBPB 
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20. Xq24 duplication (CUL4B gene duplication) 
 
Patient #23 
 
This patient is a 8 years old boy without psychometric criteria for classification as ID (IQ= 80), but 
who has familial history of ID (two brothers and cousins with ID), cardiac arrhythmia10 (apparently 
benign) generalized obesity, testicular asymmetry (atrophic left testicle), stereotypies (shaking 
hands when excited) and hyperactivity.     
aCGH revealed a 0.3 Mb duplication inherited from the mother at chromosome region Xq24 
(chrX:119,476,634-119,789,009) containing 4 genes. Figure 2.29A presents the facial appearance 
of patient 23 while figure 2.29B shows the alteration detected by aCGH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
10
 Cardiac arrhythmia is a designation used to describe a large and heterogeneous group of conditions in which there is 
abnormal electrical activity of the heart (the heart beat is irregular, to fast or to slow).  
Figure 2.29 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 23. (A) The facial appearance of the patient. (B) The genomic alteration is represented by the green line 
above the Xq24 cytoband where it is possible to observe the increased mean ratio of the probes contained in that region. 
The UCSC genes present in the genomic region altered in the patient in also represented. (C) The patient is represented 
by the arrow. The patient has a brother with mild ID and other one with ID and dysmorphic features. The patient also has 
2 cousins (both sons of the mothers’ brother) with ID and dysmorphisms.   
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The duplication found the patient covers, among others, the CUL4B gene. Point mutations and a 
deletion encompassing the entire CUL4B gene were described in patients with X-linked ID 280. Until 
now, duplications affecting CUL4B have not been described. 
CUL4B encodes for a ubiquitously expressed cullin protein that is a component of the ubiquitin 
ligase complex. Mutations in CUL4B gene were found in patients with X-linked ID, generalized 
obesity, delayed puberty, hypogonadism, relative macrocephaly, moderate short stature and 
aggressiveness.  
CUL4B qPCR quantification analysis was performed for the patient, one of the brothers (for the 
other brother it was not possible to collect DNA sample) and the mother. The qPCR analysis 
revealed the existence of 2 CUL4B copies in the index case as well as in one of the affected 
brothers and three copies in the mother, leading us to believe that the alteration segregates with 
the disease. The brother for which was not possible to collect DNA samples is now a working adult 
who is thought to have a very mild cognitive impairment. The duplication present in the patient also 
covers the C1GALT1C1 (C1GALT1 - core 1 beta-3-galactosyltransferase-specific molecular 
chaperone 1), LAMP2 (lysosome-associated membrane protein 2) and MCTS1 (malignant T-cell 
amplified sequence 1).      
C1GALT1C1 is a molecular chaperone that contains beta-1,3-galactosyltransferase activity and 
specifically associates with C1GALT1. Mutations in C1GALT1 have been described in patients with 
Tn syndrome11 281.  
The LAMP2 protein is thought to protect the lysosomal membrane from proteolytic enzymes as well 
as to display a receptor function for proteins to be imported into lysosomes 282. Patients with Danon 
disease12 were found to carry mutations in LAMP2. Mice models for this disorder revealed that 
LAMP2 has a crucial role in autophagy and that Danon disease is caused by the accumulation if 
autophagic material in the striated myocytes 283. Since LAMP2 gene may be disrupted with the 
duplication, a more detailed cardiac assessment should be carried out in the patient.    
MCTS1 gene was found to be amplified in a T-cell lymphoma cell line and, consequently, was 
named after that 284, 285. The protein is currently thought to be involved in cell cycle progression and 
is ubiquitously expressed in tissues 285.  
 
 
 
 
 
 
                                                          
11
 Tn syndrome is a rare autoimmune disease in which subpopulations of blood cells of all lineages carry an incompletely 
glycosylated membrane glycoprotein (called the Tn antigen). This syndrome is caused by mutation is the C1GALT1 coding 
gene. This pathology is caused by recessive mutations in somatic cells.  
12
 Danon disease, also known as X-linked vacuolar cardiomyopathy and myopathy, is an X-linked dominant disorder 
predominantly affecting cardiac muscle and that in some cases can be seen together with skeletal muscle involvement and 
ID. The disease is caused by mutations in LAMP2 gene which leads to the intracytoplasmic autophagic vacuoles with 
sarcolemmal features.     
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TS-CoExp analysis retrieved CUL4B and LAMP2 genes as the 2 more likely to cause ID, among 
those covered by the duplication. 
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.29. 
 
 
Table 2.29 - Summary of the alteration in patient 23 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
Patient 
Number Event 
Number of 
Genes 
Involved 
Number of 
Probes 
Involved 
Genes Ts-CoExp 
#23 Xq24(119,476,634-119,789,009)X3 4 19 C1GALT1C1, CUL4B, LAMP2, MCTS1 
CUL4B, 
LAMP2 
 
 
XCI for the patient´s mother revealed a skewed XCI with a normalized ratio of 4.5 (about 85% of 
XCI deviation).  This value is consistent with the fact that the mother is not suspected to have any 
form of ID and that she has 3 affected sons. This data also lead us to believe that similar to what 
happens in CUL4B point mutations and deletions, its duplication is also causing the disease. The 
most likely scenario is that CUL4B gene is a dosage-sensitive gene essential for intellectual 
functioning.  
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 Patients with copy number changes associated with Susceptibility loci 
 
1. 1q21.1 recurrent microduplication 
 
Patient #24 
 
This patient is a 5 years old boy with moderate ID (IQ= 44), familiar history of psychiatric disorders 
(brother with Autism/Asperger and a second grade cousin with ID), thin corpus calosum, autism, 
hyperactivity and attention deficit. The patient doesn´t display any significant dysmorphisms or 
malformation.   
aCGH revealed a 2.5 Mb duplication inherited from the father at chromosome region 1q21.1 
(chr1:144,577,524-147,095,314) containing 43 genes. Figure 2.30A presents the facial appearance 
of patient 24 while figure 2.30B shows the alteration detected by aCGH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.30 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 24. (A) The facial appearance of the patient reveals lack of significant dysmorphisms. (B) The genomic 
alteration is represented by the green line above the 1q21.1 cytoband where it is possible to observe the increased mean 
ratio of the probes contained in that region. The UCSC genes present in the genomic region altered in the patient in also 
represented. (C) The patient is represented by the arrow. The patient has a brother with Asperger’s syndrome and a 
cousin with hyperactivity and attention deficit. A second grade cousin from the father side of the family also displays ID and 
behavioral alterations. 
ID/Autism 
ID/Behavior alterations 
Hyperactivity and attention deficit 
Autism (Asperger) 
A B 
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The 1q21.1 recurrent microduplication is considered a possible susceptibility locus for 
neurodevelopment disorders. The main features of patients carrying duplications in this region are 
autism or autism spectrum disorders, development delay and ID. Less frequent, but also present in 
some cases reported, are macrocephaly (around 50% of the cases) and dysmorphic features 286. A 
peculiar characteristic of this region and other susceptibility loci, is that the alterations present in 
the patients are also commonly found in the phenotypically normal parents, implying the incomplete 
penetrance of this genomic imbalance 286, 287.  
Our patient displays phenotypic features concordant with those described in the literature 286. The 
father is a carrier for this alteration and closer analyses of his IQ level and psychiatric profile should 
be performed in order to determine is he is a truly non affected individual or an underdiagnosed 
case of a less severe psychiatric trait. The fact that the patient also has a familial history of autism 
(brother) and ID (second grade cousin from the father side) indicates that the father could also 
have transmitted the alteration to the brother and even that the alteration could also be present in 
more members of the family.  
The phenotypically diversity and incomplete penetrance of this alteration raises complex 
counseling questions for the families. 
The duplication present in the patient covers, among others, three interesting genes based on their 
described function: BCL9 (B-cell CLL/lymphoma 9), GJA5 (GAP junction protein, alpha-5) and 
GJA8 (GAP junction protein, alpha-8).  
BCL9 protein is described as playing a critical role in the regulation of Wnt signaling pathway in the 
developing embryonic body axis 288. Genome wide association studies in schizophrenic patients 
have described variants in BCL9 gene as conferring risk for the disease 289.   
GJA5 encodes for a conexin protein that belongs to a wide family of protein that form intercellular 
channels (so called GAP junctions) that participate in the exchange of ions and small molecules 
between adjacent molecules 290. Mice models lacking GJA5 showed cardiac malformations, 
indicating that its reduced expression may have a role in cardiac tissue correct development 291.  
GJA8 encodes also a conexin protein, for which mutations were described in patients with visual 
impairments caused by cataract 292.   
 
TS-CoExp analysis retrieved PRKAB2 (protein kinase, AMP-activated, beta 2 non-catalytic subunit) 
and CHD1L (chromodomain helicase DNA binding protein 1-like) genes as the 2 more likely to 
cause ID, among those covered by the duplication. 
PRKAB2 encodes an AMP-activated protein kinase subunit that acts a metabolic stress-sensing 
protein kinase and is highly expressed in skeletal muscle 293. No association between PRKAB2 
gene and disease has been established so far.  
CHD1L interacts with poly(ADP-ribose) (PAR) and contributes to the cromatin relaxation following 
DNA damage 294. CHD1L overexpression has been found in hepatocellular carcinoma 295. 
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A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.30. 
 
Table 2.30 - Summary of the alteration in patient 24 and genes involved. In bold are represented the most likely 
significant gene for the phenotype based on their function. 
 
Patient 
Number Event 
Number 
of Genes 
Involved 
Number 
of Probes 
Involved 
Genes Ts-CoExp 
#24 
1q21.1 
(144,577,524-
147,095,314)X3 
43 93 
ACP6, AF131738, AF380582, AK023548, AK023809, 
AK091688, AK309393, BC036212, BC041003, 
BC110832, BCL9, CHD1L, CR610404, CR617196, 
DKFZp434H1228, DKFZp451B1418, DQ576969, 
FAM108A3, FMO5, GJA5, GJA8, GPR89A, GPR89B, 
GPR89C, KIAA1693, LOC200030, LOC728989, NBPF1, 
NBPF10, NBPF11, NBPF12, NBPF14, NBPF15, 
NBPF16, NBPF20, NBPF24, PDIA3P, PDZK1P1, 
PPIAL4D, PPIAL4E, PPIAL4F, PRKAB2, hPACPL1 
PRKAB2, 
CHD1L 
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2. 16p13.11 recurrent microduplication 
 
Patient #25 
 
This patient is a 5 years old boy without psychometric criteria for classification as ID (IQ= 88) but 
with verbal IQ scoring 58 (speech delay), who has familiar history of ID (cousin with ID and sister 
with learning difficulties) and was born with an interventricular communication corrected by surgery. 
The patient has small stature, squint, dysmorphic features (micrognathia, retrognathia, bulbous 
nose, thin upper lip), short neck, hirsutism and hyperactivity.    
aCGH revealed a 0.8 Mb duplication inherited from the mother at chromosome region 16p13.11 
(chr16:15,391,681-16,215,845) containing 9 genes. Figure 2.31A presents the facial appearance of 
patient 25 while figure 2.31B shows the alteration detected by aCGH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Despite the fact that alteration in the 16p13.11 region still raise conflicts regarding its pathogenicity 
or only susceptibility for neurocognitive disorders, deletions in this region have been found in 
patients with ID and/or multiple congenital abnormalities as well as in phenotypically healthy 
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Figure 2.31 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 25. (A) The facial appearance of the patient reveals squint, dysmorphic features (micrognathia, retrognathia, 
bulbous nose, thin upper lip) and a short neck. (B) The genomic alteration is represented by the green line above the 
16p13.11 cytoband where it is possible to observe the increased mean ratio of the probes contained in that region. The 
UCSC genes present in the genomic region altered in the patient in also represented. (C) The patient is represented by 
the arrow. The patient has a sister with learning difficulties in school and a cousin with ID (mother´s side of the family). A 
cousin from the father side of the family has Down syndrome. 
ID 
Trisomy 21 
Learning difficulties 
Chromosome 16 A 
B 
C 
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parents. It is currently widely accepted that deletion is a risk factor for ID and congenital 
malformations while the real significance of the duplications remains uncertain 296.   
In the patients reported by Hannes FD and colleagues, brain abnormalities (namely microcephaly) 
and seizures were both main features in the patients. Additionally, small stature and some 
unspecified dysmorphic features were also present. Patient 5 presents no IQ criteria for 
classification as intellectually handicapped, was born with a heart congenital malformation, has 
short stature and facial dysmorphisms. The fat that the mother carries the same alteration and that 
the patient has a cousin (from the mother side) with ID may indicate that this alteration is also 
present in the mother´s sister and son. The absence of ID in the patient but the presence of 
malformations and concordant characteristics with previously described cases, together with the 
fact that the mother is a carrier and there are more cases of ID in the maternal side of the family 
reveal once again the incomplete penetrance find in this kind of alterations.   
 
A very interesting gene present covered by the duplication in this patient is the NED1 (nudE 
nuclear distribution gene E homolog 1, A. nidulans) gene. In the work published by Hannes FD et 
al, 2008 the authors propose the NDE1 as a good candidate for the abnormal brain size detected in 
patients with ID and/or multiple congenital anomalies. NED1 protein is highly expressed in the brain 
and Nde1-null mice have microcephaly. However, the screening for mutations in NED1 searching 
for sequence alterations in the remaining allele revealed no mutations 296. However, our patient 
doesn´t have an altered brain size. 
 
TS-CoExp analysis retrieved ABCC1 (ATP-binding cassette, sub-family C (CFTR/MRP), member 
1), NDE1 (nudE nuclear distribution gene E homolog 1, A. nidulans) and KIAA0430 (KIAA0430) 
genes as the 3 more likely to cause ID, among those covered by the duplication. 
ABCC1, also called multidrug resistance-associated protein (MRP), is a plasma membrane drug-
efflux pump. The blocking of ABCC1 function increases the cells susceptibility for suffering toxic 
effects. One example is the case of the increase in unconjugated bilirubin and its association with 
neonatal encephalopathy 297. The KIAA0430 gene has no entrance in OMIM and very little is 
known about its function.    
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.31.  
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Table 2.31 - Summary of the alteration in patient 25 and genes involved. In bold are represented the most likely 
significant genes for the phenotype based on their function. 
 
 
  
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#25 16p13.11(15,391,681
-16,215,845)X3 9 51 
ABCC1, ABCC6, C16orf45, 
C16orf63, KIAA0430, MIR484, 
MPV17L, MYH11, NDE1 
ABCC1, NDE1, 
KIAA0430 
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Patient #26 
 
This patient is a 4 years old boy with moderate ID (IQ= 49); the most significant fact in the family 
history is the epilepsy presented by the patient´s aunt (mother´s sister). The mother had 
chickenpox at 36 weeks of pregnancy; the patient was born with normal somatometry and facial 
palsy. The patient has weight and occipital-frontal circumference close to 95th centile, is hypotonic, 
has abnormal positioning of the arms (pronation), autism and dysmorphisms, such as 
brachycephaly, round face, small nose and short neck.  
aCGH revealed a 0.9 Mb duplication inherited from the mother at chromosome region 16p13.11 
(chr16:15,384,327-16,351,469), containing 11 genes. Figure 2.32A presents the facial appearance 
of patient 26 while figure 2.32B shows the alteration detected by aCGH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast to patient 25 who had no quantitative criteria for ID, patient 26 is moderately 
intellectually handicapped. This patient presents dysmorphisms, autism and hypotony.  
One important difference between patient 24 and 26, is the fact that patient 26 has two more genes 
possibly covered by the duplication: LOC339047 and NOMO3 (nodal modulator 3). For the 
LOC339047 gene there is no entrance in OMIM or PubMed yet. NOMO3 is a gene with a metal-
binding domain with high similarity with NOMO1, a protein that is part of a protein complex that 
Figure 2.32 - Facial appearance, schematic representation of the genomic alteration and pedigree representation 
for patient 26. (A) The facial appearance of the patient reveals his brachycephaly, round face, small nose and short neck. 
(B) The genomic alteration is represented by the green line above the 16p13.11 cytoband where it is possible to observe 
the increased mean ratio of the probes contained in that region. The UCSC genes present in the genomic region altered in 
the patient in also represented. (C) The patient is represented by the arrow. The patient has aunt (mother´s sister) with 
epilepsy. 
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participates in the Nodal signaling pathway, an important pathway for differentiation during 
development.    
Similarly to the previous patient, NED1 gene is also covered by the duplication, being a good 
candidate for the increased head circumference of the patient and, consequently, ID phenotype. 
 
Ts-CoExp analysis retrieved the same results as in patient 25.    
 
A summary of the alteration, genes involved and genes pinpointed by the TS-CoExp tool is 
represented in table 2.32. 
 
Table 2.32 - Summary of the alteration in patient 26 and genes involved. In bold are represented the most likely 
significant genes for the phenotype based on their function. 
Patient 
Number Event 
Number 
of 
Genes 
Involved 
Number 
of 
Probes 
Involved 
Genes TS-CoExp 
#26 16p13.11(15,384,327
-16,351,469)X3 11 54 
ABCC1, ABCC6, C16orf45, 
C16orf63, KIAA0430, LOC339047, 
MIR484, MPV17L, MYH11, NDE1, 
NOMO3 
ABCC1, NDE1, 
KIAA0430 
 
 
Once again, the fact that the mother carries the same alteration and her sister has epilepsy raises 
the hypothesis of the presence of this alteration in more members of the family revealing the 
incomplete penetrance of the alteration.   
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Challenges in the interpretation of aCGH results 
1. CNVs present in healthy parents 
 
Copy number variations of large dimensions and/or encompassing possibly interesting genes were 
found to be carried by healthy parents.  
 
In patient 27, two alterations of unknown significance were found by aCGH. One of these 
alterations was a 0.07 Mb deletion in region 4q24 (chr4:107,322,522-107,395,454) (figure 2.33A) 
and a 0.17 Mb deletion in 7p21.1 (chr7:16,449,856-16,625,033) (figure 2.33B).         
 
 
 
 
 
 
 
 
 
 
 
 
Both alterations could possibly cause the disruption of the genes involved, however they were 
found to be inherited from the healthy mother. The confirmation of the presence of the alterations in 
the mother excluded them as causative of pathology which ended in a negative case for 
pathogenic CNVs.  
 
In patient 28, a 0.1 Mb deletion was found in 13q14.3 (chr13:51,413,362-51,515,663) (figure 2.34) 
covering three genes.  
 
 
 
 
 
 
 
 
 
 
Figure 2.33 – Representation of the genomic alterations found in patient 27. In (A) is represented the deletion 
found in 4q24 while in (B) is represented the deletion found in 7p21.1. 
Figure 2.34 - Representation of the 13q14.3 deletion found in patient 28.  
Chromosome 13 
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One of those genes was the ATP7B (ATPase, Cu(2+)-transporting, beta polypeptide), the gene 
mutated in Wilson disease13. In this case, qPCR analysis for ATP7B gene showed the presence of 
the alteration in the father. Thus we found that father and son are heterozigous carriers of a 
pathogenic variant causing autosomal recessive disorder, raising genetic counselling issues, such 
as if the finding  of genomic information not requested by the genomic test should be given to the 
patient or not.   
 
In patient 29, three alterations of unknown significance were find by aCGH: a 0.1 Mb duplication at 
4q13.2 (chr4:69,038,815-69,170,341), a 0.5 Mb duplication at 4q13.3 (chr4:70,766,959-
71,285,452) region and a 0.2 Mb duplication at 4q21.1 (chr4:76,987,928-77,215,148) (figure 
2.35A). 
   
 
 
 
 
 
 
 
 
 
 
aCGH analysis in the parents revealed the presence of the first alteration in the mother (figure 
2.35B), while the other two were present in the father (figure 2.35C). The 4q13.2 duplication alone 
(present in the healthy mother) has criteria for classification as a benign CNV since it is present in 
more than 3 healthy controls. However, this is not the case for 4q13.3 and 4q21.1 duplications 
(both present in the father).  Together, these duplications encompassed 23 genes, for which no 
significant CNVs were reported in DGV.  
In this case, the patient inherited both CNVs from each parent ending out with a chromosome 4 
with 3 distinct alterations. We cannot conclude that these two alterations are benign because when 
alone they may not cause the phenotype, but together they may account for the disease in the 
child. This is one case for which, even though we have data from the parents, no clear conclusions 
will be achieved.  
 
                                                          
13
 Wilson disease is an autosomal recessive disorder characterized by dramatic build-up of intracellular hepatic copper with 
subsequent hepatic and neurologic abnormalities.  
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A B C 
Figure 2.35 - Representation of the genomic alterations found in patient 29. In (A) is represented the duplications 
found in 4q13.2, 4q13.3 and 4q21.1 present in the index case. In (B) is represented the 4q13.2 duplication found 
in the mother and in (C) are represented the 4q13.3 and 4q21.1 duplications found in the father. 
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In patient 30, a 0.7 Mb duplication at 19p13.3-p13.2 (chr19:6,283,716-6,944,284) and a 0.6 Mb 
duplication at 19p13.2 (chr19:7,028,066-7,633,437) were found (figure 2.36) encompassing a total 
of 34 genes together. Exactly the same alteration was found in the mother, for whom a suspicion of 
mild ID was raised. From the paternal side of the family there is also history of ID and deaths 
during childhood and teenage years (patients suspected to have ID). A cousin of the patient has 
optical atrophy and diabetes.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once again, in this case we cannot clearly conclude about the significance of the alteration is 
present in the mother also suspected to have a milder form of ID. Adequate psychometric 
evaluation needs to be performed in the mother in order to assess her IQ. Another important 
aspect to take into account is that this alteration can also be a susceptibility locus that together with 
any other alteration inherited from the father can account for the more severe phenotype in the 
child while by itself has a lighter phenotype (the case of the mother). 
 
 
 
 
 
 
Index case 
ID without dysmorphic features + motor alterations 
Optic atrophy (blindness) + Diabetes 
Suspicion of ID 
A B 
Figure 2.36 - Representation of the genomic alterations found in patient 30. In (A) is represented the duplications 
found in 4q13.2, 4q13.3 and 4q21.1 present in the index case. In (B) is represented the 4q13.2 duplication 
found in the mother and in (C) are represented the 4q13.3 and 4q21.1 duplications found in the father. 
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The summary of these four cases as well as the genes involved in the alterations is represented in 
table 2.33. 
 
Table 2.33 – Summary of the alterations described above as well as the genes involved in each case.  
Patient Alteration Cytoband Location Inheritance Genes 
A 
Deletion 4q24 
chr4:107,322,522-
107,395,454 
Mother TBCK 
Deletion 7p21.1 
chr7:16,449,856-
16,625,033 
Mother ANKMY2, SOSTDC1 
B Deletion 13q14.3 
chr13:51,413,362-
51,515,663 
Father ALG11, ATP7B, UTP14C 
C 
Duplication 4q13.2 
chr4:69,038,815-
69,170,341 
Mother TMPRSS11E, UGT2B17 
Duplication 4q13.3 
chr4:70,766,959-
71,285,452 
Father 
C4orf35, C4orf40, C4orf7, CSN1S1, CSN1S2A, CSN1S2B, 
CSN2, CSN3, HTN1, HTN3, ODAM, SMR3A, SMR3B, 
STATH 
Duplication 4q21.1 
chr4:76,987,928-
77,215,148 
Father ART3, CXCL10, CXCL11, CXCL9, NAAA, PPEF2, SDAD1 
D 
Duplication 
19p13.3-
p13.2 
chr19:6,283,716-
6,944,284 
Mother 
ACER1, ALKBH7, C3, CD70, CLPP, CRB3, DENND1C, 
EMR1, EMR4P, GPR108, GTF2F1, KHSRP, MIR220B, 
PSPN, SH2D3A, SLC25A23, SLC25A41, TNFSF14, 
TNFSF9, TRIP10, TUBB4, VAV1 
Duplication 19p13.2 
chr19:7,028,066-
7,633,437 
Mother 
ARHGEF18, C19orf45, INSR, KIAA1543, LOC100128573, 
LOC100131801, MCOLN1, PCP2, PEX11G, PNPLA6, 
STXBP2, XAB2, ZNF358, ZNF557 
 
 
 
The surprising discovery for these four cases highlights the crucial importance of confirmation in 
the parents and, consequently, of the collection of parents’ samples and clinical information. 
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CNVs of unknown significance 
 
The increasing resolution achieved by aCGH platforms nowadays allows a deeper look at the 
alterations present in the patients, many times not easy to interpret. In spite of the adopted 
strategies for CNV classification, doubts in the application of the criteria many times arise and 
fitting certain alterations in each one of the categories established is often difficult.  
For 27 cases in the present cohort alterations were found that are still raising doubts concerning 
their clinical significance. Whenever a case like this is found, it is necessary to delineate a 
confirmatory strategy for the case and parents. The decision of the approach to use will be taken 
based on the (I) the number of alterations that are necessary to confirm, (II) the nature of the 
alterations (deletion or duplication, size, mean probes ratio, if there are described controls) and (III) 
the number and nature of the affected genes.  
A large portion of these alterations are: 
- Deletions or duplications for which CNVs have been described in control cases, but in less 
than 3 controls and/or not covering the entire region.  
- Presence of deletions or duplications not described in the control database, for which a 
large number of the reciprocal alterations (duplications or deletions, respectively) are 
present in controls. Given the comparative nature of the method, and given that the 
reference samples is actually a pool of DNAs from healthy individuals, the excessive 
presence of one type of CNVs in the reference samples may lead to the observation of a 
false reciprocal CNVs in our test sample often with dubious signal. In these cases, the 
confirmation of the alteration by another method (real time quantitative PCR) is often 
necessary. In figure 2.37 there is represented an example of the previous described 
situation. 
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Chromosome 4 A 
B 
Figure 2.37 – Schematic representation of a dubious mean probes ratio. An example of an alteration 
present in 4p16.1 cytoband where the probe mean ration is near the lower treshold to call an aberration 
(A). In image (B) there is represented the described CNVs in control in healthy individuals in DGV for the 
same region (blue lines for the duplications and red lines for the deleltions). Notive the increase number 
of duplications (blue lines) described when compared with the deletions (red lines). 
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- In genomic imbalances for which controls have a deletion described while the patient has 
duplication, if the breakpoints affect the same genes, it is more likely that the duplication in 
the patient is not causing the disease, since deletions that lead to haploinsufficiency of the 
encompassed genes are not pathogenic as well. However, if the situation is the other way 
around, pathogenicity is more likely and a confirmatory test (using qPCR, for instance) is 
required.   
 
In cases like the ones described above, the genomic analysis for the parents may not always be 
helpful for the determination of its significance. We cannot forget that a large portion of mutations 
(either point mutations or genomic imbalances) occur de novo during development and their 
absence in the parents may not give us its real significance for the phenotype.  
Other type of alterations that may lead to necessity of confirmatory techniques is when a alteration 
is found in a region not covered by CNVs described in controls and encompasses genes. The 
nature of the gene may give us clues about its possible significance for the disease displayed by 
the patient. In this work, special attention was given to genes that are expressed in the nervous 
system (particularly in brain) and that, based on their function, can play important roles in any of 
the pathways described to be involved in the pathogenesis of ID. 
The most significant alterations found in these 27 patients as well as the genes involved and 
associated function are briefly described in table 2.34.   
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Table 2.34 – Summary of the cases still in study and for which confirmation with another technique or assessment of the parents is required in order to conclude about the clinical 
significance of the aCGH findings. The symbol * indicates the gene that could be disrupted by the breakpoint in the alteration (duplication or deletion). 
Patient 
Code Event 
Chromosome 
Region Cytoband Genes Involved 
Possible most 
relevant gene for ID 
Function/Phenotype  
associated 
Confirmation strategy 
(ongoing) 
389 Duplication chrX:70,352,533-70,433,152 Xq13.1 GJB1*, NONO*, ZMYM3 ZMYM3 ID qPCR; Evaluate parents  
453 Duplication chrX:70,352,533-70,433,152 Xq13.1 GJB1*, NONO*, ZMYM3 ZMYM3 ID qPCR; Evaluate parents  
403 Duplication chr3:53,118,008-53,329,390 3p21.1 DCP1A*, MIR1303, PRKCD, RFT1*, TKT PRKCD, TKT Brain function qPCR; Evaluate parents 
412 Duplication chr7:151,439,244-151,528,655 7q36.1 GALNT11*, MLL3* MLL3 Brain function qPCR; Evaluate parents 
421 Duplication chr16:73,949,117-74,057,944 16q23.1 CFDP1*, TMEM170A CFDP1 
Craniofacial 
development function qPCR; Evaluate parents 
423 
Duplication chr1:61,470,344-61,899,438 1p31.3 NFIA* NFIA 
Central nervous system 
function 
aCGH; Evaluate 
parents 
Deletion chr9:118,317,581- 118,573,731 9q33.1 ASTN2*, TRIM32 TRIM32 
Ubiquitin ligase E3; 
Obesity, ID and 
dysmorphic features 
aCGH; Evaluate 
parents 
443 Duplication chr10:73,517,597-73,583,426 10q22.1 ASCC1*, SPOCK2* ASCC1 
Component of the extra-
cellular matrix highly 
expressed in brain 
? 
455 Deletion chrX:122,924,947-122,981,041 Xq25 STAG2* STAG2 
Interacts with cohesin 
proteins qPCR; Evaluate parents 
464 Duplication chr3:48,439,971-48,549,239 3p21.31 
ATRIP, CCDC51, CCDC72, PFKFB4*, PLXNB1*, 
SHISA5, TREX1 PLXNB1 Semaphorin receptor qPCR; Evaluate parents 
479 Duplication chr2:106,632,846-106,910,178 
2q12.2-
q12.3 ST6GAL2* ST6GAL2 ? ? 
480 Duplication chr2:182,411,985-182,561,778 2q31.3 PPP1R1C*, SSFA2 PPP1R1C Cell cycle function qPCR; Evaluate parents 
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515 Duplication chr4:174,658,836-174,718,746 4q34.1 HAND2, NBLA00301 HAND2 Heart function qPCR; Evaluate parents 
563 Deletion chr17:60,712-155,836 17p13.3 RPH3AL* RPH3AL 
Exocytosis and 
Cytoskeleton function qPCR; Evaluate parents 
572 
Deletion chr7:1,998,754-2,047,386 7p22.3 MAD1L1* MAD1L1 Chromosomal instability 
aCGH; Evaluate 
parents 
Duplication chr16:10,638,423-10,751,290 16p13.13 NUBP1*, TEKT5* TEKT5 
Structural component of 
microtubules 
aCGH; Evaluate 
parents 
575 
Duplication chr1:36,547,812-36,690,552 1p34.3 C1orf113*, FAM176B, LSM10, OSCP1*, STK40 Not determined Not determined 
aCGH; Evaluate 
parents 
Deletion chr2:130,497,826-130,676,027 2q21.1 
CCDC74B, FAM128B, LOC440905*, POTEF, 
SMPD4, TUBA3E* 
TUBA3E, FAM128B 
 
Tubulin or tubulin 
association 
aCGH; Evaluate 
parents 
Deletion chr16:2,521,392-2,638,612 16p13.3 CEMP*1, FLJ42627*, LOC652276, PDPK1 PDPK1 Phosphorylation 
aCGH; Evaluate 
parents 
Deletion chr16:29,048,939-29,247,323 16p11.2 RUNDC2C* Not determined Not determined 
aCGH; Evaluate 
parents 
607 
Deletion chr5:1,220,200-1,335,461 5p15.33 SLC6A18, SLC6A19, TERT* SLC6A18, SLC6A19 
Neurotransmitter 
transporters 
aCGH; Evaluate 
parents 
Deletion chr22:49,210,215-49,329,334 22q13.33 
ADM2, LMF2, MIOX, NCAPH2, ODF3B, SAPS2, 
SBF1, SCO2, TYMP* SBF1 
Myotubulin family 
member 
aCGH; Evaluate 
parents 
658 Deletion chr16:367,675-488,401 16p13.3 
DECR2, LOC100134368, NME4, RAB11FIP3*, 
TMEM8A* RAB11FIP3 Rab GTPase 
aCGH; Evaluate 
parents 
787 Deletion chr17:78,070,140-78,294,730 17q25.3 FN3K*, FN3KRP, FOXK2*, RAB40B, WDR45L FOXK2, RAB40B 
Transcription regulation 
and spontaneous 
occlusion of the circle of 
Willis 
qPCR; Evaluate parents 
(?) 
639 Duplication chr6:90,479,080-90,629,922 6q15 CASP8AP2*, MDN1* Not determined Not determined qPCR; Evaluate parents 
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659 Duplication chr5:177,335,291-177,389,093 5q35.3 FAM153C*, PROP1 PROP1 Transcription regulation qPCR; Evaluate parents 
669 Duplication chr17:74,618,880-74,966,215 17q25.3 HRNBP3* HRNBP3 Neuronal function qPCR; Evaluate parents 
732 Duplication chr18:75,287,551-75,353,034 18q23 NFATC1* NFATC1 Not determined qPCR; Evaluate parents 
743 
Duplication chr1:103,836,427-104,103,459 1p21.1 
AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, 
LOC648740, RNPC3* Not determined Not determined 
aCGH; Evaluate 
parents 
Duplication chr17:45,956,061-46,132,442 17q21.33 
ABCC3, ANKRD40*, CACNA1G, EPN3, 
MYCBPAP*, SPATA20 Not determined Not determined 
aCGH; Evaluate 
parents 
Duplication chrX:1,333,567-1,382,414 Xp22.33 CSF2RA* Not determined Not determined 
aCGH; Evaluate 
parents 
745 
Duplication chr4:92,412,048-92,542,935 4q22.1 FAM190A* FAM190A Not determined 
aCGH; Evaluate 
parents 
Duplication chr7:154,904,327-154,995,882 7q36.3 CNPY1*, EN2 EN2 Autism 
aCGH; Evaluate 
parents 
Duplication chr22:29,558,944-29,617,330 22q12.2 OSBP2* OSBP2 Neuronal function 
aCGH; Evaluate 
parents 
763 Deletion chrX:32,177,045-32,421,416 Xp21.1 DMD* DMD 
Duchene muscular 
dystrophy qPCR; Evaluate parents 
776 Deletion chr7:81,647,142-81,725,143 7q21.11 CACNA2D1* CACNA2D1 Not determined qPCR; Evaluate parents 
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General discussion 
 
We used aCGH to investigate DNA copy number imbalances in 130 patients with idiopathic ID. All 
the patients included in this study were previously studied for the routinely performed laboratory 
tests such as high-resolution G-banding karyotype, study of subtelomeric rearrangements (by 
MLPA or FISH), other fluorescence in situ hybridization studies when a specific syndrome was 
suspected, metabolic screening, and fragile X testing when clinically indicated (FRAXA and 
FRAXE). 
Using the same platform and consensual workflow criteria, a total of 23 genomic imbalances that 
were very likely to account for the phenotype were found in 26 patients. 
The distribution based on the size of the genomic alterations is described in table 2.35. 
 
Table 2.35 – Number of alterations found distributed by their size. 
 
 
 
 
 
 
 
 
 
Of all the alterations found in the 26 described patients, 40% were alterations below 1 Mb of size 
and would for sure be missed in a conventional karyotype.  
If we consider only this set of patients, we achieved a diagnostic yield of 20% in patients that were 
extensively studied without success before. However, this number can even be increased with the 
determination of the clinical significance of the remaining 27 cases of less clear pathogenicity. It is 
also important to highlight that, when used as a routine diagnostic tool, the criteria for patient 
selection are less stringent and one might be able to achieve higher detection rates. Another 
important factor for the detection rate is the array resolution and design. The platform used here 
allows a mean resolution of 17 Kb, achieving resolutions as high as 11 Kb in regions known to be 
associated with development disorders/congenital abnormalities. This particular array (AMADID 
023363) was designed by the LLC Dutch consortium, for its implementation as a first-tier diagnostic 
test in the study of children with ID and/or congenital abnormalities in the Netherlands. 
Consequently, the array is enriched in probes in regions known to be associated with ID/DD, 
allowing a higher detection rate           
The largest alteration was found in patient 9 and has 10.2 Mb size. The most likely scenario is that 
this alteration would be found by conventional karyotyping in a retrospective analysis. This would 
Size of imbalance Number of cases Percentage of cases (%) 
>10 Mb 1 4% 
5-10 Mb 4 15% 
1-5 Mb 10 39% 
<1 Mb 11 42% 
TOTAL 26 100% 
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also be possible for the four alterations found between 5 and 10 Mb size. However, the majority of 
the chromosomal changes found in the study (80%) were below 5 Mb in size, a dimension already 
critical for detection by conventional karyotyping, revealing once again the large number of 
explainable cases missed by this technique.  
When the patients carry de novo relatively large alterations, it is reasonable to assume that the 
imbalance is causing the disease. On the other hand, when the alteration or at least a very similar 
one is present in affected and non-affected members of the family, these findings have high impact 
for genetic counseling. This situation occurs for patients 24, 25 and 26. The alterations described 
for these 3 cases are present in regions of susceptibility for developmental disorders and were 
described to be present either in affected, mildly affected and healthy individuals 286, 296. The 
presence of more affected individuals in the family raises the hypothesis of the alteration being 
present not only the parent, but also in other siblings, something that needs to be further analyzed 
(the case of susceptibility loci). 
Still in the same topic, are the cases were the alteration (or at least a very similar one) is also found 
in one of the parents and a suspicion is raised if the progenitor is in fact unaffected. Many times the 
correct assessment of the carrier parent is only performed after the discovery of the alteration and 
not rarely it is found that the father or mother are not absolutely healthy but display a milder form of 
ID or behavior alterations. This possibility is present in some of the cases reported in this work 
(such as patient 7).    
  
Other interesting alterations were found in patients 1 and 2, in whom the imbalance size seems to 
correlate with the severity of the disease. Although both patients have criteria for classification and 
MECP2 duplication syndrome, patient 1 has three more genes covered by the duplication for which 
point mutations are known to be involved in X-linked ID. If the increased severity of the disease in 
patient 1 is due to the genomic imbalance of any of those genes individually, or to the combination 
of all of them remains unknown.       
Only 6 patients presented alterations fully concordant with previous described syndromes in 
Decipher. The remaining 18 patients presented alterations not previously described at all or only 
partially overlapping with syndrome regions. These alterations may represent novel pathogenic 
genomic imbalances. Another important contribution of these new previously non-reported 
alterations is the identification of the genes encompassed by them, which raises the need to clarify 
their contribution for the etiology of ID. 
In spite of the use of established consensus criteria for evaluation of the genomic alterations 
described, we should keep in mind that genotype-phenotype correlations can be challenging in 
some cases, such as when (I) the inheritance of the CNVs cannot be determined (in cases for 
which parents samples are not available, there is incomplete penetrance of an alteration, that can 
be present in both affected and unaffected individuals). Also, (II) a small alteration can be 
pathogenic even if it involves genes of unknown or apparently not relevant function, (III) an 
alteration can be pathogenic even if it doesn´t cover genes, (IV) a deletion can be pathogenic by 
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unmasking a recessive mutation in the other allele and (V) a CNV can be pathogenic only in 
combination with mutations in other genes 113. All these aspects should be taken into account 
since, the correct interpretation of the results is crucial for the physician in order to perform a 
correct counseling and patient management.  
 
Regarding the still inconclusive cases, special attention needs to be given to the duplication effects 
when this is not covering the totality of a gene. The most straightforward way of interpreting the 
duplications pathogenicity is when it encompasses the entire gene. In this case, the most likely way 
to cause the disease is if the affected gene(s) are dosage sensitive and either by their deregulation 
or downstream targets/interactors deregulation, leading to disease. On the other hand, whenever a 
duplication doesn´t cover the totality of the gene, a set of possible consequences needs to be 
confirmed. If located in tandem, the alteration may lead to the disruption of the gene (either by 
encoding a mutant protein that is degraded or has altered functions) causing a similar 
consequence to a deletion of the gene. The other possible outcome, is that if the duplicated 
segment is located somewhere else in the genome. In this case, it is less likely that the duplication 
could account for the disease, unless the duplicated genomic portion is able to encode for a protein 
that as noxious function in the same pathway as the original one, leading also to the disease. 
Either way, whenever a duplication that may disrupt a gene is found in a patient, FISH studies and 
possible mRNA analysis are required in order to better understand its functional consequences. 
 
Other important aspect to take into account is that when a large rearrangement if found, usually 
dozens of genes are covered by the alteration but not all of them will be dosage sensitive and 
relate to the phenotype. An important aspect of the clinical interpretation of this type of genomic 
alterations is the look for the key gene(s) that may be causing the phenotypes. This type of search 
can be performed by two ways: (I) look for the described function for each of the genes involved in 
the alteration (a laborious and time consuming strategy that is subjected to human errors and 
knowledge of the molecular mechanisms behind the etiology of ID) or (II) by using bioinformatics 
tools that help in the prioritization the most interesting genes for each phenotypic alteration. By the 
analysis of either ways for each of the patients described, we believe that the most reliable method 
for avoiding false positive results is the use of both strategies together. Another important 
improvement that can be made to this approach is the use of more bioinformatics tools that not 
take into account only the co-expression patterns of the genes but also its function, tissue 
expression, species conservation and so on. This type of approach will allow not only the discovery 
of new genes that account for ID but also genes that are related with other phenotypic features 
often seen in these patients (such as congenital malformations and behavior alterations). 
 
In the recent years, new conceptual insights have been acquired regarding the fundamental 
constitution and function of the genome elements 298, 299, 300. The existence of long-range regulatory 
functional domains is for a long time supported by genomic functional studies and their importance 
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in the regulation of differential gene expression at several stages of development is undeniable 299. 
Consequently, alterations in regions that don´t encompass genes may have severe consequences 
for the regulation of crucial elements for development and account as well for disease 298, 301.   
 
For the described alterations (regarding patients 1-30) a total of 13 patients (43%) presented 
genomic imbalances that also covered miRNAs.  Whenever a large genomic imbalance is found in 
a patient, special attention is given to the genes involved, namely their function, expression pattern 
and interacting proteins. However, the presence of miRNAs in those regions can also lead to the 
de-regulation of target mRNAs, crucial for disease. In spite of the advances in the clarification of 
miRNAs’ role in DD spectrum disease, no significant conclusions can be made for diagnosis 
purposes so far regarding deletions/duplications of those genomic elements.  
 
This work revealed a 20% yield of detection in patients with idiopathic ID and for which no 
explanation was possible to be given to the parents so far. With the integration in this study, the 
parents of at least 26 children will have now the possibility of genetic counseling. Besides the fact 
that for a set of patients the ID could finally be explained, a larger experience was taken from this 
work. This study revealed the importance of the parent’s analysis in order to conclude about the 
clinical significance of the alterations found and that copy number variations in regions not 
previously described as imbalance do not invariably imply pathogenicity. Conversely, in the 
diagnostic service front, this technique also requires caution when asserting that a CNV is not 
pathogenic just because is reported in healthy parents. The parents should always be further 
evaluated in this situation in order to search for undetermined or minimal clinical symptoms. The 
genomic imbalance may also have an incomplete penetrance or milder expression of in the parents 
(or even in very few control individuals), and be expressed in a more severe way in the child due to 
a more complex mechanism (a variation in other allele or even another CNVs that also predispose 
to the disease). Indeed, false positive results that require parental testing comprise the 
weaknesses of this technique since they increase the costs of the test in a 3x fold.  
Another important aspect that may lead to limitations in the interpretation of the results is the lack 
of a CNVs study in control Portuguese cases. Since the genetic background of the Portuguese 
population is different from the one present in the DGV database and the one constituted by the 
Dutch parents, there may be CNVs in the Portuguese cases that, despite being benign and have 
relatively high recurrence rates, are not described in the other databases and may lead to 
false/dubious alterations among our patients.     
 
Despite all the limitations still found by the users of aCGH as a diagnostic tool of children with ID, 
this approach is the currently recommended by international guidelines and is already used as a 
first-tier test in the USA and several European countries 114, 148, 302. We believe that this pioneer 
study in Portugal gave a crucial contribute to the implementation of this technique as a first test 
used in the diagnostic of children with ID/DD and congenital abnormalities, either by the technical 
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formation as well as by the preparation and self-learning skills acquired regarding the interpretation 
of the results. 
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Final remarks 
 
In the last 40 years conventional karyotyping has been the most used methodology to study human 
chromosomes, allowing increasingly subtle abnormalities of the human genome to be discovered 
and linked to specific diseases. The improvements in the conventional cytogenetics (such as higher 
resolution and different FISH approaches) quickly proved to be insufficient and soon the need was 
felt for a technique that allowed the possibility to identify genomic imbalances across the entire 
genome at a much higher resolution and less labour-intensivily than conventional karyotyping 
methodologies. Array CGH appeared as a molecular cytogenetic approach designed to provide 
genome-wide screening of the amplification and deletion of specific chromosome regions. 
The impact of aCGH in the practice of Medical Genetics in the recent years has been 
transformative and a even better understanding of the full clinical spectrum of these disorders will 
be achieved as the use of array CGH in the clinical becomes more prevalent and as correlations of 
these clinical findings with the genomic lesions are increasingly made. The use of aCGH in Clinical 
Genetics has allowed researchers and clinicians to (I) expand the phenotype of previous existing 
conditions, (II) identify reciprocal products of known conditions, (III) determine the genomic 
alterations in known conditions and (IV) discover many new syndromes.  In addition to cancer and 
neurological conditions, there is a clear indication that constitutional chromosomal alterations 
detected by aCGH may affect many organ systems and that CNVs may play important roles in 
many multifactorial conditions, such as Crohn´s disease, immunodeficiency  disorders, psoriasis 
and isolated congenital heart diseases 303, 304, 305, 306.    
Although our understanding of CNVs and their role in health and disease is improving, it is still 
common to identify alterations of unclear clinical significance that cause considerable interpretive 
difficulties for the laboratory and create significant counseling dilemmas for the clinician. 
Contemporary cytogenetics has already integrated array technologies into clinical use in many 
countries around the world. Well-designed arrays for clinical use allow easy interpretation and are 
likely to provide diagnosis in a substantial number of currently undiagnosed cases of human 
genetic disorders. Molecular karyotyping has already transformed the practice of both Medical 
Genetics and Cytogenetics laboratories ushering in the new era of genomic medicine.  
Our main proposal with this work is to highlight the advantages of aCGH technology for the 
diagnosis of ID patients and its adoption as the first-tier test to be used in Portugal for this 
condition.     
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Table S1 – Genes used for PRC amplification of HUMARA locus. 
Direction Sequence 5’3’ Size TmºC Modifications Cycling conditions 
Forward TCCAGAATCTGTTCCAGAGCGTGC 24 69 6-FAM (5’) 96ºC – 10’  
Reverse GCTGTGAAGGTTGCTGTTCCTCAT 24 66 None 
96ºC – 45’’’ 
67ºC – 30’’ 
72ºC – 45’’ 
40 X 
 
72 ºC – 15’ 
4ºC - ∞ 
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Table S2 – OMIM entrances used as training set for the gene prioritization in Ts-CoExp web tool. 
OMIM 
entrance Title 
#300419 MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED; MRXARX 
#309500 RENPENNING SYNDROME 1; RENS1 
#300055 MENTAL RETARDATION, X-LINKED, SYNDROMI C 13; MRXS13; MENTAL RETARDATION, X-LINKED 79; MRX79 
#303350 MASA SYNDROME 
#309510 PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS 
#300624 FRAGILE X MENTAL RETARDATION SYNDROME; PRIMARY OVARIAN INSUFFICIENCY, FRAGILE X-ASSOCIATED, INCLUDED 
#224050 CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 1; CAMRQ1 
#300260 LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL 
#300354 MENTAL RETARDATION, X-LINKED, WITH SHORT STATURE, HYPOGONADISM, AND ABNORMAL GAIT 
#300749 MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA; MENTAL RETARDATION, X-LINKED, CASK-RELATED, INCLUDED 
#300220 MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10 
#309530 MENTAL RETARDATION, X-LINKED 1; MRX1; MENTAL RETARDATION, X-LINKED 18, INCLUDED; MRX18, INCLUDED 
#309580 MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1 
#300486 MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVE FACIAL APPEARANCE 
#300523 ALLAN-HERNDON-DUDLEY SYNDROME; AHDS 
#309548 MENTAL RETARDATION, X-LINKED, ASSOCIAT ED WITH FRAGILE SITE FRAXE 
#141750 ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, DELETION-TYPE 
#300558 MENTAL RETARDATION, X-LINKED 30; MRX30 
#300243 MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE 
#300352 CREATINE DEFICIENCY SYNDROME, X-LINKED 
#300143 MENTAL RETARDATION, X-LINKED 21; MRX21 
#607417 MENTAL RETARDATION, AUTOSOMAL RECESSIV E 2; MRT2 
#300659 MENTAL RETARDATION, X-LINKED 93; MRX93 
#300263 SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME 
#300705 MENTAL RETARDATION, X-LINKED 17; MRX17 
#241080 HYPOGONADISM, ALOPECIA, DIABETES MELLITUS, MENTAL RETARDATION, AND EXTRAPYRAMIDAL SYNDROME 
#309549 MENTAL RETARDATION, X-LINKED 9; MRX9 
#613227 CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 3; CAMRQ3 
#600176 MICROCEPHALY, CORTICAL MALFORMATIONS, AND MENTAL RETARDATION 
#300706 MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE 
#300387 MENTAL RETARDATION, X-LINKED 63; MRX63 
#300123 MENTAL RETARDATION, X-LINKED, WITH PAN HYPOPITUITARISM; MENTAL RETARDATION, X-LINKED, WITH ISOLATED GROWTH HORMONE DEFICIENCY, INCLUDED; MRGH, INCLUDED 
#300434 STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME 
#612292 BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME 
#300534 MENTAL RETARDATION, X-LINKED, SYNDROMIC, JARID1C-RELATED 
#235730 MOWAT-WILSON SYNDROME 
#305450 OPITZ-KAVEGGIA SYNDROME; OKS 
#300088 EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION; EFMR 
#249500 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 1; MRT1 
#239300 HYPERPHOSPHATASIA WITH MENTAL RETARDATION 
#206700 ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION 
#300630 MENTAL RETARDATION, X-LINKED 59; MRX59 
#610954 PITT-HOPKINS SYNDROME; PTHS 
#608443 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 3; MRT3 
#300436 MENTAL RETARDATION, X-LINKED 46; MRX46 
#304400 DEAFNESS, X-LINKED 2; DFNX2; PERILYMPHATIC GUSHER DURING STAPES SURGERY, INCLUDED 
#606612 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT MENTAL RETARDATION), TYPE B, 5; MDDGB5 
#300676 MENTAL RETARDATION, X-LINKED, SYNDROMIC 14; MRXS14 
#300271 MENTAL RETARDATION, X-LINKED 72; MRX72 
#613155 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 1; MDDGB1 
#612447 SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION 
#608840 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6; MDDGB6 
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#309583 MENTAL RETARDATION, X-LINKED, SNYDER-ROBINSON TYPE 
#180849 RUBINSTEIN-TAYBI SYNDROME 1; RSTS1 
#156200 MENTAL RETARDATION, AUTOSOMAL DOMINANT1; MRD1 
#613192 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 13; MRT13 
#136630 MENTAL RETARDATION, FRA12A TYPE 
#604278 RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTAL RETARDATION 
#611093 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7 
#300643 ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, X-LINKED; RESDX 
#610003 CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT 
#606858 PREMATURE CHROMOSOME CONDENSATION WITH MICROCEPHALY AND MENTAL RETARDATION 
#300578 CHROMOSOME Xp11.3 DELETION SYNDROME 
#300495 AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2 MENTAL RETARDATION, X-LINKED, INCLUDED 
#300472 CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA, AND MICROGNATHIA 
#194072 WILMS TUMOR, ANIRIDIA, GENITOURINARY A NOMALIES, AND MENTAL RETARDATION SYNDROME; WAGR 
#613670 MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND AUTISTIC FEATURES 
#613156 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY 
#613151 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY 
#300799 MENTAL RETARDATION, X-LINKED, SYNDROMIC, ZDHHC9-RELATED 
#300498 MENTAL RETARDATION, X-LINKED 45; MRX45 
#300194 AMME COMPLEX 
#612780 SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, AND ELECTROLYTE IMBALANCE 
#612652 MENTAL RETARDATION, JOINT HYPERMOBILITY, AND SKIN LAXITY, WITH OR WITHOUT METABOLIC ABNORMALITIES 
#309520 LUJAN-FRYNS SYNDROME 
#300423 MENTAL RETARDATION, X-LINKED, WITH EPILEPSY; XMRE 
#177980 PTERYGIA, MENTAL RETARDATION, AND DISTINCTIVE CRANIOFACIAL FEATURES 
#612580 MENTAL RETARDATION, AUTOSOMAL DOMINANT3; MRD3 
#300699 MENTAL RETARDATION, X-LINKED 94; MRX94 
#300210 MENTAL RETARDATION, X-LINKED 58; MRX58 
#610156 MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENIS 
#608747 INSULIN-LIKE GROWTH FACTOR I DEFICIENCY 
#241410 HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD 
#164280 FEINGOLD SYNDROME 
#613671 MENTAL RETARDATION, ANTERIOR MAXILLARY PROTRUSION, AND STRABISMUS; MRAMS 
#613152 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY(CONGENITAL WITHOUT MENTAL RETARDATION), TYPE B, 4; MDDGB4 
#612581 MENTAL RETARDATION, AUTOSOMAL DOMINANT4; MRD4 
#611092 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 6; MRT6 
#300803 MENTAL RETARDATION, X-LINKED, ZNF711-RELATED 
#300802 MENTAL RETARDATION, X-LINKED, SYP-RELATED 
#300716 MENTAL RETARDATION, X-LINKED 95; MRX95 
#225060 CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1; OROFACIAL CLEFT 7, INCLUDED; OFC7, INCLUDED 
#606937 SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 5; SCAR5 
#613443 MENTAL RETARDATION, STEREOTYPIC MOVEMENTS, EPILEPSY, AND/OR CEREBRAL MALFORMATIONS 
#612621 MENTAL RETARDATION, AUTOSOMAL 5; MRD5 DOMINANT 
#300831 CK SYNDROME 
#119540 CLEFT PALATE, ISOLATED; CPI; CLEFT PALATE, ISOLATED, AND MENTAL RETARDATION, INCLUDED 
#609579 SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION 
#300577 MENTAL RETARDATION, X-LINKED 91; MRX91 
#612469 WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION, AND OBESITY SYNDROME; WAGRO 
#308100 ICHTHYOSIS, X-LINKED; XLI 
#301040 ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, NONDELETION TYPE, X-LINKED; ATRX 
#218040 COSTELLO SYNDROME 
#303600 COFFIN-LOWRY SYNDROME; CLS 
#608636 CHROMOSOME 15q11-q13 DUPLICATION SYNDROME; AUTISM, SUSCEPTIBILITY TO, 4, INCLUDED; AUTS4, INCLUDED 
#300672 EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2 
#257300 MOSAIC VARIEGATED ANEUPLOIDY SYNDROME; MVA 
#216550 COHEN SYNDROME; COH1 
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#194050 WILLIAMS-BEUREN SYNDROME; WBS 
#105830 ANGELMAN SYNDROME; AS; ANGELMAN SYNDROME CHROMOSOME REGION, INCLUDED; ANCR, INCLUDED 
#612001 CHROMOSOME 15q13.3 DELETION SYNDROME 
#123450 CRI-DU-CHAT SYNDROME 
#300257 DANON DISEASE 
#606777 GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1 
#601224 POTOCKI-SHAFFER SYNDROME 
#300049 HETEROTOPIA, PERIVENTRICULAR, X-LINKED DOMINANT; HETEROTOPIA, PERIVENTRICULAR NODULAR, WITH FRONTOMETAPHYSEAL DYSPLASIA, INCLUDED 
#259730 OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3 
#606407 HYPOTONIA-CYSTINURIA SYNDROME; HOMOZYGOUS 2p21 DELETION SYNDROME, INCLUDED 
#310200 MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD 
#307000 HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS; HYDROCEPHALUS, X-LINKED, WITH CONGENITAL IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION, INCLUDED 
#242860 IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 
#609308 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY(LIMB-GIRDLE), TYPE C, 1; MDDGC1 
#605899 GLYCINE ENCEPHALOPATHY; GCE; HYPERGLYCINEMIA, TRANSIENT NEONATAL, INCLUDED; TNH, INCLUDED 
#601808 CHROMOSOME 18q DELETION SYNDROME 
#261600 PHENYLKETONURIA; PKU; 
#216360 COACH SYNDROME 
#191100 TUBEROUS SCLEROSIS 1; TSC1 
#190685 DOWN SYNDROME; TRISOMY 21, INCLUDED 
#147920 KABUKI SYNDROME 
#122470 CORNELIA DE LANGE SYNDROME 1; CDLS1 
#117550 SOTOS SYNDROME 
#236670 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1 
#612475 CHROMOSOME 1q21.1 DUPLICATION SYNDROME 
#607872 CHROMOSOME 1p36 DELETION SYNDROME 
#600118 WARBURG MICRO SYNDROME; WARBM 
#308350 EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1 
#253280 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3 
#235510 HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 
#212720 MARTSOLF SYNDROME 
#208400 ASPARTYLGLUCOSAMINURIA; AGU 
#145410 OPITZ GBBB SYNDROME, AUTOSOMAL DOMINANT 
#115150 CARDIOFACIOCUTANEOUS SYNDROME 
#301900 BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS 
#188025 THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT 
#612474 CHROMOSOME 1q21.1 DELETION SYNDROME, 1.35-MB 
#609425 CHROMOSOME 3q29 DELETION SYNDROME 
#608363 CHROMOSOME 22q11.2 DUPLICATION SYNDROME 
#310600 NORRIE DISEASE; ND 
#300004 CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA 
#266265 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C 
#256850 GIANT AXONAL NEUROPATHY 1; GAN1 
#250800 METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE; METHEMOGLOBINEMIA, TYPE I, INCLUDED 
#248800 MARINESCO-SJOGREN SYNDROME; MSS 
#248510 MANNOSIDOSIS, BETA A, LYSOSOMAL 
#236200 HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY; HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS- RELATED, INCLUDED 
#216400 COCKAYNE SYNDROME, TYPE A; CSA 
#192430 VELOCARDIOFACIAL SYNDROME 
#182212 SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME 
#146390 CHROMOSOME 18p DELETION SYNDROME 
#606232 CHROMOSOME 22q13.3 DELETION SYNDROME 
#300815 CHROMOSOME Xq28 DUPLICATION SYNDROME 
#251200 MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 1; MCPH1 
#162200 NEUROFIBROMATOSIS, TYPE I; NF1 
#103050 ADENYLOSUCCINASE DEFICIENCY 
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#613026 CHROMOSOME 19q13.11 DELETION SYNDROME 
#612513 CHROMOSOME 2p16.1-p15 DELETION SYNDROME 
#612164 EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4 
#611603 LISSENCEPHALY 3; LIS3 
#610443 CHROMOSOME 17q21.31 DELETION SYNDROME 
#610253 KLEEFSTRA SYNDROME 
#609625 CHROMOSOME 10q26 DELETION SYNDROME 
#608716 MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 5; MCPH5 
#607855 MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A; MUSCULAR DYSTROPHY, CONGENITAL, DUE TO PARTIAL LAMA2 DEFICIENCY, INCLUDED 
#607426 COENZYME Q10 DEFICIENCY 
#309000 LOWE OCULOCEREBRORENAL SYNDROME; OCRL 
#300801 CHROMOSOME Xp11.23-p11.22 DUPLICATION SYNDROME 
#300673 ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS 
#300337 HYPOMELANOSIS OF ITO; HMI 
#276710 TYROSINEMIA, TYPE III 
#270400 SMITH-LEMLI-OPITZ SYNDROME; SLOS 
#269700 LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2 
#246560 SPLIT-HAND/FOOT MALFORMATION 3; SHFM3 
#238970 HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME 
#219000 FRASER SYNDROME CRYPTOPHTHALMOS-SYNDACTYLY SYNDROME, INCLUDED 
#213700 CEREBROTENDINOUS XANTHOMATOSIS 
#210600 SECKEL SYNDROME 1; SCKL1 
#200990 ACROCALLOSAL SYNDROME; ACLS 
#182290 SMITH-MAGENIS SYNDROME; SMS;: SMITH-MAGENIS CHROMOSOME REGION, INCLUDED; SMCR, INCLUDED 
#176270 PRADER-WILLI SYNDROME; PWS; PRADER-WILLI SYNDROME CHROMOSOME REGION, INCLUDED; PWCR, INCLUDED 
#175700 GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS 
#160900 DYSTROPHIA MYOTONICA 1 
#158900 FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY1A; FSHMD1A 
#300830 CHROMOSOME Xp22 DELETION SYNDROME 
#612736 GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY 
#609307 SPINOCEREBELLAR ATAXIA 27; SCA27 
#609192 LOEYS-DIETZ SYNDROME, TYPE 1A; LDS1A 
#602481 MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2 
#601803 PALLISTER-KILLIAN SYNDROME; PKS; HEXASOMY 12p, MOSAIC, INCLUDED 
#601675 TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP; ICHTHYOSIFORM ERYTHRODERMA WITH HAIR A BNORMALITY AND MENTAL AND GROWTH RETARDATION, INCLUDED 
#312920 SPASTIC PARAPLEGIA 2, X-LINKED; SPG2 
#312750 RETT SYNDROME; RTT 
#312170 PYRUVATE DECARBOXYLASE DEFICIENCY; LACTIC ACIDEMIA, THIAMINE-RESPONSIVE, INCLUDED 
#311200 OROFACIODIGITAL SYNDROME I; OFD1 
#308205 ICHTHYOSIS FOLLICULARIS, ATRICHIA, AND PHOTOPHOBIA SYNDROME 
#300322 LESCH-NYHAN SYNDROME; LNS; HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED 
#300067 LISSENCEPHALY, X-LINKED, 1; LISX1; SUBCORTICAL LAMINAR HETEROTOPIA, X-LINKED, INCLUDED; SCLH, INCLUDED 
#278250 WRINKLY SKIN SYNDROME; WSS 
#276880 UROCANASE DEFICIENCY 
#276600 TYROSINEMIA, TYPE II 
#270700 SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15 
#256540 GALACTOSIALIDOSIS; GSL 
#253800 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4 
#250850 METHIONINE ADENOSYLTRANSFERASE DEFICIENCY 
#248600 MAPLE SYRUP URINE DISEASE 
#248500 MANNOSIDOSIS, ALPHA B, LYSOSOMAL; ALPHA-MANNOSIDOSIS, TYPE II, INCLUDED 
#234050 TRICHOTHIODYSTROPHY, NONPHOTOSENSITIVE 1; TTDN1 
#230650 GM1-GANGLIOSIDOSIS, TYPE III 
#220110 MITOCHONDRIAL COMPLEX IV DEFICIENCY 
#218000 AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN 
#214800 CHARGE SYNDROME 
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#214450 GRISCELLI SYNDROME, TYPE 1; GS1 
#207800 ARGININEMIA 
#204000 LEBER CONGENITAL AMAUROSIS 1; LCA1 
#194190 WOLF-HIRSCHHORN SYNDROME; WHS 
#158170 CHROMOSOME 9p DELETION SYNDROME 
#147791 JACOBSEN SYNDROME; JBS 
#613675 CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-Mb; NF1 MICRODUPLICATION SYNDROME, INCLUDED 
#613436 AUTISM, SUSCEPTIBILITY TO, 17; AUTS17 
#611913 CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KB; AUTISM, SUSCEPTIBILITY TO, 14, INCLUDED; AUTS14, INCLUDED 
#181500 SCHIZOPHRENIA; SCZD 
#613174 CHROMOSOME 5p13 DUPLICATION SYNDROME 
#613161 BETA-UREIDOPROPIONASE DEFICIENCY 
#613038 PITUITARY HORMONE DEFICIENCY, COMBINED, 1; CPHD1 
#612936 CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3; CPSQ3 
#612626 CHROMOSOME 15q26-qter DELETION SYNDROME 
#612582 CHROMOSOME 6pter-p24 DELETION SYNDROME 
#612379 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q 
#612285 JOUBERT SYNDROME 9; JBTS9 
#611584 WAARDENBURG SYNDROME, TYPE 2E; WS2E 
#610688 JOUBERT SYNDROME 6; JBTS6 
#610532 LEUKODYSTROPHY, HYPOMYELINATING, 5 
#610031 POLYMICROGYRIA, ASYMMETRIC 
#606854 POLYMICROGYRIA, BILATERAL FRONTOPARIETAL 
#605259 SPINOCEREBELLAR ATAXIA 13; SCA13 
#604369 SIALURIA, FINNISH TYPE 
#604360 SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11 
#604168 CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY 
#600513 EPILEPSY, NOCTURNAL FRONTAL LOBE, TYPE 
#600462 MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1 
#600430 BRACHYDACTYLY-MENTAL RETARDATION SYNDROME; BDMR; CHROMOSOME 2q37 DELETION SYNDROME, INCLUDED 
#309900 MUCOPOLYSACCHARIDOSIS TYPE II 
#309400 MENKES DISEASE 
#304800 DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED 
#304100 CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED 
#300661 PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY GOUT, PRPS-RELATED, INCLUDED 
#300653 PHOSPHOGLYCERATE KINASE 1 DEFICIENCY 
#300166 MICROPHTHALMIA, SYNDROMIC 2; MCOPS2 
#275350 TRANSCOBALAMIN II DEFICIENCY 
#271980 SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY 
#268300 ROBERTS SYNDROME; RBS 
#266510 REFSUM DISEASE, INFANTILE FORM 
#266150 PYRUVATE CARBOXYLASE DEFICIENCY 
#252150 MOLYBDENUM COFACTOR DEFICIENCY 
#250940 METHYLCOBALAMIN DEFICIENCY, cblG TYPE 
#239500 HYPERPROLINEMIA, TYPE I; HPI 
#236792 L-2-HYDROXYGLUTARIC ACIDURIA 
#235800 HISTIDINEMIA 
#234100 HALLERMANN-STREIFF SYNDROME; HSS 
#230400 GALACTOSEMIA 
#229050 FOLATE MALABSORPTION, HEREDITARY 
#227650 FANCONI ANEMIA; FA 
#222300 WOLFRAM SYNDROME 1; WFS1 
#213300 JOUBERT SYNDROME; JBTS 
#182601 SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4 
#179613 RECOMBINANT CHROMOSOME 8 SYNDROME 
#158350 COWDEN DISEASE; CD; DYSPLASTIC GANGLIOCYTOMA OF THE CEREBELLUM, INCLUDED 
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#153480 BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS 
#147950 KALLMANN SYNDROME 2; KAL2 
#133540 COCKAYNE SYNDROME, TYPE B; CSB 
#124200 DARIER-WHITE DISEASE; DAR 
#107480 TOWNES-BROCKS SYNDROME; TBS 
#101200 APERT SYNDROME 
#613154 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6 
#613150 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2 
#300679 CHROMOSOME Xp21 DELETION SYNDROME 
#190350 TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1 
#170100 PROLIDASE DEFICIENCY 
#613254 TUBEROUS SCLEROSIS 2; TSC2 
#612463 PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP 
#612462 PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C 
#612079 ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME 
#612073 MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH METHYLMALONIC ACIDURIA); MTDPS5 
#611936 CHROMOSOME 3q29 DUPLICATION SYNDROME 
#611726 EPILEPSY, PROGRESSIVE MYOCLONIC 3; EPM 
#610651 XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB 
#610474 CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME 
#610198 3-@METHYLGLUTACONIC ACIDURIA, TYPE V 
#610188 JOUBERT SYNDROME 5; JBTS5 
#610168 LOEYS-DIETZ SYNDROME, TYPE 1B; LDS1B 
#609152 HYPERTHYROIDISM, NONAUTOIMMUNE 
#609029 EMANUEL SYNDROME 
#608688 AICAR TRANSFORMYLASE/IMP CYCLOHYDROLAS E DEFICIENCY 
#608328 WEILL-MARCHESANI SYNDROME, AUTOSOMAL DOMINANT 
#608233 HERMANSKY-PUDLAK SYNDROME 2; HPS2 
#608091 JOUBERT SYNDROME 2; JBTS2 
#608033 ENCEPHALOPATHY, ACUTE NECROTIZING 1, SUSCEPTIBILITY TO; ANE1 
#607596 PONTOCEREBELLAR HYPOPLASIA TYPE 1 
#607432 LISSENCEPHALY 1; LIS1; SUBCORTICAL LAMINAR HETEROTOPIA, INCLUDED; SCLH, INCLUDED 
#607330 LATHOSTEROLOSIS 
#606812 FUMARASE DEFICIENCY 
#606369 EPILEPTIC ENCEPHALOPATHY, LENNOX-GASTA UT TYPE 
#603513 CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 1; CPSQ1 
#602849 MUENKE SYNDROME 
#602668 DYSTROPHIA MYOTONICA 2; DM2 
#601186 MICROPHTHALMIA, SYNDROMIC 9; MCOPS9 
#600721 D-2-@HYDROXYGLUTARIC ACIDURIA 1 
#600002 EIKEN SKELETAL DYSPLASIA 
#500001 LEBER OPTIC ATROPHY AND DYSTONIA 
#312080 PELIZAEUS-MERZBACHER DISEASE; PMD 
#311300 OTOPALATODIGITAL SYNDROME, TYPE I; OPD 1 
#311250 ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO VALPROATE SENSITIVITY, INCLUDED 
#309801 MICROPHTHALMIA, SYNDROMIC 7; MCOPS7 
#308050 CONGENITAL HEMIDYSPLASIA WITH ICHTHYOS IFORM ERYTHRODERMA AND LIMB DEFECTS 
#305600 FOCAL DERMAL HYPOPLASIA; FDH 
#305400 FACIOGENITAL DYSPLASIA 
#302960 CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2 
#300607 HYPEREKPLEXIA AND EPILEPSY 
#300438 17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY 
#300240 HOYERAAL-HREIDARSSON SYNDROME; HHS 
#300209 SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2 
#277600 WEILL-MARCHESANI SYNDROME, AUTOSOMAL RECESSIVE 
#277400 METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE 
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#274600 PENDRED SYNDROME; PDS 
#274270 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY5-@FLUOROURACIL TOXICITY, INCLUDED 
#274000 CHROMOSOME 1q21.1 DELETION SYNDROME, 200-KB; TETRAPHOCOMELIA-THROMBOCYTOPENIA SYNDROME, INCLUDED 
#271930 STRIATONIGRAL DEGENERATION, INFANTILE; SNDI 
#271245 MITOCHONDRIAL DNA DEPLETION SYNDROME 7(HEPATOCEREBRAL TYPE); MTDPS7 
#269150 SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME 
#266130 GLUTATHIONE SYNTHETASE DEFICIENCY 
#261640 HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A 
#261630 HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C 
#261540 PETERS-PLUS SYNDROME 
#257200 NIEMANN-PICK DISEASE, TYPE A 
#256731 CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5 
#256730 CEROID LIPOFUSCINOSIS, NEURONAL, 1; CL 
#256710 ELEJALDE DISEASE 
#256600 NEURODEGENERATION WITH BRAIN IRON MULATION 2A; NBIA2A ACCU 
#256000 LEIGH SYNDROME; LS 
#253220 MUCOPOLYSACCHARIDOSIS TYPE VII 
#252600 MUCOLIPIDOSIS III ALPHA/BETA 
#251450 DESBUQUOIS DYSPLASIA; DBQD 
#251260 NIJMEGEN BREAKAGE SYNDROME 
#245400 MITOCHONDRIAL DNA DEPLETION SYNDROME 9(ENCEPHALOMYOPATHIC TYPE WITH METHYLMALONIC ACIDURIA); MTDPS9 
#245348 PYRUVATE DEHYDROGENASE E2 DEFICIENCY 
#243800 JOHANSON-BLIZZARD SYNDROME; JBS 
#242600 IMINOGLYCINURIA 
#239510 HYPERPROLINEMIA, TYPE II; HPII 
#238700 HYPERLYSINEMIA 
#233910 HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B; DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED 
#231550 ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; 
#230350 GALACTOSE EPIMERASE DEFICIENCY 
#230000 FUCOSIDOSIS 
#228000 FARBER LIPOGRANULOMATOSIS 
#222748 DIHYDROPYRIMIDINASE DEFICIENCY 
#221750 PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3 
#219200 CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; 
#218600 BALLER-GEROLD SYNDROME; BGS 
#215700 CITRULLINEMIA, CLASSIC 
#215100 RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1 
#214100 ZELLWEGER SYNDROME; ZS 
#212066 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A 
#210720 MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II 
#210200 3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY 
#207900 ARGININOSUCCINIC ACIDURIA 
#193700 ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A 
#187600 THANATOPHORIC DYSPLASIA, TYPE I; TD1; ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS, INCLUDED; SADDAN, INCLUDED 
#164200 OCULODENTODIGITAL DYSPLASIA; ODDD 
#163950 NOONAN SYNDROME 1; NS1 
#157170 HOLOPROSENCEPHALY 2; HPE2 
#151100 LEOPARD SYNDROME 1 
#150230 TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2 
#148820 WAARDENBURG SYNDROME, TYPE 3; WS3 
#136760 FRONTONASAL DYSPLASIA 1; FND1 
#135100 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP 
#115470 CAT EYE SYNDROME; CES 
#113620 BRANCHIOOCULOFACIAL SYNDROME; BOFS 
#104290 ALTERNATING HEMIPLEGIA OF CHILDHOOD 
#103580 PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A 
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#101600 PFEIFFER SYNDROME 
#613564 CHROMOSOME 2p12-p11.2 DELETION SYNDROME 
#612345 CHROMOSOME 2q31.2 DELETION SYNDROME 
#610042 CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME 
#312870 SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1 
#300422 FG SYNDROME 4; FGS4 
#253200 MUCOPOLYSACCHARIDOSIS TYPE VI 
#229100 FORMIMINOTRANSFERASE DEFICIENCY 
#209900 BARDET-BIEDL SYNDROME; BBS 
#176200 PORPHYRIA VARIEGATA 
#110100 BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPES 
#106210 ANIRIDIA; AN 
#613180 POLYMICROGYRIA WITH OPTIC NERVE HYPOPLASIA 
#613179 PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY 
#613090 BARTTER SYNDROME, TYPE 4B 
#613068 NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY 
#612716 DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY 
#612233 LEUKODYSTROPHY, HYPOMYELINATING, 4 
#610127 CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10 
#609975 HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4 
#609528 CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMA SYNDROME 
#609460 GOLDBERG-SHPRINTZEN MEGACOLON SYNDROME 
#609241 SCHINDLER DISEASE, TYPE I; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE III, INCLUDED 
#608782 PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY 
#608629 JOUBERT SYNDROME 3; JBTS3 
#608393 MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 6; MCPH6 
#608093 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J 
#607341 FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT 
#607095 ANAUXETIC DYSPLASIA 
#606762 HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6 
#604804 MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 3; MCPH3 
#604292 ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3; EEC3 
#604004 MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS; MLC 
#602522 BARTTER SYNDROME, TYPE 4A 
#602485 HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3 
#602473 ENCEPHALOPATHY, ETHYLMALONIC 
#601815 PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY 
#601776 EHLERS-DANLOS SYNDROME, MUSCULOCONTRAC TURAL TYPE 
#601678 BARTTER SYNDROME, ANTENATAL, TYPE 1 
#598500 
#500007 CYCLIC VOMITING SYNDROME; CVS 
#308300 INCONTINENTIA PIGMENTI; IP 
#307030 HYPERGLYCEROLEMIA 
#305620 FRONTOMETAPHYSEAL DYSPLASIA; FMD 
#304120 OTOPALATODIGITAL SYNDROME, TYPE II; OPD2 
#302350 NANCE-HORAN SYNDROME; NHS 
#300496 AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3 
#300425 AUTISM, SUSCEPTIBILITY TO, X-LINKED 1; AUTSX1 
#300373 OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS 
#277590 WEAVER SYNDROME 
#277410 METHYLMALONIC ACIDURIA AND HOMOCYSTINU RIA, cblD TYPE 
#275630 CHANARIN-DORFMAN SYNDROME; CDS 
#275100 HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4 
#274900 THYROID DYSHORMONOGENESIS 5; TDH5 
#274800 THYROID DYSHORMONOGENESIS 4; TDH4 
#274700 THYROID DYSHORMONOGENESIS 3; TDH3 
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#274400 THYROID DYSHORMONOGENESIS 1; TDH1 
#270550 SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS 
#270200 SJOGREN-LARSSON SYNDROME; SLS 
#268400 ROTHMUND-THOMSON SYNDROME; RTS 
#268310 ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS 
#266100 EPILEPSY, PYRIDOXINE-DEPENDENT; EPD 
#264470 PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY 
#260400 SHWACHMAN-DIAMOND SYNDROME; SDS 
#259770 OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG 
#256800 INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA 
#256550 NEURAMINIDASE DEFICIENCY SIALIDOSIS, TYPE I, INCLUDED 
#256450 HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1 
#255800 SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1 
#252940 MUCOPOLYSACCHARIDOSIS TYPE IIID 
#252930 MUCOPOLYSACCHARIDOSIS TYPE IIIC 
#252920 MUCOPOLYSACCHARIDOSIS TYPE IIIB 
#252900 MUCOPOLYSACCHARIDOSIS TYPE IIIA 
#252650 MUCOLIPIDOSIS IV 
#252605 MUCOLIPIDOSIS III GAMMA 
#247200 MILLER-DIEKER LISSENCEPHALY SYNDROME; 
#245349 PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY 
#245150 KEUTEL SYNDROME 
#242100 ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL, NONBULLOUS, 1; NCIE1 
#241200 BARTTER SYNDROME, ANTENATAL, TYPE 2 
#240800 HYPOGLYCEMIA, LEUCINE-INDUCED; LIH 
#237300 CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO 
#230500 GM1-GANGLIOSIDOSIS, TYPE I 
#225500 ELLIS-VAN CREVELD SYNDROME; EVC 
#225250 HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5 
#222765 RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2 
#219500 CYSTATHIONINURIA 
#214150 CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1 
#210900 BLOOM SYNDROME; BLM 
#208050 ARTERIAL TORTUOSITY SYNDROME; ATS 
#207410 ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS; ABS2 
#204200 CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3 
#204100 LEBER CONGENITAL AMAUROSIS 2; LCA2 
#203750 ALPHA-METHYLACETOACETIC ACIDURIA 
#202370 ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL FORM 
#175780 PORENCEPHALY, FAMILIAL 
#166780 OTOFACIOCERVICAL SYNDROME 
#150250 LARSEN SYNDROME, AUTOSOMAL DOMINANT; LRS 
#146000 HYPOCHONDROPLASIA; HCH 
#129850 EDINBURGH MALFORMATION SYNDROME 
#125800 DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL 
#124000 MITOCHONDRIAL COMPLEX III DEFICIENCY 
#123500 CROUZON SYNDROME 
#120330 PAPILLORENAL SYNDROME 
#118450 ALAGILLE SYNDROME 1; ALGS1 
#109400 BASAL CELL NEVUS SYNDROME; BCNS 
#105650 DIAMOND-BLACKFAN ANEMIA; DBA 
#101400 SAETHRE-CHOTZEN SYNDROME; SCS 
#613729 CHROMOSOME 7q11.23 DELETION SYNDROME, DISTAL, 1.2-MB 
#613604 CHROMOSOME 16p12.2-p11.2 DELETION SYNDROME, 7.1- TO 8.7-MB 
#612313 CHROMOSOME 2q32-q33 DELETION SYNDROME 
#611881 GLYCOGEN STORAGE DISEASE XII; GSD12 
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#610883 POTOCKI-LUPSKI SYNDROME; PTLS 
#609334 CHROMOSOME 18 PERICENTRIC INVERSION 
#607208 DRAVET SYNDROME; EPILEPSY, INTRACTABLE CHILDHOOD, WITH GENERALIZED TONIC-CLONIC SEIZURES 
#605021 MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME 
#312000 PANHYPOPITUITARISM, X-LINKED; PHPX 
#304150 OCCIPITAL HORN SYNDROME; OHS 
#302950 CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1 
#300623 FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS 
#300448 ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS 
#300376 MUSCULAR DYSTROPHY, BECKER TYPE; BMD 
#300215 LISSENCEPHALY, X-LINKED, 2; LISX2 
#269160 SCHIZENCEPHALY 
#217095 CONOTRUNCAL HEART MALFORMATIONS; CTHM 
#212112 CARDIOMYOPATHY, DILATED, WITH HYPERGON ADOTROPIC HYPOGONADISM 
#208900 ATAXIA-TELANGIECTASIA; AT 
#185500 SUPRAVALVULAR AORTIC STENOSIS; SVAS 
#182900 SPHEROCYTOSIS, TYPE 1; SPH1 
#181450 ULNAR-MAMMARY SYNDROME; UMS 
#175100 ADENOMATOUS POLYPOSIS OF THE COLON; APC 
#133701 EXOSTOSES, MULTIPLE, TYPE II 
#125370 DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA 
#121200 EPILEPSY, BENIGN NEONATAL, 1; EBN1 
#613732 JMP SYNDROME 
#613700 SUPERNUMERARY DER(22)t(8;22) SYNDROME 
#613638 CHROMOSOME 19p13.13 DELETION SYNDROME 
#613444 CHROMOSOME 16p11.2 DELETION SYNDROME, 220-KB 
#613406 CHROMOSOME 15q24 DELETION SYNDROME 
#613153 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5 
#612718 ARGININE:GLYCINE AMIDINOTRANSFERASE DEFICIENCY 
#612337 CHROMOSOME 1q43-q44 DELETION SYNDROME 
#612126 GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2 
#611588 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY(LIMB-GIRDLE), TYPE C, 4; MDDGC4 
#611560 JOUBERT SYNDROME 7; JBTS7 
#611209 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G 
#611102 DEAFNESS, SENSORINEURAL, AND MALE INFERTILITY 
#609757 WILLIAMS-BEUREN REGION DUPLICATION SYNDROME 
#607014 HURLER SYNDROME 
#605289 SPLIT-HAND/FOOT MALFORMATION 4; SHFM4 
#600850 SCHIZOPHRENIA 4; SCZD4 
#600651 FRAGILE SITE 11B; FRA11B 
#500002 MITOCHONDRIAL MYOPATHY WITH DIABETES 
#305100 ECTODERMAL DYSPLASIA, HYPOHIDROTIC, X- LINKED; XHED 
#305000 DYSKERATOSIS CONGENITA, X-LINKED; DKC 
#300615 BRUNNER SYNDROME 
#300321 FG SYNDROME 2; FGS2 
#300048 INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED 
#300000 OPITZ GBBB SYNDROME, X-LINKED 
#278700 XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA 
#269000 SC PHOCOMELIA SYNDROME 
#257320 LISSENCEPHALY 2; LIS2 
#255200 MYOPATHY, CENTRONUCLEAR, AUTOSOMAL RECESSIVE 
#253250 MULIBREY NANISM 
#249700 LANGER MESOMELIC DYSPLASIA 
#249420 FRANK-TER HAAR SYNDROME; FTHS 
#242900 IMMUNOOSSEOUS DYSPLASIA, SCHIMKE TYPE 
#230200 GALACTOKINASE DEFICIENCY 
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#212065 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A 
#208920 ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH 
#194070 WILMS TUMOR 1; WT1 
#182600 SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A 
#180860 SILVER-RUSSELL SYNDROME; SRS 
#180500 AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1 
#143465 ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD 
#130070 EHLERS-DANLOS SYNDROME, PROGEROID FORM 
#120200 COLOBOMA, OCULAR 
#113300 BRACHYDACTYLY, TYPE E1; BDE1 
#107250 ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS; ASMD 
#613728 SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 10; SCAR10 
#613684 RUBINSTEIN-TAYBI SYNDROME 2; RSTS2 
#613676 SECKEL SYNDROME 4; SCKL4 
#613674 VESICOURETERAL REFLUX 3; VUR3 
#613615 SENIOR-LOKEN SYNDROME 7; SLSN7 
#613612 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I 
#613603 CHROMOSOME 4q32.1-q32.2 TRIPLICATION SYNDROME 
#613533 CHROMOSOME 17q21.31 DUPLICATION SYNDROME 
#613477 EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 5 
#613470 HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY 
#613458 CHROMOSOME 16p13.3 DUPLICATION SYNDROME 
#613457 CHROMOSOME 14q11-q22 DELETION SYNDROME 
#613456 FRONTONASAL DYSPLASIA 3; FND3 
#613454 RETT SYNDROME, CONGENITAL VARIANT 
#613451 FRONTONASAL DYSPLASIA 2; FND2 
#613402 MICROCEPHALY, SEIZURES, AND DEVELOPMEN TAL DELAY; MCSZ 
#613224 NOONAN SYNDROME 6; NS6 
#613215 CHROMOSOME 17p13.3 DUPLICATION SYNDROME 
#613204 MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY 
#613159 NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1; NPHPL1 
#613158 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY(LIMB-GIRDLE), TYPE C, 2; MDDGC2 
#613157 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3 
#612951 LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY 
#612940 CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B 
#612900 CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 2; CPSQ2 
#612863 CHROMOSOME 6q24-q25 DELETION SYNDROME 
#612530 CHROMOSOME 1q41-q42 DELETION SYNDROME 
#611182 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H 
#611040 MICROPHTHALMIA, ISOLATED 5; MCOP5 
#610828 HOLOPROSENCEPHALY 7; HPE7 
#610759 CORNELIA DE LANGE SYNDROME 3; CDLS3 
#610733 NOONAN SYNDROME 4; NS4 
#610623 CATARACT, POSTERIOR POLAR, 4; CTPP4 
#610549 DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS 
#610543 CHROMOSOME 16p13.3 DELETION SYNDROME 
#609924 AMINOACYLASE 1 DEFICIENCY 
#609136 PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURG SYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH 
#608808 TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1 
#608804 LEUKODYSTROPHY, HYPOMYELINATING, 2 
#608594 LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1 
#608540 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K 
#608149 UNIPARENTAL DISOMY, PATERNAL, CHROMOSOME 14 
#607906 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I 
#607734 CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F 
#607483 BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE 
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#607364 BARTTER SYNDROME, TYPE 3 
#607326 SMITH-MCCORT DYSPLASIA; SMC 
#607155 MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY(LIMB-GIRDLE), TYPE C, 5; MDDGC5 
#607136 SPINOCEREBELLAR ATAXIA 17; SCA17 
#607091 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D 
#606217 ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEP TIBILITY TO, 2; AVSD2 
#604321 MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 4; MCPH4 
#603903 SICKLE CELL ANEMIA 
#602579 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B 
#602081 SPEECH-LANGUAGE DISORDER 1; SPCH1 
#602014 HYPOMAGNESEMIA 1, INTESTINAL; HOMG1 
#601536 ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS 
#600316 DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3 
#600309 ATRIOVENTRICULAR SEPTAL DEFECT; AVSD 
#520000 DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED 
#311360 PREMATURE OVARIAN FAILURE 1; POF1 
#311070 CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5 
#310400 MYOTUBULAR MYOPATHY 1; MTM1 
#310300 EMERY-DREIFUSS MUSCULAR DYSTROPHY, 1; EDMD1 
#308930 LEIGH SYNDROME, X-LINKED 
#304110 CRANIOFRONTONASAL SYNDROME; CFNS 
#303100 CHOROIDEREMIA; CHM 
#302800 CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1 
#301835 ARTS SYNDROME; ARTS 
#301830 SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2 
#301050 ALPORT SYNDROME, X-LINKED; ATS 
#300804 JOUBERT SYNDROME 10; JBTS10 
#300590 CORNELIA DE LANGE SYNDROME 2; CDLS2 
#300555 DENT DISEASE 2 
#300500 ALBINISM, OCULAR, TYPE I; OA1 
#300068 ANDROGEN INSENSITIVITY SYNDROME; AIS 
#278780 XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG 
#278760 XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF 
#271900 CANAVAN DISEASE 
#271700 SPONDYLOPERIPHERAL DYSPLASIA 
#270800 SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A 
#269920 INFANTILE SIALIC ACID STORAGE DISORDER 
#267430 RENAL TUBULAR DYSGENESIS; RTD 
#267300 RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS 
#266900 SENIOR-LOKEN SYNDROME 1; SLSN1 
#262000 BJORNSTAD SYNDROME; BJS 
#261000 INTRINSIC FACTOR DEFICIENCY; IFD 
#258870 GYRATE ATROPHY OF CHOROID AND RETINA; GACR 
#258315 OMODYSPLASIA 1; OMOD1 
#257220 NIEMANN-PICK DISEASE, TYPE C1; NPC1 
#255310 MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD 
#253700 MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE2C; LGMD2C 
#253260 BIOTINIDASE DEFICIENCY; MULTIPLE CARBOXYLASE DEFICIENCY, LATE- ONSET 
#253230 MUCOPOLYSACCHARIDOSIS TYPE VIII 
#252700 MUCOPOLYSACCHARIDOSES, UNCLASSIFIED TYPES 
#252500 MUCOLIPIDOSIS II ALPHA/BETA 
#252010 MITOCHONDRIAL COMPLEX I DEFICIENCY 
#251290 BAND-LIKE CALCIFICATION WITH SIMPLIFIE D GYRATION AND POLYMICROGYRIA; BLCPMG 
#250100 METACHROMATIC LEUKODYSTROPHY 
#247100 LIPOID PROTEINOSIS OF URBACH AND WIETHE 
#246700 CHYLOMICRON RETENTION DISEASE; CMRD 
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#237900 HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL 
#236250 HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE REDUCTASE ACTIVITY 
#234500 HARTNUP DISORDER 
#234200 NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1 
#231670 GLUTARIC ACIDEMIA I 
#231300 GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A 
#225400 EHLERS-DANLOS SYNDROME, TYPE VI; EDS6 
#225300 SPLIT-HAND/FOOT MALFORMATION 6; SHFM6 
#222700 LYSINURIC PROTEIN INTOLERANCE; LPI 
#215400 CHORDOMA, SUSCEPTIBILITY TO; CHDM 
#210210 3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY 
#203700 MITOCHONDRIAL DNA DEPLETION SYNDROME 4 A (ALPERS TYPE); MTDPS4A 
#203100 ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A 
#201000 CARPENTER SYNDROME 
#194080 DENYS-DRASH SYNDROME; DDS 
#190351 TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3 
#188570 THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH 
#188400 DIGEORGE SYNDROME; DGS 
#184250 SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE 
#183900 SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC 
#176000 PORPHYRIA, ACUTE INTERMITTENT 
#173100 ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2 
#172800 PIEBALD TRAIT; PBT 
#169400 PELGER-HUET ANOMALY; PHA 
#167200 PACHYONYCHIA CONGENITA, TYPE 1; PC1 
#164400 SPINOCEREBELLAR ATAXIA 1; SCA1 
#163800 SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2 
#162400 NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A 
#162210 NEUROFIBROMATOSIS, FAMILIAL SPINAL 
#157640 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT, 1; PEOA1 
#154700 MARFAN SYNDROME; MFS 
#148210 KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT 
#147250 SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI 
#147060 HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT 
#146510 PALLISTER-HALL SYNDROME; PHS 
#146255 HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE 
#146200 HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH 
#142945 HOLOPROSENCEPHALY 3; HPE3 
#142900 HOLT-ORAM SYNDROME; HOS 
#142623 HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1 
#141500 MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1 
#137580 GILLES DE LA TOURETTE SYNDROME; GTS 
#136610 FRAGILE SITE 2q11 
#136570 CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KB; FRAGILE SITE 16p12, INCLUDED 
#135400 HYPERTRICHOSIS TERMINALIS, GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA 
#133700 EXOSTOSES, MULTIPLE, TYPE I 
#130650 BECKWITH-WIEDEMANN SYNDROME; BWS 
#128235 DYSTONIA 12; DYT12 
#123150 JACKSON-WEISS SYNDROME; JWS 
#121800 CORNEAL DYSTROPHY, CRYSTALLINE, OF SCHNYDER 
#120430 COLOBOMA OF OPTIC NERVE; OPTIC NERVE HEAD PITS, BILATERAL CONGENITAL, INCLUDED 
#119600 CLEIDOCRANIAL DYSPLASIA; CCD 
#118600 CHONDROCALCINOSIS 2; CCAL2 
#118400 CHERUBISM 
#116920 LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD 
#112500 BRACHYDACTYLY, TYPE A1; BDA1 
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#108300 STICKLER SYNDROME, TYPE I; STL1 
#104300 ALZHEIMER DISEASE; AD 
#101000 NEUROFIBROMATOSIS, TYPE II; NF2 
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Table S3. 1 – CNVs found for patient 1. 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1  
chr1:147,255,457-147,753,238 CN Gain 497782 2 21 q21.1 FCGR1C, LOC388692 
chr1:194,975,299-195,078,812 CN Gain 103514 3 10 q31.3 CFH, CFHR1, CFHR3 
chr1:246,667,935-246,745,152 CN Gain 77218 3 6 q44 OR2T2, OR2T3, OR2T5 
chr1:246,745,152-246,882,848 CN Loss 137697 7 9 q44 OR2G6, OR2T10, OR2T11, OR2T27, OR2T29, OR2T34, OR2T35 
chr2:242,462,319-242,486,257 CN Loss 23939 1 4 q37.3 C2orf85 
chr4:34,448,772-34,500,505 CN Loss 51734 0 4 p15.1 
 
chr4:69,038,815-69,170,341 CN Gain 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr4:70,195,060-70,269,497 CN Loss 74438 1 5 q13.2 UGT2B28 
chr5:745,872-874,147 CN Loss 128276 2 12 p15.33 TPPP, ZDHHC11 
chr5:68,866,395-68,960,939 CN Gain 94545 7 5 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, LOC653391, OCLN 
chr6:0-193,938 CN Gain 193939 0 6 p25.3 
 
chr6:327,656-666,208 CN Gain 338553 3 20 p25.3 EXOC2, HUS1B, IRF4 
chr8:7,121,948-7,803,775 CN Loss 681828 27 25 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66B, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, FAM90A5, FAM90A7, 
FAM90A8, FAM90A9, LOC349196, SPAG11A, SPAG11B, ZNF705G 
chr10:38,856,419-39,080,121 CN Loss 223703 0 5 p11.1 
 
chr14:105,493,945-
105,680,979 CN Loss 187035 1 13 q32.33 ADAM6 
chr15:19,329,731-20,235,151 CN Loss 905421 6 28 q11.2 LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:32,437,818-33,691,406 CN Loss 1253589 3 42 p11.2 SLC6A10P, TP53TG3, TP53TG3B 
chr22:18,708,904-19,069,275 CN Gain 360372 2 12 q11.21 PI4KAP1, RIMBP3 
chrX:152,001,572-154,591,854 High Copy Gain 2590283 75 217 q28 
ABCD1, ARHGAP4, ATP2B3, ATP6AP1, AVPR2, BCAP31, BGN, BRCC3, CLIC2, CTAG1A, CTAG1B, CTAG2, DKC1, DNASE1L1, 
DUSP9, EMD, F8, F8A1, F8A2, F8A3, FAM3A, FAM50A, FAM58A, FLNA, FUNDC2, G6PD, GAB3, GDI1, H2AFB1, H2AFB2, H2AFB3, 
HAUS7, HCFC1, IDH3G, IKBKG, IRAK1, L1CAM, LAGE3, LOC100132963, MAGEA1, MECP2, MIR718, MPP1, MTCP1, MTCP1NB, 
NAA10, NCRNA00204, NCRNA00204B, OPN1LW, OPN1MW, OPN1MW2, PDZD4, PLXNA3, PLXNB3, PNCK, RAB39B, RENBP, 
RPL10, SLC10A3, SLC6A8, SNORA36A, SNORA56, SNORA70, SRPK3, SSR4, TAZ, TEX28, TKTL1, TMEM187, TMLHE, TREX2, 
UBL4A, VBP1, ZFP92, ZNF275 
chrX:154,591,854-154,881,207 CN Gain 289354 3 43 q28 IL9R, SPRY3, VAMP7 
 192 
 
 
Table S3. 2 . CNVs found for patient 2.  
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1 
 
chr2:89,327,057-89,895,566 CN Gain 568510 0 16 p11.2 
 
chr5:70,043,543-70,555,896 CN Loss 512354 12 10 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, LOC653391, NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:229,040-327,656 CN Loss 98617 1 7 p25.3 DUSP22 
chr8:7,214,279-7,942,536 Homozygous Copy Loss 728258 23 24 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4, 
FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A8, FAM90A9, SPAG11A, SPAG11B 
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:46,370,252-46,573,606 CN Gain 203355 4 16 q11.22 GPRIN2, LOC728643, PPYR1, SYT15 
chr12:9,519,693-9,606,536 Homozygous Copy Loss 86844 0 6 p13.31 
 
chr14:18,436,931-19,490,518 CN Gain 1053588 9 36 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:105,602,384-105,637,917 Homozygous Copy Loss 35534 0 3 q32.33 
 
chr16:32,019,584-33,441,199 CN Loss 1421616 4 47 p11.2 HERC2P4, SLC6A10P, TP53TG3, TP53TG3B 
chr16:34,328,350-34,611,145 CN Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr22:14,433,473-14,831,547 CN Gain 398075 2 4 q11.1 OR11H1, POTEH 
chr22:17,036,669-17,240,532 CN Gain 203864 2 5 q11.21 GGT3P, USP18 
chrX:152,783,739-153,255,487 High Copy Gain 471749 16 57 q28 ARHGAP4, AVPR2, FLNA, HCFC1, IRAK1, L1CAM, MECP2, MIR718, NAA10, OPN1LW, OPN1MW, OPN1MW2, RENBP, TEX28, TKTL1, TMEM187 
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Table S3. 3 – CNVs found for patient 3 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,725,089-16,987,680 CN Loss 262592 5 15 p36.13 CROCCL1, ESPNP, MST1P2, MST1P9, NBPF1 
chr1:159,786,360-159,874,395 CN Loss 88036 4 6 q23.3 FCGR2C, FCGR3A, FCGR3B, HSPA7 
chr1:246,800,021-246,863,559 Homozygous Copy Loss 63539 3 5 q44 OR2T10, OR2T11, OR2T34 
chr2:89,064,440-89,895,566 CN Loss 831127 0 24 p11.2   
chr2:137,030,336-137,200,793 CN Gain 170458 0 11 q22.1   
chr4:3,863,079-4,243,929 CN Loss 380851 2 11 p16.2 LOC348926, OTOP1 
chr4:34,448,772-34,500,505 Homozygous Copy Loss 51734 0 4 p15.1   
chr4:69,063,649-69,207,266 CN Gain 143618 2 11 q13.2 UGT2B15, UGT2B17 
chr5:726,908-933,798 CN Loss 206891 3 20 p15.33 BRD9, TPPP, ZDHHC11 
chr5:69,138,408-70,245,600 CN Loss 1107193 9 18 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, LOC100170939, LOC653391, SERF1A, SERF1B, SMN1, SMN2 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr6:79,027,678-79,098,580 CN Gain 70903 0 4 q14.1   
chr8:7,026,686-12,529,929 CN Loss 5503244 70 275 p23.1 
AMAC1L2, BLK, C8orf12, C8orf74, CLDN23, CTSB, DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, 
DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1, DEFB109P1B, DEFB130, DEFB134, 
DEFB135, DEFB136, DEFB4, ERI1, FAM167A, FAM66A, FAM66B, FAM66D, FAM66E, FAM86B1, FAM86B2, 
FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, FAM90A5, FAM90A7, FAM90A8, 
FAM90A9, FDFT1, FLJ10661, GATA4, LOC157627, LOC349196, LOC392196, MFHAS1, MIR124-1, MIR1322, 
MIR548I3, MIR597, MIR598, MSRA, MTMR9, NEIL2, PINX1, PPP1R3B, PRAGMIN, RP1L1, SOX7, SPAG11A, 
SPAG11B, T-SP1, TDH, TNKS, USP17L2, XKR6, ZNF705D, ZNF705G 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr11:70,990,916-71,304,747 CN Loss 313832 3 14 q13.4 DEFB108B, FAM86C, LOC100133315 
chr14:18,436,931-19,490,518 CN Loss 1053588 9 36 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:21,678,281-21,794,360 CN Loss 116080 0 7 q11.2   
chr14:105,602,384-105,637,917 Homozygous Copy Loss 35534 0 3 q32.33   
chr15:18,643,606-19,221,090 CN Gain 577485 4 19 q11.2 BCL8, GOLGA6L6, GOLGA8C, LOC646214 
chr15:19,699,696-20,154,336 CN Gain 454641 4 19 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr15:32,511,473-32,641,620 CN Loss 130148 2 11 q14 GOLGA8A, GOLGA8B 
chr17:31,449,032-31,890,587 CN Loss 441556 10 11 q12 CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F, TBC1D3G, TBC1D3H 
chr17:42,963,132-43,029,201 CN Loss 66070 1 5 q21.32 NPEPPS 
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chr19:10,693,339-10,885,518 CN Loss 192180 5 12 p13.2 C19orf38, CARM1, DNM2, MIR199A1, TMED1 
chr22:14,433,473-14,831,547 CN Loss 398075 2 4 q11.1 OR11H1, POTEH 
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Table S3. 4 - CNVs found for patient 4 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:8,516,261-15,269,259 CN Loss 6752999 86 364 p36.23 - p36.21 
AADACL3, AADACL4, AGTRAP, ANGPTL7, APITD1, C1orf127, C1orf158, C1orf187, C1orf200, CA6, CASZ1, CLCN6, CLSTN1, 
CORT, CTNNBIP1, DFFA, DHRS3, ENO1, EXOSC10, FBXO2, FBXO44, FBXO6, GPR157, H6PD, HNRNPCL1, KIAA1026, 
KIAA2013, KIF1B, LOC440563, LOC649330, LZIC, MAD2L2, MASP2, MFN2, MIIP, MIR34A, MTHFR, MTOR, NMNAT1, NPPA, 
NPPB, PDPN, PEX14, PGD, PIK3CD, PLOD1, PRAMEF1, PRAMEF10, PRAMEF11, PRAMEF12, PRAMEF13, PRAMEF14, 
PRAMEF15, PRAMEF16, PRAMEF17, PRAMEF18, PRAMEF19, PRAMEF2, PRAMEF20, PRAMEF21, PRAMEF22, PRAMEF3, 
PRAMEF4, PRAMEF5, PRAMEF6, PRAMEF7, PRAMEF8, PRAMEF9, PRDM2, PTCHD2, RBP7, RERE, SLC25A33, SLC2A5, 
SLC2A7, SNORA59A, SNORA59B, SPSB1, SRM, TARDBP, TMEM201, TNFRSF1B, TNFRSF8, UBE4B, UBIAD1, VPS13D 
chr1:103,965,250-104,103,459 CN Loss 138210 4 4 p21.1 AMY1A, AMY1B, AMY1C, AMY2A 
chr1:142,453,717-142,952,778 CN Loss 499062 4 13 q21.1 FLJ39739, LOC100130000, LOC100286793, PPIAL4G 
chr1:194,979,783-195,097,982 CN Gain 118200 3 10 q31.3 CFH, CFHR1, CFHR3 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:34,448,772-34,500,505 CN Gain 51734 0 4 p15.1   
chr4:69,038,815-69,165,944 CN Loss 127130 2 9 q13.2 TMPRSS11E, UGT2B17 
chr5:742,057-900,209 CN Loss 158153 2 16 p15.33 TPPP, ZDHHC11 
chr5:68,892,660-69,177,814 CN Loss 285155 7 12 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100272216, LOC653391 
chr5:70,312,515-70,375,604 Homozygous Copy Loss 63090 5 4 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, NAIP 
chr5:70,375,604-70,671,221 CN Loss 295618 7 7 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, NAIP, OCLN 
chr6:79,027,678-79,098,580 CN Gain 70903 0 4 q14.1   
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:39,115,053-39,251,004 CN Gain 135952 1 7 p13.1 CNTNAP3 
chr9:43,413,941-43,827,369 CN Gain 413429 1 8 p11.2 FAM75A6 
chr11:55,119,157-55,178,810 CN Gain 59654 3 3 q11 OR4C11, OR4P4, OR4S2 
chr12:11,398,916-11,449,885 CN Gain 50970 2 4 p13.2 PRB1, PRB2 
chr12:17,267,054-17,361,877 CN Gain 94824 0 6 p12.3   
chr14:18,555,363-19,244,829 CN Loss 689467 2 20 q11.1 - q11.2 P704P, POTEG 
chr15:21,120,476-21,227,165 CN Loss 106690 0 5 q11.2   
chr17:31,449,032-31,762,515 CN Loss 313484 8 9 q12 CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F 
chr17:41,768,841-42,128,214 CN Gain 359374 5 7 q21.31 - q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
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chr22:22,650,373-22,676,684 CN Loss 26312 3 3 q11.23 DDT, GSTT2, GSTTP1 
chr22:22,676,684-22,729,016 CN Gain 52333 4 4 q11.23 GSTT1, GSTTP1, GSTTP2, LOC391322 
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Table S3. 5 - CNVs found for patient 5 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:1,612,252-1,686,796 CN Loss 74545 6 5 p36.33 CDK11A, CDK11B, LOC728661, MMP23A, NADK, SLC35E2 
chr1:103,961,733-104,117,636 CN Gain 155904 4 7 p21.1 AMY1A, AMY1B, AMY1C, AMY2A 
chr1:194,993,686-195,078,812 CN Gain 85127 2 8 q31.3 CFHR1, CFHR3 
chr1:241,618,630-241,805,298 CN Loss 186669 2 11 q43 - q44 AKT3, SDCCAG8 
chr1:246,667,935-246,781,770 CN Gain 113836 4 8 q44 OR2G6, OR2T2, OR2T3, OR2T5 
chr1:246,781,770-246,863,559 CN Loss 81790 4 6 q44 OR2T10, OR2T11, OR2T29, OR2T34 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1 
 
chr3:174,728,013-174,778,763 CN Gain 50751 1 4 q26.31 NLGN1 
chr4:69,038,815-69,170,341 CN Gain 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr5:68,991,456-70,312,515 CN Gain 1321060 11 25 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC653391, NAIP, SERF1A, SERF1B, SMN1, SMN2 
chr6:244,003-327,656 CN Loss 83654 1 6 p25.3 DUSP22 
chr6:32,548,396-32,600,341 Homozygous Copy Loss 51946 1 4 p21.32 HLA-DRB5 
chr6:32,600,341-32,634,334 CN Loss 33994 2 4 p21.32 HLA-DRB5, HLA-DRB6 
chr7:143,509,786-143,693,789 CN Gain 184004 8 8 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:38,701,870-38,942,543 CN Loss 240674 0 14 p13.1 
 
chr12:9,519,693-9,606,536 Homozygous Copy Loss 86844 0 6 p13.31 
 
chr14:105,954,649-106,023,194 High Copy Gain 68546 1 5 q32.33 LOC100133469 
chr16:0-19,827 CN Loss 19828 1 3 p13.3 LOC100288778 
chr16:68,697,986-68,774,654 CN Loss 76669 2 5 q22.1 CLEC18C, PDPR 
chr17:31,378,710-31,541,638 CN Loss 162929 4 11 q12 CCL18, CCL3, CCL4, TBC1D3B 
chr19:20,391,455-20,502,094 CN Loss 110640 1 8 p12 ZNF826 
chr22:18,708,904-19,014,218 CN Gain 305315 2 9 q11.21 PI4KAP1, RIMBP3 
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chrX:40,705,283-40,826,725 CN Gain 121443 0 6 p11.4 
 
chrX:62,356,295-62,418,619 CN Gain 62325 0 4 q11.1 
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Table S3. 6 - CNVs found for patient 6 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1 
 
chr1:103,961,733-104,103,459 CN Loss 141727 4 5 p21.1 AMY1A, AMY1B, AMY1C, AMY2A 
chr1:194,993,686-195,078,812 CN Loss 85127 2 8 q31.3 CFHR1, CFHR3 
chr2:70,748,414-74,540,348 CN Loss 3791935 49 241 p13.3 - p13.1 
ACTG2, ADD2, ALMS1, ALMS1P, ANKRD53, ATP6V1B1, BOLA3, C2orf7, C2orf78, C2orf81, CCT7, CD207, CLEC4F, CYP26B1, DCTN1, 
DGUOK, DUSP11, DYSF, EGR4, EMX1, EXOC6B, FBXO41, FIGLA, INO80B, LOC100189589, MCEE, MOBKL1B, MPHOSPH10, MTHFD2, 
NAGK, NAT8, NAT8B, NOTO, OR7E91P, PAIP2B, RAB11FIP5, RTKN, SFXN5, SLC4A5, SMYD5, SPR, STAMBP, TET3, TEX261, TPRKB, 
VAX2, WBP1, WDR54, ZNF638 
chr2:74,558,382-74,840,026 CN Loss 281645 13 24 p13.1 AUP1, C2orf65, CCDC142, DOK1, DQX1, HTRA2, LBX2, LOC151534, LOXL3, PCGF1, SEMA4F, TLX2, TTC31 
chr3:120,201,772-120,294,810 High Copy Gain 93039 1 5 q13.32 IGSF11 
chr3:163,987,281-164,108,596 Homozygous Copy Loss 121316 0 7 q26.1 
 
chr4:48,953,993-49,276,565 CN Gain 322573 0 3 p11 
 
chr4:69,038,815-69,170,341 CN Gain 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr5:68,892,660-70,696,119 CN Loss 1803460 15 41 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC647859, LOC653391, NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:193,938-327,656 CN Loss 133719 1 9 p25.3 DUSP22 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr6:32,563,029-32,600,341 Homozygous Copy Loss 37313 1 3 p21.32 HLA-DRB5 
chr6:32,600,341-32,703,052 CN Loss 102712 3 10 p21.32 HLA-DRB1, HLA-DRB5, HLA-DRB6 
chr6:79,027,678-79,131,904 CN Loss 104227 0 6 q14.1 
 
chr7:143,548,913-143,667,377 CN Loss 118465 6 6 q35 CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,705,464-8,124,705 CN Loss 419242 17 13 p23.1 DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4, FAM66E, FLJ10661, MIR548I3, SPAG11A, SPAG11B 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr8:145,486,966-145,761,617 CN Gain 274652 24 28 q24.3 ADCK5, C8ORFK29, CPSF1, CYHR1, DGAT1, FBXL6, FOXH1, GPR172A, GPT, HSF1, KIAA1688, KIFC2, LRRC14, LRRC24, MFSD3, MGC70857, MIR1234, MIR939, NFKBIL2, PPP1R16A, RECQL4, SCRT1, SLC39A4, VPS28 
chr9:38,769,965-38,942,543 CN Gain 172579 0 10 p13.1 
 
chr9:41,791,678-43,613,184 CN Loss 1821507 10 55 p12 - p11.2 ANKRD20A2, ANKRD20A3, AQP7P3, FAM75A6, FAM95B1, FOXD4L2, FOXD4L4, KGFLP2, LOC642929, MGC21881 
chr9:65,222,385-65,792,243 CN Gain 569859 4 6 q12 FAM74A2, FAM74A4, FAM75A5, FAM75A7 
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chr10:39,008,638-39,080,121 CN Loss 71484 0 2 p11.1 
 
chr14:19,304,869-19,507,271 CN Gain 202403 5 12 q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2 
chr14:105,136,197-105,194,518 High Copy Gain 58322 0 5 q32.33 
 
chr14:105,194,518-105,330,429 CN Gain 135912 0 10 q32.33 
 
chr15:18,643,606-20,154,336 CN Loss 1510731 11 52 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr15:21,989,766-22,270,122 CN Gain 280357 0 16 q11.2 
 
chr16:32,437,818-33,691,406 CN Loss 1253589 3 42 p11.2 SLC6A10P, TP53TG3, TP53TG3B 
chr17:40,937,706-41,021,360 CN Loss 83655 1 3 q21.31 LRRC37A4 
chr19:20,374,751-20,421,451 CN Loss 46701 1 3 p12 ZNF826 
chr19:20,421,451-20,502,094 Homozygous Copy Loss 80644 0 6 p12 
 
chr20:60,310,050-60,343,063 CN Gain 33014 2 4 q13.33 ADRM1, LAMA5 
chr20:62,390,214-62,435,964 CN Loss 45751 0 4 q13.33 
 
   
 201 
 
Table S3. 7 - CNVs found for patient 7 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:147,255,486-148,058,610 CN Loss 803125 8 30 q21.1 - q21.2 FCGR1A, FCGR1C, HIST2H2BF, HIST2H3D, LOC388692, LOC728855, PPIAL4A, PPIAL4C 
chr1:194,979,812-195,098,012 CN Loss 118201 3 10 q31.3 CFH, CFHR1, CFHR3 
chr1:200,721,902-200,794,272 CN Loss 72371 1 5 q32.1 PPP1R12B 
chr1:241,114,655-241,213,134 CN Loss 98480 0 5 q43 
 
chr2:87,872,712-88,037,639 CN Gain 164928 2 6 p11.2 RGPD1, RGPD2 
chr2:89,017,454-89,176,704 CN Loss 159251 0 6 p11.2 
 
chr2:101,122,697-105,631,450 CN Loss 4508754 24 197 q11.2 - q12.2 C2orf29, C2orf49, CREG2, FHL2, GPR45, IL18R1, IL18RAP, IL1R1, IL1R2, IL1RL1, IL1RL2, LOC150568, MAP4K4, MFSD9, MRPS9, POU3F3, RFX8, RNF149, SLC9A2, SLC9A4, SNORD89, TBC1D8, TGFBRAP1, TMEM182 
chr2:194,430,401-194,546,889 CN Loss 116489 0 6 q32.3 
 
chr3:65,489,585-65,574,328 CN Gain 84744 1 5 p14.1 MAGI1 
chr3:75,849,278-75,886,078 CN Gain 36801 1 3 p12.3 ZNF717 
chr3:152,985,044-153,033,954 CN Loss 48911 2 3 q25.1 AADAC, LOC201651 
chr3:196,848,458-196,944,322 CN Loss 95865 3 6 q29 MIR570, MUC20, SDHAP2 
chr4:34,448,802-34,500,534 CN Gain 51733 0 4 p15.1 
 
chr4:48,818,175-49,276,624 CN Loss 458450 0 9 p11 
 
chr4:68,978,217-69,170,363 CN Loss 192147 2 12 q13.2 TMPRSS11E, UGT2B17 
chr5:68,866,425-68,913,120 CN Loss 46696 7 3 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, LOC653391, OCLN 
chr6:244,029-327,686 CN Loss 83658 1 6 p25.3 DUSP22 
chr6:32,548,425-32,600,368 CN Loss 51944 1 4 p21.32 HLA-DRB5 
chr6:79,027,708-79,098,610 CN Loss 70903 0 4 q14.1 
 
chr7:143,503,240-143,693,818 CN Gain 190579 8 9 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,303,319-8,141,220 CN Loss 837902 25 24 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, 
FLJ10661, MIR548I3, SPAG11A, SPAG11B 
chr8:15,986,485-16,062,660 CN Loss 76176 1 5 p22 MSR1 
chr8:39,349,089-39,508,394 High Copy Gain 159306 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:46,132,024-47,327,989 CN Loss 1195966 16 42 q11.22 ANTXRL, ANXA8, ANXA8L1, ANXA8L2, BMS1P1, BMS1P5, FAM25B, FAM25C, FAM25G, FAM35B, FAM35B2, GPRIN2, LOC642826, LOC728643, PPYR1, SYT15 
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chr10:47,521,106-47,911,496 CN Loss 390391 6 6 q11.22 ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, LOC642826 
chr10:81,053,624-81,631,465 CN Loss 577842 4 10 q22.3 LOC642361, LOC650623, SFTPA1, SFTPA2 
chr10:88,911,213-89,220,524 CN Loss 309312 5 10 q23.2 FAM22A, FAM22D, FAM35A, LOC439994, LOC728190 
chr11:337,945-470,027 CN Gain 132083 5 11 p15.5 ANO9, B4GALNT4, PKP3, PTDSS2, SIGIRR 
chr11:134,395,794-134,452,384 CN Gain 56591 0 6 q25 
 
chr12:0-54,932 CN Loss 54933 2 4 p13.33 FAM138D, IQSEC3 
chr12:31,170,817-31,239,425 CN Loss 68609 0 5 p11.21 
 
chr14:18,436,960-19,244,853 CN Gain 807894 3 21 q11.1 - q11.2 OR11H12, P704P, POTEG 
chr14:106,219,129-106,256,008 CN Gain 36880 0 3 q32.33 
 
chr15:18,561,649-20,154,365 CN Loss 1592717 11 52 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr15:32,469,503-32,641,649 CN Loss 172147 2 13 q14 GOLGA8A, GOLGA8B 
chr15:82,611,372-82,737,224 CN Loss 125853 1 6 q25.2 LOC388152 
chr16:22,377,731-22,631,044 CN Loss 253314 5 11 p12.1 LOC100132247, LOC100190986, LOC641298, LOC653786, NPIPL3 
chr17:41,521,693-42,128,243 CN Loss 606551 6 21 q21.31 - q21.32 ARL17A, ARL17B, KIAA1267, LRRC37A, LRRC37A2, NSF 
chr19:20,374,780-20,502,123 CN Loss 127344 1 7 p12 ZNF826 
chr22:14,433,473-14,831,576 CN Gain 398104 2 5 q11.1 OR11H1, POTEH 
chr22:17,036,698-17,294,519 CN Loss 257822 4 9 q11.21 DGCR6, GGT3P, PRODH, USP18 
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Table S3. 8 - CNVs found for patient 8 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:102,431,081-102,633,897 CN Loss 202817 0 11 p21.1   
chr1:142,117,366-142,453,717 CN Loss 336352 0 4 q12 - q21.1   
chr1:194,993,686-195,097,982 CN Gain 104297 2 9 q31.3 CFHR1, CFHR3 
chr2:91,273,082-91,625,698 CN Loss 352617 2 11 p11.1 FKSG73, GGT8P 
chr2:96,098,910-97,594,697 CN Gain 1495788 24 88 q11.2 
ADRA2B, ANKRD23, ANKRD36, ANKRD36B, ANKRD39, ARID5A, ASTL, CIAO1, CNNM3, CNNM4, DUSP2, FAHD2B, 
FAM178B, FER1L5, ITPRIPL1, KIAA1310, LMAN2L, LOC285033, NCAPH, NEURL3, SEMA4C, SNRNP200, STARD7, 
TMEM127 
chr2:130,418,126-130,467,710 CN Loss 49585 1 4 q21.1 RAB6C 
chr2:131,811,198-131,860,657 CN Loss 49460 1 5 q21.1 LOC150786 
chr3:75,752,964-75,905,213 CN Loss 152250 3 12 p12.3 FRG2C, MIR1324, ZNF717 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:34,448,772-34,500,505 CN Gain 51734 0 4 p15.1   
chr4:68,978,187-69,170,341 CN Gain 192155 2 12 q13.2 TMPRSS11E, UGT2B17 
chr4:70,227,242-70,269,497 CN Loss 42256 0 3 q13.2   
chr5:742,057-839,349 CN Gain 97293 1 9 p15.33 TPPP 
chr5:70,245,600-70,375,604 CN Gain 130005 9 5 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, NAIP, SERF1A, SERF1B, SMN1, SMN2 
chr6:193,938-327,656 CN Loss 133719 1 9 p25.3 DUSP22 
chr6:32,548,396-32,600,341 Homozygous Copy Loss 51946 1 4 p21.32 HLA-DRB5 
chr6:32,600,341-32,623,614 CN Gain 23274 1 3 p21.32 HLA-DRB5 
chr6:32,623,614-32,681,379 CN Loss 57766 2 5 p21.32 HLA-DRB1, HLA-DRB6 
chr6:79,027,678-79,098,580 CN Gain 70903 0 4 q14.1   
chr6:168,076,174-168,333,368 CN Gain 257195 4 18 q27 FRMD1, HGC6.3, KIF25, MLLT4 
chr7:38,284,089-38,349,754 CN Loss 65666 0 5 p14.1   
chr7:124,186,384-124,227,026 High Copy Gain 40643 1 3 q31.33 GPR37 
chr7:142,066,473-142,209,840 CN Loss 143368 3 11 q34 PRSS1, PRSS2, TRY6 
chr7:142,947,514-143,049,236 CN Gain 101723 2 4 q35 FAM115C, LOC441294 
chr8:12,270,256-12,366,919 Homozygous Copy Loss 96664 3 3 p23.1 DEFB109P1, FAM66A, FAM86B2 
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chr8:12,366,919-12,554,253 CN Loss 187335 0 4 p23.1   
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:39,999,379-40,265,103 CN Loss 265725 0 5 p13.1 - p12   
chr9:65,525,874-65,792,243 CN Loss 266370 0 4 q12   
chr10:38,948,353-39,080,121 CN Loss 131769 0 4 p11.1   
chr10:45,969,999-46,573,606 CN Loss 603608 10 31 q11.21 - q11.22 BMS1P1, BMS1P5, FAM35B, FRMPD2L1, GPRIN2, LOC728643, PPYR1, PTPN20A, PTPN20B, SYT15 
chr10:47,169,331-47,451,593 CN Loss 282263 3 4 q11.22 ANTXRL, ANXA8L2, FAM21B 
chr10:48,381,494-49,040,567 CN Loss 659074 7 9 q11.22 FAM25B, FAM25C, FAM25G, FRMPD2, LOC399753, PTPN20A, PTPN20B 
chr11:18,851,036-18,925,523 CN Loss 74488 1 5 p15.1 MRGPRX1 
chr11:55,119,157-55,178,810 CN Gain 59654 3 3 q11 OR4C11, OR4P4, OR4S2 
chr12:8,208,895-8,273,494 CN Loss 64600 3 4 p13.31 FAM66C, FAM90A1, ZNF705A 
chr12:31,170,795-31,292,064 CN Gain 121270 0 8 p11.21   
chr14:18,436,931-19,490,518 CN Loss 1053588 9 36 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:40,669,880-40,734,612 CN Loss 64733 0 3 q21.1   
chr14:105,602,384-105,693,838 CN Loss 91455 0 9 q32.33   
chr15:18,561,627-20,154,336 CN Loss 1592710 11 55 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:22,377,707-22,631,014 CN Loss 253308 5 11 p12.1 LOC100132247, LOC100190986, LOC641298, LOC653786, NPIPL3 
chr16:32,096,628-32,582,495 CN Loss 485868 0 17 p11.2   
chr16:33,230,071-33,720,310 CN Loss 490240 0 26 p11.2   
chr16:34,345,125-34,600,842 CN Loss 255718 2 15 p11.2 - p11.1 LOC146481, LOC283914 
chr16:58,848,869-59,019,408 CN Loss 170540 0 9 q21   
chr16:68,697,986-68,774,654 CN Gain 76669 2 5 q22.1 CLEC18C, PDPR 
chr17:31,459,116-31,511,535 CN Loss 52420 0 5 q12   
chr17:41,577,131-41,768,841 CN Gain 191711 3 11 q21.31 ARL17B, KIAA1267, LRRC37A 
chr19:17,330,586-17,377,389 CN Gain 46804 2 4 p13.11 BST2, PLVAP 
chr19:20,067,301-20,148,413 CN Loss 81113 2 5 p12 ZNF486, ZNF90 
chr19:20,374,751-20,502,094 CN Loss 127344 1 9 p12 ZNF826 
chr22:14,433,473-14,629,187 CN Loss 195715 0 2 q11.1   
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chr22:17,036,669-17,240,532 CN Loss 203864 2 5 q11.21 GGT3P, USP18 
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Table S3. 9 - CNVs found for patient 9 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,746,886-16,923,881 CN Loss 176996 4 10 p36.13 CROCCL1, ESPNP, MST1P2, NBPF1 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr1:194,993,686-195,059,281 CN Loss 65596 2 6 q31.3 CFHR1, CFHR3 
chr2:89,244,042-89,895,566 CN Loss 651525 0 19 p11.2   
chr3:132,898,329-132,993,320 Homozygous Copy Loss 94992 1 6 q22.1 CPNE4 
chr3:132,993,320-136,601,728 CN Loss 3608409 23 223 q22.1 - q22.2 ACAD11, ACPP, AMOTL2, ANAPC13, BFSP2, C3orf36, CCRL1, CDV3, CEP63, CPNE4, DNAJC13, EPHB1, KY, NCRNA00119, NPHP3, RAB6B, RYK, SLCO2A1, SRPRB, TF, TMEM108, TOPBP1, UBA5 
chr3:136,601,728-136,808,917 Homozygous Copy Loss 207190 0 11 q22.2   
chr3:136,808,917-143,101,242 CN Loss 6292326 41 382 q22.2 - q23 
A4GNT, ACPL2, ARMC8, ATP1B3, BPESC1, C3orf72, CEP70, CLDN18, CLSTN2, COPB2, DBR1, DZIP1L, ESYT3, FAIM, 
FOXL2, GRK7, IL20RB, MRAS, MRPS22, MSL2, NCK1, NMNAT3, PCCB, PIK3CB, PISRT1, PPP2R3A, PRR23A, PRR23B, 
PRR23C, RASA2, RBP1, RBP2, RNF7, SLC25A36, SOX14, SPSB4, STAG1, TMEM22, TRIM42, TXNDC6, ZBTB38 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr3:196,885,475-196,942,769 CN Loss 57295 3 4 q29 MIR570, MUC20, SDHAP2 
chr4:68,978,187-69,170,341 CN Loss 192155 2 12 q13.2 TMPRSS11E, UGT2B17 
chr6:212,083-327,656 CN Loss 115574 1 8 p25.3 DUSP22 
chr6:168,076,174-168,333,368 CN Gain 257195 4 18 q27 FRMD1, HGC6.3, KIF25, MLLT4 
chr7:100,750,082-100,924,707 CN Gain 174626 2 11 q22.1 EMID2, RABL5 
chr8:7,121,948-8,104,612 CN Loss 982665 29 30 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66B, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, FAM90A5, 
FAM90A7, FAM90A8, FAM90A9, LOC349196, MIR548I3, SPAG11A, SPAG11B, ZNF705G 
chr9:38,769,965-38,942,543 CN Gain 172579 0 10 p13.1   
chr17:41,521,663-41,768,841 CN Gain 247179 3 14 q21.31 ARL17B, KIAA1267, LRRC37A 
chrX:154,690,941-154,846,576 CN Loss 155636 1 25 q28 VAMP7 
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Table S3. 10 - CNVs found for patient 10 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,778,535-17,218,740 CN Gain 440206 9 25 p36.13 ATP13A2, CROCC, CROCCL1, ESPNP, MFAP2, MST1P2, MST1P9, NBPF1, SDHB 
chr1:72,532,314-72,609,367 Homozygous Copy Loss 77054 0 4 p31.1   
chr1:153,239,357-153,361,162 CN Gain 121806 6 9 q21.3 - q22 ADAM15, DCST1, DCST2, EFNA3, EFNA4, ZBTB7B 
chr4:70,170,112-70,285,238 CN Gain 115127 1 7 q13.2 UGT2B28 
chr5:69,585,286-70,043,543 CN Gain 458258 4 5 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, LOC653391 
chr5:70,043,543-70,375,604 CN Loss 332062 10 6 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC653391, NAIP, SERF1A, SERF1B, SMN1, SMN2 
chr5:176,544,003-176,734,904 CN Gain 190902 6 14 q35.3 LMAN2, MXD3, NSD1, PRELID1, RAB24, RGS14 
chr6:32,609,419-32,659,791 CN Loss 50373 2 4 p21.32 HLA-DRB1, HLA-DRB6 
chr8:143,526,840-143,626,016 CN Loss 99177 1 8 q24.3 BAI1 
chr9:65,222,385-65,955,080 CN Loss 732696 4 7 q12 FAM74A2, FAM74A4, FAM75A5, FAM75A7 
chr10:45,969,999-46,477,067 CN Loss 507069 8 24 q11.21 - q11.22 BMS1P1, BMS1P5, FAM35B, FRMPD2L1, GPRIN2, PTPN20A, PTPN20B, SYT15 
chr10:46,477,067-46,573,606 Homozygous Copy Loss 96540 2 7 q11.22 LOC728643, PPYR1 
chr10:48,381,494-49,040,567 CN Loss 659074 7 9 q11.22 FAM25B, FAM25C, FAM25G, FRMPD2, LOC399753, PTPN20A, PTPN20B 
chr12:19,358,692-19,474,911 CN Gain 116220 1 7 p12.3 PLEKHA5 
chr14:18,149,473-19,244,829 CN Gain 1095357 3 27 q11.1 - q11.2 OR11H12, P704P, POTEG 
chr15:18,561,627-20,154,336 CN Loss 1592710 11 55 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:83,706,547-84,115,992 CN Gain 409446 0 22 q24.1   
chr17:19,439,761-19,486,821 CN Loss 47061 0 3 p11.2   
chr17:41,577,131-42,142,705 CN Gain 565575 6 19 q21.31 - q21.32 ARL17A, ARL17B, KIAA1267, LRRC37A, LRRC37A2, NSF 
chr19:9,468,575-9,748,852 CN Gain 280278 6 17 p13.2 ZNF121, ZNF426, ZNF560, ZNF561, ZNF562, ZNF846 
chr19:59,929,792-60,074,245 CN Gain 144454 8 6 q13.42 KIR2DL1, KIR2DL3, KIR2DL4, KIR2DS4, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1 
chr22:19,386,371-19,792,906 CN Gain 406536 14 33 q11.21 AIFM3, CRKL, FLJ39582, LOC400891, LZTR1, MGC16703, P2RX6, P2RX6P, PI4KA, SERPIND1, SLC7A4, SNAP29, THAP7, TMEM191A 
chr22:23,983,829-24,247,592 CN Loss 263764 2 19 q11.23 IGLL3, LRP5L 
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Table S3. 11 - CNVs found for patient 11 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:147,255,457-147,553,575 CN Gain 298119 1 16 q21.1 LOC388692 
chr1:246,682,708-246,781,770 CN Gain 99063 4 7 q44 OR2G6, OR2T2, OR2T3, OR2T5 
chr1:246,781,770-246,882,848 CN Loss 101079 6 7 q44 OR2T10, OR2T11, OR2T27, OR2T29, OR2T34, OR2T35 
chr2:132,594,362-132,762,389 CN Loss 168028 2 8 q21.2 MIR663B, NCRNA00164 
chr2:242,507,916-242,683,523 CN Loss 175608 1 17 q37.3 LOC728323 
chr3:101,814,939-101,906,244 CN Gain 91306 1 6 q12.2 GPR128 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:34,429,336-34,500,505 CN Gain 71170 0 5 p15.1   
chr4:69,038,815-69,165,944 CN Gain 127130 2 9 q13.2 TMPRSS11E, UGT2B17 
chr5:745,872-874,147 CN Loss 128276 2 12 p15.33 TPPP, ZDHHC11 
chr5:32,135,149-32,197,234 CN Gain 62086 2 4 p13.3 GOLPH3, PDZD2 
chr5:179,345,860-180,237,221 CN Gain 891362 12 57 q35.3 CNOT6, FLT4, GFPT2, LOC729678, MAPK9, MGAT1, MIR340, OR2Y1, RASGEF1C, RNF130, SCGB3A1, ZFP62 
chr6:212,083-343,443 CN Loss 131361 2 9 p25.3 DUSP22, IRF4 
chr6:79,027,678-79,116,521 CN Loss 88844 0 5 q14.1   
chr8:7,245,105-7,830,098 CN Loss 584994 21 21 p23.1 DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, SPAG11A, SPAG11B 
chr8:11,976,320-12,548,010 CN Loss 571691 9 13 p23.1 DEFB109P1, DEFB130, FAM66A, FAM66D, FAM86B1, FAM86B2, LOC392196, USP17L2, ZNF705D 
chr8:39,332,477-39,508,365 CN Loss 175889 2 11 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:38,848,109-42,219,258 CN Loss 3371150 13 93 p13.1 - p12 CNTNAP3, FAM74A1, FAM74A3, FAM75A1, FAM75A2, FAM75A3, FAM75A5, FAM75A7, KGFLP2, LOC653501, MGC21881, ZNF658, ZNF658B 
chr9:43,131,618-47,055,569 CN Loss 3923952 5 68 p11.2 - p11.1 FAM27A, FAM27C, FAM75A6, KGFLP1, LOC642929 
chr9:65,222,385-65,955,080 CN Loss 732696 4 7 q12 FAM74A2, FAM74A4, FAM75A5, FAM75A7 
chr11:76,562,765-76,611,534 CN Loss 48770 2 3 q13.5 GDPD4, MYO7A 
chr12:46,240,128-46,335,778 High Copy Gain 95651 0 5 q13.11   
chr14:105,602,384-105,637,917 Homozygous Copy Loss 35534 0 3 q32.33   
chr14:105,818,109-106,012,840 CN Loss 194732 1 15 q32.33 LOC100133469 
chr15:19,796,307-20,044,857 CN Loss 248551 4 15 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr15:82,558,171-82,881,345 CN Loss 323175 3 14 q25.2 GOLGA6L5, LOC388152, UBE2Q2P1 
chr16:68,697,986-68,752,812 High Copy Gain 54827 1 4 q22.1 PDPR 
chr16:72,921,969-73,017,673 High Copy Gain 95705 2 6 q22.3 CLEC18B, LOC283922 
chr17:41,555,382-41,713,328 CN Loss 157947 1 11 q21.31 KIAA1267 
chr17:42,994,344-43,029,201 CN Loss 34858 1 3 q21.32 NPEPPS 
chr21:45,629,020-45,951,495 CN Gain 322476 3 21 q22.3 COL18A1, NCRNA00175, SLC19A1 
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Table S3. 12 - CNVs found for patient 12 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,725,089-17,166,694 CN Loss 441606 6 24 p36.13 CROCC, CROCCL1, ESPNP, MST1P2, MST1P9, NBPF1 
chr1:141,494,201-141,663,976 CN Gain 169776 0 6 q12   
chr1:159,748,177-159,827,104 CN Gain 78928 4 7 q23.3 FCGR2A, FCGR2C, FCGR3A, HSPA6 
chr1:194,975,299-195,078,812 CN Loss 103514 3 10 q31.3 CFH, CFHR1, CFHR3 
chr2:242,507,916-242,951,149 CN Loss 443234 1 20 q37.3 LOC728323 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr3:196,933,249-196,956,726 CN Loss 23478 1 3 q29 MUC20 
chr4:48,953,993-49,276,565 CN Loss 322573 0 3 p11   
chr4:69,038,815-69,170,341 CN Loss 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr4:70,141,356-70,269,497 CN Gain 128142 1 8 q13.2 UGT2B28 
chr6:32,563,029-32,600,341 Homozygous Copy Loss 37313 1 3 p21.32 HLA-DRB5 
chr6:32,600,341-32,647,235 CN Gain 46895 2 5 p21.32 HLA-DRB5, HLA-DRB6 
chr6:32,647,235-32,681,379 CN Loss 34145 1 3 p21.32 HLA-DRB1 
chr6:108,537,896-108,829,534 CN Gain 291639 3 18 q21 LACE1, NR2E1, SNX3 
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:6,792,781-6,902,081 CN Loss 109301 1 6 p24.1 KDM4C 
chr9:17,639,085-17,725,970 CN Gain 86886 1 5 p22.2 SH3GL2 
chr9:39,081,057-39,251,004 CN Gain 169948 1 8 p13.1 CNTNAP3 
chr11:55,119,157-55,178,810 CN Loss 59654 3 3 q11 OR4C11, OR4P4, OR4S2 
chr13:62,664,941-62,752,472 CN Loss 87532 0 5 q21.31   
chr14:18,436,931-19,507,271 CN Loss 1070341 9 38 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:105,602,384-105,637,917 Homozygous Copy Loss 35534 0 3 q32.33   
chr14:105,637,917-105,889,976 CN Loss 252060 0 23 q32.33   
chr15:18,856,397-19,441,979 CN Gain 585583 7 23 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, NF1P1, POTEB 
chr16:488,401-617,378 CN Loss 128978 7 10 p13.3 C16orf10, C16orf11, NHLRC4, PIGQ, RAB11FIP3, RAB40C, SOLH 
chr16:54,345,532-54,383,408 CN Loss 37877 1 3 q12.2 CES4 
chr16:54,383,408-54,441,898 CN Gain 58491 2 4 q12.2 CES1, CES7 
chr16:88,395,085-88,444,115 CN Gain 49031 2 4 q24.3 FANCA, SPIRE2 
chr17:31,449,032-31,890,587 CN Loss 441556 10 11 q12 CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F, TBC1D3G, TBC1D3H 
chr17:40,937,706-41,036,432 CN Gain 98727 2 4 q21.31 LOC644172, LRRC37A4 
chr17:41,521,663-41,648,920 CN Gain 127258 1 9 q21.31 KIAA1267 
chr19:20,357,873-20,502,094 CN Loss 144222 1 10 p12 ZNF826 
chr21:9,896,630-10,034,406 CN Loss 137777 1 5 p11.2 - p11.1 TPTE 
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chr22:22,659,866-22,792,316 CN Gain 132451 5 9 q11.23 CABIN1, GSTT1, GSTTP1, GSTTP2, LOC391322 
chrX:1,333,567-1,390,376 CN Gain 56810 1 8 p22.33 CSF2RA 
chrX:83,129,544-83,184,995 CN Gain 55452 0 3 q21.1   
chrX:137,447,004-137,563,727 CN Gain 116724 2 7 q26.3 FGF13, LOC158696 
  
 211 
 
Table S3. 13 - CNVs found for patient 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr1:194,979,783-195,064,797 CN Loss 85015 3 8 q31.3 CFH, CFHR1, CFHR3 
chr2:88,975,437-89,895,566 CN Loss 920130 0 29 p11.2   
chr5:103,341,259-103,428,149 CN Loss 86891 0 5 q21.2   
chr6:32,563,029-32,634,334 Homozygous Copy Loss 71306 2 7 p21.32 HLA-DRB5, HLA-DRB6 
chr6:32,634,334-32,666,536 CN Loss 32203 2 3 p21.32 HLA-DRB1, HLA-DRB6 
chr6:156,054,446-158,724,482 CN Loss 2670037 7 140 q25.3 ARID1B, GTF2H5, SERAC1, SNX9, SYNJ2, TULP4, ZDHHC14 
chr7:76,269,619-76,451,792 CN Gain 182174 1 9 q11.23 PMS2L11 
chr8:144,959,805-145,133,898 CN Loss 174094 8 12 q24.3 EPPK1, MIR661, MIR937, NRBP2, PARP10, PLEC, PUF60, SCRIB 
chr14:18,741,463-19,490,518 CN Gain 749056 7 23 q11.1 - q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P 
chr14:105,602,384-105,854,362 CN Gain 251979 0 23 q32.33   
chr15:28,271,861-28,589,267 CN Loss 317407 2 11 q13.2 CHRFAM7A, DKFZP434L187 
chr16:31,908,350-32,582,495 CN Gain 674146 1 24 p11.2 HERC2P4 
chr16:34,328,350-34,611,145 High Copy Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr18:1,706,128-1,828,669 CN Loss 122542 0 7 p11.32   
chr20:27,100,000-28,266,113 CN Loss 1166114 1 6 q11.1 FRG1B 
chr20:60,516,643-60,570,962 CN Loss 54320 3 4 q13.33 C20orf166, C20orf200, MIR1-1 
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Table S3. 14 - CNVs found for patient 14 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:147,255,457-147,526,118 CN Loss 270662 0 15 q21.1   
chr1:194,993,686-195,078,812 Homozygous Copy Loss 85127 2 8 q31.3 CFHR1, CFHR3 
chr3:196,826,201-196,942,769 CN Gain 116569 3 6 q29 MIR570, MUC20, SDHAP2 
chr4:68,872,534-69,207,266 CN Loss 334733 4 21 q13.2 TMPRSS11E, UGT2B15, UGT2B17, YTHDC1 
chr5:769,844-827,999 High Copy Gain 58156 0 5 p15.33   
chr5:827,999-900,209 CN Gain 72211 1 8 p15.33 ZDHHC11 
chr5:68,892,660-69,300,554 CN Gain 407895 7 14 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100272216, LOC653391 
chr5:69,585,286-69,823,666 High Copy Gain 238381 4 4 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, LOC653391 
chr7:72,091,520-72,241,581 CN Gain 150062 5 6 q11.23 GTF2IP1, LOC100093631, PMS2L2, SPDYE8P, STAG3L3 
chr7:72,379,797-72,783,852 CN Loss 404056 11 28 q11.23 BAZ1B, BCL7B, DNAJC30, FKBP6, FZD9, MLXIPL, STX1A, TBL2, TRIM50, VPS37D, WBSCR22 
chr8:39,349,059-39,439,185 High Copy Gain 90127 2 6 p11.23 ADAM3A, ADAM5P 
chr9:94,114,736-94,296,418 CN Gain 181683 5 13 q22.31 ASPN, CENPP, NOL8, OGN, OMD 
chr10:133,163,835-133,323,898 CN Loss 160064 0 8 q26.3   
chr12:9,519,693-9,606,536 High Copy Gain 86844 0 6 p13.31   
chr14:19,122,778-19,490,518 CN Gain 367741 6 15 q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3 
chr14:105,602,384-105,637,917 Homozygous Copy Loss 35534 0 3 q32.33   
chr15:19,074,651-19,777,939 CN Gain 703289 5 22 q11.2 BCL8, CXADRP2, LOC646214, NF1P1, POTEB 
chr15:19,777,939-20,154,336 High Copy Gain 376398 4 18 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr16:32,848,712-33,548,689 CN Gain 699978 2 27 p11.2 TP53TG3, TP53TG3B 
chr16:34,310,061-34,625,973 CN Gain 315913 2 19 p11.2 - p11.1 LOC146481, LOC283914 
chr17:33,379,598-33,681,159 CN Loss 301562 2 5 q12 TBC1D3, TBC1D3F 
chr19:48,342,188-48,449,551 CN Loss 107364 3 7 q13.31 PSG4, PSG5, PSG9 
chr21:9,896,630-10,198,129 CN Gain 301500 6 14 p11.2 - p11.1 BAGE, BAGE2, BAGE3, BAGE4, BAGE5, TPTE 
chr22:37,683,134-37,724,108 Homozygous Copy Loss 40975 2 4 q13.1 APOBEC3A, APOBEC3B 
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Table S3. 15 - CNVs found for patient 15 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:120,339,508-120,431,061 CN Loss 91554 1 7 p12 NOTCH2 
chr1:143,921,320-144,079,918 CN Loss 158599 2 9 q21.1 NBPF10, NOTCH2NL 
chr1:146,886,639-148,058,580 CN Loss 1171942 11 36 q21.1 - q21.2 FCGR1A, FCGR1C, HIST2H2BF, HIST2H3D, LOC388692, LOC645166, LOC728855, NBPF16, PPIAL4A, PPIAL4C, PPIAL4E 
chr1:221,119,130-221,263,305 CN Loss 144176 1 9 q41 DISP1 
chr2:89,265,770-89,895,566 CN Loss 629797 0 16 p11.2   
chr2:97,134,097-97,288,036 CN Loss 153940 1 8 q11.2 ANKRD36 
chr2:132,157,969-132,284,054 CN Loss 126086 2 11 q21.1 - q21.2 C2orf27A, C2orf27B 
chr4:69,008,654-69,117,422 CN Loss 108769 2 7 q13.2 TMPRSS11E, UGT2B17 
chr5:742,057-900,209 CN Gain 158153 2 12 p15.33 TPPP, ZDHHC11 
chr5:68,866,395-70,671,221 CN Loss 1804827 15 42 q13.2 
GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC647859, LOC653391, NAIP, OCLN, SERF1A, 
SERF1B, SMN1, SMN2 
chr5:175,557,661-175,689,861 CN Loss 132201 1 9 q35.2 C5orf25 
chr6:193,938-327,656 CN Loss 133719 1 9 p25.3 DUSP22 
chr7:61,060,605-61,374,646 CN Loss 314042 0 4 q11.1 - q11.21   
chr7:72,052,516-72,359,842 CN Loss 307327 12 14 q11.23 GTF2IP1, GTF2IRD2P1, LOC100093631, NCF1B, NSUN5, NSUN5C, NSUN5P2, PMS2L2, POM121, SPDYE8P, STAG3L3, TRIM74 
chr7:143,596,593-143,693,789 CN Loss 97197 6 4 q35 ARHGEF5, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A9P 
chr8:7,121,948-8,124,705 CN Loss 1002758 30 31 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, 
DEFB4, FAM66B, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, FAM90A5, FAM90A7, FAM90A8, 
FAM90A9, FLJ10661, LOC349196, MIR548I3, SPAG11A, SPAG11B, ZNF705G 
chr8:11,934,392-12,554,253 CN Loss 619862 9 16 p23.1 DEFB109P1, DEFB130, FAM66A, FAM66D, FAM86B1, FAM86B2, LOC392196, USP17L2, ZNF705D 
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 9 p11.23 - p11.22 ADAM3A, ADAM5P 
chr8:137,744,855-137,920,248 CN Loss 175394 0 8 q24.23   
chr9:42,403,900-42,625,244 CN Loss 221345 1 8 p11.2 FAM95B1 
chr10:38,856,419-39,080,121 CN Loss 223703 0 5 p11.1   
chr10:46,907,108-47,077,489 CN Loss 170382 0 5 q11.22   
chr10:81,342,341-81,667,828 CN Loss 325488 3 9 q22.3 LOC642361, LOC650623, SFTPA1 
chr11:4,180,454-4,346,983 CN Loss 166530 1 8 p15.4 OR52B4 
chr14:18,149,473-18,640,884 CN Loss 491412 2 11 q11.1 OR11H12, POTEG 
chr14:18,704,526-19,528,037 CN Loss 823512 8 29 q11.1 - q11.2 OR4K1, OR4K15, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P 
chr14:40,669,880-40,734,612 CN Loss 64733 0 3 q21.1   
chr15:19,101,155-19,796,307 CN Gain 695153 6 22 q11.2 BCL8, CXADRP2, LOC646214, LOC727924, NF1P1, POTEB 
chr16:381,902-488,401 CN Loss 106500 4 10 p13.3 DECR2, LOC100134368, NME4, RAB11FIP3 
chr16:31,389,482-31,419,934 CN Gain 30453 3 5 p11.2 C16orf58, SLC5A2, TGFB1I1 
chr16:32,079,878-33,691,406 CN Loss 1611529 3 55 p11.2 SLC6A10P, TP53TG3, TP53TG3B 
chr16:34,345,125-34,656,892 CN Loss 311768 2 19 p11.2 - p11.1 LOC146481, LOC283914 
chr17:31,459,116-31,762,515 CN Loss 303400 7 8 q12 CCL3L1, CCL3L3, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F 
chr17:41,052,171-41,334,928 CN Gain 282758 7 16 q21.31 C17orf69, CRHR1, IMP5, LOC100128977, LOC100130148, MAPT, MGC57346 
chr17:41,577,131-41,768,841 CN Gain 191711 3 10 q21.31 ARL17B, KIAA1267, LRRC37A 
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chr19:0-213,756 CN Loss 213757 6 3 p13.3 FAM138A, FAM138C, FAM138F, FLJ45445, LOC375690, OR4F17, hsa-mir-1302-2 
chr21:12,300,000-13,397,475 CN Loss 1097476 1 5 q11.1 - q11.2 C21orf99 
chr22:23,983,829-24,247,592 CN Loss 263764 2 15 q11.23 IGLL3, LRP5L 
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Table S3. 16 - CNVs found for patient 16 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:2,311,143-2,437,924 CN Gain 126782 5 9 p36.32 MORN1, PANK4, PEX10, PLCH2, RER1 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr1:103,905,063-104,103,459 CN Gain 198397 6 9 p21.1 AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, LOC648740 
chr1:120,594,254-120,815,510 CN Loss 221257 3 7 p12 - p11.2 FAM72B, FCGR1B, HIST2H2BA 
chr1:147,255,457-147,430,850 Homozygous Copy Loss 175394 0 8 q21.1   
chr1:147,430,850-147,503,409 CN Loss 72560 0 5 q21.1   
chr1:147,526,118-148,032,481 CN Loss 506364 7 15 q21.1 - q21.2 FCGR1A, FCGR1C, HIST2H2BF, LOC388692, LOC728855, PPIAL4A, PPIAL4C 
chr1:194,993,686-195,078,812 CN Loss 85127 2 8 q31.3 CFHR1, CFHR3 
chr1:246,667,935-246,726,094 CN Loss 58160 3 5 q44 OR2T2, OR2T3, OR2T5 
chr2:91,095,408-91,376,821 CN Loss 281414 2 11 p11.1 GGT8P, LOC654342 
chr3:163,987,281-164,108,596 Homozygous Copy Loss 121316 0 7 q26.1   
chr4:69,063,649-69,170,341 CN Loss 106693 1 9 q13.2 UGT2B17 
chr4:191,050,769-191,127,447 CN Loss 76679 1 8 q35.2 FRG1 
chr5:745,872-900,209 High Copy Gain 154338 2 15 p15.33 TPPP, ZDHHC11 
chr5:68,877,031-69,300,554 CN Loss 423524 9 15 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100272216, LOC647859, LOC653391, OCLN 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr7:0-171,033 CN Gain 171034 0 3 p22.3   
chr7:1,345,917-1,488,005 CN Gain 142089 2 9 p22.3 INTS1, MICALL2 
chr7:132,827,191-134,903,411 . 2076221 15 131 q33 
AGBL3, AKR1B1, AKR1B10, AKR1B15, BPGM, C7orf49, CALD1, CNOT4, EXOC4, LRGUK, NUP205, SLC35B4, STRA8, 
TMEM140, WDR91 
chr7:143,509,786-143,667,377 CN Gain 157592 7 7 q35 ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:39,349,059-39,526,316 CN Loss 177258 2 11 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:138,350,119-138,387,209 CN Gain 37091 3 3 q34.3 CARD9, DNLZ, GPSM1 
chr9:139,219,916-139,267,322 CN Gain 47407 7 5 q34.3 C9orf169, C9orf173, FAM166A, NDOR1, RNF208, SLC34A3, TUBB2C 
chr14:18,555,363-19,490,518 CN Loss 935156 8 33 q11.1 - q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr15:18,467,080-19,777,939 CN Gain 1310860 7 39 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, NF1P1, POTEB 
chr16:1,754,188-1,778,414 CN Gain 24227 6 4 p13.3 EME2, MAPK8IP3, MRPS34, NME3, NUBP2, SPSB3 
chr16:33,266,719-33,485,002 CN Gain 218284 0 17 p11.2   
chr17:31,449,032-31,541,638 CN Loss 92607 2 7 q12 CCL4, TBC1D3B 
chr20:27,100,000-28,266,113 CN Loss 1166114 1 6 q11.1 FRG1B 
chr22:14,433,473-14,831,547 CN Loss 398075 2 4 q11.1 OR11H1, POTEH 
chr22:17,036,669-17,240,532 CN Loss 203864 2 5 q11.21 GGT3P, USP18 
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Table S3. 17 - CNVs found for patient 17 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:17,077,550-17,131,728 CN Loss 54179 1 4 p36.13 CROCC 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1 
 
chr2:75,302,024-76,665,026 CN Gain 1363003 3 82 p13.1 - p12 C2orf3, FAM176A, MRPL19 
chr2:110,037,747-110,667,961 CN Gain 630215 7 21 q13 LIMS3, LIMS3-LOC440895, LOC151009, LOC440895, MALL, NCRNA00116, NPHP1 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1 
 
chr4:34,448,772-34,500,505 CN Gain 51734 0 4 p15.1 
 
chr4:69,008,654-69,170,341 CN Gain 161688 2 11 q13.2 TMPRSS11E, UGT2B17 
chr4:70,151,754-70,345,475 CN Loss 193722 1 11 q13.2 UGT2B28 
chr5:769,844-857,045 CN Gain 87202 1 8 p15.33 ZDHHC11 
chr5:12,845,443-13,146,867 CN Loss 301425 0 8 p15.2 
 
chr6:193,938-244,003 CN Loss 50066 1 3 p25.3 DUSP22 
chr6:244,003-343,443 CN Gain 99441 2 7 p25.3 DUSP22, IRF4 
chr6:32,563,029-32,634,334 Homozygous Copy Loss 71306 2 7 p21.32 HLA-DRB5, HLA-DRB6 
chr6:32,634,334-32,711,050 CN Loss 76717 2 7 p21.32 HLA-DRB1, HLA-DRB6 
chr6:115,364,925-115,464,319 High Copy Gain 99395 0 5 q22.1 
 
chr6:115,464,319-115,567,351 CN Gain 103033 0 5 q22.1 
 
chr7:43,970,243-44,035,484 High Copy Gain 65242 3 4 p13 POLR2J4, RASA4P, SPDYE1 
chr7:45,762,511-45,827,273 CN Gain 64763 1 4 p13 13-Set 
chr7:143,509,786-143,693,789 CN Loss 184004 8 8 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,214,279-7,942,536 CN Loss 728258 23 24 p23.1 DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, SPAG11A, SPAG11B 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:134,757,732-140,273,252 CN Gain 5515521 135 371 q34.13 - q34.3 
ABCA2, ABO, ADAMTS13, ADAMTSL2, AGPAT2, ANAPC2, ARRDC1, BRD3, C8G, C9orf116, C9orf139, C9orf140, C9orf142, C9orf163, 
C9orf167, C9orf169, C9orf172, C9orf173, C9orf37, C9orf69, C9orf7, C9orf75, C9orf86, C9orf96, CACNA1B, CAMSAP1, CARD9, CEL, CELP, 
CLIC3, COBRA1, COL5A1, DBH, DNLZ, DPP7, EDF1, EGFL7, EHMT1, ENTPD2, ENTPD8, EXD3, FAM157B, FAM163B, FAM166A, FAM69B, 
FBXW5, FCN1, FCN2, FLJ40292, FUT7, GBGT1, GFI1B, GLT6D1, GPSM1, GRIN1, GTF3C5, INPP5E, KCNT1, KIAA0649, KIAA1984, LCN1, 
LCN10, LCN12, LCN15, LCN6, LCN8, LCN9, LCNL1, LHX3, LOC100131193, LOC100289341, LOC26102, LRRC26, MAMDC4, MAN1B1, 
MED22, MIR126, MIR602, MRPL41, MRPS2, NACC2, NCRNA00094, NDOR1, NELF, NOTCH1, NOXA1, NPDC1, NRARP, OBP2A, OBP2B, 
OLFM1, PAEP, PHPT1, PMPCA, PNPLA7, PTGDS, QSOX2, RALGDS, REXO4, RNF208, RNU6ATAC, RPL7A, RXRA, SARDH, SDCCAG3, 
SEC16A, SLC2A6, SLC34A3, SNAPC4, SNHG7, SNORA17, SNORA43, SNORD24, SNORD36A, SNORD36B, SNORD36C, SOHLH1, SSNA1, 
SURF1, SURF2, SURF4, SURF6, TMEM141, TMEM203, TMEM8C, TRAF2, TSC1, TUBB2C, TUBBP5, UAP1L1, UBAC1, VAV2, WDR5, WDR85, 
ZMYND19 
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chr10:81,172,311-81,570,873 CN Loss 398563 3 5 q22.3 LOC650623, SFTPA1, SFTPA2 
chr14:19,304,869-19,490,518 CN Loss 185650 5 10 q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2 
chr14:21,641,899-22,013,947 CN Loss 372049 0 23 q11.2 
 
chr14:102,028,863-103,648,365 CN Gain 1619503 22 105 q32.31 - q32.33 
AMN, ANKRD9, ASPG, BAG5, C14orf153, C14orf2, C14orf73, CDC42BPB, CKB, EIF5, KLC1, MARK3, PPP1R13B, RCOR1, SNORA28, TDRD9, 
TECPR2, TNFAIP2, TRAF3, TRMT61A, XRCC3, ZFYVE21 
chr14:104,175,876-105,602,384 CN Gain 1426509 24 106 q32.33 ADAM6, ADSSL1, AHNAK2, AKT1, BRF1, BTBD6, C14orf79, C14orf80, CDCA4, CRIP1, CRIP2, GPR132, INF2, JAG2, KIAA0125, KIAA0284, MGC23270, MTA1, NUDT14, PACS2, PLD4, SIVA1, TMEM121, ZBTB42 
chr14:105,602,384-105,637,917 High Copy Gain 35534 0 3 q32.33 
 
chr14:105,637,917-105,765,096 CN Gain 127180 0 13 q32.33 
 
chr14:105,954,649-106,012,840 CN Loss 58192 1 4 q32.33 LOC100133469 
chr15:18,717,290-18,902,988 CN Gain 185699 0 6 q11.2 
 
chr15:19,074,651-20,154,336 High Copy Gain 1079686 9 40 q11.2 BCL8, CXADRP2, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:33,230,071-33,345,494 CN Gain 115424 0 8 p11.2 
 
chr16:33,345,494-33,535,805 CN Loss 190312 0 13 p11.2 
 
chr16:34,328,350-34,611,145 CN Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr17:21,285,538-21,447,302 CN Loss 161765 1 9 p11.2 C17orf51 
chr17:35,072,144-35,116,013 CN Gain 43870 5 5 q12 ERBB2, PGAP3, PNMT, STARD3, TCAP 
chr22:17,036,669-17,240,532 CN Gain 203864 2 5 q11.21 GGT3P, USP18 
chr22:18,708,904-19,044,001 CN Gain 335098 2 10 q11.21 PI4KAP1, RIMBP3 
chrX:44,334,447-44,423,226 High Copy Gain 88780 0 5 p11.3 
 
chrX:114,131,819-114,286,055 CN Loss 154237 2 11 q23 IL13RA2, LRCH2 
chrX:148,485,054-148,559,717 High Copy Gain 74664 1 6 q28 TMEM185A 
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Table S3. 18 - CNVs found for patient 18 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,778,535-16,987,680 CN Gain 209146 5 13 p36.13 CROCCL1, ESPNP, MST1P2, MST1P9, NBPF1 
chr1:246,781,770-246,863,559 CN Loss 81790 4 6 q44 OR2T10, OR2T11, OR2T29, OR2T34 
chr2:89,064,440-89,895,566 CN Loss 831127 0 24 p11.2   
chr2:90,979,707-91,625,698 CN Loss 645992 3 23 p11.2 - p11.1 FKSG73, GGT8P, LOC654342 
chr4:69,063,649-69,207,266 CN Gain 143618 2 11 q13.2 UGT2B15, UGT2B17 
chr5:745,872-857,045 CN Loss 111174 2 10 p15.33 TPPP, ZDHHC11 
chr6:32,563,029-32,634,334 Homozygous Copy Loss 71306 2 7 p21.32 HLA-DRB5, HLA-DRB6 
chr7:0-171,033 CN Gain 171034 0 3 p22.3   
chr7:143,509,786-143,705,809 CN Gain 196024 8 9 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,026,686-7,803,775 CN Loss 777090 27 29 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, 
DEFB107B, DEFB109P1B, DEFB4, FAM66B, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, 
FAM90A5, FAM90A7, FAM90A8, FAM90A9, LOC349196, SPAG11A, SPAG11B, ZNF705G 
chr8:39,349,059-39,526,316 CN Loss 177258 2 11 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:38,748,218-38,887,219 CN Gain 139002 0 9 p13.1   
chr9:122,564,885-122,884,841 CN Gain 319957 7 21 q33.2 C5, FBXW2, LOC253039, LOC402377, PHF19, PSMD5, TRAF1 
chr9:122,884,841-126,227,440 High Copy Gain 3342600 45 211 q33.2 - q33.3 
C9orf45, CEP110, CRB2, DAB2IP, DENND1A, GGTA1, GPR21, GSN, LHX2, LHX6, LOC100129034, MIR548D1, MIR600, 
MIR601, MORN5, MRRF, NDUFA8, NEK6, OR1B1, OR1J1, OR1J2, OR1J4, OR1K1, OR1L1, OR1L3, OR1L4, OR1L6, 
OR1L8, OR1N1, OR1N2, OR1Q1, OR5C1, PDCL, PSMB7, PTGS1, RAB14, RABGAP1, RBM18, RC3H2, SNORD90, 
STOM, STRBP, TTLL11, ZBTB26, ZBTB6 
chr12:7,885,718-8,020,685 CN Gain 134968 2 8 p13.31 SLC2A14, SLC2A3 
chr12:9,519,693-9,580,901 Homozygous Copy Loss 61209 0 4 p13.31   
chr12:31,129,983-31,239,395 CN Loss 109413 1 8 p11.21 DDX11 
chr15:18,985,008-20,154,336 CN Gain 1169329 11 42 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:22,377,707-22,615,315 CN Loss 237609 5 10 p12.1 LOC100132247, LOC100190986, LOC641298, LOC653786, NPIPL3 
chr17:31,449,032-31,762,515 CN Loss 313484 8 9 q12 CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F 
chr17:41,535,964-42,142,705 CN Loss 606742 6 21 q21.31 - q21.32 ARL17A, ARL17B, KIAA1267, LRRC37A, LRRC37A2, NSF 
chr22:43,812,038-43,961,595 CN Loss 149558 1 8 q13.31 NUP50 
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Table S3. 19 - CNVs found for patient 19 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:12,867,822-13,013,869 CN Loss 146048 6 6 p36.21 PRAMEF10, PRAMEF22, PRAMEF4, PRAMEF6, PRAMEF7, PRAMEF8 
chr1:16,860,419-16,943,714 CN Gain 83296 1 5 p36.13 ESPNP 
chr1:194,979,783-195,078,812 CN Loss 99030 3 9 q31.3 CFH, CFHR1, CFHR3 
chr1:246,781,770-246,882,848 CN Gain 101079 6 7 q44 OR2T10, OR2T11, OR2T27, OR2T29, OR2T34, OR2T35 
chr2:110,194,966-110,427,222 CN Gain 232257 3 12 q13 MALL, NCRNA00116, NPHP1 
chr4:48,818,145-48,953,993 CN Loss 135849 0 5 p11   
chr4:69,008,654-69,106,362 CN Loss 97709 2 6 q13.2 TMPRSS11E, UGT2B17 
chr6:229,040-327,656 CN Loss 98617 1 7 p25.3 DUSP22 
chr7:57,806,031-57,931,397 CN Loss 125367 0 4 p11.1   
chr7:143,509,786-143,693,789 CN Loss 184004 8 8 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:39,349,059-39,508,365 CN Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:131,264,691-131,920,458 CN Loss 655768 3 40 q26.3 EBF3, GLRX3, MGMT 
chr14:18,436,931-18,640,884 CN Gain 203954 2 7 q11.1 OR11H12, POTEG 
chr14:19,244,829-19,490,518 CN Gain 245690 6 13 q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3 
chr15:18,822,832-18,902,988 High Copy Gain 80157 0 4 q11.2   
chr15:19,033,127-19,480,163 CN Gain 447037 6 19 q11.2 BCL8, CXADRP2, GOLGA8C, LOC646214, NF1P1, POTEB 
chr15:19,796,307-20,154,336 High Copy Gain 358030 4 17 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr15:32,469,479-32,656,070 CN Loss 186592 2 14 q14 GOLGA8A, GOLGA8B 
chr17:31,459,116-31,599,722 CN Loss 140607 5 7 q12 CCL3L1, CCL3L3, CCL4L1, CCL4L2, TBC1D3B 
chr17:41,577,131-41,768,841 CN Gain 191711 3 11 q21.31 ARL17B, KIAA1267, LRRC37A 
chr18:35,207,077-35,309,059 CN Loss 101983 1 6 q12.2 LOC647946 
chr20:62,390,214-62,435,964 CN Loss 45751 0 4 q13.33   
chr22:14,433,473-14,875,192 CN Gain 441720 2 5 q11.1 OR11H1, POTEH 
chr22:17,272,553-17,391,813 CN Gain 119261 5 11 q11.21 DGCR10, DGCR5, DGCR6, DGCR9, PRODH 
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Table S3. 20 - CNVs found for patient 20 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:147,095,314-147,503,409 CN Loss 408096 1 15 q21.1 LOC645166 
chr1:174,497,709-174,552,884 CN Gain 55176 0 3 q25.2   
chr1:194,993,686-195,078,812 CN Loss 85127 2 8 q31.3 CFHR1, CFHR3 
chr2:91,273,082-91,625,698 CN Gain 352617 2 11 p11.1 FKSG73, GGT8P 
chr3:131,276,416-131,385,677 CN Gain 109262 2 6 q21.3 ALG1L2, LOC729375 
chr3:163,987,281-164,108,596 CN Gain 121316 0 7 q26.1   
chr3:196,848,435-196,956,726 CN Loss 108292 3 7 q29 MIR570, MUC20, SDHAP2 
chr4:4,033,732-4,174,459 CN Gain 140728 0 3 p16.2   
chr4:34,448,772-34,500,505 CN Loss 51734 0 4 p15.1   
chr4:68,978,187-69,165,944 CN Loss 187758 2 11 q13.2 TMPRSS11E, UGT2B17 
chr4:70,195,060-70,269,497 CN Loss 74438 1 5 q13.2 UGT2B28 
chr6:79,027,678-79,098,580 CN Gain 70903 0 4 q14.1   
chr7:38,262,476-38,336,127 CN Loss 73652 1 6 p14.1 TARP 
chr7:61,060,605-61,574,690 CN Gain 514086 0 8 q11.1 - q11.21   
chr7:97,344,237-97,453,585 CN Gain 109349 2 7 q21.3 MGC72080, OCM2 
chr8:7,214,279-8,124,705 CN Gain 910427 25 28 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, 
FAM90A9, FLJ10661, MIR548I3, SPAG11A, SPAG11B 
chr8:11,976,320-12,139,755 CN Gain 163436 5 5 p23.1 FAM66D, FAM86B1, LOC392196, USP17L2, ZNF705D 
chr8:12,366,919-12,554,253 CN Gain 187335 0 4 p23.1   
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:38,856,419-39,080,121 CN Gain 223703 0 5 p11.1   
chr11:3,436,246-3,539,381 CN Gain 103136 0 3 p15.4   
chr12:113,989,883-115,926,066 CN Loss 857445 8 53 q24.21 - q24.22 C12orf49, FBXW8, HRK, MAP1LC3B2, MED13L, MIR620, NCRNA00173, RNFT2 
chr14:18,520,876-19,490,518 CN Loss 969643 8 34 q11.1 - q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:43,993,122-44,089,370 CN Loss 96249 1 6 q21.3 FSCB 
chr15:18,717,290-18,902,988 CN Loss 185699 0 6 q11.2   
chr15:19,101,155-20,154,336 CN Loss 1053182 9 39 q11.2 BCL8, CXADRP2, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:31,878,102-32,546,468 CN Gain 668367 1 24 p11.2 HERC2P4 
chr16:33,345,494-33,548,689 CN Gain 203196 0 14 p11.2   
chr16:34,328,350-34,611,145 CN Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr17:31,511,535-31,903,419 CN Loss 391885 9 6 q12 CCL3L1, CCL3L3, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F, TBC1D3G, TBC1D3H 
chr17:40,937,706-41,021,360 CN Gain 83655 1 3 q21.31 LRRC37A4 
chr17:41,521,663-41,648,920 CN Gain 127258 1 9 q21.31 KIAA1267 
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chr19:47,927,296-48,058,449 CN Gain 131154 3 10 q13.31 PSG10, PSG3, PSG8 
chr22:17,036,669-17,240,532 CN Gain 203864 2 5 q11.21 GGT3P, USP18 
chr22:22,667,137-22,729,016 CN Gain 61880 4 5 q11.23 GSTT1, GSTTP1, GSTTP2, LOC391322 
chrX:103,063,574-103,207,921 CN Gain 144348 4 10 q22.2 H2BFM, H2BFWT, H2BFXP, TMSB15B 
chrX:140,498,089-140,604,390 CN Gain 106302 2 7 q27.2 SPANXA1, SPANXA2 
chrX:154,043,595-154,085,916 CN Loss 42322 0 4 q28   
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Table S3. 21 - CNVs found for patient 21 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,886,363-16,943,714 CN Loss 57352 1 4 p36.13 ESPNP 
chr3:196,885,475-196,956,726 CN Loss 71252 3 6 q29 MIR570, MUC20, SDHAP2 
chr4:34,448,772-34,500,505 CN Gain 51734 0 4 p15.1   
chr4:69,038,815-69,207,266 CN Loss 168452 3 12 q13.2 TMPRSS11E, UGT2B15, UGT2B17 
chr5:754,690-874,147 CN Loss 119458 1 11 p15.33 ZDHHC11 
chr5:68,866,395-70,452,813 CN Gain 1586419 15 37 q13.2 
GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC647859, LOC653391, 
NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr6:170,767,027-170,899,992 CN Loss 132966 0 4 q27   
chr8:7,319,013-7,775,352 CN Gain 456340 18 14 p23.1 
DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, FAM90A10, 
FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, SPAG11A, SPAG11B 
chr8:12,233,164-12,529,929 High Copy Gain 296766 3 6 p23.1 DEFB109P1, FAM66A, FAM86B2 
chr8:39,332,477-39,473,281 CN Loss 140805 2 9 p11.23 ADAM3A, ADAM5P 
chr9:2,917,236-3,001,419 CN Loss 84184 0 4 p24.2   
chr9:39,131,028-39,410,420 CN Gain 279393 3 13 p13.1 CNTNAP3, FAM75A1, FAM75A2 
chr11:38,952,791-38,996,778 CN Gain 43988 0 3 p12   
chr12:9,519,693-9,591,347 
Homozygous Copy 
Loss 
71655 0 5 p13.31   
chr12:31,185,572-31,239,395 CN Loss 53824 0 4 p11.21   
chr12:85,034,910-85,215,631 
Homozygous Copy 
Loss 
180722 1 11 q21.31 - q21.32 MGAT4C 
chr12:85,215,631-85,399,218 CN Loss 183588 1 11 q21.32 MGAT4C 
chr12:114,893,119-115,188,686 CN Gain 295568 2 19 q24.21 MED13L, MIR620 
chr16:33,740,983-33,798,908 High Copy Gain 57926 0 3 p11.2   
chr16:34,328,350-34,611,145 High Copy Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr17:33,338,413-33,649,919 CN Loss 311507 2 4 q12 TBC1D3, TBC1D3F 
chr17:41,521,663-41,713,328 CN Loss 191666 1 13 q21.31 KIAA1267 
chr18:0-131,060 CN Gain 131061 0 5 p11.32   
chr19:0-572,272 CN Gain 572273 19 33 p13.3 
BSG, C19orf20, C2CD4C, CDC34, FAM138A, FAM138C, FAM138F, FLJ45445, GZMM, HCN2, LOC375690, 
MADCAM1, MIER2, ODF3L2, OR4F17, POLRMT, PPAP2C, SHC2, THEG 
chrX:90,045,791-90,178,305 CN Gain 132515 0 7 q21.31   
chrX:149,223,089-149,345,498 CN Gain 122410 0 7 q28   
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Table S3. 22 - CNVs found for patient 22 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:147,408,706-147,526,118 CN Loss 117413 0 8 q21.1   
chr2:87,237,617-87,750,596 CN Gain 512980 1 26 p11.2 NCRNA00152 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:0-68,743 CN Loss 68744 2 5 p16.3 ZNF595, ZNF718 
chr4:48,921,615-49,276,565 CN Loss 354951 0 4 p11   
chr4:69,038,815-69,185,257 CN Loss 146443 2 11 q13.2 TMPRSS11E, UGT2B17 
chr5:0-140,194 CN Loss 140195 0 8 p15.33   
chr6:193,938-327,656 CN Loss 133719 1 9 p25.3 DUSP22 
chr6:102,775,955-102,844,521 CN Loss 68567 0 4 q16.3   
chr8:7,214,279-7,942,536 CN Loss 728258 23 24 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, 
SPAG11A, SPAG11B 
chr8:39,349,059-39,508,365 CN Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:41,983,501-42,393,913 CN Loss 410413 3 19 p12 ANKRD20A2, ANKRD20A3, KGFLP2 
chr12:9,519,693-9,606,536 High Copy Gain 86844 0 6 p13.31   
chr15:19,138,672-20,258,362 CN Loss 1119691 10 39 q11.2 BCL8, CXADRP2, GOLGA8DP, LOC646214, LOC727924, NF1P1, OR4M2, OR4N3P, OR4N4, POTEB 
chr16:32,914,009-33,871,999 CN Loss 957991 2 38 p11.2 TP53TG3, TP53TG3B 
chr17:31,459,116-32,016,320 CN Loss 557205 13 18 q12 CCL3L1, CCL3L3, CCL4L1, CCL4L2, GGNBP2, MYO19, PIGW, TBC1D3B, TBC1D3C, TBC1D3F, TBC1D3G, TBC1D3H, ZNHIT3 
chr17:41,577,131-41,768,841 CN Gain 191711 3 11 q21.31 ARL17B, KIAA1267, LRRC37A 
chr20:27,100,000-28,266,113 CN Loss 1166114 1 6 q11.1 FRG1B 
chr20:42,717,234-48,284,251 CN Loss 5567018 88 363 q13.12 - q13.13 
ACOT8, ARFGEF2, B4GALT5, C20orf123, C20orf165, C20orf199, CD40, CDH22, CEBPB, CSE1L, CTSA, DBNDD2, DDX27, 
DNTTIP1, ELMO2, EYA2, KCNB1, KCNK15, KCNS1, LOC100131496, LOC100240726, LOC284749, MATN4, MIR1259, MMP9, 
NCOA3, NCOA5, NEURL2, PABPC1L, PCIF1, PI3, PIGT, PLTP, PREX1, PTGIS, RBPJL, RIMS4, RNF114, SDC4, SEMG1, 
SEMG2, SLC12A5, SLC13A3, SLC2A10, SLC35C2, SLC9A8, SLPI, SNAI1, SNORD12, SNORD12B, SNORD12C, SNX21, 
SPATA2, SPINLW1, SPINT3, SPINT4, STAU1, STK4, SULF2, SYS1, SYS1-DBNDD2, TMEM189, TMEM189-UBE2V1, TNNC2, 
TOMM34, TP53RK, TP53TG5, UBE2C, UBE2V1, WFDC10A, WFDC10B, WFDC11, WFDC12, WFDC13, WFDC2, WFDC3, 
WFDC5, WFDC6, WFDC8, WFDC9, WISP2, YWHAB, ZMYND8, ZNF334, ZNF335, ZNFX1, ZSWIM1, ZSWIM3 
chr21:10,003,548-10,198,129 CN Gain 194582 6 10 p11.1 BAGE, BAGE2, BAGE3, BAGE4, BAGE5, TPTE 
chr22:48,295,275-48,356,493 CN Loss 61219 0 4 q13.33   
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Table S3. 23 - CNVs found for patient 23 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,725,089-16,817,477 CN Gain 92389 2 5 p36.13 CROCCL1, NBPF1 
chr1:16,817,477-16,962,625 High Copy Gain 145149 4 8 p36.13 CROCCL1, ESPNP, MST1P2, MST1P9 
chr1:16,962,625-17,025,806 CN Gain 63182 1 3 p36.13 MST1P9 
chr1:103,918,406-103,961,733 CN Gain 43328 2 3 p21.1 AMY2A, AMY2B 
chr1:103,961,733-104,103,459 CN Loss 141727 4 5 p21.1 AMY1A, AMY1B, AMY1C, AMY2A 
chr1:159,773,725-159,912,273 CN Loss 138549 5 10 q23.3 FCGR2B, FCGR2C, FCGR3A, FCGR3B, HSPA7 
chr1:194,993,686-195,037,455 CN Loss 43770 1 4 q31.3 CFHR3 
chr2:132,121,275-132,284,054 CN Loss 162780 2 13 q21.1 - q21.2 C2orf27A, C2orf27B 
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:69,038,815-69,165,944 CN Loss 127130 2 9 q13.2 TMPRSS11E, UGT2B17 
chr5:794,486-866,296 CN Loss 71811 1 7 p15.33 ZDHHC11 
chr5:68,991,456-69,300,554 CN Loss 309099 2 10 q13.2 GUSBP3, LOC653391 
chr5:69,300,554-69,451,454 CN Gain 150901 5 5 q13.2 LOC653391, SERF1A, SERF1B, SMN1, SMN2 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr7:0-171,033 CN Gain 171034 0 3 p22.3   
chr7:76,255,603-76,451,792 CN Gain 196190 1 10 q11.23 PMS2L11 
chr7:143,509,786-143,667,377 CN Gain 157592 7 7 q35 ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,214,279-7,942,536 CN Loss 728258 23 24 p23.1 DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, FAM90A8, FAM90A9, SPAG11A, SPAG11B 
chr8:12,270,256-12,366,919 Homozygous Copy Loss 96664 3 3 p23.1 DEFB109P1, FAM66A, FAM86B2 
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:38,848,109-41,858,396 CN Loss 3010288 11 76 p13.1 - p12 CNTNAP3, FAM74A1, FAM74A3, FAM75A1, FAM75A2, FAM75A3, FAM75A5, FAM75A7, LOC653501, ZNF658, ZNF658B 
chr9:43,361,452-43,613,184 CN Loss 251733 1 5 p11.2 FAM75A6 
chr9:65,426,303-65,955,080 CN Loss 528778 0 6 q12   
chr14:18,149,473-19,490,518 CN Loss 1341046 9 40 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:40,669,880-40,734,612 Homozygous Copy Loss 64733 0 3 q21.1   
chr14:105,602,384-105,637,917 CN Gain 35534 0 3 q32.33   
chr15:19,796,307-20,235,151 CN Loss 438845 4 18 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr16:14,942,869-15,031,536 CN Loss 88668 2 8 p13.11 NPIP, PDXDC1 
chr16:34,328,350-34,611,145 CN Loss 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr16:68,697,986-68,774,654 CN Gain 76669 2 5 q22.1 CLEC18C, PDPR 
chr17:41,577,131-41,713,328 CN Gain 136198 1 10 q21.31 KIAA1267 
chr17:42,963,132-43,029,201 CN Loss 66070 1 5 q21.32 NPEPPS 
chr22:14,433,473-15,135,777 CN Loss 702305 2 7 q11.1 OR11H1, POTEH 
chr22:17,036,669-17,240,532 CN Gain 203864 2 5 q11.21 GGT3P, USP18 
chrX:89,937,438-90,084,709 CN Loss 147272 0 6 q21.31   
chrX:119,476,634-119,789,009 High Copy Gain 312376 4 19 q24 C1GALT1C1, CUL4B, LAMP2, MCTS1 
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Table S3. 24 - CNVs found for patient 24 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,860,419-16,923,881 CN Loss 63463 2 4 p36.13 AL035288, ESPNP 
chr1:16,923,881-17,025,806 CN Gain 101926 3 5 p36.13 KIAA0445, MST1P9, MSTP9 
chr1:26,465,912-26,498,891 CN Gain 32980 5 3 p36.11 CCDC21, CEP85, SH3BGRL3, UBXD5, UBXN11 
chr1:120,354,903-120,594,254 CN Gain 239352 3 11 p12 N2, NOTCH2, NOTCH2NL 
chr1:143,698,897-144,079,918 CN Gain 381022 12 26 q21.1 AK000887, BX647792, DQ586480, KIAA1245, KIAA1693, NBPF10, NBPF14, NBPF20, NBPF8, NOTCH2NL, PDE4DIP, SEC22B 
chr1:144,577,524-147,095,314 CN Gain 2517791 43 93 q21.1 
ACP6, AF131738, AF380582, AK023548, AK023809, AK091688, AK309393, BC036212, BC041003, BC110832, BCL9, CHD1L, 
CR610404, CR617196, DKFZp434H1228, DKFZp451B1418, DQ576969, FAM108A3, FMO5, GJA5, GJA8, GPR89A, GPR89B, GPR89C, 
KIAA1693, LOC200030, LOC728989, NBPF1, NBPF10, NBPF11, NBPF12, NBPF14, NBPF15, NBPF16, NBPF20, NBPF24, PDIA3P, 
PDZK1P1, PPIAL4D, PPIAL4E, PPIAL4F, PRKAB2, hPACPL1 
chr1:147,095,314-147,753,238 CN Loss 657925 8 23 q21.1 AK310441, AK311729, BC023516, FCGR1B, FCGR1C, LOC388692, LOC645166, NBPF20 
chr1:147,753,238-147,887,475 CN Gain 134238 5 3 q21.1 AB074166, AK307112, AK309334, BC005949, BC094809 
chr1:194,979,783-195,051,521 CN Gain 71739 3 6 q31.3 CFH, CFHR1, CFHR3 
chr1:246,667,935-246,707,859 CN Loss 39925 2 4 q44 OR2T2, OR2T3 
chr3:163,987,281-164,108,596 High Copy Gain 121316 1 7 q26.1 BC073807 
chr4:48,868,216-49,276,565 CN Gain 408350 1 7 p11 DQ593719 
chr5:70,312,515-70,375,604 CN Loss 63090 2 4 q13.2 GTF2H2, NAIP 
chr6:32,563,029-32,600,341 CN Loss 37313 2 3 p21.32 HLA-DRB1, HLA-DRB5 
chr6:79,027,678-79,098,580 CN Loss 70903 0 4 q14.1 
 
chr7:143,548,913-143,705,809 CN Gain 156897 9 8 q35 ARHGEF5, BC040701, FKSG35, LOC728377, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:7,214,279-7,638,263 CN Loss 423985 18 12 p23.1 DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4, DEFB4B, FAM90A18, FAM90A19, FAM90A7, FAM90A8, HE2, SPAG11B 
chr8:7,638,263-7,741,568 Homozygous Copy Loss 103306 2 6 p23.1 FAM90A10, FAM90A9 
chr8:7,741,568-7,942,536 CN Loss 200969 9 6 p23.1 DEFB103A, DEFB4, DEFB4A, FAM66E, HE2, LOC100132396, SPAG11A, SPAG11B, ZNF705D 
chr8:39,349,059-39,526,316 CN Loss 177258 3 11 p11.23 - p11.22 ADAM3A, ADAM5P, tMDC 
chr9:38,769,965-38,942,543 CN Gain 172579 0 10 p13.1 
 
chr9:39,061,678-39,251,004 CN Loss 189327 2 9 p13.1 CNTNAP3, KIAA1714 
chr9:43,361,452-43,827,369 CN Loss 465918 3 9 p11.2 AK054645, CNTNAP3B, FAM75A6 
chr9:44,722,011-46,339,951 CN Gain 1617941 9 33 p11.2 AK131029, BC134347, CR615666, DQ594366, DQ594428, FAM27A, FAM27C, FAM27E3, LOC100132167 
chr9:65,222,385-65,792,243 CN Gain 569859 2 6 q12 FAM74A2, FAM74A4 
chr12:9,519,693-9,591,347 High Copy Gain 71655 0 5 p13.31 
 
chr12:55,616,671-55,667,718 CN Loss 51048 1 4 q13.3 RDH16 
chr14:19,244,829-19,490,518 CN Loss 245690 7 13 q11.2 OR11H2, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3 
chr14:21,583,358-22,028,382 CN Loss 445025 31 28 q11.2 
AK093552, AK125397, AK310110, AV1S3A1T, AV25S1, AV2S1A1, AV30S1, AV4S1, TCR V alpha 8.1, J alpha IGRJa07, TCR-[alpha] V 
33.1, TCR-alpha, TCRA, TCRAV14.1a, TCRAV8.1a, TCRAVN1, TCRD, TCRDV2, TCRVA13, TRA@, TRAC, TRD, TRD@, V alpha 
immunoglobulin, X61074, av27s1, hADV23S1, hADV29S1, hADV36S1, hADV38S2, hDV102S1, hDV103S1 
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chr15:19,033,127-19,583,601 CN Loss 550475 14 21 q11.2 A26B1, AL832227, BC047459, CXADRP2, DQ582025, DQ582260, DQ786202, GOLGA8C, GOLGA8E, LOC646214, M84131, NBEAP1, NF1P1, POTEB 
chr16:34,328,350-34,611,145 CN Gain 282796 6 17 p11.2 - p11.1 BC023607, BC038761, BC045579, LOC100130700, LOC146481, LOC283914 
chr16:69,397,161-69,724,827 CN Gain 327667 6 21 q22.1 - q22.2 DKFZp434D0513, DKFZp434I0850, DKFZp761B238, HYDIN, HYDIN2, KIAA1864 
chr17:41,555,382-41,768,841 CN Loss 213460 7 12 q21.31 ARL17, ARL17B, ARL17P1, KIAA1267, LOC51326, LOC644246, LRRC37A 
chr17:41,768,841-42,128,214 CN Gain 359374 9 7 q21.31 - q21.32 ARL17, ARL17A, ARL17B, ARL17P1, LOC51326, LRRC37A, LRRC37A2, NSF, NSFP1 
chr18:1,896,940-1,965,541 CN Loss 68602 0 4 p11.32 
 
chr18:25,844,492-26,393,582 CN Loss 549091 1 33 q12.1 MIR302F 
chr19:61,855,379-61,922,492 CN Gain 67114 3 4 q13.43 AK095199, LOC147670, ZNF835 
chr22:37,683,134-37,724,108 CN Loss 40975 2 4 q13.1 APOBEC3A, APOBEC3B 
chrX:154,881,207-154,913,754 CN Gain 32548 3 6 q28 IL9R, WASH1, interleukin 9 receptor 
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Table S3. 25 - CNVs found for patient 25 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr1:195,037,455-195,157,595 CN Loss 120141 2 9 q31.3 CFHR1, CFHR4 
chr4:69,008,654-69,170,341 CN Loss 161688 2 11 q13.2 TMPRSS11E, UGT2B17 
chr4:70,170,112-70,333,309 CN Loss 163198 1 9 q13.2 UGT2B28 
chr4:190,715,999-190,919,040 CN Loss 203042 0 12 q35.2   
chr5:754,690-900,209 CN Loss 145520 1 14 p15.33 ZDHHC11 
chr5:68,938,168-70,671,221 CN Gain 1733054 15 38 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC647859, LOC653391, NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:57,304,911-57,774,413 CN Gain 469503 1 18 p11.2 PRIM2 
chr6:57,917,805-58,142,695 CN Gain 224891 0 5 p11.2   
chr7:143,548,913-143,596,593 Homozygous Copy Loss 47681 6 3 q35 CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr7:143,596,593-143,667,377 CN Loss 70785 5 3 q35 CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A9P 
chr8:12,233,164-12,366,919 CN Gain 133756 3 4 p23.1 DEFB109P1, FAM66A, FAM86B2 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:48,381,494-49,040,567 CN Gain 659074 7 9 q11.22 FAM25B, FAM25C, FAM25G, FRMPD2, LOC399753, PTPN20A, PTPN20B 
chr14:105,602,384-105,650,001 CN Gain 47618 0 4 q32.33   
chr15:18,467,080-19,074,651 CN Gain 607572 2 17 q11.2 GOLGA6L6, GOLGA8C 
chr15:19,796,307-20,154,336 CN Loss 358030 4 17 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr16:14,748,555-15,045,422 CN Gain 296868 5 17 p13.11 ABCC6P2, NOMO1, NPIP, NTAN1, PDXDC1 
chr16:15,391,681-16,215,845 CN Gain 824165 9 51 p13.11 ABCC1, ABCC6, C16orf45, C16orf63, KIAA0430, MIR484, MPV17L, MYH11, NDE1 
chr17:31,459,116-31,762,515 CN Loss 303400 7 8 q12 CCL3L1, CCL3L3, CCL4L1, CCL4L2, TBC1D3B, TBC1D3C, TBC1D3F 
chr17:41,648,920-42,128,214 CN Gain 479295 5 12 q21.31 - q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
chr17:78,632,251-78,774,742 CN Loss 142492 1 4 q25.3 METRNL 
chr22:18,708,904-18,851,705 CN Gain 142802 2 6 q11.21 PI4KAP1, RIMBP3 
chr22:23,983,829-24,247,592 High Copy Gain 263764 2 19 q11.23 IGLL3, LRP5L 
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Table S3. 26 - CNVs found for patient 26 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr1:120,406,782-120,528,618 CN Gain 121837 1 6 p12 NOTCH2 
chr1:146,795,981-147,494,816 CN Gain 698836 4 19 q21.1 LOC645166, NBPF15, NBPF16, PPIAL4E 
chr1:150,775,626-150,864,838 CN Gain 89213 5 6 q21.3 LCE3A, LCE3B, LCE3C, LCE3D, LCE3E 
chr1:195,008,432-195,078,812 CN Loss 70381 2 7 q31.3 CFHR1, CFHR3 
chr2:132,229,559-132,331,391 CN Gain 101833 2 6 q21.2 C2orf27A, C2orf27B 
chr3:75,390,841-75,784,380 CN Gain 393540 2 16 p12.3 FAM86D, MIR1324 
chr3:163,987,281-164,108,596 Homozygous Copy Loss 121316 0 7 q26.1   
chr3:196,826,201-197,001,270 CN Gain 175070 4 11 q29 MIR570, MUC20, MUC4, SDHAP2 
chr4:8,982,874-9,383,286 CN Gain 400413 3 21 p16.1 DEFB131, LOC650293, MIR548I2 
chr5:68,938,168-70,043,543 CN Gain 1105376 11 25 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC653391, SERF1A, SERF1B, SMN1, SMN2 
chr5:70,043,543-70,413,976 CN Loss 370434 12 7 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, LOC653391, NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:29,951,068-29,994,193 CN Loss 43126 2 3 p21.33 HCG2P7, HLA-H 
chr6:32,563,029-32,600,341 High Copy Gain 37313 1 3 p21.32 HLA-DRB5 
chr6:32,600,341-32,725,877 CN Gain 125537 4 12 p21.32 HLA-DQA1, HLA-DRB1, HLA-DRB5, HLA-DRB6 
chr6:79,027,678-79,098,580 CN Gain 70903 0 4 q14.1   
chr7:5,286,433-5,325,459 CN Gain 39027 2 4 p22.1 SLC29A4, TNRC18 
chr7:43,970,243-44,035,484 CN Gain 65242 3 4 p13 POLR2J4, RASA4P, SPDYE1 
chr7:101,892,363-102,138,397 CN Gain 246035 8 8 q22.1 LRWD1, POLR2J, POLR2J2, POLR2J3, RASA4, SPDYE2, SPDYE2L, UPLP 
chr7:143,548,913-143,667,377 CN Loss 118465 6 6 q35 CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:11,953,787-12,601,257 CN Gain 647471 9 17 p23.1 DEFB109P1, DEFB130, FAM66A, FAM66D, FAM86B1, FAM86B2, LOC392196, USP17L2, ZNF705D 
chr8:145,674,701-145,708,648 High Copy Gain 33948 4 4 q24.3 GPT, MFSD3, PPP1R16A, RECQL4 
chr11:3,357,125-3,583,730 CN Gain 226606 1 8 p15.4 LOC650368 
chr12:0-54,903 CN Gain 54904 2 4 p13.33 FAM138D, IQSEC3 
chr14:18,750,780-19,507,271 CN Gain 756492 7 24 q11.1 - q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P 
chr14:105,095,304-105,361,965 CN Gain 266662 0 20 q32.33   
chr15:19,922,429-20,154,336 CN Loss 231908 0 8 q11.2   
chr15:42,919,752-43,044,136 CN Gain 124385 1 8 q21.1 C15orf43 
chr15:76,751,572-76,825,339 CN Gain 73768 0 5 q25.1   
chr16:0-36,949 CN Gain 36950 1 5 p13.3 LOC100288778 
chr16:617,378-687,501 CN Gain 70124 11 11 p13.3 C16orf13, FAM195A, FBXL16, JMJD8, RAB40C, RHBDL1, RHOT2, STUB1, WDR24, WDR90, WFIKKN1 
chr16:14,695,541-15,031,536 CN Gain 335996 5 18 
p13.12 - 
p13.11 ABCC6P2, NOMO1, NPIP, PDXDC1, PLA2G10 
chr16:15,384,327-16,351,469 CN Gain 967143 11 54 p13.11 ABCC1, ABCC6, C16orf45, C16orf63, KIAA0430, LOC339047, MIR484, MPV17L, MYH11, NDE1, NOMO3 
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chr17:0-80,275 CN Gain 80276 1 7 p13.3 RPH3AL 
chr17:25,839,797-25,930,310 CN Gain 90514 3 8 q11.2 GOSR1, LRRC37B2, TBC1D29 
chr17:41,521,663-41,703,816 CN Gain 182154 1 12 q21.31 KIAA1267 
chr17:41,768,841-42,142,705 CN Loss 373865 5 8 
q21.31 - 
q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
chr17:69,753,244-69,901,172 CN Gain 147929 5 8 q25.1 BTBD17, DNAI2, GPR142, KIF19, TTYH2 
chr17:77,286,848-77,401,037 CN Gain 114190 3 7 q25.3 DYSFIP1, P4HB, SLC25A10 
chr18:0-117,644 CN Gain 117645 0 4 p11.32   
chr19:48,029,654-48,470,723 CN Gain 441070 9 30 q13.31 PSG1, PSG10, PSG11, PSG2, PSG4, PSG5, PSG6, PSG7, PSG9 
chr20:25,691,766-25,830,492 CN Gain 138727 1 5 p11.21 - p11.1 FAM182B 
chr21:13,555,699-13,647,953 CN Gain 92255 0 3 q11.2   
chr21:13,647,953-13,861,001 CN Loss 213049 0 8 q11.2   
chr22:16,941,475-17,316,844 CN Gain 375370 6 19 q11.21 DGCR6, GGT3P, PEX26, PRODH, TUBA8, USP18 
chr22:18,670,410-19,056,269 CN Gain 385860 3 14 q11.21 DGCR6L, PI4KAP1, RIMBP3 
chrX:1,376,768-1,592,621 CN Gain 215854 6 26 p22.33 ASMTL, CSF2RA, IL3RA, NCRNA00105, P2RY8, SLC25A6 
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Table S3. 27 - CNVs found for patient 27 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:16,886,363-16,943,714 CN Gain 57352 1 4 p36.13 ESPNP 
chr1:141,494,201-141,652,073 CN Loss 157873 0 5 q12   
chr1:147,255,457-147,482,142 CN Gain 226686 0 11 q21.1   
chr1:167,483,633-167,531,051 
Homozygous Copy 
Loss 47419 1 3 q24.2 NME7 
chr1:195,008,432-195,078,812 CN Loss 70381 2 7 q31.3 CFHR1, CFHR3 
chr1:246,781,770-246,863,559 CN Loss 81790 4 6 q44 OR2T10, OR2T11, OR2T29, OR2T34 
chr2:89,244,042-89,895,566 CN Loss 651525 0 19 p11.2   
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:54,609-111,638 CN Gain 57030 2 5 p16.3 ZNF595, ZNF718 
chr4:34,448,772-34,500,505 CN Loss 51734 0 4 p15.1   
chr4:69,063,649-69,185,257 CN Gain 121609 1 10 q13.2 UGT2B17 
chr4:107,322,522-107,395,454 CN Loss 72933 1 4 q24 TBCK 
chr5:742,057-894,896 CN Gain 152840 2 15 p15.33 TPPP, ZDHHC11 
chr5:68,960,939-70,312,515 CN Loss 1351577 12 26 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC653391, NAIP, SERF1A, SERF1B, SMN1, SMN2 
chr5:70,312,515-70,375,604 CN Gain 63090 5 4 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, NAIP 
chr5:70,375,604-70,696,119 CN Loss 320516 7 8 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, NAIP, OCLN 
chr5:97,834,591-97,950,837 CN Loss 116247 0 7 q21.1   
chr6:32,563,029-32,600,341 High Copy Gain 37313 1 3 p21.32 HLA-DRB5 
chr6:32,600,341-32,711,050 CN Gain 110710 3 11 p21.32 HLA-DRB1, HLA-DRB5, HLA-DRB6 
chr7:16,449,856-16,625,033 CN Loss 175178 2 11 p21.1 ANKMY2, SOSTDC1 
chr7:61,060,605-61,374,646 CN Loss 314042 0 4 q11.1 - q11.21   
chr8:39,349,059-39,508,365 High Copy Gain 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr9:45,086,142-45,569,831 CN Loss 483690 0 9 p11.2   
chr14:18,149,473-19,490,518 CN Loss 1341046 9 40 q11.1 - q11.2 OR11H12, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr15:19,583,601-20,258,362 CN Loss 674762 5 22 q11.2 GOLGA8DP, LOC727924, OR4M2, OR4N3P, OR4N4 
chr16:2,583,264-2,680,019 CN Gain 96756 4 8 p13.3 FLJ42627, KCTD5, LOC652276, PDPK1 
chr16:32,096,628-32,650,001 CN Loss 553374 2 18 p11.2 TP53TG3, TP53TG3B 
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Table S3. 28 - CNVs found for patient 28 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:17,077,550-17,203,213 CN Gain 125664 3 8 p36.13 ATP13A2, CROCC, MFAP2 
chr1:194,993,686-195,051,521 CN Gain 57836 1 5 q31.3 CFHR3 
chr4:34,429,336-34,500,505 CN Loss 71170 0 5 p15.1   
chr4:63,644,174-63,790,657 CN Gain 146484 0 8 q13.1   
chr4:69,038,815-69,170,341 CN Loss 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr5:69,661,014-70,452,813 CN Loss 791800 12 12 q13.2 GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, LOC647859, LOC653391, NAIP, OCLN, SERF1A, SERF1B, SMN1, SMN2 
chr6:256,093-327,656 CN Loss 71564 1 5 p25.3 DUSP22 
chr6:32,563,029-32,634,334 CN Loss 71306 2 7 p21.32 HLA-DRB5, HLA-DRB6 
chr8:12,270,256-12,580,432 CN Gain 310177 3 8 p23.1 DEFB109P1, FAM66A, FAM86B2 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:135,088,908-135,230,109 CN Gain 141202 3 12 q26.3 CYP2E1, LOC619207, SYCE1 
chr11:55,119,157-55,178,810 Homozygous Copy Loss 59654 3 3 q11 OR4C11, OR4P4, OR4S2 
chr13:51,413,362-51,515,663 CN Loss 102302 3 8 q14.3 ALG11, ATP7B, UTP14C 
chr15:19,699,696-20,235,151 CN Loss 535456 4 20 q11.2 LOC727924, OR4M2, OR4N3P, OR4N4 
chr15:30,378,732-30,674,063 CN Gain 295332 2 7 q13.3 FAM7A1, FAM7A2 
chr17:41,768,841-42,128,214 CN Gain 359374 5 7 q21.31 - q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
chr19:59,929,792-60,074,245 CN Gain 144454 8 6 q13.42 KIR2DL1, KIR2DL3, KIR2DL4, KIR2DS4, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1 
chr21:9,896,630-10,198,129 CN Gain 301500 6 14 p11.2 - p11.1 BAGE, BAGE2, BAGE3, BAGE4, BAGE5, TPTE 
chr22:22,676,684-22,729,016 CN Loss 52333 4 4 q11.23 GSTT1, GSTTP1, GSTTP2, LOC391322 
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Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:0-688,026 CN Loss 688027 13 8 p36.33 
FAM138A, FAM138C, FAM138F, LOC100132062, LOC100132287, LOC100133331, LOC100288778, MIR1977, OR4F16, 
OR4F29, OR4F3, OR4F5, WASH5P, hsa-mir-1977, hsa-mir-1302-2 
chr1:72,532,314-72,590,954 Homozygous Copy Loss 58641 0 3 p31.1   
chr3:163,987,281-164,108,596 High Copy Gain 121316 0 7 q26.1   
chr4:0-54,609 CN Loss 54610 2 4 p16.3 ZNF595, ZNF718 
chr4:69,038,815-69,170,341 CN Gain 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr4:70,766,959-71,285,452 CN Gain 518494 14 35 q13.3 C4orf35, C4orf40, C4orf7, CSN1S1, CSN1S2A, CSN1S2B, CSN2, CSN3, HTN1, HTN3, ODAM, SMR3A, SMR3B, STATH 
chr4:76,987,928-77,215,148 CN Gain 227221 7 18 q21.1 ART3, CXCL10, CXCL11, CXCL9, NAAA, PPEF2, SDAD1 
chr5:742,057-866,296 CN Loss 124240 2 12 p15.33 TPPP, ZDHHC11 
chr5:68,877,031-70,696,119 CN Loss 1819089 15 42 q13.2 
GTF2H2, GTF2H2B, GTF2H2C, GTF2H2D, GUSBP3, LOC100170939, LOC100272216, LOC647859, LOC653391, NAIP, OCLN, 
SERF1A, SERF1B, SMN1, SMN2 
chr6:193,938-327,656 CN Loss 133719 1 9 p25.3 DUSP22 
chr6:29,951,068-30,013,265 CN Loss 62198 3 4 p21.33 HCG2P7, HCG4P6, HLA-H 
chr6:30,013,265-30,072,018 CN Gain 58754 2 4 p21.33 HCG9, HLA-A 
chr6:32,563,029-32,634,334 CN Loss 71306 2 7 p21.32 HLA-DRB5, HLA-DRB6 
chr7:38,262,476-38,336,127 CN Loss 73652 1 6 p14.1 TARP 
chr7:61,060,605-61,197,061 CN Loss 136457 0 2 q11.1 - q11.21   
chr8:7,121,948-7,942,536 CN Gain 820589 28 27 p23.1 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, DEFB106A, DEFB106B, DEFB107A, DEFB107B, 
DEFB109P1B, DEFB4, FAM66B, FAM66E, FAM90A10, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A20, 
FAM90A5, FAM90A7, FAM90A8, FAM90A9, LOC349196, SPAG11A, SPAG11B, ZNF705G 
chr8:39,332,477-39,526,316 CN Loss 193840 2 12 p11.23 - p11.22 ADAM3A, ADAM5P 
chr8:146,240,172-146,274,826 CN Loss 34655 1 3 q24.3 C8orf33 
chr12:9,519,693-9,591,347 Homozygous Copy Loss 71655 0 5 p13.31   
chr14:19,244,829-19,490,518 CN Loss 245690 6 13 q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3 
chr14:21,678,281-22,042,277 CN Loss 363997 0 23 q11.2   
chr14:106,079,453-106,137,200 CN Loss 57748 0 5 q32.33   
chr15:18,775,860-19,480,163 CN Gain 704304 7 27 q11.2 BCL8, CXADRP2, GOLGA6L6, GOLGA8C, LOC646214, NF1P1, POTEB 
chr16:31,840,621-33,691,406 CN Loss 1850786 4 64 p11.2 HERC2P4, SLC6A10P, TP53TG3, TP53TG3B 
chr17:31,459,116-31,511,535 CN Loss 52420 0 5 q12   
chr17:41,555,382-41,768,841 CN Loss 213460 3 12 q21.31 ARL17B, KIAA1267, LRRC37A 
chr17:41,768,841-42,128,214 CN Gain 359374 5 7 q21.31 - q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
chr17:78,638,125-78,774,742 CN Loss 136618 1 3 q25.3 METRNL 
chr20:62,379,348-62,435,964 CN Loss 56617 0 5 q13.33   
chr21:14,190,683-14,248,706 CN Loss 58024 1 4 q11.2 C21orf81 
chr21:46,908,131-46,944,323 CN Loss 36193 1 3 q22.3 PRMT2 
chr22:22,676,684-22,729,016 CN Gain 52333 4 4 q11.23 GSTT1, GSTTP1, GSTTP2, LOC391322 
Table S3. 29 - CNVs found for patient 29 
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chrX:7,773,321-8,217,918 CN Gain 444598 3 27 p22.31 MIR651, PNPLA4, VCX2, hsa-mir-651 
chrX:154,043,595-154,085,916 CN Loss 42322 0 4 q28   
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Table S3. 30 - CNVs found for patient 30 
Chromosome Region Event Length Genes Probes Cytoband Gene Symbols 
chr1:103,905,063-103,965,250 CN Gain 60188 3 5 p21.1 AMY2A, AMY2B, LOC648740 
chr1:194,993,686-195,078,812 CN Gain 85127 2 8 q31.3 CFHR1, CFHR3 
chr3:198,840,959-198,876,555 CN Gain 35597 0 3 q29   
chr4:69,038,815-69,170,341 CN Loss 131527 2 10 q13.2 TMPRSS11E, UGT2B17 
chr5:290,282-334,827 CN Gain 44546 2 4 p15.33 PDCD6, SDHA 
chr5:69,661,014-70,245,600 CN Gain 584587 6 5 q13.2 GTF2H2B, GTF2H2C, GTF2H2D, LOC653391, SERF1A, SERF1B 
chr6:32,576,756-32,711,050 CN Loss 134295 3 13 p21.32 HLA-DRB1, HLA-DRB5, HLA-DRB6 
chr7:143,509,786-143,693,789 CN Gain 184004 8 8 q35 ARHGEF5, ARHGEF5L, CTAGE4, OR2A1, OR2A20P, OR2A42, OR2A7, OR2A9P 
chr8:12,139,755-12,366,919 CN Gain 227165 4 5 p23.1 DEFB109P1, DEFB130, FAM66A, FAM86B2 
chr8:39,349,059-39,508,365 Homozygous Copy Loss 159307 2 10 p11.23 - p11.22 ADAM3A, ADAM5P 
chr10:67,871,783-68,019,393 CN Gain 147611 1 8 q21.3 CTNNA3 
chr12:9,519,693-9,591,347 Homozygous Copy Loss 71655 0 5 p13.31   
chr14:18,555,363-19,490,518 CN Loss 935156 8 33 q11.1 - q11.2 OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, P704P, POTEG 
chr14:27,289,441-27,363,658 CN Gain 74218 0 5 q12   
chr16:22,377,707-22,615,315 CN Loss 237609 5 10 p12.1 LOC100132247, LOC100190986, LOC641298, LOC653786, NPIPL3 
chr16:34,328,350-34,611,145 CN Gain 282796 2 17 p11.2 - p11.1 LOC146481, LOC283914 
chr16:72,921,969-73,030,768 CN Gain 108800 2 7 q22.3 CLEC18B, LOC283922 
chr17:31,449,032-31,511,535 High Copy Gain 62504 1 6 q12 CCL4 
chr17:41,577,131-41,768,841 CN Loss 191711 3 11 q21.31 ARL17B, KIAA1267, LRRC37A 
chr17:41,768,841-42,128,214 High Copy Gain 359374 5 7 q21.31 - q21.32 ARL17A, ARL17B, LRRC37A, LRRC37A2, NSF 
chr19:6,283,716-6,944,284 CN Gain 660569 22 42 p13.3 - p13.2 
ACER1, ALKBH7, C3, CD70, CLPP, CRB3, DENND1C, EMR1, EMR4P, GPR108, GTF2F1, KHSRP, MIR220B, PSPN, SH2D3A, 
SLC25A23, SLC25A41, TNFSF14, TNFSF9, TRIP10, TUBB4, VAV1 
chr19:6,944,284-7,028,066 CN Loss 83783 6 5 p13.2 FLJ25758, MBD3L2, MBD3L3, MBD3L4, MBD3L5, ZNF557 
chr19:7,028,066-7,633,437 CN Gain 605372 14 39 p13.2 
ARHGEF18, C19orf45, INSR, KIAA1543, LOC100128573, LOC100131801, MCOLN1, PCP2, PEX11G, PNPLA6, STXBP2, XAB2, 
ZNF358, ZNF557 
chr19:8,698,817-8,822,409 CN Gain 123593 4 8 p13.2 MBD3L1, MUC16, OR2Z1, ZNF558 
chr21:45,191,792-45,278,798 CN Gain 87007 2 6 q22.3 C21orf70, NCRNA00162 
chr22:48,228,521-48,341,402 CN Loss 112882 0 7 q13.33   
 
